Document and Entity Information
Document and Entity Information | 12 Months Ended |
Dec. 31, 2021shares | |
Statement | |
Document Type | 20-F |
Document Registration Statement | false |
Document Annual Report | true |
Document Period End Date | Dec. 31, 2021 |
Document Transition Report | false |
Document Shell Company Report | false |
Entity Registrant Name | Grifols SA |
Entity File Number | 001-35193 |
Entity Incorporation, State or Country Code | U3 |
Contact Personnel Email Address | david.bell@grifols.com |
Entity Address, Address Line One | Avinguda de la Generalitat, 152-158 |
Entity Address, Address Line Two | Parc de Negocis Can Sant Joan |
Entity Address, Address Line Three | Sant Cugat del Vallès |
Entity Address, City or Town | Barcelona |
Entity Address, Country | ES |
Entity Address, Postal Zip Code | 08174 |
Title of 12(b) Security | American Depositary Shares |
Trading Symbol | GRFS |
Security Exchange Name | NASDAQ |
Entity Well-known Seasoned Issuer | Yes |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Large Accelerated Filer |
Entity Emerging Growth Company | false |
Document Accounting Standard | International Financial Reporting Standards |
Entity Shell Company | false |
Entity Central Index Key | 0001438569 |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Year Focus | 2021 |
Document Fiscal Period Focus | FY |
Amendment Flag | false |
ICFR Auditor Attestation Flag | true |
Auditor Name | KPMG Auditores, S.L |
Auditor Firm ID | 1027 |
Auditor Location | Madrid, Spain |
Business Contact | |
Statement | |
Contact Personnel Name | David Ian Bell |
Entity Address, Address Line One | Grifols Shared Services North America, Inc. |
Entity Address, Address Line Two | 2410 Lillyvale Ave |
Entity Address, City or Town | Los Angeles |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 90032 |
City Area Code | 34 |
Local Phone Number | 93 571 02 21 |
Class A, Ordinary shares | |
Statement | |
Entity Common Stock, Shares Outstanding | 426,129,798 |
Class B, Preference shares | |
Statement | |
Entity Common Stock, Shares Outstanding | 261,425,110 |
Consolidated Balance Sheet
Consolidated Balance Sheet - EUR (€) | Dec. 31, 2021 | Dec. 31, 2020 |
Non-current assets | ||
Goodwill (note 7) | € 6,228,901,000 | € 5,332,271,000 |
Other intangible assets (note 8) | 1,636,950,000 | 1,557,650,000 |
Rights of use (note 9) | 795,657,000 | 678,696,000 |
Property, plant and equipment (note 10) | 2,547,497,000 | 2,324,107,000 |
Investment in equity-accounted investees (note 11) | 1,999,776,000 | 1,869,020,000 |
Non-current financial assets | ||
Non-current financial assets measured at fair value | 4,106,000 | 3,008,000 |
Non-current financial assets at amortised cost | 358,161,000 | 195,149,000 |
Total non-current financial assets (note 12) | 362,267,000 | 198,157,000 |
Deferred tax assets | 152,507,000 | 149,921,000 |
Total non-current assets | 13,723,555,000 | 12,109,822,000 |
Inventories (note 13) | 2,259,354,000 | 2,002,281,000 |
Current contract assets | 1,939,000 | 0 |
Trade and other receivables | ||
Trade receivables | 432,197,000 | 383,233,000 |
Other receivables | 55,063,000 | 72,360,000 |
Current income tax assets | 12,448,000 | 64,565,000 |
Trade and other receivables (note 14) | 499,708,000 | 520,158,000 |
Other current financial assets (note 12) | ||
Current financial assets measured at fair value | 3,238,000 | 0 |
Current financial assets at amortized cost | 2,026,469,000 | 11,118,000 |
Total current financial assets (note 12) | 2,029,707,000 | 11,118,000 |
Other current assets | 64,079,000 | 51,750,000 |
Cash and cash equivalents (note 15) | 655,493,000 | 579,647,000 |
Total current assets | 5,510,280,000 | 3,164,954,000 |
Total assets | 19,233,835,000 | 15,274,776,000 |
Equity and liabilities | ||
Share capital | 119,603,705 | 119,603,705 |
Share premium | 910,728,000 | 910,728,000 |
Reserves | 4,133,388,000 | 3,776,932,000 |
Treasury stock | (164,189,000) | (43,734,000) |
Profit for the year attributable to the Parent | 188,726,000 | 618,546,000 |
Total equity | 5,188,257,000 | 5,382,076,000 |
Cash Flow hedges | 3,130,000 | 0 |
Other comprehensive Income | (869,000) | (1,155,000) |
Translation differences | 333,091,000 | (272,529,000) |
Other comprehensive expenses | 335,352,000 | (273,684,000) |
Equity attributable to the Parent (note 16) | 5,523,609,000 | 5,108,392,000 |
Non-controlling interests (note 18) | 1,793,489,000 | 1,611,663,000 |
Total equity | 7,317,098,000 | 6,720,055,000 |
Non-current liabilities | ||
Grants (note 19) | 15,036,000 | 17,008,000 |
Provisions (note 20) | 24,122,000 | 27,271,000 |
Non-current financial liabilities (note 21) | 7,768,950,000 | 6,602,100,000 |
Other non-current liabilities | 333,000 | 16,391,000 |
Deferred tax liabilities (note 28) | 633,984,000 | 556,813,000 |
Total non-current liabilities | 8,442,425,000 | 7,219,583,000 |
Provisions (note 20) | 31,407,000 | 11,175,000 |
Current financial liabilities (note 21) | 2,438,291,000 | 424,612,000 |
Trade and other payables | ||
Suppliers | 628,992,000 | 601,618,000 |
Other payables | 151,834,000 | 141,089,000 |
Current income tax liabilities | 4,516,000 | 3,482,000 |
Total trade and other payables (note 22) | 785,342,000 | 746,189,000 |
Other current liabilities (note 23) | 219,272,000 | 153,162,000 |
Total current liabilities | 3,474,312,000 | 1,335,138,000 |
Total liabilities | 11,916,737,000 | 8,554,721,000 |
Total equity and liabilities | € 19,233,835,000 | € 15,274,776,000 |
Consolidated Statements of Prof
Consolidated Statements of Profit and Loss - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Continuing Operations | |||
Net revenue (notes 6 and 24) | € 4,933,118 | € 5,340,038 | € 5,098,691 |
Cost of sales | (2,970,522) | (3,084,873) | (2,757,459) |
Gross Margin | 1,962,596 | 2,255,165 | 2,341,232 |
Research and development | (354,881) | (294,216) | (276,018) |
Selling, general and administration expenses | (1,061,508) | (985,616) | (942,821) |
Operating Expenses | (1,416,389) | (1,279,832) | (1,218,839) |
Other Income | 16,302 | 0 | 0 |
Profit/(loss) of equity accounted investees with similar activity to that of the Group (note 11) | 32,555 | 20,799 | 8,972 |
Operating Result | 595,064 | 996,132 | 1,131,365 |
Finance income | 11,551 | 8,021 | 114,197 |
Finance costs | (277,994) | (249,639) | (342,965) |
Change in fair value of financial instruments | 246 | 55,703 | 1,326 |
Impairment of financial assets at amortized cost | 0 | 0 | (37,666) |
Exchange differences | (11,602) | 8,246 | (9,616) |
Finance result (note 27) | (277,799) | (177,669) | (274,724) |
Profit/(loss) of equity accounted investees (note 11) | 33,188 | 60,166 | (39,538) |
Profit before income tax from continuing operations | 350,453 | 878,629 | 817,103 |
Income tax expense (note 28) | (85,126) | (169,639) | (168,459) |
Profit after income tax from continuing operations | 265,327 | 708,990 | 648,644 |
Consolidated profit for the year | 265,327 | 708,990 | 648,644 |
Profit attributable to the Parent | 188,726 | 618,546 | 625,146 |
Profit attributable to non-controlling interest (note 18) | € 76,601 | € 90,444 | € 23,498 |
Basic earnings per share (Euros) (see note 17) | € 0.28 | € 0.90 | € 0.91 |
Diluted earnings per share (Euros) (see note 17) | € 0.28 | € 0.90 | € 0.91 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Consolidated Statements of Comprehensive Income | |||
Consolidated profit for the year | € 265,327 | € 708,990 | € 648,644 |
Items for reclassification to profit or loss | |||
Translation differences | 811,683 | (747,221) | 33,256 |
Equity accounted investees (note 11) / Translation differences | (95,939) | 21,916 | (4,360) |
Cash flow hedges - effective portion of changes in fair value | 5,306 | 0 | 0 |
Cash flow hedges - amounts taken to profit or loss | (1,133) | 0 | 0 |
Tax effect | (1,043) | 0 | 0 |
Other | 286 | (252) | (349) |
Other comprehensive income for the year, after tax | 719,160 | (725,557) | 28,547 |
Total comprehensive income for the year | 984,487 | (16,567) | 677,191 |
Total comprehensive income attributable to the Parent | 797,762 | 1,408 | 641,772 |
Total comprehensive income attributable to non-controlling interests | € 186,725 | € (17,975) | € 35,419 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Cash flows from operating activities | |||
Profit before tax | € 350,453 | € 878,629 | € 817,103 |
Adjustments for: | 574,493 | 409,766 | 569,960 |
Amortization and depreciation (note 26) | 359,767 | 321,533 | 302,455 |
Other adjustments: | 214,726 | 88,233 | 267,505 |
(Profit) / losses on equity accounted investments (note 11) | (65,744) | (80,965) | 30,566 |
Impairment of assets and net provision charges | 64,091 | (17,148) | (19,518) |
(Profit) / losses on disposal of fixed assets (notes 8, 9 and 10) | 1,196 | 1,067 | 1,399 |
Government grants taken to income (note 19) | (5,608) | (1,683) | (1,388) |
Finance cost / (income) | 246,189 | 170,535 | 255,841 |
Other adjustments | (25,398) | 16,427 | 605 |
Change in operating assets and liabilities | (140,908) | 106,283 | (481,537) |
Change in inventories | (157,474) | 164,631 | (323,748) |
Change in trade and other receivables | (16,806) | (35,429) | (99,374) |
Change in current financial assets and other current assets | (7,075) | (20,600) | (13,871) |
Change in current trade and other payables | 40,447 | (2,319) | (44,544) |
Other cash flows used in operating activities | (187,063) | (284,342) | (336,593) |
Interest paid | (155,120) | (155,788) | (236,179) |
Interest received | 407 | 3,773 | 9,487 |
Income tax (paid) / received | (30,595) | (131,510) | (107,797) |
Other received / (paid) | (1,755) | (817) | (2,104) |
Net cash from operating activities | 596,975 | 1,110,336 | 568,933 |
Cash flows from investing activities | |||
Payments for investments | (876,678) | (858,387) | (551,497) |
Group companies, associates and business units (notes 3, 2 (b) and 11) | (519,128) | (468,589) | (119,745) |
Property, plant and equipment and intangible assets | (315,088) | (362,560) | (412,305) |
Property, plant and equipment | (247,373) | (280,154) | (310,383) |
Intangible assets | (67,715) | (82,406) | (101,922) |
Other financial assets | (42,462) | (27,238) | (19,447) |
Proceeds from the sale of investments | 22,529 | 272 | 2,708 |
Group companies, associates and business units (notes 3, 2 (b) and 11) | 20,399 | ||
Property, plant and equipment | 639 | 272 | 2,708 |
Other financial assets | 1,491 | ||
Net cash used in investing activities | (854,149) | (858,115) | (548,789) |
Cash flows from financing activities | |||
Proceeds from and payments for equity instruments | (125,703) | ||
Payments for treasury stock | (125,703) | ||
Proceeds from and payments for financial liability instruments | 2,746,380 | (243,373) | (7,515) |
Issue | 3,324,399 | 108,541 | 120,079 |
Redemption and repayment | (495,327) | (272,877) | (53,809) |
Lease payments | (82,692) | (79,037) | (73,785) |
Dividends and interest on other equity instruments | (247,498) | (103,075) | (234,271) |
Dividends paid | (258,946) | (113,230) | (238,740) |
Dividends received | 11,448 | 10,155 | 4,469 |
Other cash flows from / (used in) financing activities | (75,500) | (7,953) | (90,552) |
Financing costs included in the amortized costs of the debt | (78,165) | (9,227) | (84,346) |
Other amounts from / (used in) financing activities | 2,665 | 1,274 | (6,206) |
Transaction with minority interests with no loss of control (note 3) | (18) | ||
Net cash from/(used in) financing activities | 2,297,679 | (354,401) | (332,356) |
Effect of exchange rate fluctuations on cash | 55,459 | (60,155) | 20,402 |
Net increase / (decrease) in cash and cash equivalents | 2,095,964 | (162,335) | (291,810) |
Cash and cash equivalents at beginning of the year | 579,647 | 741,982 | 1,033,792 |
Cash and cash equivalents at year end | € 2,675,611 | € 579,647 | € 741,982 |
Statement of Changes in Consoli
Statement of Changes in Consolidated Equity - EUR (€) € in Thousands | Equity attributable to parent | Share capital | Share premium. | Reserves | Profit attributable to parent | Interim dividend | Treasury stock | Translation differences | Other comprehensive incomes | Cash flow hedges | Non-controlling interests [Member] | Total |
Balance at beginning of the year at Dec. 31, 2018 | € 4,225,554 | € 119,604 | € 910,728 | € 2,441,931 | € 596,642 | € (136,747) | € (55,441) | € 349,391 | € (554) | € 471,050 | € 4,696,604 | |
Translation differences | 16,975 | 16,975 | 11,921 | 28,896 | ||||||||
Other comprehensive income | (349) | (349) | (349) | |||||||||
Other comprehensive income / (expense) for the year | 16,626 | 16,975 | (349) | 11,921 | 28,547 | |||||||
Profit/(loss) for the year | 625,146 | 625,146 | 23,498 | 648,644 | ||||||||
Total comprehensive income for the year | 641,772 | 625,146 | 16,975 | (349) | 35,419 | 677,191 | ||||||
Net change in treasury stock (note 16 (d)) | 5,857 | 5,857 | 5,857 | |||||||||
Acquisition / Divestment of non-controlling interests (note 16 (c)) | 198,967 | 220,976 | (22,009) | 1,517,180 | 1,716,147 | |||||||
Other changes | (11,291) | (11,291) | (11,291) | |||||||||
Interim dividend | (136,828) | (136,828) | (136,828) | |||||||||
Distribution of prior year profit, Reserves | 459,895 | (459,895) | ||||||||||
Distribution of prior year profit, Dividends | (101,912) | (101,912) | (101,912) | |||||||||
Distribution of prior year profit, Interim dividend | (136,747) | 136,747 | ||||||||||
Operations with shareholders or owners | (45,207) | 567,668 | (596,642) | (81) | 5,857 | (22,009) | 1,517,180 | 1,471,973 | ||||
Balance at end of the year at Dec. 31, 2019 | 4,822,119 | 119,604 | 910,728 | 3,009,599 | 625,146 | (136,828) | (49,584) | 344,357 | (903) | 2,023,649 | 6,845,768 | |
Translation differences | (616,886) | (616,886) | (108,419) | (725,305) | ||||||||
Other comprehensive income | (252) | (252) | (252) | |||||||||
Other comprehensive income / (expense) for the year | (617,138) | (616,886) | (252) | (108,419) | (725,557) | |||||||
Profit/(loss) for the year | 618,546 | 618,546 | 90,444 | 708,990 | ||||||||
Total comprehensive income for the year | 1,408 | 618,546 | (616,886) | (252) | (17,975) | (16,567) | ||||||
Net change in treasury stock (note 16 (d)) | 5,850 | 5,850 | 5,850 | |||||||||
Acquisition / Divestment of non-controlling interests (note 16 (c)) | 405,698 | 405,698 | (405,698) | |||||||||
Other changes | (13,453) | (13,453) | 11,687 | (1,766) | ||||||||
Distribution of prior year profit, Reserves | 488,318 | (488,318) | ||||||||||
Distribution of prior year profit, Dividends | (113,230) | (113,230) | (113,230) | |||||||||
Distribution of prior year profit, Interim dividend | (136,828) | 136,828 | ||||||||||
Operations with shareholders or owners | 284,865 | 767,333 | (625,146) | € 136,828 | 5,850 | (394,011) | (109,146) | |||||
Balance at end of the year at Dec. 31, 2020 | 5,108,392 | 119,604 | 910,728 | 3,776,932 | 618,546 | (43,734) | (272,529) | (1,155) | 1,611,663 | 6,720,055 | ||
Translation differences | 605,620 | 605,620 | 110,124 | 715,744 | ||||||||
Cash flow hedges | 3,130 | € 3,130 | 3,130 | |||||||||
Other comprehensive income | 286 | 286 | 286 | |||||||||
Other comprehensive income / (expense) for the year | 609,036 | 605,620 | 286 | 3,130 | 110,124 | 719,160 | ||||||
Profit/(loss) for the year | 188,726 | 188,726 | 76,601 | 265,327 | ||||||||
Total comprehensive income for the year | 797,762 | 188,726 | 605,620 | 286 | 3,130 | 186,725 | 984,487 | |||||
Net change in treasury stock (note 16 (d)) | (120,455) | (120,455) | (120,455) | |||||||||
Acquisition / Divestment of non-controlling interests (note 16 (c)) | (1,611) | (1,611) | 1,522 | (89) | ||||||||
Other changes | (8,036) | (8,036) | 82 | (7,954) | ||||||||
Distribution of prior year profit, Reserves | 618,546 | (618,546) | ||||||||||
Distribution of prior year profit, Dividends | (252,443) | (252,443) | (6,503) | (258,946) | ||||||||
Operations with shareholders or owners | (382,545) | 356,456 | (618,546) | (120,455) | (4,899) | (387,444) | ||||||
Balance at end of the year at Dec. 31, 2021 | € 5,523,609 | € 119,604 | € 910,728 | € 4,133,388 | € 188,726 | € (164,189) | € 333,091 | € (869) | € 3,130 | € 1,793,489 | € 7,317,098 |
Nature, Principal Activities an
Nature, Principal Activities and Subsidiaries | 12 Months Ended |
Dec. 31, 2021 | |
Nature, Principal Activities and Subsidiaries | |
Nature, Principal Activities and Subsidiaries | (1) Nature, Principal Activities and Subsidiaries Grifols, S.A. (hereinafter the Company) was incorporated with limited liability under Spanish law on 22 June 1987. Its registered and tax offices are in Jesús i Maria, 6, 08022, Barcelona. The Company’s statutory activity consists of providing corporate and business administrative, management and control services, as well as investing in assets and property. Its principal activity involves rendering administrative, management and control services to its subsidiaries. On 17 May 2006 the Company completed its flotation on the Spanish securities market, which was conducted through the public offering of 71,000,000 ordinary shares of Euros 0.50 par value each and a share premium of Euros 3.90 per share. The total capital increase (including the share premium) amounted to Euros 312.4 million, equivalent to a price of Euros 4.40 per share. The Company’s shares were floated on the Spanish stock exchange IBEX-35 index on 2 January 2008. All of the Company’s shares are listed on the Barcelona, Madrid, Valencia and Bilbao securities markets and on the Spanish Automated Quotation System (SIBE/Continuous Market). On 2 June 2011, Class B non-voting shares (ADRs) were listed on the NASDAQ (USA) and on the Spanish Automated Quotation System (SIBE/Continuous Market). Grifols, S.A. is the Parent of the subsidiaries listed in Appendix I of this note to the consolidated financial statements. Grifols, S.A. and subsidiaries (hereinafter the Group) act on an integrated basis and under common management and their principal activity is the procurement, manufacture, preparation and sale of therapeutic products, especially hemoderivatives. The main factory locations of the Group’s Spanish companies are in Parets del Vallés (Barcelona) and Torres de Cotilla (Murcia), while the US companies are located in Los Angeles (California), Clayton (North Carolina), Emeryville (California), and San Diego (California). |
Basis of Presentation
Basis of Presentation | 12 Months Ended |
Dec. 31, 2021 | |
Basis of Presentation | |
Basis of Presentation | (2) Basis of Presentation The consolidated financial statements have been prepared on the basis of the accounting records of Grifols, S.A. and of the Group companies. The consolidated financial statements for 2021 have been prepared under International Financial Reporting Standards as issued by the International Accounting Standard Board (IFRS-IASB) which for Grifols Group purposes, are identical to the standards as endorsed by the International Financial Reporting Standards as adopted by the European Union (IFRS-EU) to present fairly the consolidated equity and consolidated financial position of Grifols, S.A. and subsidiaries at 31 December 2021, as well as the consolidated results from their operations, consolidated cash flows and consolidated changes in equity for the year then ended. These consolidated financial statements were authorized for issue by the Board of Directors on 28 April 2022 and will be submitted for approval by the shareholders at their General Meeting. These consolidated financial statements for 2021 show comparative figures for 2020 and voluntarily show figures for 2019 from the consolidated statement of profit and loss, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows and their corresponding notes thereto. For the purposes of comparing the consolidated statement of profit and loss for 2021, 2020 and 2019 and the consolidated balance sheet for 2021 and 2020, the effects of the application new standards described in note 2 must be taken into account. The Group adopted IFRS-EU for the first time on 1 January 2004 and has been preparing its financial statements under International Financial Reporting Standards, as adopted by the European Union (IFRS-EU) as required by Spanish capital market regulations governing the presentation of financial statements by companies whose debt or own equity instruments are listed on a regulated market. In accordance with the provision of section 357 of the Irish Companies Act 2014, the Company has irrevocably guaranteed all liabilities of an Irish subsidiary undertaking, Grifols Worldwide Operations Limited (Ireland) (see Appendix I), for the financial year ended 31 December 2021 as referred to in subsection 1(b) of that Act, for the purposes of enabling Grifols Worldwide Operations Limited to claim exemption from the requirement to file their own financial statements in Ireland. (a) Relevant accounting estimates, assumptions and judgments used when applying accounting principles The preparation of the consolidated financial statements in conformity with IFRS-IASB requires management to make judgments, estimates and assumptions that affect the application of Group accounting policies. The following notes include a summary of the relevant accounting estimates and judgments used to apply accounting policies which have the most significant effect on the amounts recognized in the consolidated financial statements. ● Assumptions used to test non-current assets and goodwill for impairment. Relevant cash generating units are tested annually for impairment. These are based on risk-adjusted future cash flows discounted using appropriate interest rates. The key assumptions used are specified in note 7. Assumptions relating to risk-adjusted future cash flows and discount rates are based on business forecasts and are therefore inherently subjective. Future events could cause a change in business forecasts, with a consequent adverse effect on the future results of the Group. To the extent considered a reasonably possible change in key assumptions could result in an impairment of goodwill, a sensitivity analysis has been disclosed to show the effect of changes to these assumptions and the effect of the cash generating unit (CGU) on the recoverable amount. ● Evaluation of the capitalization of development costs (see note 4(h)). The key assumption is related to the estimation of sufficient future economic benefits of the projects. ● The calculation of the income tax expense requires tax legislation interpretations in the jurisdictions where Grifols operates. The decision as to whether the tax authority will accept a given uncertain tax treatment and the expected outcome of outstanding litigation requires significant estimates and judgements. Likewise, Grifols recognizes deferred tax assets, mainly from tax credits and rights to deduct to the extent that it is probable that sufficient taxable income will be available against which temporary differences can be utilized, based on management assumptions regarding amount and payments of future taxable profits (see notes 4(t) and 28). ● Determination of chargebacks made to certain customers in the United States (see note 4 s) No changes have been made to prior year judgments relating to existing uncertainties. The Group is also exposed to interest rate and currency risks. Refer to sensitivity analysis in note 30. (b) Basis of consolidation Appendix I shows details of the percentages of direct or indirect ownership of subsidiaries by the Company at 31 December 2021, 2020 and 2019, as well as the consolidation method used in each case for preparation of the accompanying consolidated financial statements. Subsidiaries in which the Company directly or indirectly owns the majority of equity or voting rights have been fully consolidated. Associates in which the Company owns between 20% and 50% of share capital and over which it has no control but does have significant influence, have been accounted for under the equity method. Although the Group holds 49% of the shares with voting rights of Grifols Malaysia Sdn Bhd, it controls the majority of the economic and voting rights of Grifols Malaysia Sdn Bhd through a contract with the other shareholder and a pledge on its shares. As a consequence, it has been fully consolidated. Grifols (Thailand) Ltd. has two classes of shares and it grants the majority of voting rights to the class of shares held by the Group. As a consequence, it has been fully consolidated. Changes in associates and jointly controlled entities are detailed in note 11. Changes in subsidiaries In 2021: ● Grifols Pyrenees Research Center, SL Grifols, through its wholly-owned subsidiary Grifols Innovation and New Technologies Limited (“GIANT”), owns 80% of the company Grifols Pyrenees Research Center, SL, which has been created to develop and manage a new research center specializing in immunology, which will enhance the knowledge of the human immune system and develop new immunological therapies. The contribution made by the Group amounts to Euros 2 thousand. The remaining 20% belongs to the Government of Andorra, through its economic promotion office Andorra Desenvolupament i Inversió. ● Gigagen, Inc. On 8 March 2021, Grifols, through its wholly owned subsidiary Grifols Innovation and New Technologies Limited (“GIANT”), reached an agreement to acquire all of the shares of Gigagen, Inc. for a total consideration of US Dollars 90.5 million. With the acquisition of 100% of the shareholding, Grifols obtained control over Gigagen and, therefore, it is considered a group company and to be consolidated under the full integration method. Until that date, the previous shareholding of 43.96% was accounted for by the equity method. The difference between the fair value of the previous shareholding and the value recognized in books is Euros 34,525 thousand (US Dollars 41,758 thousand), recognizing a gain for this amount “Profit/Loss of equity accounted investees” in the income statement (see note 3). ● Prometic Plasma Resources, Inc. On 31December 2021, Grifols, through its wholly owned subsidiary Grifols Canada Therapeutics Inc., reached an agreement to acquire all of the shares of Prometic Plasma Resources Inc. for a total consideration of US Dollars 8,805 thousand (see note 3). ● Grifols Escrow Issuer, S.A. On August 26, 2021, Grifols, S.A. acquired all of the shares of Grifols Escrow Issuer, S.A. for a total consideration of US Dollars 60 thousand. ● Araclon Biotech, SL On October 2021 Araclon Biotech, S.L carried out a share capital increases of Euros 10 million. After the latter capital increase Grifols’ interest rises to 75.85%. The following companies have been incorporated during 2021 and have been included in the consolidated Grifols Group. ● Grifols Middle East&Africa, LLC ● Grifols Bio North America, LLC ● Biomat Holdco, LLC ● Biomat Newco, Corp In 2020: ● Grifols Diagnostic Solutions, Inc. On 30 March 2020, Grifols closed a share exchange agreement with Shanghai RAAS Blood Products Co. Ltd. (hereinafter SRAAS), through which Grifols delivered 90 shares of its US subsidiary Grifols Diagnostic Solutions Inc. (hereinafter GDS) (representing 45% of the economic rights and 40% of the voting rights), and in exchange received 1,766 million SRAAS shares (representing 26.2% of the share capital). Thus, Grifols became the largest shareholder of SRAAS, while maintaining operational, political and economic control of GDS (see note 11). ● Plasmavita Healthcare GmbH On 14 April 2020, Grifols made a contribution of Euros 10 million in cash that was recognized as a shareholder contribution in Plasmavita. The equity shares of 50% has remained unaffected after the contribution. However, in assessing the existence of control due to the new shareholders’ agreement signed on this date, it can be concluded that Grifols has control over Plasmavita and, therefore, it is considered part of the group and it has been fully consolidated (see note 3). ● Alkahest, Inc. On 2 September 2020, the Group reached an agreement with the shareholders of Alkahest Inc. (“Alkahest”) to acquire 57.55% of Alkahest’s shares for a total price of US Dollars 146 million, on a debt free basis (see note 3). ● Green Cross On 20 July 2020, Grifols executed share purchase arrangements with the South Korean-based GC Pharma (Group) (“GC Pharma”) and other investors for the purchase of a plasma fractionation facility and two purification facilities located in the city of Montreal, Canada, (the “Factories”) and 11 plasma collection centers located in the United States (“the “Donation Centers”), for a total price of Euros 387,917 thousands (US Dollars 457,160 thousand), on a debt free basis. Grifols will not require supplementary financing for this transaction. On 1 October 2020, the transaction was closed (see note 3). ● VCN Biosciences, S.L. On 2 December 2020, VCN Biosciences, S.L. carried out a share capital increase of Euros 5 million. Consequently, the Group interest rises from 81.34% to 86.83%. In 2019: ● Interstate Blood Bank On 11 May 2016 Grifols acquired a 49.19% stake in Interstate Blood Bank, Inc. (IBBI), 48.97% of Bio-Blood Components, Inc. (Bio-Blood) and 48.90% of Plasma Biological Services, LLC. (PBS) (“IBBI Group”), a group based in Memphis, USA, for the price of US Dollars 100 million (Euros 88,215 thousand). The Group also entered into a call option on the remaining shares for a price of US Dollars 100 million, having agreed a payment of US Dollars 10 million (Euros 9,007 thousand) for the call option. The purchase price and the call right were paid upon signature of the contract. The principal business activity of IBBI and its affiliates is the collection of plasma for the plasma fractionation industry, with 26 plasma collection centers, 9 blood donation centers and one laboratory In April 2019, the Group exercised the call option and has completed the acquisition of the remaining shares of the IBBI companies (see note 3). ● Progenika Biopharma On 24 July 2019, the Group acquired 33 shares of Progenika Biopharma, S.A for an amount of Euros 4 thousand. As a result, the Group increased its interest from 99.99% to 100%. With this acquisition, the Group has the full control of Progenika Biopharma, S.A and therefore it ceased to have non-controlling interest (see notes 18 and 16 (c)). ● Araclon Biotech, SL On 16 April 2019 and 3 December 2019 Araclon Biotech, S.L carried out two share capital increases of Euros 16.8 million and Euros 5.9 million, respectively. After the latter capital increase Grifols’ interest rises to 75.1% (see notes 18 and 16 (c)). ● Instituto Grifols, S.A. With effect as of 1 January 2019, Instituto Grifols, S.A. and Gri-Cel, S.A. entered into a merger agreement. The surviving company was Instituto Grifols, S.A. (c) Amendments to IFRS in 2021, 2020 and 2019 In accordance with IFRS, the following should be noted in connection with the scope of application of IFRS and the preparation of these consolidated financial statements of the Group. Effective in 2019 Mandatory application for annual periods beginning on or after: Standards IASB effective date EU effective date IFRS 16 Leases (Issued on 13 January 2016) 1 January 2019 1 January 2019 IFRIC 23 Uncertainty over Income Tax Treatments (issued on 7 June 2017) 1 January 2019 1 January 2019 IFRS 9 Prepayment Features with Negative Compensation (issued on 12 October 2017) 1 January 2019 1 January 2019 IAS 28 Long-term interests in Associates and Joint Ventures (issued on 12 October 2017) 1 January 2019 1 January 2019 Various Annual Improvements to IFRS Standards 2015-2017 Cycle (issued on 12 December 2017) 1 January 2019 1 January 2019 IAS 19 Plan Amendment, Curtailment or Settlement (issued on 7 February 2018) 1 January 2019 1 January 2019 The application of these standards and interpretations has not had any significant impact on the consolidated financial statements, except for IFRS 16 “Leases”, as follows: IFRS 16 “Leases” IFRS 16 brings in a single model for lease accounting by lessees in the statement of financial position. A lessee recognizes a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are optional exemptions for short-term leases and leases of low value items. Lessor accounting remains similar to the current standard. Lessors continue to classify leases as finance or operating leases. IFRS 16 replaces existing guidance on leases, including IAS 17 Leases, IFRIC 4 Determining whether an arrangement contains a lease, SIC-15 Operating leases-Incentives and SIC-27 Evaluating the substance of transactions involving the legal form of a lease. The Group adopted IFRS 16 for the first time on 1 January 2019 but did not restated comparative figures for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules were therefore recognized in the opening balance sheet at 1 January 2019. On 1 January 2019 there was no impact on equity due to the first-time application of IFRS 16. The main policies, estimates and criteria for the application of IFRS 16 are as follows: ● Scope: IFRS 16 evaluation considers all the contracts in which the Group acts as lessee, except for contracts between the Group companies and the cancelable contracts. ● Transition approach: The Group opted to implement IFRS 16 using the modified retrospective approach, whereby the right-of-use asset was measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognized in the consolidated statement of financial position immediately before the date of initial application. When applying this modified retrospective approach, the Group did not re-express the comparative information. ● Discount rates: under IFRS 16, a lessee discounts the future lease payments using the interest rate implicit in the lease if that rate can be readily determined. Otherwise, the lessee uses the incremental borrowing rate. The Group uses the incremental borrowing rate. This is the rate that a lessee would have to pay at the commencement date of the lease for a loan over a similar term, and with similar security, to obtain an asset of a similar value to the right–of-use asset. At 31 December 2021, an incremental effective interest rate has been applied and varies from 2.12% to 8.37% depending on the geographical area and the term of the lease agreement at the transition date (1.55% to 7.21% at 31 December 2020). ● The lease term is the non-cancellable period considering the initial term of each contract unless Grifols has a unilateral extension or termination option and there is reasonable certainty that this option will be exercised, in which case the corresponding extension term or early termination will be taken into account. The Group leases several buildings, equipment and vehicles. Leases agreements are usually made for fixed periods, as shown below: Average lease term Buildings and warehouses 10 to 15 years Donor centers 13 to 15 years PCs and hardware 3 to 5 years Machinery 4 to 5 years Vehicles 3 to 5 years The lease terms of the agreements are negotiated on an individual basis and contain a wide range of terms and conditions. The Group’s activities as a lessor are immaterial, and therefore the application of IFRS 16 did not have a significant impact on the consolidated financial statements. IFRIC 23 - “Uncertainty in the treatment of income taxes” IFRIC 23 “Uncertainty in the treatment of income taxes” clarifies how to apply the recognition and measurement requirements of IAS 12 “Income taxes” when there is uncertainty as to the treatment of income taxes. In this situation, an entity reflects the effect of uncertainty when determining taxable earnings, tax bases, unused tax losses, unused tax credits and tax rates. Grifols did not identify significant uncertain tax lawsuits, and consequently the application of the criteria contained in the mentioned interpretation did not have a significant impact on Grifols for fiscal year 2019 nor in the following. This evaluation consisted of a review of the criteria applied to estimate income tax and the tax loss carryforwards and deductions to be offset, and it was determined that these comply substantially with the current tax regulations where Grifols operates. In this evaluation, it was considered that the deferred tax assets, mainly for tax credits for tax losses carryforwards and deductions to be offset, is the main line item that includes assumptions and uncertainties to estimate their recognition (see note 28(b)). The recognition and/or recoverability of such assets is based on the ability to generate future taxable profits. In this analysis, the following assumptions are considered: ● Future taxable income based on the economic plans and budgets approved for the various Grifols Group companies, ● Tax regulation of the different countries in which they operate, ● Scheduled calendar for reversal of deferred tax liabilities. In this regard, the Group estimated that of the total amount of tax credits for tax losses recognized in the balance sheet as of December 31, 2019 amounting Euros 60.7 million, about Euros 48 million will be recovered in a period of less than 5 years. In relation to the unused deductions, mainly for R&D and donations to non-profit entities, practically the entire amount will be applied in seven years. Finally, a scenario of discrepancies with the taxation authorities that imply the need to make significant adjustments to the tax result or the balances of assets and/or liabilities related to the income tax was considered unlikely based on our experience of the different tax inspections carried out in the different jurisdictions where Grifols operates. As mentioned in note 28, Grifols assesses uncertain tax treatments and recognizes the effect of the uncertainty on taxable profit or loss. At December 31, 2021, Grifols has adequately hedged potential tax claim liabilities with no individually significant uncertain tax treatments. Effective in 2020 Mandatory application for annual periods Standards EU effective date IASB effective date IAS 1 Definition of Material (issued on 31 October 2018) 1 January 2020 1 January 2020 Various Amendments to references to the Conceptual Framework in IFRS Standards (issued on 29 March 2018) 1 January 2020 1 January 2020 IFRS 3 Amendment to IFRS 3 Business Combination (issued on 22 October 2018) 1 January 2020 1 January 2020 IFRS 9 IAS 39 Interest rate Benchmark Reform (issued on 26 September 2019) 1 January 2020 1 January 2020 IFRS 7 IFRS 16 As a consequence of the Covid 19 - Related Rent concessions (issued on 28 May 2020) 1 June 2020 1 June 2020 Effective in 2021 The following standards published by the IASB and the IFRS Interpretations Committee and adopted by the European Union for application in Europe came into force in 2021 and, therefore, have been taken into account in the preparation of these consolidated financial statements: Mandatory application for annual periods Standards EU effective date IASB effective date IFRS 4 Amendments to IFRS 4 Insurance Contracts – deferral of IFRS 9 (issued on 25 June 2020) 1 January 2021 1 January 2021 Various Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2 (issued on 27 August 2020) 1 January 2021 1 January 2021 IFRS 16 Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions beyond 30 June 2021 (issued on 31 March 2021) 1 April 2021 1 April 2021 The application of these standards and interpretations has had no significant impact on these consolidated financial statements. Standards issued but not effective in 2021 At the date these consolidated financial statements were authorized for issue, the following IFRS, amendments and IFRIC interpretations have been published by the European Union but their application is not mandatory until the future periods indicated below: Mandatory application for annual periods Standards EU effective date IASB effective date IFRS 17 Insurance Contracts (issued on 18 May 2017); including 1 January 2023 1 January 2023 IFRS 17 Amendments to IFRS 17 Isurance contracts: Initial Application of IFRS 17 and IFRS 9 - Comparative Information (issued on 9 December 2021) Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current and pending pending IAS 1 Classification of Liabilities as Current or Non-current - Deferral of Effective Date (issued on 23 January 2020 and 15 July 2020 respectively). pending 1 January 2023 IAS 1 Amendments issued 12 February 2021 to:• IAS 1 Presentation of Financial Statements ;• IFRS Practice Statement 2: Disclosure of Accounting policies 1 January 2023 1 January 2023 IAS 8 Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estitmates (issued on 12 February 2021) 1 January 2023 1 January 2023 IAS 12 Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (issued on 7 May 2021) pending 1 January 2023 Various Amendments issued 14 May 2020 to:• IFRS 3 Business Combinations: references to the Conceptual Framework;• IAS 16 Property, Plant and Equipment: Proceeds before Intended Use; • IAS 37 Provisions, Contingent Liabilities and Contingent Assets: Onerous Contracts — Cost of Fulfilling a Contract ; and• Annual Improvements to IFRSs 2018-2020: IFRS 1, IFRS 9, 1 January 2022 1 January 2022 The Group has not applied any of these standards or interpretations in advance of their effective date. The application of these standards and interpretations has had no significant impact on these consolidated financial statements. |
Business Combinations
Business Combinations | 12 Months Ended |
Dec. 31, 2021 | |
Business combinations | |
Business combinations | (3) Business Combinations 2021 ● Gigagen, Inc. On 8 March 2021, Grifols, through its wholly owned subsidiary Grifols Innovation and New Technologies Limited (“GIANT”), reached an agreement to acquire all of the shares of Gigagen, Inc. for a total consideration of US Dollars 90.5 million. GigaGen is a U.S. biotechnology company specializing in the discovery and early development of recombinant biotherapeutic drugs. GigaGen’s research focuses on the discovery of new biological treatments based on antibodies derived from millions of donor-derived immune system cells. With the acquisition of 100% of the shareholding, Grifols obtains control over Gigagen and, therefore, it is considered a group company and is consolidated under the full consolidation method. Until that date, the previous shareholding of 43.96% was accounted for using the equity method. The difference between the fair value of the previous shareholding and the value recognized in books is Euros 34,525 thousand (US Dollars 41,758 thousand), recognizing a profit for this amount under “Profit/(loss) of equity accounted investees “ in the income statement. From the total amount agreed, as of 31 December 2021, an amount of Euros 38,201 thousand has been paid in cash and Euros 36,591 thousand are payable. This amount is presented under “Current financial liabilities” in the balance sheet and matures in March 2022. The Group has recognized an amount of Euros 404 thousand of transaction costs under operating expenses in the consolidated income statement. Aggregate details of the cost of the business combination, the fair value of the net assets acquired and the goodwill at the acquisition date are shown below: Thousandss of Thousandss of Euros US Dollars Consideration paid First repurchase of non-controlling interests 38,201 46,203 Second repurchase of non-controlling interests (discounted amount) 35,227 42,608 Total consideration paid 73,428 88,811 Fair value of the previous investment in the company 50,792 61,434 Fair value of net assets acquired 18,760 22,691 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 105,460 127,554 The amounts determined at the acquisition date of the assets, liabilities and contingent liabilities acquired are as follows: Fair value Thousandss of Thousands of Euros US Dollars Development costs in progress (note 8) 24,027 29,061 Property, plant and equipment (note 8) 1,168 1,413 Non-current financial assets 151 183 Trade and other receivables 56 68 Other current assets 2,368 2,864 Cash and cash equivalents 12,389 14,985 Total assets 40,159 48,574 Non current liabilities (17,792) (21,520) Current liabilities (3,607) (4,363) Total liabilities and contingent liabilities (21,399) (25,883) Total net assets identified 18,760 22,691 The fair value of the R&D projects in progress has been estimated based on market approach of comparable transactions. The resulting goodwill was allocated to the others segment and includes the specialized R&D workforce and the portfolio of future early stage products. The acquired business has generated consolidated results for the Group during the period from the acquisition date to year-end in the amount of Euros 4,350 thousand. If the acquisition had occurred as of 1 January 2021, the Group’s net revenues and results would not have changed significantly. ● BPL Plasma, Inc. On 28 February 2021, Biomat USA, Inc. the Group’s American subsidiary, acquired 25 plasma donation centers in the United States from BPL Plasma, Inc. a subsidiary of Bio Products Laboratory Holdings Limited, for US Dollars 385 million. The transaction has received the necessary regulatory approvals and has been financed with its own resources, without issuing debt. Grifols will obtain approximately one million liters of plasma per year from these centers. The Group has recognized transaction costs of Euros 2,764 thousand in operating expenses in the consolidated income statement. Aggregate details of the cost of the business combination, the provisional definitive fair value of the net assets acquired and the provisional definitive goodwill at the acquisition date are shown below: Thousands of Euros Thousands of US Dollars Consideration paid First payment performed 9,921 12,000 Cash paid at the transaction closing date 308,016 372,548 Total consideration paid 317,937 384,548 Fair value of net assets acquired 15,039 18,190 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 302,898 366,358 The amounts determined at the acquisition date of the assets, liabilities and contingent liabilities acquired are as follows: Fair value Thousands of Euros Thousands of US Dollars Property, plant and equipment (note 10) 14,406 17,424 Non-current financial assets 85 103 Inventories 557 674 Total assets 15,048 18,201 Current liabilities (9) (11) Total liabilities and contingent liabilities (9) (11) Total net assets identified 15,039 18,190 The resulting goodwill has been allocated to the Bioscience segment and includes the donor database, licenses and workforce. ● Acquisition of plasma centers from Kedplasma, LLC. On 31 March 2021, Biomat USA, Inc., the Group’s American subsidiary, acquired 7 plasma donation centers in the United States from the company Kedplasma, LLC for US Dollars 55.2 million. All the centers acquired are licensed by the U.S. Food and Drug Administration (FDA) and the European authorities. Grifols will have immediate access to the plasma obtained at these centers, which obtain approximately 240,000 liters of plasma per year. The transaction has received the necessary regulatory approvals and has been financed with equity without issuing debt. The Group has recognized transaction costs of Euros 625 thousand in operating expenses in the consolidated income statement. Aggregate details of the cost of the business combination, the definitive fair value of the net assets acquired and the definitive goodwill at the acquisition date are shown below: Thousands of Euros Thousands of US Dollars Consideration paid Cash paid 45,638 55,200 Total consideration paid 45,638 55,200 Fair value of net assets acquired 2,692 3,256 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 42,946 51,944 The amounts determined at the acquisition date of the assets, liabilities and contingent liabilities acquired are as follows: Fair value Thousands of Euros Thousands of US Dollars Property, plant and equipment (note 10) 2,448 2,961 Inventories 244 295 Total assets 2,692 3,256 Total net assets identified 2,692 3,256 The resulting goodwill has been allocated to the Bioscience segment and includes the donor database, licenses and workforce. ● Prometic Plasma Resources, Inc. On 31 December 2021, Grifols, through its wholly owned subsidiary Grifols Canada Therapeutics Inc., acquired all of the shares of Prometic Plasma Resources Inc. for a total consideration of US Dollars 8,805 thousand (see note 2). The purchase price has been assigned provisionally to Goodwill in the consolidated balance sheet, considering that the initial accounting has not been completed at the end of the reporting period. 2020 (a) In November 2017, Grifols established Plasmavita Healthcare GmbH (hereinafter Plasmavita), a joint venture between Grifols (50%) and two other partners (50%) for the construction and operation of 10 plasma donor centers in Germany. On 14 April 2020, Grifols made a contribution of Euros 10 million in cash that was recognized as a shareholder contribution in Plasmavita. The equity share of 50% has remained unchanged after the contribution. However, in assessing the existence of control due to new shareholder agreement signed on this date, the following was concluded: - Grifols has a casting vote for any decision, determination and approval, with respect to the annual budget of Plasmavita and the distribution of dividends. Grifols has the power to make key business decisions. - Grifols is involved in the decision-making related to exposure or rights to variable returns from the investee. - Grifols has the casting vote to distribute dividends. Considering the above, it was concluded that Grifols has control over Plasmavita and, therefore, it is considered part of the group and it has been fully consolidated. Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at the acquisition date are provided below: Thousands of Euros Consideration paid Cash paid 10,000 Total consideration paid 10,000 Fair value of the previous investment in the company 10,674 Fair value of net assets acquired 21,374 Minority interest (10,687) Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 9,987 The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as follows: Fair Value Thousand of Euros Intangible assets (note 8) 177 Rights of use (note 9) 7,856 Property, plant and equipment (note 10) 6,506 Investment in group companies 9,548 Non-current financial assets 5,017 Inventories 1,114 Trade and other receivables 811 Other current assets 333 Cash and cash equivalents 359 Total assets 31,721 Deferred tax liabilities (1,364) Other non current liabilites (7,575) Current liabilities (1,408) Total liabilities and contingent liabilities (10,347) Total net assets acquired 21,374 The resulting goodwill has been allocated to the Bioscience segment, and it includes the donor data base, licenses and workforce If the acquisition had taken place on 1 January 2020, the net amount of the Group´s revenue and profit would not have differed significantly. The revenue and consolidated profit generated by Plasmavita between the acquisition date and 31 December 2020 are not significant for the Group. The difference between the fair value of the previous investment and the book value amounted to Euros 5,357 thousand and has been recognized as income under “Profit/(loss) of equity accounted investees with similar activity to that of the Group” in the consolidated statement of profit and loss. The minority interest’s share of the contribution made amounts to Euros 5 million and has been recognized as a loss under the same line item. (b) On 2 September 2020, Grifols signed an agreement to acquire all the shares of Alkahest Inc. (“Alkahest”) for a total amount of Euros 123,425 thousand (US Dollars 146,000 thousand), which was subject to approval by regulatory authorities. As part of the agreement, the Group had: ● Grifols has a casting vote for any decision, determination and approval, with respect to the annual budget of Alkahest and the distribution of dividends. Grifols has the power to decide on key business decisions. ● Grifols is involved in the decision-making related to exposure or rights to variable returns from the investee. Considering the above, it was concluded that Grifols has control over Alkahest and, therefore, it is considered part of the group and it has been fully consolidated. Until that date, the previous 42.45% stake in Alkahest was recorded using the equity method. The difference between the fair value of the previous investment and the book value amounted to Euros 86,743 thousand (US Dollars 102,552 thousand) and has been recognized as income under “Profit/(loss) of equity accounted investees” in the consolidated statement of profit and loss. On 15 October 2020, and as a result of the aforementioned share purchase agreement, Grifols proceeded to acquire 57.55% of the capital of Alkahest. After the transaction, the Group owns 100% of the company’s share capital. Given that Grifols already had control of Alkahest, the transaction has been recorded as an agreement with the non-controlling interest, which has meant the recognition of a liability at amortized cost of Euros 121,149 thousand (US Dollars 143,706 thousand) and a decrease in “Non-controlling interests” in the amount of Euros 121,486 thousand (US Dollars 143,307 thousand), net of recorded losses and “Other reserves “in the amount of Euros 337 thousand (US Dollars 399 thousand). At 31 December 2020, the amount payable totaled Euros 100,492 thousand and was presented under the line item “Current financial liabilities”. This amount has been settled on 1 February 2021(see note 21). Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at the acquisition date are provided below: Thousand of US Thousand of Euros Dollars Cost of the business combination First repurchase of non-controlling interests 18,797 22,235 Second repurchase of non-controlling interests (discounted amount) 104,628 123,765 Total business combination cost 123,425 146,000 Fair value of the previous investment in the company 91,023 107,671 Fair value of net assets acquired 140,076 165,696 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) 74,372 87,975 The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as follows: Fair Value Thousand of Thousand of Euros US Dollars Other Intangible Assets (note 8) 265,617 314,198 Property, plant and equipement (note 10) 4,970 5,879 Other non current assets 178 210 Trade and other reeceivables 2,552 3,019 Other current assets 1,610 1,904 Cash and cash equivalents 7,563 8,946 Total assets 282,489 334,156 Non-current financial liabilities (42,269) (50,000) Deferred tax liability (74,372) (87,975) Other non-current liabilities (19,644) (23,237) Trade and other payables (1,863) (2,204) Other current liabilities (4,264) (5,044) Total Liabilities (142,413) (168,460) Fair value of net assets acquired 140,076 165,696 The resulting goodwill has been allocated to the Others segment and it mainly includes the workforce. The fair value of research and clinical development projects in progress that include products for neurodegenerative disorders, neuromuscular and ophthalmologic diseases have been estimated according to an income approach based on risk-adjusted discounted free cash flows. Had the acquisition taken place on 1 January 2020, the net amount of the Group´s revenue would not have changed significantly, and the net profit would have decreased by Euros 30,045 thousand. The profit of Alkahest between the acquisition date and 31 December 2020 amounted to Euros (12,317) thousand. The amount of net revenue has not changed significantly. (c) Green Cross On 20 July 2020, Grifols signed share purchase arrangements with the South Korean based GC Pharma Group and other investors for the acquisition of a plasma fractionation facility and two purification facilities located in the city of Montreal, Canada, and 11 plasma collection centers located in the United States, for a total consideration of Euros 387,917 thousand (US Dollars 457,160 thousand), on a debt free basis. On 1 October 2020, the transaction was closed. The consideration was paid with Grifols’ own cash resources, and at the close of the Transaction certain equity, working capital and cash targets were guaranteed. The factories are currently in the process of obtaining the required licenses and regulatory approvals from the competent health authorities for the manufacturing of plasma-derived products. When licensed and approved, Grifols will become the only commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 M liters. Grifols plans to be ready to manufacture IVIG and Albumin at the factories to be able to supply the Canadian market starting in 2023. The collection centers achieved a collection volume of 350,000 liters of plasma in 2019. Upon the consummation of the Transaction, and by means of a plasma supply agreement, the Group has also committed to supplying certain output of plasma arising out of the collection centers to GC Pharma for a 24-month period. Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at the acquisition date are provided below: Thousands of US Thousands of Euros Dollars Consideration paid Cash paid 387,917 457,160 Total consideration paid 387,917 457,160 Fair value of net assets acquired 194,227 228,897 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) 193,690 228,263 The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as follows: Fair Value Thousand of Euros Thousand of US Dollars Other Intangible Assets 2,877 3,390 Rights of Use 11,642 13,720 Property, plant and equipement 158,148 186,377 Deferred tax assets 33,081 38,986 Other non current assets 122 144 Inventories 2,999 3,534 Trade and other reeceivables 3,484 4,106 Other current assets 943 1,111 Cash and cash equivalents 6,053 7,133 Total assets 219,349 258,501 Non-current financial liabilities (13,150) (15,497) Current financial liabilities (797) (939) Trade and other payables (11,175) (13,168) Total Liabilities (25,122) (29,604) Fair value of net assets acquired 194,227 228,897 The resulting goodwill was allocated to the Bioscience segment, and it includes the donor data base, current licenses and future authorizations and workforce Had the acquisition taken place on 1 January 2020, the net amount of the Group´s revenue would have increased by Euros 31,197 thousand and the net profit would have decreased by Euros 32,423 thousand. The revenue and profit of Green Cross between the acquisition date and 31 December 2020 amounted to Euros 4,625 thousand and Euros (5,023) thousand respectively. 2019 (a) Acquisition of assets used in plasma donor centers On 31 May 2019 the Group, through its subsidiary Haema AG, acquired four plasma donor centers from Kedplasma, GmbH. The agreed purchase price was Euros 20,500 thousand. Aggregate details of the combination cost, fair value of the net assets acquired and goodwill at the acquisition date are as follows: Thousands of Euros Cost of the business combination Payment in cash 20,500 Total business combination cost 20,500 Fair value of net assets acquired 1,620 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 18,880 The resulting goodwill was allocated to the Bioscience segment and it included the donor data base, FDA licenses and workforce. The fair value of net assets acquired mainly included property, plant and equipment amounting to Euros 1,396 thousand. (b) Acquisition of Interstated Blood Bank, Inc. Group On 11 May 2016 Grifols acquired a 49.19% stake in Interstate Blood Bank, Inc. (IBBI), 48.97% of Bio-Blood Components, Inc. (Bio-Blood) and 48.90% of Plasma Biological Services, LLC. (PBS) (“IBBI Group”), with headquarters in Memphis, USA, for the price of US Dollars 100 million (Euros 88,215 thousand). The Group also entered into a call option on the remaining shares for a price of US Dollars 100 million, having agreed a payment of US Dollars 10 million (Euros 9,007 thousand) for the call option. The purchase price and the call right were paid upon signature of the contract. The principal business activity of IBBI and its affiliates is the collection of plasma for the plasma fractionation industry, with 26 plasma collection centers, 9 blood donation centers and one laboratory. In April 2019, the Group exercised the call option and has completed the acquisition of the remaining shares of the IBBI group companies. Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at the acquisition date are provided below: Thousands of Euros Thousands of US Dollars Consideration paid Cash paid 88,984 100,000 Total consideration paid 88,984 100,000 Fair value of the previous investment in the company 94,126 105,779 Fair value of the call option 8,898 10,000 Fair value of net assets acquired 19,345 21,744 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 172,663 194,035 The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as follows: Fair value Thousands of Euros Thousands of US Dollars Intangible assets (note 8) 77 87 Property, plant and equipment (note 10) 23,724 26,661 Inventories 10,271 11,543 Trade and other receivables 12,080 13,575 Other current assets 2,015 2,265 Cash and cash equivalents 1,961 2,204 Total assets 50,128 56,335 Non-current liabilities (10,233) (11,500) Current liabilities (20,550) (23,091) Total liabilities and contingent liabilities (30,783) (34,591) Total net assets acquired 19,345 21,744 The resulting goodwill was allocated to the Bioscience segment. The difference between the fair value of the previous investment and the book value amounts to Euros 4,521 thousand and was recognized as an income in section “Share of income/(losses) of equity accounted investees with group’s similar activity” in the consolidated statement of profit or loss. Had the acquisition taken place on 1 January 2019, the net amount of the Group´s revenue would have increased by Euros 10,146 thousand and profit would have decreased by Euros 1,436 thousand. IBBI’s net revenue and profit between the acquisition date and 31 December 2019 amounted to Euros 13,364 thousand and Euros 280 thousand, respectively. |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies | |
Significant Accounting Policies | (4) Significant Accounting Policies (a) Subsidiaries and associates Subsidiaries are entities, including special purpose entities (SPE), over which the Group exercises control, either directly or indirectly, through subsidiaries. The Group controls a subsidiary when it has the substantive rights in force that provide the ability to manage relevant activities. The Group is exposed or has the right to variable returns for its involvement in the subsidiaries when the returns obtained vary depending on the economic performance of the subsidiaries. The income, expenses and cash flows of subsidiaries are included in the consolidated financial statements from the date of acquisition, which is when the Group takes control. Subsidiaries are excluded from the consolidated Group from the date on which control is lost. Transactions and balances with Group companies and unrealized gains or losses have been eliminated upon consolidation. The accounting policies of subsidiaries have been adapted to those of the Group for transactions and other events in similar circumstances. The financial statements of consolidated subsidiaries have been prepared as of the same date and for the same reporting period as the financial statements of the Company. Associates are entities over which the Company, either directly or indirectly through subsidiaries, exercises significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those entities. The existence of potential voting rights that are exercisable or convertible at the end of each reporting period, including potential voting rights held by the Group or other entities, are considered when assessing whether an entity has significant influence. Investments in associates are initially recognized at acquisition cost, including any cost directly attributable to the acquisition and any consideration receivable or payable contingent on future events or on compliance with certain conditions. Subsequently, investments in associates are accounted for using the equity method from the date that significant influence commences until the date that significant influence ceases. The excess of the cost of the investment over the Group’s share of the fair values of the identifiable net assets is recognized as goodwill, which is included in the carrying amount of the investment. Any shortfall, once the cost of the investment and the identification and measurement of the associate’s net assets have been evaluated, is recognized as income when determining the investor’s share of the profit and loss of the associate for the year in which it was acquired. The accounting policies of associates have been harmonized in terms of timing and measurement, applying the policies described for subsidiaries. The Group’s share of the profit and loss of an associate from the date of acquisition is recognized as an increase or decrease in the value of the investments, with a credit or debit to share of the profit and loss for the year of “equity-accounted investees” in the consolidated statement of profit and loss (consolidated statement of comprehensive income). The Group’s share of other comprehensive income of associates from the date of acquisition is recognized as an increase or decrease in the investments in associates with a balancing entry recognized by type in other comprehensive income. The distribution of dividends is recognized as a decrease in the value of the investment. The Group’s share of profit and loss, including impairment losses recognized by the associates, is calculated based on income and expenses arising from application of the acquisition method. When the Group’s share of the losses in an investment accounted for using the equity method equals or exceeds its interest in the entity, the Group does not recognize additional losses, unless it has incurred in obligations or made payments on behalf of the other entity. The Group’s share of the profit and loss of an associate and changes in equity is calculated to the extent of the Group’s interest in the associate at year end and does not reflect the possible exercise or conversion of potential voting rights. However, the Group’s share is calculated taking into account the possible exercise of potential voting rights and other derivative financial instruments which, in substance, currently allow access to the economic benefits associated with the interests held, such as entitlement to a share in future dividends and changes in the value of associates. Information on the subsidiaries and associates included in the consolidated Group is presented in Appendix I. (b) Business combinations On the date of transition to IFRS-IASB, the Group applied the exception permitted under IFRS 1 “First-time adoption of International Financial Reporting Standards”, whereby only those business combinations performed as from 1 January 2004 have been recognized using the acquisition method. Entities acquired prior to that date were recognized in accordance with accounting prevailing at that time, taking into account the necessary corrections and adjustments at the transition date. The Group applies the revised IFRS 3 “Business combinations” in transactions made subsequent to 1 January 2010. The Group applies the acquisition method for business combinations. The acquisition date is the date on which the Group obtains control of the acquiree. The cost of the business combination is calculated as the sum of the acquisition-date fair values of the assets transferred, the liabilities incurred or assumed, equity instruments issued and any additional consideration contingent on future events or the fulfilment of certain conditions, in exchange for control of the acquiree. The consideration paid excludes all amounts that do not form part of the exchange for the acquired business. Acquisition-related costs are accounted for as expenses when incurred. Share increase costs are recognized as equity when the increase takes place and borrowing costs are deducted from the financial liability when it is recognized. At the acquisition date the Group recognizes at fair value the assets acquired and liabilities assumed. Liabilities assumed include any contingent liabilities that represent present obligations arising from past events for which the fair value can be reliably measured. The Group also recognizes indemnification assets transferred by the seller at the same time and following the same measurement criteria as the item that is subject to indemnification from the acquired business, taking into consideration, where applicable, the insolvency risk and any contractual limit on the indemnity amount. This criterion does not include non-current assets or disposal groups of assets which are classified as held for sale, long-term defined benefit employee benefit liabilities, share-based payment transactions, deferred tax assets and liabilities and intangible assets arising from the acquisition of previously transferred rights. Assumed assets and liabilities are classified and designated for subsequent measurement in accordance with the contractual terms, economic conditions, operating or accounting policies and other factors that exist at the acquisition date, except for leases and insurance contracts. The excess between the consideration transferred and the value of net assets acquired and liabilities assumed, less the value assigned to non-controlling interests, is recognized as goodwill. Where applicable, any shortfall, after evaluating the consideration transferred, the value assigned to non-controlling interests and the identification and measurement of net assets acquired, is recognized in profit and loss. When a business combination has been provisionally determined, net identifiable assets have initially been recognized at their provisional value, and any adjustments made during the measurement period have been recorded as if they had been known at that date. Where applicable, comparative figures for the prior year have been restated. Adjustments to the provisional values only reflect information relating to events and circumstances existing at the acquisition date and which, had they been known, would have affected the amounts recognized at that date. Once this period has elapsed, adjustments are only made to initial values when errors must be corrected. Any potential benefits arising from tax losses and other deferred tax assets of the acquiree that have not been recorded as they did not qualify for recognition at the acquisition date, are accounted for as income tax revenue, provided the adjustments were not made during the measurement period. The contingent consideration is classified in accordance with underlying contractual terms as a financial asset or financial liability, equity instrument or provision. Provided that subsequent changes to the fair value of a financial asset or financial liability do not relate to an adjustment of the measurement period, they are recognized in consolidated profit and loss. The contingent consideration classified, where applicable, as equity is not subject to subsequent change, with settlement being recognized in equity. The contingent consideration classified, where applicable, as a provision is recognized subsequently in accordance with the relevant measurement standard. (c) Non-controlling interests Non-controlling interests in subsidiaries acquired after 1 January 2004 are recognized at the acquisition date at the proportional part of the fair value of the identifiable net assets. Non-controlling interests in subsidiaries acquired prior to the transition date were recognized at the proportional part of the equity of the subsidiaries at the date of first consolidation. Non-controlling interests are disclosed in the consolidated balance sheet under equity separately from equity attributable to the Parent. Non-controlling interests’ share in consolidated profit and loss for the year (and in consolidated comprehensive income for the year) is disclosed separately in the consolidated statement of profit and loss (consolidated statement of comprehensive income). The consolidated profit and loss for the year, consolidated comprehensive income and changes in equity of the subsidiaries attributable to the Group and non-controlling interests after consolidation adjustments and eliminations, is determined in accordance with the percentage ownership at year end, without considering the possible exercise or conversion of potential voting rights. However, Group and non-controlling interests are calculated taking into account the possible exercise of potential voting rights and other derivative financial instruments which, in substance, currently allow access to the economic benefits associated with the interests held, such as entitlement to a share in future dividends and changes in the value of subsidiaries. Profit and loss and each component of other comprehensive income are assigned to equity attributable to shareholders of the Parent and to non-controlling interests in proportion to their interest, although this implies a balance receivable from non-controlling interests. Agreements signed between the Group and the non-controlling interests are recognized as a separate transaction. The increase and reduction of non-controlling interests in a subsidiary in which control is retained is recognized as an equity instrument transaction. Consequently, no new acquisition cost arises on increases, nor is a gain recorded on reductions; rather, the difference between the consideration transferred or received and the carrying amount of the non-controlling interests is recognized in the reserves of the investor, without prejudice to reclassifying consolidation reserves and reallocating other comprehensive income between the Group and the non-controlling interests. When a Group’s interest in a subsidiary diminishes, non-controlling interests are recognized at their share of the net consolidated assets, including goodwill. (d) Joint arrangements Joint arrangements are those in which there is a contractual agreement to share the control over an economic activity, in such a way that the decisions over relevant activities require the unanimous consent of the Group and the remaining venturers. Under IFRS 11 “Joint arrangements” investments in joint arrangements are classified as joint operations or joint ventures. The classification depends on the contractual rights and obligations of each investor, rather than on the legal structure of the joint agreement. Interests in joint ventures are accounted for using the equity method, after initially being recognized at cost in the consolidated balance sheet. The acquisition cost of investments in joint arrangements is determined consistently with that established for investments in associates. (e) Foreign currency transactions and balances (i) Functional and presentation currency The consolidated financial statements are presented in thousands of Euros, which is the functional and presentation currency of the Parent. (ii) Foreign currency transactions, balances and cash flows Foreign currency transactions are translated into the functional currency using the previous month’s exchange rate for all transactions performed during the current month. This method does not differ significantly from applying the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies have been translated into thousands of Euros at the closing rate, while non-monetary assets and liabilities measured at historical cost have been translated at the exchange rate prevailing at the transaction date. Non-monetary assets measured at fair value have been translated into thousands of Euros at the exchange rate at the date that the fair value was determined. In the consolidated statement of cash flows, cash flows from foreign currency transactions have been translated into thousands of Euros at the exchange rates prevailing at the dates the cash flows occur. The effect of exchange rate fluctuations on cash and cash equivalents denominated in foreign currencies is recognized separately in the statement of cash flows as “Effect of exchange rate fluctuations on cash and cash equivalents”. Exchange gains and losses arising on the settlement of foreign currency transactions and the translation into thousands of Euros of monetary assets and liabilities denominated in foreign currencies are recognized in profit and loss. (iii) Translation of foreign operations The translation into thousands of Euros of foreign operations for which the functional currency is not the currency of a hyperinflationary economy is based on the following criteria: ● ● ● (f) Borrowing costs In accordance with IAS 23 “Borrowing Costs”, the Group recognizes borrowing costs directly attributable to the purchase, construction or production of qualifying assets as an increase in the value of these assets. Qualifying assets are those which require a substantial period of time before they can be used or sold. To the extent that funds are borrowed specifically for the purpose of obtaining a qualifying asset, the amount of borrowing costs eligible for capitalization is determined as the actual borrowing costs incurred, less any investment income on the temporary investment of those funds. Capitalized borrowing costs corresponding to general borrowing are calculated as the weighted average of the qualifying assets without considering specific funds. The amount of borrowing costs capitalized cannot exceed the amount of borrowing costs incurred during that period. The capitalized borrowing costs include adjustments to the carrying amount of financial liabilities arising from the effective portion of hedges entered into by the Group. The Group begins capitalizing borrowing costs as part of the cost of a qualifying asset when it incurs expenditure for the asset, interest is accrued, and it undertakes activities that are necessary to prepare the asset for its intended use or sale, and ceases capitalizing borrowing costs when all or substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete. Nevertheless, capitalization of borrowing costs is suspended when active development is interrupted for extended periods. The remaining interest costs are recognized as an expense in the year in which they are incurred. (g) Property, plant and equipment (i) Initial recognition Property, plant and equipment are recognized at cost, less accumulated depreciation and any accumulated impairment losses. Land is not subject to depreciation. The cost of self-constructed assets is determined using the same principles as for an acquired asset, while also considering the criteria applicable to production costs of inventories. Capitalized production costs are recognized by allocating the costs attributable to the asset to “Self-constructed non-current assets” in the consolidated statement of profit and loss. (ii) Depreciation Property, plant and equipment are depreciated by allocating the depreciable amount of an asset on a systematic basis over its useful life. The depreciable amount is the cost or deemed cost of an asset, less its residual value. The Group determines the depreciation charge separately for each item for a component of property, plant and equipment with a cost that is significant in relation to the total cost of the asset. Property, plant and equipment are depreciated using the following criteria: Depreciation method Rates Buildings Straight line 1% Other property, technical equipment and machinery Straight line 4% - 10% Other property, plant and equipment Straight line 7% The Group reviews residual values, useful lives and depreciation methods at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates. (iii) Subsequent recognition Subsequent to initial recognition of the asset, only those costs incurred which will probably generate future profits and for which the amount may reliably be measured are capitalized. Costs of day-to-day servicing are recognized in profit and loss as incurred. Replacements of property, plant and equipment which qualify for capitalization are recognized as a reduction in the carrying amount of the items replaced. Where the cost of the replaced items has not been depreciated independently and it is not possible to determine the respective carrying amount, the replacement cost is used as indicative of the cost of items at the time of acquisition or construction. (iv) Impairment The Group tests for impairment and reversals of impairment losses on property, plant and equipment based on the criteria set out in note 4(j) below. (h) Intangible assets (i) Goodwill Goodwill is generated on the business combinations and is calculated using the criteria described in the section on business combinations. Goodwill is not amortized but is tested for impairment annually or more frequently whenever there is an indication that goodwill may be impaired. Goodwill acquired in business combinations is allocated to the cash-generating units (CGUs) or groups of CGUs which are expected to benefit from the synergies of the business combination and the criteria described in note 7 are applied. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Gains and losses on the sale of an entity include the carrying amount of the goodwill related to the entity sold. (ii) Internally generated intangible assets Any research and development expenditure incurred during the research phase of projects is recognized as an expense when incurred. Costs related with development activities are capitalized when: ● The Group has technical studies that demonstrate the feasibility of the production process; ● The Group has undertaken a commitment to complete production of the asset, to make it available for sale or internal use; ● The asset will generate sufficient future economic benefits; ● The Group has sufficient technical and financial resources to complete development of the asset and has devised budget control and cost accounting systems that enable monitoring of budgetary costs, modifications and the expenditure actually attributable to the different projects. The cost of internally generated assets by the Group is calculated using the same criteria established for determining production costs of inventories. The production cost is capitalized by allocating the costs attributable to the asset to self-constructed non-current assets in the consolidated statement of profit and loss. Expenditure on activities that contribute to increasing the value of the different businesses in which the Group as a whole operates is expensed when incurred. Replacements or subsequent costs incurred on intangible assets are generally recognized as an expense, except where they increase the future economic benefits expected to be generated by the assets. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. (iii) Other intangible assets Other intangible assets are carried at cost, or at fair value if they arise on business combinations, less accumulated amortization and impairment losses. Intangible assets with indefinite useful lives are not amortized but tested for impairment at least annually. (iv) Intangible assets acquired in business combinations The cost of identifiable intangible assets acquired in business combinations normally includes the fair value of R&D projects, Intellectual Property Patents, current contracts and products currently being marketed, and are included within “Other intangible assets” and “Development expenses” as appropriate. (v) Useful life and amortization rates The Group assesses whether the useful life of each intangible asset acquired is finite or indefinite. An intangible asset is regarded as having an indefinite useful life when there is no foreseeable limit to the period over which the asset will generate net cash inflows. Intangible assets with finite useful lives are amortized by allocating the depreciable amount of an asset on a systematic basis over its useful life, by applying the following criteria: Amortisation method Rates Development expenses Straight line 10% Concessions, patents, licences, trademarks and similar Straight line 4% Computer software Straight line 33% Currently marketed products Straight line 3% The depreciable amount is the cost or deemed cost of an asset, less its residual value. The Group does not consider the residual value of its intangible assets to be material. The Group reviews the residual value, useful life and amortization method for intangible assets at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates. (i) Leases The Group changed its accounting policies in relation to leases when it is a lessee as a result of adopting IFRS 16. The policy is described in note 2(c) and the impact of the change in notes 2 (c) and 9. (i) Definitions Lease contracts A lease contract is a contract that fulfills the following conditions: ● There is an identified asset explicitly specified in the contract or implicitly specified when it is made available for use by the Group. When the asset is a portion of an asset’s capacity it could also be an identified asset if it is physically distinct (a floor of a building, a storage location in a warehouse) or the Group has the right to receive substantially all its of capacity. ● The lessee has the right to direct the use of the identified asset that means the right to determine how and for what purpose the asset will be used. ● The lessee has the right to obtain all the economic benefits from that use throughout the period of use. Non-lease contracts Even if an asset is specified in the contract, if the lessor has a substantive substitution right throughout the period of use, the asset is not identified and the contract does not contain a lease. When the lessee does not have the right to control the use of the asset, the contract does not contain a lease. Non-lease contracts are not under this policy and the accounting treatment will be that of a service contract (usually recognized as an expense). (ii) Accounting policies Lease contracts, where the Group acts as lessee, is recognized at inception of the contract as: ● A lease liability representing its obligation to make future lease payments and, ● A right of use representing its right to use the identified asset. Exception: lease contracts that fulfill any of the following conditions will be recognized as monthly expense over the lease term: ● For lease contracts where the lease term is 12 months or less at the commencement date. ● For lease contracts where the value of the leased asset (individually), when new, is lower than US Dollars 5,000 or its equivalent in another currency. Lease liability Initial measurement The lease liability corresponds to the present value of the lease payments during the lease term using the interest rate implicit in the lease or, if this cannot be readily determined, the incremental borrowing lending rate, as follows: ● Lease payments Only lease components included in the lease contract are part of the liability calculation: - Fixed payments, less any lease incentives receivable; - Variable lease payments that depend on a known index or a rate; - The exercise price of the purchase option if the lessee is reasonably certain to exercise that option; - Any amount already paid at the contract commencement date must not be included. Non-lease components that could be included in a lease contract (e.g. maintenance services, electricity, water, gas and other services such as surveillance, cleaning, etc.) are not part of the lease liability and must be recognized as an expense as soon as the service is rendered to Grifols using the corresponding account according to its nature. ● Lease term The lease term is the non-cancellable period considering the initial term of each contract unless Grifols has a unilateral option to extend or terminate the lease and there is reasonable certainty that this option will be exercised, in which case the corresponding extension term or early termination will be taken into account. The lease liability is calculated at the present value of the future lease payments during the lease term, using an incremental discount rate, except for those contracts in which the implicit interest rate is used because it is specifically mentioned in the contract. ● Discount rate Under IFRS 16, a lessee shall discount the future lease payments using the lease implicit interest rate if this can be reliably determined. Otherwise, the lessee shall use the incremental borrowing rate. The Group uses the incremental borrowing rate. This is the rate that a lessee would have to pay at the commencement date of the lease for a loan of a similar term, and with a similar security, to obtain an asset of similar value to the right-of-use asset in a similar economic environment. The incremental borrowing rate is determined considering the following criteria: - - - - - Subsequent measurement Subsequently, the lease financial liability will be increased by the interest on the lease liability and reduced by the payments made. The liability will be remeasured if there are changes in the amounts payable and the lease terms. Lease liabilities will: ● Increase the carrying amount to interest on the lease liability; ● Reduce the carrying amount to reflect the lease payments made; and ● Remeasure (increase or reduce) the carrying amount to reflect any reassessment or lease modifications. The balancing entry will be a lease expense for retrospective lease payments or right-of-use-assets for future lease payments. The discount rate to be used depends on the event causing the reassessment or modification. Right-of-use asset (ROU asset) Initial measurement ROU assets are initially measured at cost, which comprises: ● The amount of the initial measurement of the lease liability, ● Any lease payments made to the lessor at or before the commencement date, ● Estimated costs to dismantle or to remove the underlying asset, ● Less any discount or incentive received from the lessor. Subsequent measurement The ROU asset is measured at cost, less any accumulated depreciation and any accumulated impairment losses. Net book value of the ROU asset must be adjusted as for any re-measurement of the lease liability. Depreciation method and useful life Depreciation method: straight-line basis. Depreciation starts at the lease commencement date (when the asset is available for use). Useful life: ● If the purchase option is reasonably certain to be exercised: Useful life of the underlying asset. ● Otherwise: The earlier of the end of the useful life of the right-of-use asset or the end of the lease term. (j) Impairment of goodwill, other intangible assets and other non-financial assets subject to depreciation or amortization The Group evaluates whether there are indications of possible impairment losses on non-financial assets subject to amortization or depreciation, to verify whether the carrying amount of these assets exceeds the recoverable amount. The Group tests goodwill, intangible assets with indefinite useful lives and intangible assets with finite useful lives that are not available for use for potential impairment at least annually, irrespective of whether there is any indication that the assets may be impaired. The recoverable amount of the assets is the higher of their fair value less costs of disposal and their value in use. An asset’s value in use is calculated, where applicable, based on an estimate of the future cash flows expected to derive from the use of the asset, expectations about possible variations in the amount or timing of those future cash flows, the time value of money, the price for bearing the uncertainty inherent in the asset and other factors that market participants would reflect in pricing the future cash flows deriving from the asset. Negative differences arising from comparison of the carrying amounts of the assets with their recoverable amounts are recognized in the consolidated statement of profit and loss. Recoverable amount is determined for each individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If this is the case, recoverable amount is determined for the cash-generating unit (CGU) to which the asset belongs. Impairment losses recognized for cash-generating units are first allocated to reduce, where applicable, the carrying amount of goodwill allocated to the CGU and then to the other assets of the CGU pro rata on the basis of the carrying amount of each asset. The carrying amount of each asset may not be reduced below the highest of its fair value less costs of disposal, its value in use and zero. At the end of each reporting period the Group assesses whether there is any indication that an impairment loss recognized in prior periods may no longer exist or may have decreased. Impairment losses on goodwill are not reversible. Impairment losses on other assets are only reversed if there has been a change in the estimates used to calculate the recoverable amount of the asset. A reversal of an impairment loss is recognized in consolidated profit and loss. The increased carrying amount of an asset attributable to a reversal of an impairment loss may not exceed the carrying amount that would have been determined, net of depreciation or amortization, had no impairment loss been recognized. A reversal of an impairment loss for a CGU is allocated to the assets of each unit, except goodwill, pro rata with the carrying amounts of those assets. The carrying amount of an asset may not be increased above the lower of its recoverable amount and the carrying amount that would have been disclosed, net of amortization or depreciation, had no impairment loss been recognized. (k) Financial instruments (i) Classification of the financial instruments Financial instruments are classified at the time of their initial recognition as a financial asset, a financial liability or an equity instrument, in accordance with the economic substance of the contractual agreement and with the definitions of financial assets, financial liabilities or equity instruments indicated in IAS 32 “Financial instruments: Presentation”. For purposes of its valuation, |
Financial Risk Management Polic
Financial Risk Management Policy | 12 Months Ended |
Dec. 31, 2021 | |
Financial Risk Management Policy | |
Financial Risk Management Policy | (5) Financial Risk Management Policy (a) General The Group is exposed to the following risks associated with the use of financial instruments: ● ● ● This note provides information on the Group’s exposure to each of these risks, the Group’s objectives and procedures to measure and mitigate this risk, and the Group’s capital management strategy. More exhaustive quantitative information is disclosed in note 30 to the consolidated financial statements. The Group’s risk management policies are established to identify and analyze the risks faced by the Group, define appropriate risk limits and controls and to control risks and comply with limits. Risk management policies and procedures are reviewed regularly so that they reflect changes in market conditions and the Group’s activities. The Group’s management procedures and rules are designed to create a strict and constructive control environment in which all employees understand their duties and obligations. The Group’s Audit Committee supervises how management controls compliance with the Group’s risk management procedures and policies and reviews whether the risk management policy is suitable considering the risks to which the Group is exposed. This committee is assisted by Internal Audit which acts as supervisor. Internal Audit performs regular and ad hoc reviews of the risk management controls and procedures and reports its findings to the Audit Committee. Credit risk Credit risk is the risk to which the Group is exposed in the event that a customer or counterparty to a financial instrument fails to discharge a contractual obligation, and mainly results from trade receivables and the Group’s investments in financial assets. Trade receivables The Group does not predict any significant insolvency risks as a result of delays in receiving payment from some European countries due to their current economic situation. The main risk in these countries is that of late payments, which is mitigated through the possibility of claiming interest as foreseen by prevailing legislation. No significant bad debt or late payment issues have been detected for sales to private entities. The Group recognizes impairment based on its best estimate of the expected losses on trade and other receivables. The main impairment losses recognized are due to specific losses relating to individually identified risks. At year end, these impairment losses are immaterial. Concentration of credit risk For trade receivables the Group uses the simplified approach, estimating lifetime expected credit losses, while for all other financial assets the Group uses the general approach for calculating expected credit losses. In both cases, due to the customers’ credit rating, as well as the internal classification systems currently in place for new customers and considering that collection periods are mostly under 30 days, there is no significant impact for the Group. In this context, Grifols made an assessment of possible changes in the credit risk through the estimation of the expected credit loss model, to ensure that it is reflecting the global economic impact of COVID-19. This assessment took into consideration available information on past events, the current situation and future economic forecasts having a potential impact on the credit risk. The update of the model mainly entailed the application of an incremental coefficient to the historical default rate to reflect the greater uncertainty regarding future economic scenarios and its impact on the expected credit loss. Based on the available information, it was concluded that there is no significant impact on the credit portfolio impairment as a result of the economic consequences of COVID-19. In addition, at 31 December 2021, no significant changes were observed in the payment profile of the main customers with which Grifols holds outstanding balances that are not subject to receivable sales and purchases with financial institutions. Details of exposure to credit risk are disclosed in note 30. Liquidity risk Liquidity risk is the risk that the Group cannot meet its financial obligations as they fall due. The Group’s approach to managing liquidity is to ensure where possible, that it always has sufficient liquidity to settle its obligations at the maturity date, both in normal conditions and in times of tension, to avoid incurring unacceptable losses or tarnishing the Group’s reputation. The Group manages liquidity risk on a prudent basis, based on availability of cash and sufficient committed unused long-term credit facilities, enabling the Group to implement its business plans and carry out operations using stable and secure sources of financing. In October 2021 Grifols completed the issuance of two bonds (Senior Notes) for an amount of Euros 1,400 million and US Dollars 705 million, both maturing in 2028 (see note 21). On 7 May 2020, the Group concluded the upsize of the multi-currency revolving credit facility from US Dollars 500 million to US Dollars 1,000 million with maturity in November 2025. On 15 November 2019 the Group concluded the refinancing process of its senior secured debt for approximately Euros 5,800 million. The new financing includes a Term Loan B for US Dollars 2,500 million and Euros 1,360 million, both aimed at institutional investors; the issue of two bonds for Euros 1,675 million (Senior Secured Notes); and the extension of a multi-currency revolving credit facility up to US Dollars 500 million. In September 2018 the Group received an additional non-current loan from the European Investment Bank totaling Euros 85,000 thousand. The loan will be used to support certain investments in R&D which are mainly focused on searching for new therapeutic for plasmatic proteins. Financial terms include a fixed interest rate for a period of 10 years with a grace period of two years. At 31 December 2021, the carrying amount of the loans obtained from the European Investment Bank is Euros 180,625 thousand (Euros 212,500 thousand at 31 December 2020). At 31 December 2021 the Group has total cash and cash equivalents of Euros 655,493 thousand (Euros 579,647 thousand at 31 December 2020). The Group also has approximately Euros 621,989 thousand in unused credit facilities (Euros 922,553 thousand at 31 December 2020), including Euros 534,429 thousand on the revolving credit facility (Euros 817,394 thousand at 31 December 2020). As in previous years, the Group continues with its quarterly program for optimization of working capital, which is mainly based on contracts to sell receivables without recourse. Market risk Market risk comprises the risk of changes in market prices, for example, exchange rates, interest rates, or the prices of equity instruments affecting the Group’s revenues or the value of financial instruments it holds. The objective of managing market risk is to manage and control the Group’s exposure to this risk within reasonable parameters at the same time as optimizing returns. (i) Currency risk The Group operates internationally and is therefore exposed to currency risk when operating with foreign currencies, especially with regard to the US Dollar. Currency risk is associated with future commercial transactions, recognized assets and liabilities, and net investments in foreign operations. The Group holds significant investments in foreign operations, the net assets of which are exposed to currency risk. The conversion risk affecting net assets of the Group’s foreign operations in US Dollars is mitigated primarily through borrowings in this foreign currency. The Group’s main exposure to currency risk is with regard to the US Dollar, which is used in a significant percentage of transactions in foreign functional currencies. As mentioned in note 21, the Group has issued a US Dollars 705 million bond, therefore the Group uses a US Dollars 500 million currency swap to hedge, in part, its exposure to the currency risk associated with this transaction. The Group applies the cost of hedging method. This method enables the Group to exclude the currency basis spread from the designated hedging instrument and, subject to certain requirements, changes in their fair value attributable to this component are recognized in other comprehensive income. Details of the Group’s exposure to currency risk at 31 December 2021 and 2020 of the most significant financial instruments are shown in note 30. (ii) Interest rate risk The Group’s interest rate risks arise from current and non-current borrowings. Borrowings at variable interest rates expose the Group to cash flow interest rate risks. Fixed-rate borrowings expose the Group to fair value interest rate risk. The objective of the management of interest rate risk is to achieve a balance in the structure of the debt, keeping part of the external resources issued at a fixed rate and covering part of the variable rate debt through hedges. A significant part of the financing obtained accrues interest at fixed rates. This fixed interest debt amounts to Euros 4,878 million, which represents approximately 60% of the Group’s total debt (46% at 31 December 2020). It corresponds to the senior notes, senior unsecured notes and the loans received from the European Investment Bank. Senior debt in Euros represents approximately 38% of the Group’s total Senior debt at 31 December 2021 (40% at 31 December 2020). Details of the Group’s exposure to interest rate risk at 31 December 2021 and 2020 are shown in note 30. (iii) Market price risk Price risk affecting raw materials is mitigated by the vertical integration of the hemoderivatives business in a highly concentrated sector. (b) Capital management The directors’ policy is to maintain a solid capital base in order to ensure investor, creditor and market confidence and sustain future business development. The board of directors defines and proposes the level of dividends paid to shareholders. The directors consider various arguments to calculate capital structure: ● The directors control capital performance using rates of returns on equity (ROE). In 2021 the ROE stood at 3% (12% in 2020). The ROE is calculated by dividing profit attributable to the Parent by the equity attributable to the Parent. Thousands of Euros 2021 2020 Profit attributable to the Parent 188,726 618,546 Equity attributable to the Parent 5,523,609 5,108,392 ROE 3 % 12 % ● In accordance with the senior secured debt contract, the Group is subject to compliance with some covenants. At 31 December 2021 and 2020, the Group complies with the covenants in the contract. ● Consideration of the Group’s credit rating (see note 21 (d)). The Parent held Class B treasury stock equivalent to 1.31% of its capital at 31 December 2021 (0.4% at 31 December 2020). |
Segment Reporting
Segment Reporting | 12 Months Ended |
Dec. 31, 2021 | |
Segment Reporting | |
Segment Reporting | (6) Segment Reporting In accordance with IFRS 8 “Operating Segments”, financial information for operating segments is reported in the accompanying Appendix II, which forms an integral part of this note to the consolidated financial statements. Group companies are divided into four areas: companies from the industrial area, companies from the commercial area, companies from the services area and companies from the research area. Within each of these areas, activities are organized based on the nature of the products and services manufactured and marketed. Assets, liabilities, income and expenses for segments include directly and reliably attributable items. Items which are not attributed to segments by the Group are: ● Balance sheet: equity, cash and cash equivalents and loans and borrowings. ● Statement of profit and loss: finance result and income tax. (a) Operating segments The operating segments defined by the steering committee are as follows: ● Bioscience: including all activities related with products derived from human plasma for therapeutic use. ● Hospital: comprising all non-biological pharmaceutical products and medical supplies manufactured by Group companies earmarked for hospital pharmacy. Products related with this business which the Group does not manufacture but markets as supplementary to its own products are also included. ● Diagnostic: including the marketing of diagnostic testing equipment, reagents and other equipment, manufactured by Group or other companies. ● Bio Supplies: groups together all transactions related to biological products for non-therapeutic use, Kedrion production agreements, and third-party plasma sales channeled through Haema and Biotest. ● Others: including the rendering of manufacturing services to third party companies and other research activities. Details of sales by groups of products for 2021, 2020 and 2019 are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Bioscience Haemoderivatives 3,814,983 4,242,502 3,993,462 Diagnostic Transfusional medicine 712,238 714,164 680,766 Other diagnostic 23,625 27,630 19,937 Hospital Fluid therapy and nutrition 46,670 41,359 47,677 Hospital supplies 70,217 58,303 67,489 Bio supplies 225,765 224,090 266,540 Others 39,620 31,990 22,820 Total 4,933,118 5,340,038 5,098,691 At 31 December 2021, 97.4% of the income from the sale of goods and services has been recognized at a certain point-in-time (97.5% in 2020 and 97.2% in 2019). The Group has concluded that hemoderivative products are sufficiently alike to be considered as a whole for the following reasons: ● ● ● (b) Geographical information is grouped into four areas: ● ● ● ● The definition of these four segments is mainly due to the geographical level that Group management sets to manage its revenue as they respond to specific economic scenarios. The main framework of the Group is consistent with this geographical segment grouping, including the monitoring of its commercial operations and its information systems. The financial information reported for geographical areas is based on sales to third parties in these markets as well as the location of assets. (c) In 2021, no customer has accounted for more than 10% of the Group’s gross revenues. In 2020, 10.38% of the Group’s gross revenues corresponded to revenues from a |
Goodwill
Goodwill | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill | |
Goodwill | (7) Goodwill Details of and movement in this caption of the consolidated balance sheet at 31 December 2021 were as follows: Thousands of Euros Balance at Business Translation Balance at Segment 31/12/2020 Combination Transfers differences 31/12/2021 Net value Grifols UK.Ltd. (UK) Bioscience 7,674 — — 511 8,185 Grifols Italia.S.p.A. (Italy) Bioscience 6,118 — — — 6,118 Biomat USA, Inc.(USA) Bioscience 234,791 345,844 51,364 44,322 676,321 Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) Diagnostic 9,538 — — 214 9,752 Grifols Therapeutics, Inc. (USA) Bioscience 1,816,404 — — 145,620 1,962,024 Araclon Biotech, S.L. (Spain) Diagnostic 6,000 (6,000) — — — Progenika Biopharma, S.A. (Spain) Diagnostic 40,516 — — — 40,516 Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) Diagnostic 2,376,978 — — 188,515 2,565,493 Kiro Grifols S.L. (Spain) Hospital 24,376 — — — 24,376 Goetech LLC (USA) Hospital 55,167 — — 4,423 59,590 Haema AG (Germany) Bioscience 190,014 — — — 190,014 BPC Plasma, Inc. (formerly Biotest Pharma Corp; USA) Bioscience 140,334 — — 11,250 151,584 Interstate Blood Bank, Inc. (USA) Bioscience 158,479 — — 12,705 171,184 Plasmavita Healthcare GmbH (Alemania) Bioscience 9,987 — — — 9,987 Alkahest, Inc (EEUU) Others 71,910 — — 5,765 77,675 Grifols Canada Therapeutics, Inc (formerly Green Cross Biotherapeutics, Inc.) (Canada) Bioscience 134,569 16,667 — 12,225 163,461 GCAM, Inc (formerly Green Cross America Inc.) (USA) Bioscience 49,416 — (51,364) 1,948 — GigaGen, Inc (ver nota 3) Others 105,460 — 7,161 112,621 5,332,271 461,971 0 434,659 6,228,901 Details of and movement in this caption of the consolidated balance sheet at 31 December 2020 are as follows: Thousands of Euros Balance at Business Translation Balance at Segment 31/12/2019 Combination Disposals differences 31/12/2020 Net value Grifols UK.Ltd. (UK) Bioscience 8,107 — — (433) 7,674 Grifols Italia.S.p.A. (Italy) Bioscience 6,118 — — — 6,118 Biomat USA, Inc.(USA) Bioscience 255,896 — — (21,105) 234,791 Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) Diagnostic 9,472 — — 66 9,538 Grifols Therapeutics, Inc. (USA) Bioscience 1,979,678 — — (163,274) 1,816,404 Araclon Biotech, S.L. (Spain) Diagnostic 6,000 — — — 6,000 Progenika Biopharma, S.A. (Spain) Diagnostic 40,516 — — — 40,516 Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) Diagnostic 2,600,950 — (12,902) (211,070) 2,376,978 Kiro Grifols S.L. (Spain) Hospital 24,376 — — — 24,376 Goetech LLC (USA) Hospital 60,126 — — (4,959) 55,167 Haema AG (Germany) Bioscience 190,014 — — — 190,014 BPC Plasma, Inc. (formerly Biotest Pharma Corp; USA) Bioscience 152,948 — — (12,614) 140,334 Interstate Blood Bank, Inc. (USA) Bioscience 172,862 — — (14,383) 158,479 Plasmavita Healthcare GmbH (Germany) Bioscience — 9,987 — — 9,987 Alkahest, Inc (USA) Others — 74,372 — (2,462) 71,910 Green Cross Biotherapeutics, Inc. (Canada) Bioscience — 133,443 — 1,126 134,569 Green Cross America Inc.(USA) Bioscience — 51,299 — (1,883) 49,416 5,507,063 269,101 (12,902) (430,991) 5,332,271 (See note 3) Impairment testing: As a result of the acquisition of Talecris in 2011, and for impairment testing purposes, the Group combines the CGUs allocated to the Bioscience segment, grouping them together at segment level, because substantial synergies were expected to arise on the acquisition of Talecris, and due to the vertical integration of the business and the lack of an independent organized market for the products. Because the synergies benefit the Bioscience segment globally they cannot be allocated to individual CGUs. The Bioscience segment represents the lowest level to which goodwill is allocated and is subject to control by Group management for internal control purposes. As a result of the acquisition of Novartis’ Diagnostic business unit in 2014, the Group decided to combine Araclon, Progenika, Australia and Hologic’s share of NAT donor screening unit acquisition into a single CGU for the Diagnostic business as the acquisition is supporting not only the vertically integration business but also cross-selling opportunities. In addition, for management purposes, the Group’s management is focused on the business more than geographical areas or individual companies. Due to the acquisition of an additional 40% stake in Kiro Grifols S.L. and a 51% stake in Goetech LLC (Medkeeper), the Group decided to group Kiro Grifols S.L., Laboratorios Grifols S.L. and Medkeeper into a single CGU for the Hospital business since the acquisitions are supporting cross-selling opportunities. The CGUs established by management are: ● ● ● The COVID-19 pandemic has caused unprecedented turmoil in the global economy. Our products from Bioscience CGU are considered lifesaving and have been identified as a strategic industry for most governments and therefore are prevented from being suspended. However, at the preparation date of the financial statements, Grifols has estimated a temporary impact derived from COVID-19 (see note 34). The recoverable amount of the Bioscience CGU and Hospital CGU has been calculated based on its value in use calculated as the present value of the five-year future cash flows discounted at a discount rate considering the related inherent risk. The recoverable amount of the Diagnostic CGU has been calculated based on its fair value less costs of disposal calculated as the present value of the five-year future cash flows discounted at a discount rate considering the related inherent risk. Management has determined the gross margin based on past experience and the current situation derived from the COVID-19 pandemic, investments in progress which would imply significant growth in production capacity and its forecast international market development. Unlike the previous year, the recoverable amount calculations of the CGUs do not use expected cash flow projections based on different scenarios considered in respect of COVID-19 impact since full recovery is expected in 2022. Cash flows estimated as of the year in which stable growth in the CGU has been reached are extrapolated using the estimated growth rates indicated below. Perpetual growth rates are consistent with the forecasts included in industry reports. The key assumptions used in calculating impairment testing of the CGUs for 2020 were as follows: Perpetual Growth rate Pre-tax discount rate Bioscience 1.9 % 8.9 % Diagnostic 1.9 % 9.5 % Hospital 1.4 % 10.8 % The key assumptions used in calculating impairment testing of the CGUs for 2021 have been as follows: Perpetual Growth rate Pre-tax discount rate Bioscience 2.0 % 9.0 % Diagnostic 2.0 % 9.3 % Hospital 1.5 % 10.9 % The discount rate used reflects specific risks relating to the CGUs and the countries in which they operate. The main assumptions used for determining the discount rate are as follows: ● ● ● ● The reasonably possible changes considered for the Bioscience, Diagnostic and Hospital CGUs are a variation in the discount rate, as well as in the estimated perpetual growth rate, as follows: Perpetual Growth rate Pre-tax discount rate Bioscience +/- 50 bps +/- 50 bps Diagnostic +/- 50 bps +/- 50 bps Hospital +/-100 bps +/-100 bps The reasonably possible changes in key assumptions considered by management in the calculation of the CGU’s recoverable amount would not cause the carrying amount to exceed its recoverable amount. At 31 December 2021 Grifols’ stock market capitalization totals Euros 9,834 million (Euros 14,207 million at 31 December 2020). |
Other Intangible Assets
Other Intangible Assets | 12 Months Ended |
Dec. 31, 2021 | |
Other Intangible Assets | |
Other Intangible Assets | (8) Other Intangible Assets Details of other intangible assets and movement during the years ended 31 December 2021 and 2020 are included in Appendix III, which forms an integral part of these notes to the consolidated financial statements. Intangible assets acquired from Talecris mainly include currently marketed products. Identifiable intangible assets correspond to Gamunex and have been recognized at fair value at the acquisition date of Talecris and classified as currently marketed products. Intangible assets recognized comprise the rights on the Gamunex product, its commercialization and distribution license, trademark, as well as relations with hospitals. Each of these components is closely linked and fully complementary, are subject to similar risks and have a similar regulatory approval process. Intangible assets acquired from Progenika mainly include currently marketed products. Identifiable intangible assets correspond to blood, immunology and cardiovascular genotyping. These assets have been recognized at fair value at the acquisition date of Progenika and classified as currently marketed products. The cost and accumulated amortization of currently marketed products acquired from Talecris and Progenika at 31 December 2020 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2019 Additions differences 31/12/2020 Cost of currently marketed products - Gamunex 1,069,042 — (88,169) 980,873 Cost of currently marketed products - Progenika 23,792 — — 23,792 Accumulated amortisation of currently marketed products - Gamunex (305,865) (35,360) 27,890 (313,335) Accumulated amortisation of currently marketed products - Progenika (16,254) (2,379) 0 (18,633) Carrying amount of currently marketed products 770,715 (37,739) (60,279) 672,697 The cost and accumulated amortization of currently marketed products acquired from Talecris, Progenika and Gigagen at 31 December 2021 is as follows: Thousands of Euros Balance at Translation Balance at 31/12/2020 Additions differences 31/12/2021 Cost of currently marketed products - Gamunex 980,873 — 78,636 1,059,509 Cost of currently marketed products - Progenika 23,792 — — 23,792 Accumulated amortisation of currently marketed products - Gamunex (313,335) (33,610) (26,827) (373,772) Accumulated amortisation of currently marketed products - Progenika (18,633) (2,379) — (21,012) Carrying amount of currently marketed products 672,697 (35,989) 51,809 688,517 The estimated useful life of the currently marketed products acquired from Talecris is considered limited, has been estimated at 30 years on the basis of the expected life cycle of the product (Gamunex) and is amortized on a straight-line basis. At 31 December 2021 the residual useful life of currently marketed products is 19 years and 5 months (20 years and 5 months at 31 December 2020). The estimated useful life of the currently marketed products acquired from Progenika is considered limited, has been estimated at 10 years on the basis of the expected life cycle of the product and is amortized on a straight-line basis. At 31 December 2021 the residual useful life of currently marketed products acquired from Progenika is 1 years and 2 months (2 years and 2 months at 31 December 2020). (a) Self — constructed intangible assets At 31 December 2021 the Group has recognized Euros 34,034 thousand as self-constructed intangible assets (Euros 32,548 thousand at 31 December 2020). (b) Purchase commitments At 31 December 2021 the Group has intangible asset purchase commitments amounting to Euros 431 thousand (Euros 9 thousand at 31 December 2020). (c) Intangible assets with indefinite useful lives and other intangibles in progress At 31 December 2021 the Group recognizes plasma center licenses with indefinite useful lives under intangible assets for a carrying amount of Euros 29,394 thousand (Euros 27,351 thousand at 31 December 2020). The Group has also an amount of Euros 432,534 thousand as development costs in progress (Euros 350,626 thousand at 31 December 2020). In 2019, Grifols reached an agreement with the US biotech company Rigel Pharmaceuticals to exclusively commercialize fostamatinib disodium hexahydrate in all potential future indications in Europe and Turkey. Under terms of the agreement, Grifols made an initial payment of US Dollars 30 million and an additional payment of US Dollars 17.5 million related to compliance with certain regulatory milestones. The Group recognized these payments as an intangible asset in accordance with IAS 38. This asset did not begin to be commercialized and amortized until 2020, as soon as was available for use, that is, after the final approval of the regulator. (d) Results on disposal of intangible assets The total losses on disposals and sale of intangible assets amounts to Euros 30 thousand in 2021 (no profit on disposal and sale of intangible assets had been recognized in 2020). (e) Impairment testing Indefinite-lived intangible assets have been allocated to the cash-generating unit (CGU) of the Bioscience segment. These assets have been tested for impairment together with goodwill (see note 7). Impairment testing has been analyzed for each of the intangible assets in progress by calculating its recoverable amount based on their fair value. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2021 | |
Leases | |
Leases | (9) Leases Details of leases in the consolidated balance sheet at 31 December 2021 and 2020 are as follows: Right-of-use assets Thousands of Euros 31/12/2021 31/12/2020 Land and Buildings 782,125 665,002 Machinery 5,283 3,671 Computer equipment 2,044 3,588 Vehicles 6,205 6,435 795,657 678,696 Lease liabilities Thousands of Euros 31/12/2021 31/12/2020 Non-current 825,157 690,857 Current 48,567 42,642 873,724 733,499 Details by maturity of lease liabilities are shown in the “Liquidity risk” section in note 30. At 31 December 2021, the Group has recognized an amount of Euros 133,442 thousand related to additions of right-of- use assets (Euros 75,077 thousand at 31 December 2020). Movement at 31 December 2021 and 2020 is included in Appendix IV, which forms an integral part of these notes to the consolidated financial statements. At 31 December 2021 and 2020, the amounts recognized in the consolidated statement of profit and loss related to lease agreements are: Right-of-use depreciation Thousands of Euros 31/12/2021 31/12/2020 Buildings 57,901 52,774 Machinery 2,120 1,588 Computer equipment 2,269 3,012 Vehicles 4,430 5,206 66,720 62,580 Thousands of Euros 31/12/2021 31/12/2020 Finance lease expenses (note 27) 35,786 35,205 35,786 35,205 Thousands of Euros 31/12/2021 31/12/2020 Expenses related to short-term contracts 3,106 3,569 Expenses related to low-value contracts 13,404 11,254 Other operating lease expenses 16,435 13,353 32,945 28,176 At 31 December 2021, the Group has paid a total of Euros 82,692 thousand related to lease contracts (Euros 79,037 thousand at 31 December 2020). The total amount recognized in the balance sheet corresponds to lease contracts in which the Group is the lessee. |
Property, Plant and Equipment
Property, Plant and Equipment | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment | |
Property, Plant and Equipment | (10) Property, Plant and Equipment Details of property, plant and equipment and movement in the consolidated balance sheet at 31 December 2021 and 2020 are included in Appendix V, which forms an integral part of this note to the consolidated financial statements. Property, plant and development under construction at 31 December 2021 and 2020 mainly comprise investments made to extend the companies’ equipment and to increase their productive capacity. In 2021, the Group has capitalized interests for a total amount of Euros 18,636 thousand (Euros 16,606 thousand in 2020). a) Insurance Group policy is to contract sufficient insurance coverage for the risk of damage to property, plant and equipment. At 31 December 2021 the Group has a combined insurance policy for all Group companies, which more than adequately covers the carrying amount of all the Group’s assets. b) Losses on disposal of property, plant and equipment Total losses incurred on disposals of property, plant and equipment for 2021 amount to Euros 2,720 thousand (losses of Euros 150 thousand in 2020). c) Self - constructed property, plant and equipment At 31 December 2021 the Group has recognized Euros 87,885 thousand as self -constructed property, plant and equipment (Euros 85,691 thousand at 31 December 2020). d) Purchase commitments At 31 December 2021 the Group has property, plant and equipment purchase commitments amounting to Euros 40,596 thousand (Euros 44,007 thousand at 31 December 2020). e) Impairment testing As a result of the discontinuation of the Blood Collection Systems activity, an impairment for some the tangible assets allocated to this business activity has been recognized for a total amount of Euros 11.5 million as an expense in the consolidated statement of profit and loss for 2021. Impairment testing for the tangible assets has been analyzed by calculating its recoverable amount based on their fair value. |
Equity-Accounted Investees
Equity-Accounted Investees | 12 Months Ended |
Dec. 31, 2021 | |
Equity-Accounted Investees | |
Equity-Accounted Investees | (11) Equity-Accounted Investees Details of this caption in the consolidated balance sheet at 31 December 2021 and 2020 are as follows: Thousands of Euros Thousands of Euros % ownership 31/12/2021 % ownership 31/12/2020 Access Biologicals LLC 49.00 % 53,264 49.00 % 46,782 Shanghai RAAS Blood Products Co., Ltd. 26.20 % 1,909,596 26.20 % 1,800,578 Grifols Egypt Plasma Derivatives 49.00 % 31,847 0.00 % — Total equity accounted investees with similar activity to that of the Group 1,994,707 1,847,360 Albajuna Therapeutics, S.L 49.00 % 1,910 49.00 % 3,378 GigaGen, Inc. 100.00 % — 43.96 % 15,677 Mecwins, S.A. 24.99 % 3,159 24.99 % 2,605 Total of the rest of equity accounted investees 5,069 21,660 Total equity-accounted investees 1,999,776 1,869,020 Movement in the investments in equity-accounted investees for the year ended 31 December 2019 is as follows: Thousands of Euros 2019 Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees Shanghai Access RAAS Blood Albajuna Biologicals Plasmavita Products Co., Therapeutics, Mecwins, Medcom LLC IBBI Group Healthcare Ltd. Total Alkahest, Inc. S.L Singulex, Inc. GigaGen, Inc. S.A. Advance, S.A Total Total Balance at 1 January 47,742 89,627 9,920 — 147,289 28,336 1,106 19,256 28,363 2,555 — 79,616 226,905 Acquisitions — — — — — — 3,750 — — — 8,619 12,369 12,369 Transfers — (94,127) — — (94,127) — — — — — — — (94,127) Share of profit / (losses) 3,938 4,586 448 — 8,972 (14,218) 383 — (5,002) (217) (690) (19,744) (10,772) Share of other comprehensive income / translation differences 966 1,658 — — 2,624 590 (11) 538 636 — (17) 1,736 4,360 Impairment losses — — — — — — — (19,794) — — — (19,794) (19,794) Collected dividends (2,725) (1,744) — — (4,469) — — — — — — — (4,469) Balance at 31 December 49,921 — 10,368 — 60,289 14,708 5,228 — 23,997 2,338 7,912 54,183 114,472 Movement in the investments in equity-accounted investees for the year ended 31 December 2020 is as follows: Thousands of Euros 2020 Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees Shanghai Access RAAS Blood Albajuna Biologicals Plasmavita Products Co., Therapeutics, Medcom LLC Healthcare Ltd. Total Alkahest, Inc. S.L GigaGen, Inc. Mecwins, S.A. Advance, S.A Total Total Balance at 1 January 49,921 10,368 — 60,289 14,708 5,228 23,997 2,338 7,912 54,183 114,472 Acquisitions — — 1,807,351 1,807,351 — — — — — — 1,807,351 Transfers — (10,674) — (10,674) (91,023) — — — — (91,023) (101,697) Share of profit / (losses) 8,962 306 11,531 20,799 76,414 (1,878) (6,725) 267 — 68,078 88,877 Share of other comprehensive income / translation differences (4,160) — (16,090) (20,250) (99) 28 (1,595) — — (1,666) (21,916) Impairment losses — — — — — — — — (7,912) (7,912) (7,912) Collected dividends (7,941) — (2,214) (10,155) — — — — — — (10,155) Balance at 31 December 46,782 — 1,800,578 1,847,360 — 3,378 15,677 2,605 — 21,660 1,869,020 Movement in the investments in equity-accounted investees for the year ended 31 December 2021 is as follows: Thousands of Euros 2021 Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees Shanghai RAAS Grifols Egypt Albajuna Access Blood Products Plasma Therapeutics, Biologicals LLC Co., Ltd. Derivatives Total S.L GigaGen, Inc. Mecwins, S.A. Total Total Balance at 1 January 46,782 1,800,578 — 1,847,360 3,378 15,677 2,605 21,660 1,869,020 Acquisitions — — 30,454 30,454 — — 860 860 31,314 Transfers — — — — — (50,794) — (50,794) (50,794) Share of profit / (losses) 8,298 24,835 (578) 32,555 (1,463) 34,957 (306) 33,188 65,743 Share of other comprehensive income / translation differences 3,929 89,886 1,971 95,786 (5) 160 — 155 95,941 Collected dividends (5,745) (5,703) — (11,448) — — — — (11,448) Balance at 31 December 53,264 1,909,596 31,847 1,994,707 1,910 — 3,159 5,069 1,999,776 The main movements of the equity-accounted investees with similar activity to that of the Group are explained below: Grifols Egypt Plasma Derivatives (GEPD) On 29 July 2021, a cooperation agreement was signed with the National Service Projects Organization (NSPO) to help build a platform to bring self-sufficiency in plasma-derived medicines to Egypt. The Company made a first contribution of US Dollars 36,750 thousand (equivalent to Euros 30,454 thousand at the date of integration), and in exchange received GEPD shares representing 49% of its share capital, which amounts to US Dollars 300 million. The Company has undertaken to make the contributions for the outstanding amount corresponding to its interest as the capital requirements are approved. Shanghai RAAS Blood Products Co. Ltd. In March 2019, Grifols entered into a share exchange agreement with Shanghai RAAS Blood Products Co. Ltd. (hereinafter SRAAS), through which Grifols would deliver 90 shares of its US subsidiary Grifols Diagnostic Solutions Inc. (hereinafter GDS) (representing 45% of the economic rights and 40% of the voting rights), and in exchange would receive 1,766 million of SRAAS shares (representing 26.2% of the share capital). Therefore, such transaction does not entail a cash flow movement nor has it required any external financing. The exchange ratio determined on that date, was estimated using different valuation methods, among others the stock price for SRAAS and discounted cash flows and market multiples for GDS. At 30 September 2019, Grifols obtained the authorization from the US agency, “Committee on Foreign Investment in the United States” (CFIUS) and on 13 November 2019, Shanghai RAAS Blood Products, Co. Ltd. obtained the authorization from the Chinese Securities Regulatory Commission (CRSC). At 31 December 2019, Grifols delivered 90 shares of its subsidiary GDS in exchange for a contractual right to receive equity instruments in an associate (equivalent to 1,766 million of SRAAS shares), because at that date no shares of SRAAS were received. As a consequence, at 31 December 2019, SRAAS was the minority shareholder owner of 45% of GDS. Grifols recorded the aforementioned contractual right for the fair value of the GDS shares delivered and subsequently, the right was measured based on its fair value through profit or loss. The delivery of GDS shares had no impact on the consolidated results of the Grifols Group for 2019 in accordance with IFRS 10 – Consolidated Financial Statements, since it is considered a transaction with non-controlling interest where Grifols retained control over GDS. The impact in the consolidated balance sheet at 31 December 2019 resulted in an increase in the following items: Other current financial assets amounting to Euros 1,717 million; Equity attributable to non-controlling interests amounting to Euros 1,511 million (note 18); Reserves amounting to Euros 227 million (note 16), a decrease in translation differences for an amount of Euros 22 million and a profit in the consolidated statement of profit and loss for 2019 amounting to Euros 1 million due to the change in the contractual right value (note 27). On 30 March 2020, the share exchange agreement was closed and Grifols received SRAAS shares corresponding to 26.2% of its share capital. Therefore, Grifols became the largest shareholder of SRAAS, while maintaining operational, political and economic control of GDS. Consequently, the consolidated balance sheet at 31 December 2020, did not longer show any financial asset related to the contractual right, but the interest in SRAAS was recorded as an investment in an associate company because the Group exercises significant influence in accordance with the criteria established in IAS 28 – Investment in Associates and Joint Ventures. SRAAS’ equity-accounted investment was recognized at the value of the shares at the closing date of the transaction. The difference between the contractual right value recognized at 31 December 2019 and SRAAS quoted value at 30 March 2020 was Euros 56,526 thousand which was recognized as finance income in the consolidated statement of profit and loss (see note 27). The impact on the consolidated statement of profit and loss related to the equity method result was included in the Operating Result under “Profit/(loss) of equity accounted investees with similar activity to that of the Group”, since SRAAS is a company dedicated to the plasma product sector. The transaction costs were recognized as part of the investment value and totaled Euros 34,088 thousand. At 31 December 2021, the quoted value of SRAAS shares was CNY 6.8 (CNY 7.4 at 31 December 2020). In accordance with IAS 28 – Investments in associates and joint ventures, possible indications of losses have been analyzed without detecting objective evidence of impairment in the investment. Plasmavita Healthcare GmbH In 2017, Grifols established PLASMAVITA GmbH, a joint venture between Grifols (50%) and two European partners (50%). On 14 April 2020, Grifols made a contribution of Euros 10 million in cash that was recognized as a shareholder contribution in Plasmavita. The equity share of 50% remained unchanged after the contribution. However, in assessing the existence of control due to the new shareholder agreement signed on that date, it was concluded that Grifols has control over Plasmavita and, therefore, it was considered part of the group and it has been fully consolidated (see note 3). Access Biologicals LLC. On 12 January 2017, the group announced the acquisition of 49% of the voting rights in Access Biologicals LLC, a company based in San Diego, California, USA, for the amount of US Dollars 51 million Grifols entered into an option agreement to purchase the remaining 51% voting rights in five years, in 2022Grifols also signed a supply agreement to sell biological products not meant for therapeutic use to Access Biologicals. The principal business activity of Access Biologicals is the collection and manufacturing of an extensive portfolio of biological products. Combined with closed-loop material sourcing, it provides critical support for various markets such as in-vitro diagnostic manufacturing, biopharmaceutical, cell culture and diagnostic research & development. The main movements for the rest of the equity-accounted investees are explained below: Alkahest, Inc. On 2 September 2020, Grifols signed an agreement to acquire all the shares of Alkahest Inc. (“Alkahest”) for a total amount of Euros 123,425 thousand (US Dollars 146,000 thousand), which was subject to approval by regulatory authorities. Likewise, as a result of agreements between shareholders, Grifols obtained control of Alkahest on 2 September 2020. Until that date, the previous 42.45% stake in Alkahest was equity accounted. The difference between the fair value of the previous stake and the book value is Euros 86,743 thousand (US Dollars 102,552 thousand), recognizing a profit for such amount under “Profit/(loss) of equity accounted investees” in the statement of profit and loss. As from this date, Alkahest was incorporated into the Group’s consolidation perimeter by the full consolidation method. Medcom Advance, S.A. In February 2019, the Group completed the acquisition of 45% of the shares in Medcom Advance, S.A. for an amount of Euros 8,602 thousand. Medcom Advance, S.A. is a company dedicated to research and development with a view to create proprietary patents using nanotechnology. The company was equity-accounted. At 31 December 2020 and 2021, this investment is fully impaired. Mecwins, S.A. On 22 October 2018 Grifols allocated Euros 2 million to the capital increase of Mecwins through Progenika Biopharma, reaching 24.99% of the total capital. Mecwins is a spin-off of the Institute of Micro and Nanotechnology of the Center for Scientific Research (CSIC), specialized in the development of innovative nanotechnological analysis tools for the diagnosis and prognosis of diseases. Mecwins has developed ultrasensitive optical reading immunoassay technology from nanosensors for the detection of protein biomarkers in blood. This technology has potential applications in fields such as oncology, cardiovascular and infectious diseases. The injection of capital, in which CRB Inverbio also participated with an additional Euros 2 million, will enable Mecwins to start developing pre-commercial prototypes of this technology and for Grifols to position itself in the field of nanotechnology applied to diagnosis. GigaGen Inc. On 5 July 2017, Grifols through its 100% subsidiary Grifols Innovation and New Technologies Limited (“GIANT”) acquired a 43.96% shareholding in GigaGen, Inc., a company based in San Francisco (USA) for the amount of US Dollars 35 million. GIANT and GigaGen entered into a Research and Collaboration Agreement whereby in exchange of a collaboration fee of US Dollars 15 million in the aggregate, GigaGen will commit to carry out research activities to develop recombinant polyclonal immunoglobulin therapies derived from human B cells for the treatment of human diseases. On 8 March 2021, Grifols, through its wholly owned subsidiary Grifols Innovation and New Technologies Limited (“GIANT”), reached an agreement to acquire all of the shares of Gigagen, Inc. for a total amount of US Dollars 90.5 million. With the acquisition of the 100% stake, Grifols obtains control over Gigagen and, therefore, becomes a group company and is consolidated under the full consolidation method (see note 3). Singulex, Inc. On 17 May 2016 Grifols subscribed and paid a capital increase for an amount of US Dollars 50 million (Euros 44,107 thousand) in the US company Singulex, Inc. (“Singulex”). As a result, Grifols held a 19.33% common stock interest in Singulex on a fully diluted basis at a pre-money valuation of US Dollars 200 million. Grifols was entitled to appoint a director to serve the board of directors of Singulex. As a result, Singulex granted Grifols an exclusive worldwide license for the use and sale of Singulex’ technology for the blood donor and plasma screening which has ensured the safety of blood and plasma products. During the second half of 2019, Singulex announced the cease of all its operations, after entering bankruptcy. Therefore, the Group impaired both the investment made and loans granted by Grifols to this company. Interstate Blood Bank, Inc. (IBBI) On 11 May 2016 Grifols acquired a 49.19% stake in Interstate Blood Bank, Inc. (IBBI), 48.97% of Bio-Blood Components, Inc. (Bio-Blood) and 48.90% of Plasma Biological Services, LLC. (PBS) (“IBBI Group”), with headquarters in Memphis, USA, for the price of US Dollars 100 million (Euros 88,215 thousand). The Group also entered into a call option on the remaining shares for a price of US Dollars 100 million, having agreed a payment of US Dollars 10 million (Euros 9,007 thousand) for the call option. The purchase price and the call right were paid upon signature of the contract. The principal business activity of IBBI and its affiliates is the collection of plasma for the plasma fractionation industry, with 26 plasma collection centers, 9 blood donation centers and one laboratory. In April 2019, the Group exercised the call option and completed the acquisition of the remaining shares of the IBBI group companies (see note 3). The last financial statements available of the main equity-accounted investments of Grifols are the following: 31/12/2021 31/12/2020 Thousands of Euros Thousands of Euros Access Access SRAAS Biologicals SRAAS Biologicals Non-current assets 2,877,382 2,707 2,617,024 2,795 Current assets 549,977 23,287 402,876 19,619 Cash and cash equivalents 401,117 3,790 250,073 4,178 Non-current liabilities (3,313) (36) (5,074) (1,497) Non-current financial liabilities (453) — — — Current liabilities (191,133) (3,615) (29,088) (3,670) Current financial liabilities — (2,649) (969) (1,486) Net assets 3,633,577 23,484 3,234,842 19,939 31/12/2021 31/12/2020 Thousands of Euros Thousands of Euros Access Access SRAAS Biologicals SRAAS Biologicals Net revenue 395,812 45,689 259,429 50,093 Profit for the year 181,395 17,380 139,459 17,221 |
Financial Assets
Financial Assets | 12 Months Ended |
Dec. 31, 2021 | |
Financial Assets [Abstract] | |
Financial Assets | (12) Financial Assets Details of non-current financial assets on the consolidated balance sheet at 31 December 2021 and 2020 are as follows: Thousands of Euros 31/12/2021 31/12/2020 Financial investments in listed shares 2,038 3,008 Non-current derivatives (see note 30) 2,068 — Total Non-current financial assets measured at fair value 4,106 3,008 Non-current guarantee deposits 7,763 6,268 Other non-current financial assets (a) 261,294 108,030 Non-current loans to related parties (see note 31) 89,104 80,851 Total Non-current financial assets measured at amortized cost 358,161 195,149 Details of current financial assets on the consolidated balance sheet at 31 December 2021 and 2020 are as follows: Thousands of Euros 31/12/2021 31/12/2020 Current derivatives (see note 30) 3,238 — Total Non-current financial assets measured at fair value 3,238 — Thousands of Euros 31/12/2021 31/12/2020 Deposits and guarantees 561 162 Other current financial assets (a) 2,025,869 10,861 Current loans to third parties 39 95 Total other current financial assets measured at amortized cost 2,026,469 11,118 (a) Other non-current and current financial assets Details of other non-current and current financial assets are as follows: Thousands of Euros 31/12/2021 31/12/2020 Other financial assets with related parties (see note 31) 220,947 114,825 Other financial assets with third parties 2,066,216 4,066 Total other non-current and current financial assets 2,287,163 118,891 “Other financial assets with third parties” is mainly composed of the cash received from the new bond issue, which will be used to acquire the existing share capital of Tiancheng (Germany) Pharmaceutical Holdings, owner of approximately 90% of Biotest ordinary shares and 1% of Biotest preferred shares. The transaction is subject to regulatory approvals and conditions and is expected to close by the end of the first half of 2022. Therefore, the received amount is restricted until official approval is obtained (see note 15 and 21). Additionally, Grifols closed a collaboration agreement with the U.S. firm ImmunoTek Bio Centers, LLC, specialized in the opening and construction of plasma centers, to open 21 plasma centers in the United States. At 31 December 2021, the Group has made advanced payments related to this project for an amount of US Dollars 47.5 million (Euros 42.3 million). |
Inventories
Inventories | 12 Months Ended |
Dec. 31, 2021 | |
Inventories. | |
Inventories | (13) Inventories Details of inventories at 31 December 2021 and 2020 are as follows: Thousands of Euros 31/12/2021 31/12/2020 Goods for resale 137,887 158,049 Raw materials and supplies 657,060 595,392 Work in progress and semi-finished goods 721,088 654,724 Finished goods 743,319 594,116 2,259,354 2,002,281 Movement in the inventory provision was as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Balance at 1 January 122,613 104,251 48,840 Net charge for the year 28,092 42,255 42,096 Cancellations for the year (269) (189) (118) Translation differences 8,288 (23,704) 13,433 Balance at 31 December 158,724 122,613 104,251 As a result of the discontinuation of the Blood Collection Systems activity, an impairment of some inventory has been recognized for a total amount of Euros 5 million as an expense in the consolidated statement of profit and loss for 2021. |
Trade and Other Receivables
Trade and Other Receivables | 12 Months Ended |
Dec. 31, 2021 | |
Trade and Other Receivables | |
Trade and Other Receivables | (14) Trade and Other Receivables Details at 31 December 2021 and 2020 are as follows: Thousands of Euros 31/12/2021 31/12/2020 Trade receivables 324,442 404,771 Receivables from 131,764 1,447 Impairment losses (note (24,009) (22,985) Trade receivables 432,197 383,233 Other receivables (note 11,014 8,324 Personnel 654 822 Advance payments (note 6,210 16,053 Taxation authorities, VAT 35,389 38,747 Other public entities 1,796 8,414 Other receivables 55,063 72,360 Current income tax assets 12,448 64,565 Total trade and other receivables 499,708 520,158 Other receivables During 2021, 2020 and 2019 the Grifols Group has sold receivables without recourse to some financial institutions (factors), to which the risks and benefits inherent to the ownership of the assigned credits are substantially transferred. Also, the control over the assigned credits, understood as the factor’s ability to sell them to an unrelated third party, unilaterally and without restrictions, has been transferred to the factor. The main conditions of these contracts include the advanced collection of the assigned credits that vary between 70%and 100% of the nominal amount and a percentage of insolvency risk coverage on the factor side that varies between 90% and 100% of the nominal of the assigned credits. These contracts have been considered as without recourse factoring and the amount advanced by the factors has been derecognized from the balance sheet Likewise, in financial years 2021 and 2020, some receivables assignment contracts were signed with a financial institution, in which Grifols retains the risks and benefits inherent to the ownership of the assigned credits. These contracts have been considered as with resource and the assigned amount remains in the consolidated balance sheet at 31 December 2021 and a short-term debt has been recognized for an amount equal to the consideration received from the factor for the assignment. The amount recognized is Euros 23,450 thousand at 31 December 2021 (Euros 18,264 thousand at 31 December 2020) (see note 21). Total receivables without recourse sold to financial institutions through the aforementioned contracts in 2021 amount to Euros 2,975,343 thousand (Euros 2,735,973 thousand in 2020 and Euros 1,593,260 thousand in 2019). The financial cost of credit rights sold for the Group totals approximately Euros 10,292 thousand which has been recognized under finance costs in the consolidated statement of profit and loss for 2021 (Euros 10,964 thousand in 2020 and Euros 9,171 thousand in 2019) (see note 27). Details of balances with related parties are shown in note 31. |
Cash and Cash Equivalents
Cash and Cash Equivalents | 12 Months Ended |
Dec. 31, 2021 | |
Cash and Cash Equivalents | |
Cash and Cash Equivalents | (15) Cash and Cash Equivalents Details of this caption of the consolidated balance sheet at 31 December 2021 and 2020 are as follows: Thousands of Euros 31/12/2021 31/12/2020 Current deposits — 134,875 Cash in hand and at banks 655,493 444,772 Total cash and cash equivalents recognized in the balance sheet 655,493 579,647 Restricted cash 2,020,118 — Total cash and cash equivalents recognized in the statement of cash flows 2,675,611 579,647 As mentioned in note 21, the Group issued a bond in two tranches for amounts of Euros 1,400 million and US Dollars 705 million. These funds are held in an escrow account and will be released once the transaction with Tiancheng (Germany) Pharmaceutical Holdings AG becomes effective. |
Equity
Equity | 12 Months Ended |
Dec. 31, 2021 | |
Equity | |
Equity | (16) Equity Details of consolidated equity and movement are shown in the consolidated statement of changes in equity. (a) Share capital At 31 December 2021 and 2020, the Company’s share capital amounts to Euros 119,603,705 and comprises: ● Class A shares: 426,129,798 ordinary shares of Euros 0.25 par value each, subscribed and fully paid and of the same class and series. ● Class B shares: 261,425,110 non-voting preference shares of 0.05 Euros par value each, of the same class and series, and with the preferential rights set forth in the Company’s by-laws. The main characteristics of the Class B shares are as follows: ● Each Class B share entitles its holder to receive a minimum annual preferred dividend out of the distributable profits at the end of each year equal to Euros 0.01 per Class B share provided that the aggregate preferred dividend does not exceed the distributable profits of that year and, subject, according to the commercial law, to the approval of the distribution of dividends by the Company’s shareholders. This preferred dividend is not cumulative if sufficient distributable profits are not obtained in the period. ● Each Class B share is entitled to receive, in addition to the above-mentioned preferred dividend, the same dividends and other distributions as for one Grifols ordinary share. ● Each Class B share entitles the holder to its redemption under certain circumstances, if a takeover bid for all or part of the shares in the Company has been made, except if holders of Class B shares have been entitled to participate in the bid on the same terms as holders of Class A shares. The redemption terms and conditions reflected in the Company’s by-laws limit the amount that may be redeemed, requiring that sufficient distributable reserves be available, and limit the percentage of shares to be redeemed in line with the ordinary shares to which the bid is addressed. ● In the event the Company were to be wound up and liquidated, each Class B share entitles the holder to receive, before any amounts are paid to holders of ordinary shares, an amount equal to the sum of (i) the par value of the Class B share, and (ii) the share premium paid for the Class B share when it was subscribed. In addition to the Class B liquidation preference amount, each holder is entitled to receive the same liquidation amount that is paid for each ordinary share. These shares are freely transferable. Since 23 July 2012 the ADSs (American Depositary Shares) representing Grifols’ Class B shares (non-voting shares) have had an exchange ratio of 1:1 in relation to Class B shares, ie.1 ADS represents 1 Class B share. The previous rate was 2 ADS per 1 Class B share. The Company’s knowledge of its shareholders is based on information provided voluntarily or in compliance with applicable legislation. According to the information available to the Company, there are no interests representing more than 10% of the Company’s total capital at 31 December 2021 and 2020. At 31 December 2021 and 2020, the number of outstanding shares is equal to the total number of Company shares, less treasury stock. Movement in outstanding shares during 2020 is as follows: Class A shares Class B shares Balance at 1 January 2020 426,129,798 258,010,058 (Acquisition) / disposal of treasury stock (note 16 (d)) — 402,888 Balance at 31 December 2020 426,129,798 258,412,946 Movement in outstanding shares during 2021 is as follows: Class A shares Class B shares Balance at 1 January 2021 426,129,798 258,412,946 (Acquisition) / disposal of treasury stock (note 16 (d)) (3,944,430) (2,058,366) Balance at 31 December 2021 422,185,368 256,354,580 (b) Share premium Movement in the share premium is described in the consolidated statement of changes in equity, which forms an integral part of this note to the consolidated financial statements. (c) Reserves The drawdown of accumulated gains is subject to legislation applicable to each of the Group companies. At 31 December 2021, Euros 29,486 thousand equivalent to the carrying amount of development costs pending amortization of certain Spanish companies (Euros 40,362 thousand at 31 December 2020) (see note 8) are, in accordance with applicable legislation, restricted reserves which cannot be distributed until these development costs have been amortized. Spanish companies are required to transfer at least 10% of the profits for each year to a reserve fund until such reserve reaches at least 20% of capital stock. This reserve is not distributable to shareholders and may only be used to cover, if no other reserves are available, the debit balance of the profit and loss account. Also, under certain conditions, the portion of this reserve in excess of 10% of the increased capital stock may be used to increase capital stock. In June 2019, Kiro Grifols, S.L. increased capital by an amount of Euro 7,500 thousand. The Group continues to hold a 90% interest, with an increase in non-controlling interest that corresponds to 10% of the capital increase. In July 2019, the Group acquired 33 shares of Progenika Biopharma, S.A for an amount of Euros 4 thousand. As a result, the Group increased its interest from 99.99% to 100%. With this acquisition, the Group has the full control of Progenika Biopharma, S.A and therefore it ceased to have non-controlling interest. In April 2019 and December 2019, the Group subscribed two share capital increases in Araclon Biotech, S.L of Euros 16.8 million and Euros 5.9 million, respectively. After the latter capital increase Grifols’ interest rises to 75.1%. At 31 December 2019, Grifols delivered 90 shares of its subsidiary Grifols Diagnostic Solutions, Inc. in exchange fora contractual right to receive equity instruments in an associate (equivalent to 1,766 million of SR shares), because at that date no shares of Shanghai RAAS Blood Products Co. Ltd. were received. This transaction generated an impact on reserves of Euros 227 million (see note 11). On 30 March 2020, the share exchange agreement was closed and Grifols received SRAAS shares corresponding to 26.2% of its share capital. Therefore, Grifols became the largest shareholder of SRAAS, while maintaining operational, political and economic control of GDS (see notes 11 and 18). This transaction generated an impact of Euros 408 million on reserves. On 14 April 2020, Grifols made a contribution of Euros 10 million in cash that was recognized as a shareholder contribution in Plasmavita. The equity share of 50% remained unchanged after the contribution. However, with the new shareholder agreement signed on this date, it was concluded that Grifols has control over Plasmavita and, therefore, it was considered part of the group and it was fully consolidated (see note 3 (a), notes 11 and 18). On 2 September 2020, Grifols signed an agreement to acquire all the shares of Alkahest Inc. (“Alkahest”) for a total amount of Euros 123,425 thousand (US Dollars 146,000 thousand). Likewise, as a result of agreements between shareholders, Grifols obtained control of Alkahest on 2 September 2020. As from this date, Alkahest was considered a group company and it was fully consolidated (see notes 3, 11 and 18). In December 2020 the Group subscribed a share capital increase in VCN Biosciences, S.L. of Euros 5 million. After this capital increase Grifols’ interest rose to 86.827% (see note 18). In December 2020, Kiro Grifols, S.L. increased capital by an amount of Euros 10,000 thousand. The Group continued to hold a 90% interest, with an increase in non-controlling interest that corresponds to 10% of the capital increase (see note 18). In April 2021 Grifols Diagnostic Solutions, Inc paid to Shanghai RAAS Blood Produtcs Co.Ltd. a dividend for an amount of Euros 8,811 thousand (US Dollars 10,485 thousand) (see note 18). In June 2021, the Group acquired 28,500 shares of Grifols Malaysia Sdn Bhd for Euros 6 thousand (US Dollars 7 thousand). As a result, the Group increased its interest from 30% to 49% (see note 18). In October 2021 the Group subscribed a share capital increase in Araclon Biotech, S.L of Euros 10 million. After this capital increase Grifols’ interest rises to 75.85% (see note 18). At 31 December 2021 and 2020 reserves include the IFRS-IASB first-time adoption revaluation reserves and legal reserve of certain Group companies. Legal reserve Companies in Spain are obliged to transfer 10% of each year’s profits to a legal reserve until this reserve reaches an amount equal to 20% of share capital. This reserve is not distributable to shareholders and may only be used to offset losses if no other reserves are available. Under certain conditions it may be used to increase share capital provided that the balance left on the reserve is at least equal to 10% of the nominal value of the total share capital after the increase. At 31 December 2021 and 2020 the legal reserve of the Parent amounts to Euros 23,921 thousand which corresponds to 20% of the share capital. Distribution of the legal reserves of Spanish companies is subject to the same restrictions as those of the Company and at 31 December 2021 and 2020 the balance of the legal reserve of other Spanish companies amounts to Euros 2,066 thousand. Other foreign Group companies have a legal reserve amounting to Euros 3,805 thousand at 31 December 2021 (Euros 3,677 thousand at 31 December 2020). Hedging reserve The hedging reserve includes the cash flow hedge reserve and the costs of hedging reserve, see note 4(l) for details. The cash flow hedge reserve is used to recognise the effective portion of gains or losses on derivatives that are designated and qualify as cash flow hedges, as described in note 30. The group defers the changes in the forward element of forward contracts and the time value of option contracts in the costs of hedging reserve. (d) Treasury stock Movement in Class A treasury stock during the year ended 31 December 2021 is as follows: No. of Class A shares Thousands of Euros Balance at 1 January 2021 — — Disposal Class A shares — — Acquisition Class A shares 3,944,430 89,959 Balance at 31 December 2021 3,944,430 89,959 At the meeting held on 11 March 2021, the Board of Directors agreed to implement a program to repurchase Grifols’ treasury stock (the Buyback Program), in accordance with the authorization granted by Grifols’ shareholders at an ordinary general meeting held on 9 October 2020, under point twelve of the agenda. The Buyback Program was created with the aim of using Grifols’ treasury stock (Class A and Class B) as consideration in certain future acquisitions that Grifols may make (as the company has done on previous occasions). This Buyback Program began on 12 March 2021 and has been in force until 14 June 2021 (both dates included). Grifols entrusted the execution of the Buyback Program to an independent bank, and therefore Grifols has not exercised any control over the bank’s decisions in this regard. At 31 December 2020 the Company did not have any Class A treasury stock. Movement in Class B treasury stock during 2020 was as follows: No. of Class B shares Thousands of Euros Balance at 1 January 2020 3,415,052 49,584 Disposal Class B shares (402,888) (5,850) Balance at 31 December 2020 3,012,164 43,734 Movement in Class B treasury stock during 2021 is as follows: No. of Class B shares Thousands of Euros Balance at 1 January 2021 3,012,164 43,734 Disposal Class B shares (361,530) (5,248) Acquisition Class B shares 2,419,896 35,744 Balance at 31 December 2021 5,070,530 74,230 In March 2021, the Group delivered 361,530 treasury stocks (Class B shares) to eligible employees as compensation under the Restricted Share Unit Retention Plan (see note 29). In March 2020 the Group delivered 402,888 treasury stocks (Class B shares) to eligible employees as compensation under the Restricted Share Unit Retention Plan (see note 29). The Parent held Class A and B treasury stock equivalent to 1.3% of its capital at 31 December 2021 (0.4% of its capital in Class B treasury stock at 31 December 2020). (e) Distribution of profit The profits of Grifols, S.A. and subsidiaries will be distributed as agreed by respective shareholders at their general meetings. The proposed distribution of profit of the Parent Grifols, S.A. for the years ended 31 December 2021, and the distribution of profit approved for 2020, presented at the general meeting held on 21 May 2021, is as follows: Thousands of Euros 31/12/2021 31/12/2020 Voluntary reserve (140,728) 62,134 Dividends — 2,614 Profit of the Parent (140,728) 64,748 The following dividends were paid in 2020: 31/12/2020 % of par value Euros per share Thousands of Euros Ordinary shares 65 % 0.16 68,859 Non-voting shares 323 % 0.16 41,757 Non-voting shares (preferred dividend) 20 % 0.01 2,614 Total dividends paid 113,230 The following dividends were paid in 2021: 31/12/2021 % of par value Euros per share Thousands of Euros Ordinary shares 146 % 0.36 154,005 Non-voting shares 729 % 0.36 93,515 Non-voting shares (preferred dividend) 20 % 0.01 2,614 Total dividends paid 250,134 During 2020 and 2021 no interim dividend has been paid. At a general meeting held on 8 and 9 October 2020 the shareholders of Grifols S.A. approved the distribution of a preferred dividend of Euros 0.01 for every Class B non-voting share. At the general meeting held on 21 May 2021 the shareholders of Grifols S.A. approved the distribution of a preferred dividend of Euros 0.01 for every Class B non-voting share, together with the approval of an ordinary dividend of Euros 0.36 for Class A and Class B share charged to voluntary reserves of the Company for an amount of Euros 247,520 thousand. The distribution of the profit for the years ended 31 December 2020 and 2021 is presented in the consolidated statement of changes in equity. (f) Restricted Share Unit Retention Plan The Group has set up a Restricted Share Unit Retention Plan (hereinafter RSU Plan) for certain employees (see note 29). This commitment will be settled using equity instruments and the cumulative accrual amounts to Euros 9,838 thousand at 31 December 2021 (Euros 13,880 thousand at 31 December 2020). |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share | |
Earnings Per Share | (17) Earnings Per Share The calculation of basic earnings per share is based on the profit for the year attributable to the shareholders of the Parent divided by the weighted average number of ordinary shares in circulation throughout the year, excluding treasury stock. Details of the calculation of basic earnings per share are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Profit for the year attributable to shareholders of the Parent (Thousands of Euros) 188,726 618,546 625,146 Weighted average number of ordinary shares outstanding 681,556,937 685,515,740 685,115,836 Basic earnings per share (Euros per share) 0.28 0.90 0.91 The weighted average of the ordinary shares outstanding (basic) is as follows: Number of shares 31/12/2021 31/12/2020 31/12/2019 Issued shares outstanding at 1 January 685,601,126 685,198,238 684,794,839 Effect of shares issued — — — Effect of treasury stock (4,044,189) 317,502 320,997 Average weighted number of ordinary shares outstanding (basic) at 31 December 681,556,937 685,515,740 685,115,836 Diluted earnings per share are calculated by dividing profit for the year attributable to shareholders of the Parent by the weighted average number of ordinary shares in circulation considering the diluting effects of potential ordinary shares. The RSU Plan granted by the Group and payable in shares, assumes the existence of dilutive potential shares. Diluted earnings per share have been calculated as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Profit for the year attributable to shareholders of the Parent (Thousands of Euros) 188,726 618,546 625,146 Weighted average number of ordinary shares outstanding (diluted) 681,404,922 685,142,749 684,719,195 Diluted earnings per share (Euros per share) 0.28 0.90 0.91 The weighted average number of ordinary shares outstanding diluted has been calculated as follows: Number of shares 31/12/2021 31/12/2020 31/12/2019 Issued shares outstanding at 1 January 685,601,126 685,198,238 684,794,839 Effect of RSU shares (152,015) (372,991) (396,641) Effect of shares issued — — — Effect of treasury stock (4,044,189) 317,502 320,997 Average weighted number of ordinary shares outstanding (diluted) at 31 December 681,404,922 685,142,749 684,719,195 |
Non-Controlling Interests
Non-Controlling Interests | 12 Months Ended |
Dec. 31, 2021 | |
Non-Controlling Interests | |
Non-Controlling Interests | (18) Non-Controlling Interests Details of non-controlling interests and movement at 31 December 2021 are as follows: Thousands of Euros Business combinations / Balance at Perimeter Dividends Translation Balance at 31/12/2020 Additions additions paid differences 31/12/2021 Grifols (Thailand) Pte Ltd 4,338 218 — — (139) 4,417 Grifols Malaysia Sdn Bhd 2,923 810 (843) — 169 3,059 Araclon Biotech, S.A. (1,088) (1,119) 2,447 — — 240 VCN Bioscience, S.L 316 (219) — — — 97 Kiro Grifols , S.L. 598 (314) — — — 284 Haema AG 231,284 2,258 — — — 233,542 BPC Plasma, Inc (formerly Biotest US Corporation) 274,995 8,014 — — 22,267 305,276 Grifols Diagnostic Solutions, Inc. 1,087,632 65,894 — (6,503) 87,827 1,234,850 Plasmavita Healthcare (see note 3) 10,665 1,059 — — — 11,724 1,611,663 76,601 1,604 (6,503) 110,124 1,793,489 Details of non-controlling interests and movement at 31 December 2020 are as follows: Thousands of Euros Business combinations / Balance at Perimeter Translation Balance at 31/12/2019 Additions additions differences 31/12/2020 Grifols (Thailand) Pte Ltd 4,549 221 — (432) 4,338 Grifols Malaysia Sdn Bhd 2,171 932 — (180) 2,923 Araclon Biotech, S.A. 429 (1,517) 0 — (1,088) VCN Bioscience, S.L (152) (235) 703 — 316 Kiro Grifols , S.L. 24 (426) 1,000 — 598 Haema AG 226,071 5,213 — — 231,284 BPC Plasma, Inc (formerly Biotest US Corporation) 280,010 19,032 — (24,047) 274,995 Grifols Diagnostic Solutions, Inc. 1,510,547 69,520 (408,675) (83,760) 1,087,632 Plasmavita Healthcare (see note 3) — (22) 10,687 — 10,665 Alkahest, Inc. — (2,274) 2,274 — 0 2,023,649 90,444 (394,011) (108,419) 1,611,663 At 31 December 2021 and 2020, the summary financial information on the non-controlling interests of Haema AG and BPC Plasma, Inc., is as follows: Thousands of Euros Thousands of Euros 31/12/2021 31/12/2020 BPC Plasma, Inc BPC Plasma, Inc (formerly Biotest (formerly Biotest Haema AG US Corporation) Haema AG US Corporation) Non-current assets 292,454 409,674 249,806 336,321 Current assets 52,211 33,404 31,237 43,750 Total Assets 344,665 443,078 281,043 380,071 Non-current liabilities 27,137 54,991 27,123 52,977 Current liabilities 83,986 82,811 22,636 52,099 Total Liabilities 111,123 137,802 49,759 105,076 Total equity 233,542 305,276 231,284 274,995 31/12/2021 31/12/2020 Thousands of Euros Thousands of Euros BPC Plasma, Inc BPC Plasma, Inc Haema AG (formerly Biotest Haema AG (formerly Biotest US Corporation) US Corporation) Profit for the year 2,258 8,014 5,213 19,032 At 31 December 2021 and 2020, the summary financial information on the non-controlling interests of GDS Group is as follows: Thousands of Euros 31/12/2021 31/12/2020 Non-current assets 3,796,855 3,393,188 Current assets 291,371 277,834 Total Assets 4,088,226 3,671,022 Non-current liabilities 278,620 256,244 Current liabilities 91,299 131,754 Total Liabilities 369,919 387,998 Total equity 3,718,307 3,283,024 Thousands of Euros 31/12/2021 31/12/2020 Profit for the year 198,416 198,182 |
Grants
Grants | 12 Months Ended |
Dec. 31, 2021 | |
Grants | |
Grants | (19) Grants Details are as follows: Thousands of Euros 31/12/2021 31/12/2020 Capital grants 14,646 16,509 Interest rate grants (preference loans) (See note 21 (d)) 390 499 15,036 17,008 Interest-rate grants (preference loans) reflect the implicit interest on loans extended by the Spanish Ministry of Science and Technology as these are interest free. Grants totaling Euros 5,608 thousand have been recognized in the consolidated statement of profit and loss for the year ended 31 December 2021 (Euros 1,683 thousand for the year ended 31 December 2020). |
Provisions
Provisions | 12 Months Ended |
Dec. 31, 2021 | |
Provisions | |
Provisions | (20) Provisions Details of provisions at 31 December 2021 and 2020 are as follows: Thousands of Euros Non-current provisions (a) 31/12/2021 31/12/2020 Provisions for pensions and similar obligations 6,717 6,767 Other provisions 17,405 20,504 Non-current provisions 24,122 27,271 Thousands of Euros Current provisions (b) 31/12/2021 31/12/2020 Trade provisions 31,407 11,175 Current provisions 31,407 11,175 (a) Non-current provisions At 31 December 2021, 2020 and 2019 provisions for pensions and similar obligations mainly comprise a provision made by certain foreign subsidiaries in respect of labor commitments with certain employees. Movement in provisions during 2019 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2018 Net charge Cancellations Reclassifications differences 31/12/2019 Non-current provisions 6,114 1,467 (30) 464 15 8,030 6,114 1,467 (30) 464 15 8,030 Movement in provisions during 2020 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2019 Net charge Cancellations Reclassifications differences 31/12/2020 Non-current provisions 8,030 414 (175) 20,527 (1,525) 27,271 8,030 414 (175) 20,527 (1,525) 27,271 Movement in provisions during 2021 is as follows: Thousands of Euros Balance at Translation Balance at 31/12/2020 Net charge Cancellations Reclassifications differences 31/12/2021 Non-current provisions 27,271 838 (77) (5,196) 1,286 24,122 27,271 838 (77) (5,196) 1,286 24,122 (b) Current provisions Movement in trade provisions during 2019 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2018 Net charge Cancellations differences 31/12/2019 Trade provisions 80,055 (25,249) (3,142) 1,445 53,109 80,055 (25,249) (3,142) 1,445 53,109 Movement in trade provisions during 2020 was as follows: Thousands of Euros Balance at Business Translation Balance at 31/12/2019 combination Net charge Cancellations Reclassifications differences 31/12/2020 Trade provisions 53,109 954 (21,998) (247) (20,059) (584) 11,175 53,109 954 (21,998) (247) (20,059) (584) 11,175 Movement in trade provisions during 2021 is as follows: Thousands of Euros Balance at Business Translation Balance at 31/12/2020 combination Net charge Cancellations Reclassifications differences 31/12/2021 Trade provisions 11,175 32 14,826 (717) 4,523 1,568 31,407 11,175 32 14,826 (717) 4,523 1,568 31,407 |
Financial Liabilities
Financial Liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Financial Liabilities | |
Financial Liabilities | (21) This note provides information on the contractual conditions of the Group’s financial liabilities, which are measured at amortized cost, except for the financial derivatives that are valued at fair value. For further information on exposure to interest rate risk, currency risk and liquidity risk and the fair values of financial liabilities, please refer to note 30. Details at 31 December 2021 and 2020 are as follows: Thousands of Euros Financial liabilities 31/12/2021 31/12/2020 Non-current bonds (a) 2,577,465 2,675,000 Senior secured debt (b) 3,296,025 3,335,415 Other loans (b) 480,836 183,771 Other non-current financial liabilities (d) 838,826 10,272 Non-current lease liabilities (note 9) 825,157 690,857 Loan transaction costs (249,359) (293,215) Total non-current financial liabilities 7,768,950 6,602,100 Current bonds (a) 2,270,474 125,843 Senior secured debt (b) — 34,035 Other loans (b) 165,139 170,730 Other current financial liabilities (d) 43,234 105,041 Current financial derivatives (note 30) 875 — Current lease liabilities (note 9) 48,567 42,642 Loan transaction costs (89,998) (53,679) Total current financial liabilities 2,438,291 424,612 On 5 October 2021, Grifols completed the issuance of two Senior Notes for amounts of Euros 1,400 million and US Dollars 705 million, both maturing in 2028. On 7 May 2020, the Group concluded the upsize of the multi-currency revolving credit facility from US Dollars 500 million to US Dollars 1,000 million with maturity in November 2025. On 15 November 2019 the Group concluded the refinancing process of its senior secured debt for Euros 5,800 million. The new financing included a Term Loan B for US Dollars 2,500 million and Euros 1,360 million, both aimed at institutional investors; the issue of two bonds for Euros 1,675 million (Senior Secured Notes); and the extension of a multi-currency revolving credit facility up to US Dollars 500 million. Grifols calculated the impact of the IFRS 9 in the new financing process concluding that it did not result in a derecognition of the liability as it has not passed the 10% quantitative test. According to the IASB’s interpretation, when a financial liability measured at amortized cost is modified or exchanged and does not result in the derecognition of the financial liability, a gain or loss should be recognized in profit or loss, calculated as the difference between the original contractual cash flows from the liability and the modified cash flows, discounted at the original effective interest rate of the liability. Following the standard, the Group recognized income of Euros 97,850 thousand in the 2019 statement of profit and loss (see note 27). In September 2018, Grifols obtained a new non-current loan from the European Investment Bank totaling Euros 85,000 thousand that will be used by Grifols to support its investments in R&D, mainly focused on the search for new therapeutic indications for plasma-derived protein therapies. The financial terms include a fixed interest rate, a maturity of 10 years with a grace period of 2 years. On 5 December 2017 and 28 October 2015, the Group arranged loans with the same entity and with the same conditions for amounts of Euros 85,000 thousand and Euros 100,000 thousand, respectively. At 31 December 2021, the carrying amount of the loans obtained from the European Investment Bank amounts to Euros 180,625 thousand (Euros 212,500 thousand at 31 December 2020). (a) Senior Notes On 5 October 2021, Grifols Escrow Issuer, S.A. closed the issuance of a senior unsecured corporate bond (Senior Unsecured Notes) in two tranches for amounts of Euros 1,400 million and US Dollars 705 million. Both tranches mature in 2028 and will accrue an annual coupon of 3.875% and 4.750%, respectively. The proceeds from the bonds will be used to finance the Euros 1.100 million acquisition of the entire share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, which holds 89.88% of the ordinary shares of Biotest AG and 1.08% of the preferred shares. In addition, the proceeds will also be used to finance the voluntary public offering for the remaining ordinary and preferred shares of Biotest AG. The funds have been transferred directly to an escrow account and access to them is restricted pending completion of the transaction and other contractual milestones (see note 3 and 15). In the event that the transaction is not carried out, the Group is willing to redeem the bonds immediately. Therefore, the liability was classified according to the earliest period in which the Group may be required to repay it. On 15 November 2019, as part of its refinancing process, Grifols, S.A. issued Euros 1,675 million of Senior Secured Notes segmented in two notes of Euros 770 million and Euros 905 million. These notes will mature in 2027 and 2025 and will bear annual interest at a rate of 2.25% and 1.625%, respectively. On 15 November 2019 the notes were admitted to listing on the Irish Stock Exchange. On 18 April 2017, Grifols, S.A., issued Euros 1,000 million of Senior Unsecured Notes that will mature in 2025 and will bear annual interest at a rate of 3.20%. On 2 May 2017 the Notes were admitted to listing on the Irish Stock Exchange. Details of movement in the Senior Notes at 31 December 2021 are as follows: Thousands of Euros Opening Opening outstanding balance Exchange outstanding balance 01/01/21 Issue differences 31/12/21 Senior unsecured notes (nominal value) 2017 1,000,000 — — 1,000,000 Senior secured notes (nominal value) 2019 1,675,000 — — 1,675,000 Senior unsecured notes (nominal value) Euros 2021 — 1,400,000 — 1,400,000 Senior unsecured notes (nominal value) US Dollars 2021 — 598,970 23,492 622,462 Total 2,675,000 1,998,970 23,492 4,697,462 On 2 December 2021, Grifols, S.A. announced a repurchase offer for the same price plus unpaid accrued interests of the mentioned bonds, up to the equivalent in Euros of US Dollars 110,317 thousand. In January 2022, the agreement with the bondholders was closed, therefore, the amount is presented in the short term at 31 December 2021. There was no movement regarding Senior Notes in 2020. At 31 December 2021 and 2020 the current obligations caption includes the issue of bearer promissory notes to Group employees, as follows: 31/12/2020 Promissory Buy backs or Interest Nominal amount notes subscribed redemptions pending accrual Maturity of promissory Interest (Thousands of (Thousands of (Thousands of Issue date date notes (Euros) rate Euros) Euros) Euros) Issue of bearer promissory notes 04/05/20 04/05/21 3,000 3.00 % 116,352 (3,612) (1,118) 31/12/2021 Promissory Buy backs or Interest Nominal amount notes subscribed redemptions pending accrual Maturity of promissory Interest (Thousands of (Thousands of (Thousands of Issue date date notes (Euros) rate Euros) Euros) Euros) Issue of bearer promissory notes 04/05/21 04/05/22 3,000 2.50 % 119,325 (1,740) (975) (b) Loans and borrowings Details of loans and borrowings at 31 December 2021 and 2020 are as follows: Thousands of Euros 31/12/2021 31/12/2020 Amount Carrying Amount Carrying Credit Currency Interest rate Date awarded Maturity date extended amount extended amount Senior debt - Tranche B Euros Euribor + 2.25% 15/11/2019 15/11/2027 1,360,000 1,258,554 1,360,000 1,332,800 Senior debt - Tranche B US Dollars Libor + 2.00% 15/11/2019 15/11/2027 2,227,171 2,037,471 2,227,171 2,002,615 Total senior debt 3,587,171 3,296,025 3,587,171 3,335,415 EIB Loan Euros 2.40% 20/11/2015 20/11/2025 100,000 31,875 100,000 42,500 EIB Loan Euros 2.02% 22/12/2017 22/12/2027 85,000 53,125 85,000 63,750 EIB Loan Euros 2.15% 25/09/2018 25/09/2028 85,000 63,750 85,000 74,375 Total EIB Loan 270,000 148,750 270,000 180,625 Revolving Credit USD Libor + 1.5% 07/05/2020 15/11/2025 882,924 330,000 817,394 — Total Revolving Credit 882,924 330,000 817,394 — Other non-current loans Euros 1.93% 25/03/2010 30/09/2024 10,000 2,086 10,000 3,146 Loan transaction costs — (197,703) — (223,944) Non-current loans and borrowings 4,750,095 3,579,158 4,684,565 3,295,242 Thousands of Euros 31/12/2021 31/12/2020 Credit Currency Interest rate Date awarded Maturity date Amount extended Carrying amount Amount extended Carrying amount Senior debt - Tranche B Euros Euribor + 2.25% 15/11/2019 15/11/2027 (*) — (*) 13,600 Senior debt - Tranche B US Dollars Libor + 2.00% 15/11/2019 15/11/2027 (*) — (*) 20,435 Total senior debt — — — 34,035 EIB Loan Euros 2.40% 20/11/2015 20/11/2025 (*) 10,625 (*) 10,625 EIB Loan Euros 2.02% 22/12/2017 22/12/2027 (*) 21,250 (*) 21,250 Total EIB Loan — 31,875 — 31,875 Other current loans 0.10% - 2.50% 211,901 133,264 241,895 138,855 Loan transaction costs — (37,244) — (35,209) Current loans and borrowings 211,901 127,895 241,895 169,556 (*) See amount granted under non-current debt Current loans and borrowings include accrued interest amounting to Euros 7,682 thousand at 31 December 2021 (Euros 7,262 thousand at 31 December 2020). On 15 November 2019 the Group refinanced its Senior Secured Debt with the existing lenders. The new senior debt consists of a Term Loan B (“TLB”), which amount US Dollars 2,500 million and Euros 1,360 million with a 2.00% margin pegged to Libor and a 2.25% margin pegged to Euribor respectively, maturity in 2027 and quasi-bullet repayment structure. The borrowers of the total senior debt are Grifols, S.A. and Grifols Worldwide Operations USA, Inc. The present value discounted from cash flows under the new agreement, including any fees paid and discounted using the original effective interest rate differed by less than 10% of the present value discounted from cash flows remaining in the original debt, whereby it was considered that the debt instrument was not been substantially modified. The costs of refinancing the senior debt amounted to Euros 84.4 million. Based on an analysis of the quantitative and qualitative factors, the Group concluded that the renegotiation of the terms of the senior debt did not imply a derecognition of the liability. According to the IASB’s interpretation published in October 2017, when a financial liability measured at amortized cost is modified or exchanged and does not result in the derecognition of the financial liability, a gain or loss should be recognized in profit or loss, calculated as the difference between the original contractual cash flows from the liability and the modified cash flows, discounted at the original effective interest rate of the liability. Following the standard, the Group recognized an income of Euros 97,850 thousand in the statement of profit and loss for the year 2019 (see note 27). The terms and conditions of the senior secured debt are as follows: o Tranche B : eight-year loan divided into two tranches: US Tranche B and Tranche B in Euros: ◾ Tranche B in US Dollars: ● ● ● ● ◾ Tranche B in Euros: ● ● ● ● Details of Tranche B by maturity at 31 December 2021 are as follows: US Tranche B Tranche B in Euros Principal in Thousands Amortization in Principal in Thousands of Currency of US Dollars Thousands of Euros Currency Euros Maturity 2023 US Dollars 6,015 5,310 Euros 3,269 2024 US Dollars 24,058 21,242 Euros 13,076 2025 US Dollars 24,058 21,242 Euros 13,076 2026 US Dollars 24,058 21,242 Euros 13,076 2027 US Dollars 2,235,700 1,973,954 Euros 1,216,058 Total US Dollars 2,313,889 2,042,990 Euros 1,258,555 At 31 December 2021, the Group has redeemed in advance an amount of Euros 74,246 thousand from Tranche B in Euros and Euros 124,798 thousand from Tranche B in US Dollars, using part of the amount received from GIC (sovereign wealth fund in Singapore) (see note 2). o US Dollar 1,000 million senior revolving credit facility: On 7 May 2020, the Group concluded the upsize of the multi-currency revolving credit facility from US Dollars 500 million to US Dollars 1,000 million with maturity in November 2025 and an applicable margin of 150 basis points (bp) pegged to US Libor . During fiscal year 2021, the Group has drawn down an amount of US Dollars 600 million, which has been repaid using the amount received from GIC (sovereign wealth fund in Singapore) (see note 2), and the amount of Euros 330 million that is still in the consolidated balance sheet at 31 December 2021. The costs of refinancing the revolving credit facility in 2020 amounted to Euros 9.3 million Both the Senior Term Loans and the Revolving Loans are secured by Grifols, S.A. and certain significant subsidiaries of Grifols, S.A., which together with Grifols, S.A., represent, in the aggregate, at least 70% of the consolidated EBITDA of the Group. The Notes have been issued by Grifols S.A. and are guaranteed on a senior secured basis by subsidiaries of Grifols, S.A. that are guarantors and co-borrower under the New Credit Facilities. The guarantors are Grifols Worldwide Operations Limited, Biomat USA, Inc., Grifols Biologicals Inc., Grifols Shared Services North America, Inc., Talecris Plasma Resources, Inc.., Grifols Therapeutics, Inc., Instituto Grifols, S.A., Grifols Worldwide Operations USA, Inc., Grifols USA, Llc. and Grifols International, S.A. (c) Credit rating In December 2021, Moody’s Investors Service confirmed the B1 corporate family rating (Ba3 in December 2020), Ba3 rating to the senior secured bank debt that was used to refinance the existing debt structure (Ba2 in December 2020). The outlook is stabilized as negative. The credit rating of the senior unsecured notes is B3 (B2 in December 2020). In September 2021, Standard & Poor’s has confirmed its BB- rating on Grifols (BB in December 2020) and has assigned BB ratings to Grifols’ senior secured debt that was used to refinance the existing debt structure (BB+ in December 2020). The outlook for the rating is downgraded to negative (stable in December 2020). The credit rating of the senior unsecured notes is B+ (B+ in December 2020). In September 2021, Fitch Ratings has confirmed its corporate global BB- rating on Grifols and has assigned BB+ ratings to Grifols’ senior secured debt and B+ rating to Grifols’ senior unsecured notes. The outlook for the rating is stable. (d) Other financial liabilities At 31 December 2021 other non-current financial liabilities include an amount of Euros 829,937 thousand (net of transaction costs) referring to the agreement with GIC (Sovereign Fund of Singapore). In November 2021 approval was received from the pertinent authorities to close this agreement, announced in June 2021, for an amount of US Dollars 990 million in exchange for 10 ordinary Class B shares in Biomat USA and nine ordinary Class B shares in a new sub-holding, Biomat Newco, created for this purpose. The main terms and conditions of the agreement with GIC at 31 December 2021 were: ● The distribution of annual preferential dividends to GIC equivalent to US Dollar 4,168 thousand per share, following majority approval of the Board of Directors of Biomat USA and Biomat Newco; ● The redemption right with respect to Class B stock for US Dollars 52,105 thousand per share, is subject to unilateral approval of the Class B stockholders (with one share annually redeemable starting as of 31 December 2022); ● From 1 December 2036, holders of Class B shares of Biomat USA will have the right to request Biomat USA to redeem up to the total of the Class B shares they hold at a value of US Dollars 52,105,263.16 per share. Class B shareholders of Biomat Newco will have the same right with respect to Biomat Newco. ● In the event that the dividends or the annual redemption at Biomat USA or Biomat NewCo, where applicable, is not approved, is partially paid, or is otherwise not paid, GIC holds the right to obtain in exchange thereof an undetermined number of shares among the following alternatives (i) an additional number of shares in Biomat USA, in lieu of the non-payment occurred at Biomat USA, (ii) an additional number of shares in Biomat NewCo, in lieu of the non-payment occurred at Biomat NewCo; or (iii) a number of ADRs of Grifols, S.A. in lieu of either (i) or (ii). ● Grifols holds the right to redeem all of the Class B stock from the fifth year onwards; ● In the event of liquidation of Biomat USA and Biomat Newco, GIC shall have the right to the preferential liquidation of US Dollars 52,105 thousand per share, but shall not have any rights over the liquidation of net assets of these companies. Grifols did not have the discretional right to avoid payment in cash and therefore, the instrument was recorded as a financial liability at 31 December 2021. The Group does not lose control of Biomat USA and will continue overseeing all aspects of the Biomat Group’s administration and operations.At 31 December 2021 “Other financial liabilities” include interest-free loans extended by governmental institutions amounting to Euros 9,637 thousand (Euros 12,060 thousand at 31 December 2020). The portion of the loans considered a grant and still to be taken to profit and loss amounts to Euros 390 thousand (Euros 499 thousand at 31 December 2020) (see note 19). At 31 December 2021 “Other current financial liabilities” include mainly the amount payable relating to the Gigagen, Inc. acquisition amounting to Euros 39,075 thousand (see note 3). At 31 December 2020 “Other current financial liabilities” included mainly the amount payable relating to the Alkahest, Inc. acquisition amounting to Euros 100,492 thousand (see note 3). Details of the maturity of other financial liabilities are as follows: Thousands of Euros 31/12/2021 31/12/2020 Maturity at: Up to one year 43,234 105,041 Two years 88,144 3,945 Three years 88,947 1,976 Four years 89,027 1,580 Five years 88,871 1,141 Over five years 483,837 1,630 882,060 115,313 (e) Changes in liabilities derived from financing activities Thousands of Euros Senior Secured debt & Other Finance lease Other financial Bonds loans liabilities liabilities Total Carrying amount at 1 January 2019 1,102,978 5,165,765 12,885 95,217 6,376,845 New financing 1,778,218 (1,522,466) — 12,249 268,001 Refunds (100,215) (145,261) (73,785) (8,152) (327,413) Interest accrued 37,095 171,535 34,558 1,166 244,354 Other movements (note 2) (108,874) 24,121 761,682 — 676,929 Interest paid/received (32,000) (204,179) — — (236,179) Business combinations (note 3) — 10,233 — — 10,233 Foreign exchange differences — 187,991 5,350 1,269 194,610 Balance at 31 December 2019 2,677,202 3,687,739 740,690 101,749 7,207,380 New financing 116,352 — — — 116,352 Refunds (105,564) (66,047) (79,037) (22,681) (273,329) Interest accrued 81,880 124,840 35,084 2,073 243,877 Other movements — (10,468) 88,867 4,837 83,236 Interest paid/received (60,355) (95,433) — — (155,788) Business combinations (note 3) — — — 34,778 34,778 Foreign exchange differences — (172,246) (52,105) (5,443) (229,794) Balance at December 31, 2020 2,709,515 3,468,385 733,499 115,313 7,026,712 New financing 2,126,979 329,555 — 829,937 3,286,471 Refunds (114,480) (266,659) (82,692) (3,507) (467,338) Interest accrued 100,948 130,327 35,786 2,165 269,226 Other movements (33,920) 5,445 135,697 729 107,951 Interest paid/received (64,031) (91,089) — — (155,120) Business combinations (note 3) — — — (64,749) (64,749) Foreign exchange differences 18,523 131,084 51,434 3,047 204,088 Balance at 31 December 2021 4,743,534 3,707,048 873,724 882,935 10,207,241 |
Trade and Other Payables
Trade and Other Payables | 12 Months Ended |
Dec. 31, 2021 | |
Trade and other payables | |
Trade and Other Payables | (22) Trade and Other Payables Details are as follows: Thousands of Euros 31/12/2021 31/12/2020 Suppliers 628,992 601,618 VAT payable 13,011 11,694 Taxation authorities, withholdings payable 7,267 6,829 Social security payable 39,191 32,640 Other public entities 92,365 89,926 Other payables 151,834 141,089 Current income tax liabilities 4,516 3,482 785,342 746,189 Suppliers Details of balances with related parties are shown in note 31. The Group’s exposure to currency risk and liquidity risk associated with trade and other payables is described in note 30. |
Other Current Liabilities
Other Current Liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Other Current Liabilities | |
Other Current Liabilities | (23) Other Current Liabilities Details at 31 December are as follows: Thousands of Euros 31/12/2021 31/12/2020 Salaries payable 175,710 121,972 Other payables 23 1,046 Deferred income 32,970 22,934 Advances received 10,569 7,210 Other current 219,272 153,162 At December 31, 2021 and December 31, 2020, the advances received are contract liabilities relate to unperformed performance obligations for which Grifols has received a consideration from the customer. |
Net Revenues
Net Revenues | 12 Months Ended |
Dec. 31, 2021 | |
Net Revenues | |
Net Revenues | (24) Net Revenues Net revenues are mainly generated from the sale of goods. The distribution of net consolidated revenues for 2021, 2020 and 2019 by segment is as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Bioscience 3,814,983 4,242,502 3,993,462 Diagnostic 779,108 775,889 733,604 Hospital 141,190 118,675 134,441 Bio supplies 225,765 224,090 266,540 Others 39,620 31,989 22,820 Intersegments (67,548) (53,107) (52,176) 4,933,118 5,340,038 5,098,691 The geographical distribution of net consolidated revenues is as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 USA and Canada 3,154,549 3,599,746 3,390,811 Spain 362,407 339,169 268,287 European Union 544,042 495,323 588,375 Rest of the world 872,120 905,800 851,218 Consolidated 4,933,118 5,340,038 5,098,691 Details of discounts and other reductions in gross income are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Gross sales 6,234,277 6,806,005 6,429,762 Chargebacks (1,101,896) (1,247,153) (1,119,540) Cash discounts (60,019) (68,912) (70,340) Volume rebates (49,043) (57,858) (56,426) Medicare and Medicaid (53,440) (61,089) (50,442) Other discounts (36,761) (30,955) (34,323) Net sales 4,933,118 5,340,038 5,098,691 Movement in discounts and other reductions in gross income during 2019 was as follows: Thousands of Euros Cash Volume Medicare / Other Chargebacks discounts rebates Medicaid discounts Total Balance at 31 December 2018 75,175 6,441 24,797 22,941 8,837 138,191 Current estimate related to sales made in current and prior year 1,119,540 70,340 56,426 50,442 34,323 1,331,071 (1) (Actual returns or credits in current period related to sales made in current period) (1,104,493) (64,523) (28,014) (34,486) (22,490) (1,254,006) (2) (Actual returns or credits in current period related to sales made in prior periods) 275 (6,385) (25,050) (20,375) (5,652) (57,187) (3) Translation differences (9) 24 546 389 53 1,003 Balance at 31 December 2019 90,488 5,897 28,705 18,911 15,071 159,072 Movement in discounts and other reductions to gross income during 2020 was as follows: Thousands of Euros Cash Volume Medicare / Other Chargebacks discounts rebates Medicaid discounts Total Balance at 31 December 2019 90,488 5,897 28,705 18,911 15,071 159,072 Current estimate related to sales made in current and prior year 1,247,153 68,912 57,858 61,089 30,955 1,465,966 (1) (Actual returns or credits in current period related to sales made in current period) (1,033,053) (61,387) (27,798) (34,564) (30,509) (1,187,311) (2) (Actual returns or credits in current period related to sales made in prior periods) (97,504) (6,030) (26,481) (14,526) (3,615) (148,156) (3) Translation differences (16,215) (597) (2,614) (2,459) (139) (22,023) Balance at 31 December 2020 190,869 6,795 29,670 28,451 11,763 267,548 Movement in discounts and other reductions to gross income during 2021 was as follows: Thousands of Euros Cash Volume Medicare / Other Chargebacks discounts rebates Medicaid discounts Total Balance at 31 December 2020 190,869 6,795 29,670 28,451 11,763 267,548 Current estimate related to sales made in current and prior year 1,101,896 60,019 49,043 53,440 36,761 1,301,159 (1) (Actual returns or credits in current period related to sales made in current period) (1,080,304) (54,554) (29,617) (42,890) (27,036) (1,234,401) (2) (Actual returns or credits in current period related to sales made in prior periods) (65,681) (6,964) (29,304) (15,422) (11,057) (128,428) (3) Translation differences 13,066 405 1,454 2,035 154 17,114 Balance at 31 December 2021 159,846 5,701 21,246 25,614 10,585 222,992 (1) Net impact in income statement: estimate for the current year plus prior years’ adjustments. Adjustments made during the year corresponding to prior years’ estimates have not been significant. (2) Amounts credited and posted against provisions for current period (3) Amounts credited and posted against provisions for prior period |
Personnel Expenses
Personnel Expenses | 12 Months Ended |
Dec. 31, 2021 | |
Personnel Expenses | |
Personnel Expenses | (25) Personnel Expenses Details of personnel expenses by function are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Cost of sales 999,347 1,058,132 988,689 Research and development 138,629 110,682 106,472 Selling, general & administration expenses 401,390 383,851 382,472 1,539,366 1,552,665 1,477,633 Details by nature are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Wages and salaries 1,231,812 1,234,761 1,178,527 Contributions to pension plans (see note 29) 31,757 33,226 29,941 Other social charges 27,387 27,462 28,785 Social Security 248,410 257,216 240,380 1,539,366 1,552,665 1,477,633 At 31 December 2021, as a result of the discontinuation of the Blood Collection Systems activity, the Group has recognized an amount of Euros 6.9 million of expense in the consolidated statement of profit and loss. |
Expenses by Nature
Expenses by Nature | 12 Months Ended |
Dec. 31, 2021 | |
Expenses by Nature | |
Expenses by Nature | (26) Expenses by Nature (a) Amortization and depreciation Expenses for the amortization and depreciation of intangible assets, right of use assets and property, plant and equipment, incurred during 2021, 2020 and 2019 classified by functions are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Cost of sales 211,676 198,310 193,081 Research and development 55,311 32,814 22,471 Selling, general & administration expenses 92,780 90,409 86,903 359,767 321,533 302,455 (b) Other operating income and expenses Other operating income and expenses incurred during 2021, 2020 and 2019 by function are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Cost of sales 535,058 500,415 467,705 Research and development 165,884 156,994 166,177 Selling, general & administration expenses 532,056 499,218 457,921 1,232,998 1,156,627 1,091,803 Details by nature are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Changes in trade provisions 4,844 (14,059) (19,811) Professional services 258,371 265,539 244,355 Commissions 28,671 27,147 32,178 Supplies and auxiliary materials 197,893 187,370 170,021 Operating leases (note 9) 32,945 28,176 33,235 Freight 148,797 137,466 130,663 Repair and maintenance expenses 150,308 147,039 136,377 Advertising 71,280 55,073 59,063 Insurance 38,724 30,776 25,647 Royalties 48,446 40,634 10,674 Travel expenses 30,334 23,005 61,346 External services 74,858 71,240 64,099 R&D Expenses 106,873 101,410 103,053 Other 40,654 55,811 40,903 Other operating income&expenses 1,232,998 1,156,627 1,091,803 |
Finance Result
Finance Result | 12 Months Ended |
Dec. 31, 2021 | |
Finance Result | |
Finance Result | (27) Finance Result Details are as follows: Thousands of Euros 31/12/2020 31/12/2020 31/12/2019 Finance income 11,551 8,021 114,197 Finance costs from Senior Unsecured Notes (104,944) (85,182) (41,920) Finance costs from senior debt (note 21 (b)) (111,719) (119,140) (262,797) Finance costs from sale of receivables (note 14) (10,292) (10,964) (9,171) Capitalized interest (note 10) 18,636 16,606 14,894 Finance lease expenses (note 9) (35,786) (35,205) (34,558) Other finance costs (33,889) (15,754) (9,413) Finance costs (277,994) (249,639) (342,965) Impairment and gains / (losses) on disposal of financial instruments — — (37,666) Change in fair value of financial instruments (note 11) 246 55,703 1,326 Exchange differences (11,602) 8,246 (9,616) Finance result (277,799) (177,669) (274,724) 2019 finance income from senior debt includes income of Euros 97,850 thousand related to the refinancing effect (see note 21). During 2021 the Group has capitalized interest at a rate of between 3.71% and 4.15% based on the financing received (between 3.72% and 4.70%% during 2020) (see note 4 (f)). “Change in fair value of financial instruments” at 31 December 2020 includes the difference between the contractual right value recognized at 31 December 2019 and the quoted value of SRAAS at 30 March 2020 for an amount of Euros 56,526 thousand (see note 11). At 31 December 2019, as part of the share exchange agreement with Shanghai RAAS Blood Products Co. Ltd., Grifols delivered 90 shares of its subsidiary Grifols Diagnostic Solutions, Inc. in exchange for a contractual right to receive equity instruments in an associate, which generated a profit related to the measurement of the contractual right amounting to Euros 1 million at 31 December 2019 (see note 11). |
Taxation
Taxation | 12 Months Ended |
Dec. 31, 2021 | |
Taxation | |
Taxation | (28) Taxation Grifols, S.A. is authorized to file consolidated tax returns in Spain with Grifols Movaco, S.A., Laboratorios Grifols, S.A., Instituto Grifols, S.A., Biomat, S.A., Grifols Viajes, S.A., Grifols International, S.A., Grifols Engineering, S.A., Gripdan Invest, S.L., Araclon Biotech, Aigües Minerals de Vilajuiga, S.A. and VCN Biosciences, S.L. Grifols, S.A., in its capacity as Parent, is responsible for the filing and settlement of the consolidated tax return. Under prevailing tax law, Spanish companies pay 25% tax, which may be reduced by certain deductions. The North American company Grifols Shared Services North America, Inc. is also authorized to file consolidated tax returns in the USA with Grifols Biologicals Inc., Grifols USA, LLC., Biomat USA, Inc., Grifols Therapeutics Inc., Talecris Plasma Resources, Inc, Interstate Blood Bank, Inc. and Goetech, LLC.. The profits of the companies domiciled in the USA, determined in accordance with prevailing tax legislation, are subject to tax of approximately 22% of taxable income, which may be reduced by certain deductions. Grifols assesses the effect of uncertain tax treatments and recognizes the effect of the uncertainty on taxable earnings. At 31 of December 2021, the potential obligations deriving from tax claims are properly covered. There are no lawsuits or uncertain tax treatments that are individually material. (a) Reconciliation of accounting and taxable income Details of the income tax expense and income tax related to profit for the year are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Profit before income tax from continuing operations 350,453 878,629 817,103 Tax at 25% 87,613 219,657 204,276 Permanent differences 2,503 (7,181) 6,104 Effect of different tax rates (8,720) (30,686) (22,564) Tax credits (deductions) (14,998) (14,980) (12,702) Prior year income tax expense 18,908 517 (3,722) Other income tax expenses/(income) (180) 2,312 (2,933) Total income tax expense 85,126 169,639 168,459 Deferred tax 17,754 43,138 58,275 Current tax 67,372 126,501 110,184 Total income tax expense 85,126 169,639 168,459 The effect of the different tax rates is basically due to a change of country mix in profits (b) Deferred tax assets and liabilities Details of deferred tax assets and liabilities are as follows: Thousands of Euros Tax effect 31/12/2021 31/12/2020 31/12/2019 Assets Provisions 8,387 3,942 6,228 Inventories 47,908 59,129 51,838 Tax credits (deductions) 26,425 57,896 61,476 Tax loss carryforwards 51,750 53,063 36,066 Other 19,993 11,004 6,531 Subtotal, assets 154,463 185,034 162,139 Goodwill (2,106) (30,040) (27,721) Fixed assets, amortisation and depreciation 3,151 (3,011) (2,821) Intangible assets (3,001) (2,062) (8,573) Subtotal, net liabilities (1,956) (35,113) (39,115) Deferred assets, net 152,507 149,921 123,024 Liabilities Goodwill (272,596) (215,907) (194,964) Intangible assets (288,819) (270,145) (214,993) Fixed assets (86,899) (78,325) (88,498) Debt cancellation costs (61,543) (66,720) (65,967) Subtotal, liabilities (709,857) (631,097) (564,422) Tax loss carryforwards 2,160 12,024 24,734 Inventories 5,532 1,673 2,408 Provisions 37,671 36,663 39,366 Other 30,510 23,924 34,087 Subtotal, net assets 75,873 74,284 100,595 Net deferred Liabilities (633,984) (556,813) (463,827) Movement in deferred tax assets and liabilities is as follows: Thousands of Euros Deferred tax assets and liabilities 31/12/2021 31/12/2020 31/12/2019 Balance at 1 January (406,892) (340,803) (291,859) Movements during the year (17,754) (43,138) (58,275) Business combination (note 3) (16,400) (47,988) — Translation differences (40,431) 25,037 9,331 Balance at 31 December (481,477) (406,892) (340,803) Detail of assets and liabilities by jurisdiction at 31 December 2021 are as follows: USA Spain Other Total 31/12/2021 31/12/2021 31/12/2021 31/12/2021 Net deferred tax (578,061) (17,963) 36,372 (559,652) Tax credit rigths — 26,425 — 26,425 Tax loss carryforwards 15,236 4,808 31,706 51,750 (562,825) 13,270 68,078 (481,477) Detail of assets and liabilities by jurisdiction at 31 December 2020 are as follows: USA Spain Other Total 31/12/2020 31/12/2020 31/12/2020 31/12/2020 Net deferred tax (466,961) (36,298) (26,616) (529,875) Tax credit rigths — 57,861 35 57,896 Tax loss carryforwards 21,277 4,928 38,882 65,087 (445,684) 26,491 12,301 (406,892) Detail of assets and liabilities by jurisdiction at 31 December 2019 are as follows: USA Spain Other Total 31/12/2019 31/12/2019 31/12/2019 31/12/2019 Net deferred tax (392,040) (35,117) (35,921) (463,078) Tax credit rigths 54,340 5,162 1,297 60,799 Tax loss carryforwards — 61,476 — 61,476 (337,700) 31,521 (34,624) (340,803) The Spanish companies have opted to apply accelerated depreciation to certain additions to property, plant and equipment, which has resulted in the corresponding deferred tax liability. The remaining assets and liabilities recognized in 2021, 2020 and 2019 were recognized in the statement of profit and loss. Estimated net deferred tax assets to be reversed in a period of less than 12 months amount to Euros 57,183 thousand at 31 December 2021 (Euros 89,750 thousand at 31 December 2020). The majority of the tax deductions pending application from Spanish companies related mainly to research and development, mature in 18 years. Likewise, the Group estimates that practically the entire amount will be applied in five years. Tax loss carryforwards pending to be offset derived from the US companies are available for 20 years from their date of origin whilst tax losses carryforwards pending to be offset from Spanish companies registered in the Basque Country are available for 15 years and there is no maturity date for other remaining Spanish companies. The Group estimates that of the total amount of tax credits for tax losses recognized in the balance sheet at 31 December 2021 for an amount of Euros 53,910 thousand, approximately Euros 48,453 thousand will be recovered in a period of less than 5 years. The Group has not recognized as deferred tax assets the tax effect of the unused tax loss carryforwards of Group companies, which amount to Euros 123,407 thousand (Euros 93,585 thousand at 31 December 2020). The amount of unrecognized deferred tax liabilities associated with investments in subsidiaries amounted to Euros 52,119 thousand as of 31 December 2021 (Euros 51,537 thousand as of 31 December 2020). The commitments from Spanish companies from the reversal of deferred tax related to provisions of investments in subsidiaries are not significant. (c) Years open to inspection Under prevailing legislation, taxes cannot be considered to be definitively settled until the returns filed have been inspected by the taxation authorities, or the prescription period has elapsed. The main tax audits currently open in the Group are as follows: ● Certain companies of the Group domiciled in Spain have been subject to an inspection by the Spanish State Tax Administration Agency in relation to Corporate Income Tax for the years 2014, 2015 and 2016 and Value Added Tax for the years 2015 and 2016. As a result of said procedure, the State Tax Administration Agency has issued assessments containing the results of the inspection, where it is indicated that the treatment of certain transactions and computations mainly related to Transfer Pricing should be adjusted, taking into consideration different interpretations related to the allocation of taxable bases between different jurisdictions. With respect to Corporate Income Tax, the deductibility of certain expenses for the computation of the tax payable has been questioned. These assessments have been signed in conformity by the Group on 8 November 2021. It should be noted that no penalties have been imposed on any of the Group companies for any of the taxes subject to verification. The results of the inspection did not have a significant impact on the Group’s consolidated financial statements, and the differences determined by the State Tax Administration Agency have been recorded as part of the current tax included under the heading “Current tax liabilities” in the Consolidated Balance Sheet as of 31 December 2021. If the result of the procedure is considered to be replicable to years not reviewed and open to inspection, the Group has estimated that it is not necessary to record provisions in the consolidated financial statements mainly because the number of transactions that gave rise to the aforementioned assessments has significantly decreased since the years in which they were inspected. Likewise, having adjusted the allocation of taxable income in accordance with the aforementioned assessments for the purposes of their consideration for the determination of Transfer Pricing, the Group now has a legal right to recover certain amounts from the corresponding Administration, in accordance with the provisions of the European Convention on International Commercial Arbitration with respect to international double taxation. The minimum amount to be recovered, upon which its realization is virtually certain, has been recorded as a non-current receivable included in the caption “other payable” as of 31 December 2021. ● Grifols Shared Services North America, Inc. and subsidiaries: In 2020 notification of an inspection was received relating to the State Income Tax for the fiscal years 2017 and 2018. Group management does not expect any significant liability to derive from these inspections. Based on its experience of the different tax inspections in the different jurisdictions in which Grifols operates, the Group considers it unlikely that there will be a scenario of discrepancy with the taxation authorities that will require significant adjustments to be made to the tax result or to the asset and/or liability balances relating to corporate income tax. |
Other Commitments with Third Pa
Other Commitments with Third Parties and Other Contingent Liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Other Commitments with Third Parties and Other Contingent Liabilities | |
Other Commitments with Third Parties and Other Contingent Liabilities | (29) Other Commitments with Third Parties and Other Contingent Liabilities (a) Guarantees The Group has no significant guarantees extended to third parties. (b) Guarantees committed with third parties The Group has no significant guarantees extended to third parties, except for those described in note 21. (c) Obligations with personnel The Group’s annual contribution to defined contribution pension plans of Spanish Group companies for 2021 has amounted to Euros 948 thousand (Euros 896 thousand for 2020). In successive years this contribution will be defined through labor negotiations. In the event that control is taken of the Company, the Group has agreements with 50 employees/directors whereby they can unilaterally rescind their employment contracts with the Company and are entitled to termination benefits ranging from two The Group has contracts with five executives entitling them to termination benefits ranging from one Restricted Share Unit Retention Plan For the annual bonus, the Group established a Restricted Share Unit Retention Plan (RSU Plan), for eligible employees. Under this plan, employees can choose to receive up to 50% of their yearly bonus in non-voting Class B ordinary shares (Grifols Class B Shares) or Grifols American Depositary Shares (Grifols ADS), and the Group will match this with an additional 50% of the employee’s choice of RSUs. Grifols Class B Shares and Grifols ADS are valued at grant date. These RSU’s will have a vesting period of 2 years and 1 day If an eligible employee leaves the Company or is terminated before the vesting period, he/she will not be entitled to the additional RSU’s. At 31 December 2021, the Group has settled the RSU plan of 2018 for an amount of Euros 7,782 thousand (Euros 7,552 thousand at 31 December 2020 corresponding to the RSU plan of 2017). This commitment is treated as equity instrument and the amount totals Euros 9,838 thousand at 31 December 2021 (Euros 13,880 thousand at 31 December 2020). Savings plan and profit-sharing plan The Group has a defined contribution plan (savings plan), which qualifies as a deferred salary arrangement under Section 401 (k) of the Internal Revenue Code (IRC). Once eligible, employees may elect to contribute a portion of their salaries to the savings plan, subject to certain limitations. The Group matches 100% of the first 4% of employee contributions and 50% of the next 2%. Group and employee contributions are fully vested when contributed. The total cost of matching contributions to the savings plan was US Dollars 31.8 million in 2021 (US Dollars 32.2 million in 2020). Other plans The Group has a defined benefit pension plan for certain former Talecris Biotherapeutics, GmbH employees in Germany as required by statutory law. The pension cost relating to this plan is not material for the periods presented. (d) Purchase commitments Details of the Group’s raw material purchase commitments at 31 December 2021 are as follows: Thousands of Euros 2022 90,413 2023 78,909 2024 72,103 2025 1,116 2026 651 More than 5 years — (e) Judicial procedures and arbitration Details of legal proceedings in which the Company or Group companies are involved are as follows: ● ABBOTT LABORATORIES v. GRIFOLS DIAGNOSTIC SOLUTIONS INC., GRIFOLS WORLDWIDE OPERATIONS LIMITED AND NOVARTIS VACCINES AND DIAGNOSTICS, INC. Served: 8 October 2019 US District Court, Northern District of Illinois Patent Infringement, Civil Action No. 1:19-cv-6587 Abbott Laboratories (“Abbott”), GDS, GWWO and Novartis Vaccines and Diagnostics, Inc. are in dispute over unpaid royalties payable by Abbott to GDS and Ortho-Clinical Diagnostics (“Ortho”) under an HIV License and Option agreement dated 16 August 2019 (the “HIV License”). On 12 September 2019, GDS and Ortho filed Notice of Arbitration. On 3 October 2019, Abbott terminated the HIV License and filed for Declaratory Relief seeking to invalidate the licensed patent. On 16 March 2020, Grifols and Ortho filed an answer and counterclaim to the litigation, while simultaneously pursuing arbitration for the pre-termination amount owed by Abbott. The arbitration hearing was 15-16 June 2020. Grifols/Ortho were awarded US Dollars4 Million. NEXT ACTION: The court litigation is continuing with regard to post termination infringement of Grifols' patents. Abbot’s Motion to Dismiss was denied 1 December 2020. Fact discovery has concluded. The court conducted a Markman (Claim Construction) hearing on February 25, 2022. Order on claim construction expected end of April, 2022. ● SIEMENS HEALTHCARE DIAGNOSTICS, INC. adv. ORTHO-CLINICAL DIAGNOSTICS, INC., GRIFOLS DIAGNOSTIC SOLUTIONS INC. Served: 10 November 2020 Contract Dispute Siemens initiated dispute resolution against Ortho and GDS under the Supply Agreement alleging overpayments after an audit by Siemens. NEXT ACTION: Arbitration is continuing. All fact witnesses have testified. Yet to be scheduled is the questioning of experts, a final briefing and final oral argument. POTENTIAL OUTCOME: Based on current financial calculations, it is probable that there may be a finding for Grifols to pay Siemens under the supply agreement, up to US Dollars 12 million (best estimate). ● RAMIREZ-VIVAR, ALFONSO v. GRIFOLS DIAGNOSTIC SOLUTIONS, INC. Served: 11 March 2021 Superior Court, CA County of Alameda Case No.: RG21089519 Wage & Hour Class Action Plaintiff claiming violation of CA wage & hour statutes. NEXT STEP: Plaintiff's deposition taken on 28 June 2021. Parties have continued with written discovery., Person Most Knowledgeable depositions are being scheduled. Belaire-West notices to proposed class members were sent out to proposed class members in March 2022. Class certification motion is currently scheduled to be filed by 2 May 2022. CLASS POTENTIAL: Approx. 300 CA GDS employees for payroll/wage & hour violations per pay period for 4 years ● VAUGHAN, BRIAN, DARNELL, JASON v. BIOMAT USA, INC., TALECRIS PLASMA RESOURCES, INC., INTERSTATE BLOOK BANK, INC. Served: 22 June 2020 Circuit Court of Cook County Case No. 2020CH04519 Illinois Biometric Information Protection Act Former donor and employee alleging violation of IL Biometric Information Protection Act in potential class action. NEXT ACTION: Motion to Dismiss and all responsive pleadings have been filed as of 17 December 2021. Await court ruling. Plaintiff has been pushing discovery even with MTD pending. Negotiating discovery parameters. If proposed discovery is limited, we will request a protective order. If it is not, a motion for stay of discovery will be initiated. CLASS POTENTIAL: Approx. 54,000 Biomat donors for Illinois Biomat Centers over 4 years x $1,000 BIPA penalty for negligent violation. This estimate is from 2020 and current numbers are being run. Interstate Blood Bank, Inc. was also added to the suit and potential donor numbers are being run. At this time, there is insufficient information to determine that there is any probability of liability on Grifols. ● CERUS CORPORATION v. LABORATORIOS GRIFOLS, S.A. Cerus Corporation (“Cerus”) and Laboratorios Grifols, S.A. (“Grifols”) entered into a Manufacturing and Supply Agreement executed in 2016, pursuant to which Grifols was to manufacture and supply to Cerus processing and filters sets to be used by Cerus in its own product (the “Agreement”). As a result of Grifols’ decision to discontinue the manufacturing, sale and support of its blood bag product business worldwide, Grifols is unable to comply with the Agreement. In December 2021, Cerus filed a notice of arbitration in the UK pursuant to the terms of the Agreement alleging wrongful termination of the Agreement by Grifols. Furthermore, in January 2022, Cerus filed injunctive measures with the Courts of Rubí (Barcelona) requiring the suspension of the closure of Grifols’ blood bags production facility until the arbitration proceedings is finalized. NEXT ACTION: The parties have agreed that the arbitration will be conducted by a 3 person tribunal. Cerus has appointed its arbitrator and Grifols is currently selecting one. The appointed arbitrators will then appoint the third arbitrator. In parallel, the hearing on the injunctive measures is set for March 2022. At the end of February the Parties requested that both the arbitration and the hearing on the injunctive measures be suspended for a period of 60 days to negotiate an out-of-court solution on the conflict. Both the arbitrators and the Court in charge of the injunctive measures accepted the suspension. At this time and based upon the current state of negotiations, the most likely resolution of the conflict is that the companies reach an amicable solution to continue their commercial relationship (manufacturing and supply agreement) on satisfactory terms for both parties. ● THE STATE CO. FOR MARKETING DRUGS AND MEDICAL APPLIANCES IN IRAQ (KIMADIA) v. LABORATORIOS GRIFOLS, S.A. The State Co. for Marketing Drugs and Medical Appliances in Iraq (“KIMADIA”) awarded a tender for the supply of blood bags to Laboratorios Grifols, S.A. (“Grifols”). Grifols, through Hali/Tiba (its agent in Iraq), informed KIMADIA on Grifols’ inability to supply the blood bags pursuant to the tender awarded, due to its decision to discontinue the manufacturing, sale and support of its blood bag product business. The tender documents set forth a list of penalties and compensations in case the awardee is unable to supply the products to KIMADIA. Further, Hali/Tiba also claims Grifols a compensation for the services performed in relation to the tender. NEXT ACTION: Grifols is going to initiate discussions with KIMADIA, with the assistance of Hali/Tiba, to agree on a possible compensation to be paid to KIMADIA, so as to avoid any possible judicial proceedings. Currently, the negotiations, which are very slow, are on-going, with the local assistance of Hali/Tiba to try to reduce the possible penalties set forth in the tender documents. |
Financial Instruments
Financial Instruments | 12 Months Ended |
Dec. 31, 2021 | |
Financial Instruments | |
Financial Instruments | (30) Financial Instruments Classification Disclosure of financial instruments by nature, category and fair value is as follows: Thousands of Euros 31/12/2021 Carrying amount Fair Value Financial assets Financial Financial Other at amortised Financial assets assets at FV liabilities at financial costs at FVTPL to OCI Hedges amortised costs liabilities Total Level 1 Level 2 Level 3 Total Non-current financial assets — 7 2,031 — — — 2,038 7 — 2,031 2,038 Derivatives instruments — — — 5,306 — — 5,306 — 5,306 — 5,306 Trade receivables — — 216,433 — — — 216,433 — 216,433 — 216,433 Financial assets measured at fair value — 7 218,464 5,306 — — 223,777 Non-current financial assets 358,161 — — — — — 358,161 Other current financial assets 2,026,469 — — — — — 2,026,469 Trade and other receivables 270,827 — — — — — 270,827 Cash and cash equivalents 655,493 — — — — — 655,493 Financial assets not measured at fair value 3,310,950 — — — — — 3,310,950 Derivatives instruments — (875) — — — (875) — (875) — (875) Financial liabilities measured at fair value — (875) — — — — (875) Senior Unsecured & Secured Notes — — — — (4,626,919) — (4,626,919) (4,697,328) — — (4,697,328) Promissory Notes — — — — (116,610) — (116,610) Senior secured debt — — — — (3,061,078) — (3,061,078) — (3,262,901) — (3,262,901) Other bank loans — — — — (645,975) — (645,975) Lease liabilities — — — — (873,724) — (873,724) Other financial liabilities — — — — (882,060) — (882,060) Other non-current debts — — — — — (333) (333) Trade and other payables — — — — (780,826) — (780,826) Other current liabilities — — — — — (219,272) (219,272) Financial liabilities not measured at fair value — — — — (10,987,192) (219,605) (11,206,797) 3,310,950 (868) 218,464 5,306 (10,987,192) (219,605) (7,672,945) The Group does not provide details of the fair value of certain financial instruments as their carrying amount is very similar to their fair value because of its short term. Thousands of Euros 31/12/2020 Carrying amount Fair Value Financial assets Financial Financial Financial Other at amortised assests at assets at FV liabilities at financial costs FV to profit or loss to OCI amortised costs liabilities Total Level 1 Level 2 Level 3 Total Non-current financial assets — 1,128 1,880 — — 3,008 1,128 — 1,880 3,008 Trade receivables — — 308,485 — — 308,485 — 308,485 — 308,485 Financial assets measured at fair value — 1,128 310,365 — — 311,493 Non-current financial assets 195,149 — — — — 195,149 Other current financial assets 11,118 — — — — 11,118 Trade and other receivables 147,108 — — — — 147,108 Cash and cash equivalents 579,647 — — — — 579,647 Financial assets not measured at fair value 933,022 — — — — 933,022 Senior Unsecured & Secured Notes — — — (2,601,479) — (2,601,479) (2,705,437) — — (2,705,437) Promissory Notes — — — (111,622) — (111,622) Senior secured debt — — — (3,110,298) — (3,110,298) — (3,358,729) — (3,358,729) Other bank loans — — — (354,501) — (354,501) Lease liabilities — — — (733,499) — (733,499) Other financial liabilities — — — (115,313) — (115,313) Other non-current debts — — — — (16,391) (16,391) Trade and other payables — — — (742,707) — (742,707) Other current liabilities — — — — (153,162) (153,162) Financial liabilities not measured at fair value — — — (7,769,419) (169,553) (7,938,972) 933,022 1,128 310,365 (7,769,419) (169,553) (6,694,457) The Group does not provide details of the fair value of certain financial instruments as their carrying amount is very similar to their fair value because of its short term. Financial derivatives At 31 December 2021 the Group has recognized the following derivatives: Thousands of Euros Notional Notional amount at amount at Value at Value at Financial derivatives Currency 31/12/2021 31/12/2020 31/12/21 31/12/20 Maturity Cross currency interest rate swap US Dollar 500,000,000 — 5,306 — 15/10/2024 Foreign exchange rate forward Canadian dollar 51,000,000 — (875) — 25/01/2022 Total 4,431 — Total Assets (notes 2 and 11) 5,306 — Total Liabilities (notes 21 and 30) (875) — (a) Hedging derivative financial instruments On 5 October 2021, the Group subscribed three cross currency interest-rate swap of US Dollars 500 million to hedge part of the Euro equivalent value of the new US Dollar unsecured notes issue. It is a fixed-to-fixed USD/EUR cross currency swap with the following characteristics: - The Group receives a loan of Euros 431.6 million at a nominal interest rate of 3.78% - The Group gives a loan of US Dollars 500 million at a nominal interest rate of 4.75% The derivative complies with the criteria required for hedge accounting. See further details in notes 4 (l) and 16 (g). (b) Derivative financial instruments at fair value through profit and loss The Group has subscribed a foreign exchange forward dated trade to partially hedge the US dollar equivalent value of a Canadian dollar intercompany loan. Since the Group chooses not to apply hedge accounting criteria, gains or losses resulting from changes in the fair value of derivatives are taken directly to “Change in fair value of financial instruments” in the consolidated statement of profit and loss. At 31 December 2021, the Group has recognized a net finance cost of Euros 280 thousand. Credit risk (a) Exposure to credit risk The carrying amount of financial assets represents the maximum exposure to credit risk. At 31 December 2021 and 2020 the maximum level of exposure to credit risk is as follows: Thousands of Euros Carrying amount Note 31/12/2021 31/12/2020 Non-current financial assets 12 362,267 198,157 Other current financial assets 12 2,029,707 11,118 Trade receivables 14 432,197 383,233 Other receivables 14 17,224 24,377 Cash and cash equivalents 15 655,493 579,647 3,496,888 1,196,532 The maximum level of exposure to risk associated with receivables at 31 December 2021 and 2020, by geographical area, is as follows. Thousands of Euros Carrying amount 31/12/2021 31/12/2020 Spain 62,108 62,358 EU countries 40,897 84,962 United States of America 108,685 157,395 Other European countries 25,163 10,525 Other regions 212,568 92,370 449,421 407,610 (b) Impairment losses A breakdown of the trade and other receivables net of the impairment losses by ageing as of 31 December 2020 is as follows: Thousands of Euros Total net trade Total gross carrying receivable third ECL Rate amount Provision party Not matured 0.19 % 283,612 (515) 283,097 Past due 0-30 days 0.19 % 34,282 (54) 34,228 Past due 31-60 days 0.62 % 9,157 (57) 9,100 Past due 61-90 days 2.03 % 6,155 (125) 6,030 Past due 91-180 days 3.01 % 16,546 (211) 16,335 Past due 181-365 days 8.52 % 34,768 (325) 34,443 More than one year 100.00 % 4,861 (4,861) — Customers with objective evidence of impairment 16,837 (16,837) — 406,218 (22,985) 383,233 A breakdown of the trade and other receivables net of the impairment losses by seniority at 31 December 2021 is as follows: Thousands of Euros Total net trade Total gross carrying receivable third ECL Rate amount Provision party Not matured 0.19 % 362,599 (445) 362,154 Past due 0-30 days 0.19 % 32,623 (51) 32,572 Past due 31-60 days 0.62 % 14,144 (79) 14,065 Past due 61-90 days 2.03 % 6,556 (133) 6,423 Past due 91-180 days 3.01 % 11,000 (311) 10,689 Past due 181-365 days 8.52 % 6,543 (249) 6,294 More than one year 100.00 % 3,911 (3,911) — — Customers with objective evidence of impairment 18,830 (18,830) — 456,206 (24,009) 432,197 Unimpaired receivables that are past due mainly relate to public entities. Movement in the bad debt provision was as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Opening balance 22,985 22,291 20,531 Net charges for the year 6,471 2,436 4,971 Net cancellations for the year (6,269) (124) (3,142) Transfers — (29) (19) Translation differences 822 (1,589) (50) Closing balance 24,009 22,985 22,291 An analysis of the concentration of credit risk is provided in note 5 (a). Liquidity risk The management of the liquidity risk is explained in note 5. Details of the contractual maturity dates of financial liabilities including committed interest calculated using interest rate forward curves are as follows: Thousands of Euros Carrying amount at Contractual 6 months 6 - 12 1-2 2 - 5 More than Carrying amount Note 31/12/21 flows or less months years years 5 years Financial liabilities Bank loans 21 3,707,053 4,309,621 476,397 78,524 102,070 3,641,777 10,853 Other financial liabilities 21 882,060 1,294,873 41,934 1,300 164,718 448,161 638,760 Bonds and other marketable securities 21 4,743,529 5,663,320 2,215,138 170,572 48,538 3,145,255 83,817 Lease liabilities 21 873,724 873,723 24,640 23,927 47,595 184,032 593,529 Payable to suppliers 22 628,992 628,992 622,091 6,901 — — — Other current liabilities 23 43,562 43,562 42,387 1,175 — — — Financial derivatives 875 875 875 — — — — Total 10,879,795 12,814,966 3,423,462 282,399 362,921 7,419,225 1,326,959 Thousands of Euros Carrying amount at Contractual 6 months 6 - 12 1-2 2 - 5 More than Carrying amount Note 31/12/20 flows or less months years years 5 years Financial liabilities Bank loans 21 3,464,799 4,176,075 190,659 89,704 134,789 502,605 3,258,318 Other financial liabilities 21 115,313 115,314 103,397 1,645 3,372 5,515 1,385 Bonds and other marketable securities 21 2,713,101 3,119,194 144,756 32,016 64,031 2,091,066 787,325 Lease liabilities 21 733,499 733,499 21,896 20,746 40,961 158,032 491,864 Payable to suppliers 22 601,618 601,618 601,585 33 — — — Other current liabilities 23 31,190 31,190 30,369 821 — — — Total 7,659,520 8,776,890 1,092,662 144,965 243,153 2,757,218 4,538,892 Currency risk The Group’s exposure to currency risk is as follows: Thousands of Euros 31/12/2021 Euros (*) Dollars (**) Trade receivables 2,023 14,800 Receivables from Group companies 141,285 7,101 Loans to Group companies 464,789 21 Cash and cash equivalents 25,766 82 Trade payables (27,098) (23,349) Payables to Group companies (62,930) (6,480) Loans from Group companies (11,495) (3) Bank loans (372,500) — Balance sheet exposure 159,840 (7,828) (*) Balances in Euros in subsidiaries with US Dollars functional currency (**) Balances in US Dollars in subsidiaries with Euros functional currency Thousands of Euros 31/12/2020 Euros (*) Dollars (**) Trade receivables 1,468 19,938 Receivables from Group companies 112,442 6,140 Loans to Group companies 221,135 55 Cash and cash equivalents 35,034 416 Trade payables (46,318) (10,822) Payables to Group companies (61,421) (72,693) Loans from Group companies (18,391) (1,726) Bank loans (53,125) — Balance sheet exposure 190,824 (58,692) (*) (**) The most significant exchange rates applied at 2021 and 2020 year ends are as follows: Closing exchange rate Euros 31/12/2021 31/12/2020 US Dollars 1.1326 1.2234 A sensitivity analysis for foreign exchange fluctuations is as follows: Had the US Dollar strengthened by 10% against the Euro at 31 December 2021, equity would have increased by Euros 812,285 thousand (Euros 750,646 thousand at 31 December 2020) and profit due to foreign exchange differences would have increased by Euros 15,201 thousand (would have increased by Euros 13,213 thousand at 31 December 2020). This analysis assumes that all other variables are held constant, especially that interest rates remain constant. A 10% weakening of the US Dollar against the Euro at 31 December 2021 and 2020 would have had the opposite effect for the amounts shown above, all other variables being held constant. The Group applies hedge accounting to partially hedge its exposure to currency risk (see note 5). Interest rate risk (a) Interest-rate profile To date, the profile of interest on interest-bearing financial instruments is as follows: Thousands of Euros 31/12/2021 31/12/2020 Fixed-interest financial instruments Financial liabilities (4,878,087) (2,887,500) (4,878,087) (2,887,500) Variable-interest financial instruments Financial liabilities (3,296,025) (3,369,451) (3,296,025) (3,369,451) (8,174,112) (6,256,951) (b) Sensitivity analysis If the interest rate had been 100 basis points higher at 31 December 2021, the interest expense would have increased by Euros 35,449 thousand. As the Group does not have any hedging derivatives in place, the net effect on cash interest payments would have increased by the same amount. If the interest rate had been 100 basis points higher at 31 December 2020, the interest expense would have increased by Euros 36,153 thousand. As the Group does not have any hedging derivatives in place, the net effect on cash interest payments would have increased by the same amount. |
Balances and Transactions with
Balances and Transactions with Related Parties | 12 Months Ended |
Dec. 31, 2021 | |
Balances and Transactions with Related Parties | |
Balances and Transactions with Related Parties | (31) Balances and Transactions with Related Parties Details of balances with related parties are as follows: Thousands of Euros 31/12/2021 31/12/2020 Receivables from associates (note 14) 131,764 1,447 Trade payables associates (3) (133) Loans to other related parties (note 12) 89,104 80,851 Other financial assets with other related parties 220,947 114,825 Debts with key management personnel (6,644) (5,934) Payables to other related parties (3,824) (6,613) 431,344 184,443 Payables are included in trade and other payables (see note 22). (a) Group transactions with related parties Group transactions with related parties during 2019 were as follows: Thousands of Euros Key management Other related Board of directors Associates personnel parties of the Company Net sales 10,196 — — — Purchases (48,300) — — — Other service expenses (25,638) — (5,586) (220) Remuneration — (16,795) — (5,517) Payments for rights of use — — (7,104) — Finance income 2,265 — — — Finance cost (158) — — — (61,635) (16,795) (12,690) (5,737) Group transactions with related parties during 2020 were as follows: Thousands of Euros Key management Other related Board of directors Associates personnel parties of the Company Net sales 10,522 — — — Purchases (459) — — — Other service expenses (15,010) — (10,344) — Remuneration — (17,164) — (4,966) Payments for rights of use — — (5,137) — Purchase of property, plant and equipment — — (13,500) — Finance income 10,939 — — — 5,992 (17,164) (28,981) (4,966) Group transactions with related parties during 2021 are as follows: Thousands of Euros Key management Other related Board of directors Associates personnel parties of the Company Net sales 220,808 — — — Purchases (613) — — — Other service expenses (2,709) — (3,963) — Remuneration — (15,136) — (4,417) Payments for rights of use — — (5,332) — Purchase of property, plant and equipment — — 7,326 — Finance income 2,638 — — — 220,124 (15,136) (1,969) (4,417) Every year the Group contributes 0.7% of its profits before tax to a non-profit organization. “Other service expenses” include contributions to non-profit organizations totaling Euros 3,963 thousand in 2021 (Euros 10,344 thousand in 2020 and Euros 5,586 thousand in 2019). During 2011 one of the Company’s directors signed a three-year consulting services contract. The director received annual fees of US Dollars 1 million for these services and an additional bonus of US Dollars 2 million for complying with certain conditions. In the years 2014, 2015, 2017 and 2018 the contract was renewed and the amount of the fees corresponded to US Dollars 1 million per year. The contract expired on 31 March 2019 and during 2019 the fees amounted to US Dollars 250 thousand. On 28 December 2018, the Group sold Biotest and Haema to Scranton Enterprises B.V (shareholder of Grifols) for US Dollars 538,014 thousand (see note 3). For the payment of the mentioned amount of the sale, Scranton signed a loan contract dated 28 December 2018 for an amount of US Dollars 95,000 thousand (Euros 82,969 thousand) with Grifols Worldwide Operations Limited. The compensation is 2%+EURIBOR and due on 28 December 2025. Directors representing shareholders´ interests have received remuneration of Euros 965 thousand in 2021 (Euros 965 thousand in 2020). The Group has not extended any advances or loans to the members of the board of directors or key management personnel nor has it assumed any guarantee commitments on their behalf. It has also not assumed any pension or life insurance obligations on behalf of former or current members of the board of directors or key management personnel. In addition, certain Company directors and key management personnel have termination benefit commitments (see note 29 (c)). (b) Conflicts of interest concerning the directors The Company’s directors and their related parties have not entered into any conflict of interest that should have been reported in accordance with article 229 of the revised Spanish Companies Act. |
COVID-19 Impact
COVID-19 Impact | 12 Months Ended |
Dec. 31, 2021 | |
COVID-19 Impact | |
COVID-19 Impact | (32) The impacts from COVID-19 pandemic are detailed in the consolidated Directors’ report included in these notes to the consolidated financial statements. |
Subsequent events
Subsequent events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent events | |
Subsequent events | (33) Subsequent events a) GIC Transaction On 28 April 2022, the consolidated annual accounts at 31 December 2021 prepared under IFRS-EU principles have been re-authorized for issue due to the need to carry out a reclassification in the balance sheet of the financial instrument signed with GIC, described in Note 21, from net equity to financial liability. However, at the date of preparation of these consolidated financial statements, the parties are analyzing the necessary modifications in the terms and conditions of the agreement in order to classify such transaction as an equity instrument, thereby reflecting their initial will of the parties. b) Biotest, AG In September 2021, Grifols announced its strategic investment in Biotest, a transaction that underscores the companies’ shared commitment to work together to globally increase the availability of plasma therapies for the benefit of patients around the world. The investment in Biotest will significantly reinforce Grifols’ scientific and industrial capabilities, helping to increase the availability of plasma medicines and broaden its commercial footprint and R&D project portfolio. Following the opening of two new centers, Biotest now has 28 plasma donation centers in Europe. In April 2022, having completed the Public Takeover Offer (PTO) and closed the acquisition of Tiancheng (Germany) Pharmaceutical Holdings, Grifols now controls 96.20% of the voting rights of Biotest AG and holds 69.72% of its share capital. Grifols has agreed to acquire the entire share capital of Tiancheng (Germany) Pharmaceutical Holdings AG for EUR 1,091 million. This amount includes a loan receivable, granted by Tiancheng (Germany) Pharmaceutical Holdings to Biotest AG, for an amount of EUR 318 million. The shares of Biotest were valued at EUR 43.00 per ordinary share (17.783.776 shares) and at EUR 37.00 per preferred share (214.581 shares). Parallel to the transaction, Grifols has closed the voluntary public tender offer (VTO) to all outstanding shareholders, resulting in the payment of EUR 362 million for 1,250,298 ordinary shares at EUR 43.00 per share and 8,340,577 preferred shares at EUR 37.00 per share. c) Endpoint Health On February 2022 Grifols announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop an antithrombin (AT) therapy to treat disseminated intravascular coagulation (DIC) caused by severe sepsis or septic shock, a life-threatening response to infection. As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of AT, a plasma protein that treats patients with blood clotting issues. In exchange for a US Dollar 10 million upfront investment, Grifols will become a 5% preferred shareholder at Endpoint Health on a fully diluted basis. The collaboration with Endpoint Health, which will furnish its proprietary diagnostic test to identify septic patients mostly likely to respond to AT therapy, aims to expand Thrombate®’s indication. Upon FDA approval and according to market sourcing needs for AT at the time, the companies will invest up to US 125 million in a multiyear build-out of AT production at Grifols sites in Barcelona, Los Angeles and North Carolina. |
Appendix I
Appendix I | 12 Months Ended |
Dec. 31, 2021 | |
Appendix I | |
Appendix I | Acquisition / 12/31/2021 12/31/2020 12/31/2019 Registered Registered Incorporation % shares % shares % shares Name Offices Office date Activity Statutory Activity Direct Indirect Direct Indirect Direct Indirect Fully Consolidated Companies Diagnostic Grifols, S.A. Spain Polígono Levante 1987 Industrial Development and manufacture of diagnostic equipment, instruments and reagents. — 100.000 % — 100.000 % — 100.000 % Instituto Grifols, S.A. Spain Polígono Levante 1987 Industrial Plasma fractioning and the manufacture of haemoderivative pharmaceutical products. 99.998 % 0.002 % 99.998 % 0.002 % 99.998 % 0.002 % Grifols Worldwide Operations Spain, S.A (formerly Logister, S.A.) Spain Polígono Levante 1987 Services Manufacture, sale and purchase, commercialisation and distribution of all types of computer products and materials. — — — — — — Laboratorios Grifols, S.A. Spain Polígono Levante 1989 Industrial Production of glass- and plastic-packaged parenteral solutions, parenteral and enteral nutrition products 98.600 % 1.400 % 98.600 % 1.400 % 98.600 % 1.400 % Biomat, S.A. Spain Polígono Levante 1991 Industrial Analysis and certification of the quality of plasma used by Instituto Grifols, S.A. It also provides 99.900 % 0.100 % 99.900 % 0.100 % 99.900 % 0.100 % centres with plasma virus inactivation services (I.P.T.H). Grifols Engineering, S.A. Spain Polígono Levante 2000 Industrial Design and development of the Group’s manufacturing installations and part of the equipment and 99.950 % 0.050 % 99.950 % 0.050 % 99.950 % 0.050 % Biomat USA, Inc. United States 2410 Lillyvale Avenue 2002 Industrial Procuring human plasma. — 100.000 % — 100.000 % — 100.000 % Grifols Biologicals LLC. United States 5555 Valley Boulevard 2003 Industrial Plasma fractioning and the production of haemoderivatives. — 100.000 % — 100.000 % — 100.000 % Grifols Australia Pty Ltd. Australia Unit 5/80 Fairbank 2009 Industrial Distribution of pharmaceutical products and the development and manufacture of reagents for 100.000 % — 100.000 % — 100.000 % — Medion Grifols Diagnostic AG Switzerland Bonnstrasse,9 2009 Industrial Development and manufacturing activities in the area of biotechnology and diagnostics. — 100.000 % — 100.000 % — 100.000 % Grifols Therapeutics LLC. United States 4101 Research Commons 2011 Industrial Plasma fractioning and the production of haemoderivatives. — 100.000 % — 100.000 % — 100.000 % Talecris Plasma Resources, Inc. United States 4101 Research Commons 2011 Industrial Procurement of human plasma. — 100.000 % — 100.000 % — 100.000 % Grifols Worldwide Operations Limited Grange Castle Business Park, 2012 Industrial Packaging, labelling, storage, distribution, manufacture and development of pharmaceutical products 100.000 % — 100.000 % — 100.000 % — Progenika Biopharma, S.A. Parque Tecnológico de Vizcaya, 2013 Industrial Development, production and commercialisation of biotechnological solutions. 91.880 % 8.120 % 91.880 % 8.120 % 91.880 % 8.120 % Asociación I+D Progenika Parque Tecnológico de Vizcaya, 2013 Industrial Coordination, representation, management and promotion of the common interests of associated — — — — — — Grifols Diagnostics Solutions Inc (formerly G-C Diagnostics Corp.) 4560 Horton Street 2013 Industrial Manufacture and sale of blood testing products — 55.000 % — 55.000 % — 55.000 % Grifols Worldwide Operations USA Inc. 13111 Temple Avenue, City of 2014 Industrial The manufacture, warehousing, and logistical support for biological products. — 100.000 % — 100.000 % — 100.000 % Grifols Asia Pacific Pte, Ltd Singapore 501 Orchard Road nº20-01 2003 Commercial Distribution and sale of medical and pharmaceutical products. 100.000 % — 100.000 % — 100.000 % — Grifols Movaco, S.A. Polígono Levante 1987 Commercial Distribution and sale of reagents, chemical products and other pharmaceutical specialities, and of medical and surgical materials, equipment and instruments for use by laboratories and health centres. 99.999 % 0.001 % 99.999 % 0.001 % 99.999 % 0.001 % Grifols Portugal Productos Farmacéuticos e Hospitalares, Lda. Portugal Rua de Sao Sebastiao,2 1988 Commercial Import, export and commercialisation of pharmaceutical and hospital equipment and products, particularly Grifols products. 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % Grifols Chile, S.A. Chile Avda. Americo Vespucio, 2242 1990 Commercial Development of pharmaceutical businesses, which can involve the import, production, commercialisation and export of related products. 99.000 % — 99.000 % — 99.000 % — Grifols USA, LLC. United States 2410 Lillyvale Avenue 1990 Commercial Distribution and marketing of company products. — 100.000 % — 100.000 % — 100.000 % Grifols Argentina, S.A. Argentina Bartolomé Mitre 3690/3790, 1991 Commercial Clinical and biological research. Preparation of reagents and therapeutic and diet products. 95.010 % 4.990 % 95.010 % 4.990 % 95.010 % 4.990 % Manufacture and commercialisation of other pharmaceutical specialities. Grifols s.r.o. Czech Republic Calle Zitna,2 1992 Commercial Purchase, sale and distribution of chemical-pharmaceutical products, including human plasma. 100.000 % — 100.000 % — 100.000 % — Grifols (Thailand) Ltd Thailand 191 Silom Complex Building, 2003 Commercial Import, export and distribution of pharmaceutical products. — 48.000 % — 48.000 % — 48.000 % Grifols Malaysia Sdn Bhd Malaysia Level 18, The Gardens North 2003 Commercial Distribution and sale of pharmaceutical products. — 49.000 % — 30.000 % — 30.000 % Grifols International, S.A. Spain Polígono Levante 1997 Commercial Coordination of the marketing, sales and logistics for all the Group’s subsidiaries operating in other 99.998 % 0.002 % 99.998 % 0.002 % 99.998 % 0.002 % Grifols Italia S.p.A Italy Via Carducci, 62d 1997 Commercial Purchase, sale and distribution of chemical-pharmaceutical products. 100.000 % — 100.000 % — 100.000 % — Grifols UK Ltd. United Kingdom Gregory Rowcliffe & Milners, 1 1997 Commercial Distribution and sale of therapeutic and other pharmaceutical products, especially haemoderivatives. 100.000 % — 100.000 % — 100.000 % — Grifols Brasil, Lda. Brazil Rua Umuarama, 263 1998 Commercial Import and export, preparation, distribution and 100.000 % 0.000 % 100.000 % 0.000 % 100.000 % 0.000 % CEP 83.325-000 Pinhais sale of pharmaceutical and chemical products for Grifols France, S.A.R.L. France Arteparc, Rue de la Belle du Canet, 1999 Commercial Commercialisation of chemical and healthcare products. 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % Grifols Polska Sp.z.o.o. Poland Grzybowska 87 street00-844 2003 Commercial Distribution and sale of pharmaceutical, cosmetic and other products. 100.000 % — 100.000 % — 100.000 % — Logística Grifols, S.A. de C.V. Mexico Calle Eugenio Cuzin, nº 909-913 2008 Commercial Manufacture and commercialisation of pharmaceutical products for human and veterinary use. 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % Grifols México, S.A. de C.V. Mexico Calle Eugenio Cuzin, nº 909-913 1993 Commercial Production, manufacture, adaptation, conditioning, sale and purchase, commissioning, representation 99.980 % 0.020 % 99.980 % 0.020 % 99.980 % 0.020 % Medion Diagnostics GmbH Germany Lochamer Schlag, 12D 2009 Commercial Distribution and sale of biotechnological and diagnostic products. — — — — — — Grifols Nordic, AB Sweden Sveavägen 166 2010 Commercial Research and development, production and marketing of pharmaceutical products, medical devices and 100.000 % — 100.000 % — 100.000 % — Grifols Colombia, Ltda Colombia Carrera 7 No. 71 52 Torre B piso 2010 Commercial Sale, commercialisation and distribution of medicines, pharmaceutical (including but not limited to 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % Grifols Deutschland GmbH Germany Lyoner Strasse 15, D- 2011 Commercial Procurement of the official permits and necessary approval for the production, commercialisation and 100.000 % — 100.000 % — 100.000 % — health centres Grifols Canada, Ltd. Canada 5060 Spectrum Way, Suite 405 2011 Commercial Distribution and sale of biotechnological products. — 100.000 % — 100.000 % — 100.000 % Grifols Pharmaceutical Technology (Shanghai) Co., Ltd. Unit 901-902, Tower 2, No. 2013 Commercial Pharmaceutical consultancy services (except for diagnosis), technical and logistical consultancy 100.000 % — 100.000 % — 100.000 % — Grifols Switzerland AG Steinengraben, 5 2013 Commercial Research, development, import and export and commercialisation of pharmaceutical products, devices — — 100.000 % — 100.000 % — Grifols (H.K.), Limited Units 1505-7 BerKshire House, 2014 Commercial Distribution and sale of diagnostic products. — 100.000 % — 100.000 % — 100.000 % Grifols Japan K.K. Hilton Plaza West Office Tower, 19th floor. 2-2, Umeda 2-chome, Kita-ku Osaka-shi Japón Hilton Plaza West Office Tower, 2014 Commercial Research, development, import and export and commercialisation of pharmaceutical products, devices 100.000 % — 100.000 % — 100.000 % — Grifols India Healthcare Private Ltd Regus Business Centre 2014 Commercial Distribution and sale of pharmaceutical products. 99.984 % 0.016 % 99.984 % 0.016 % 99.984 % 0.016 % Mumbai - 400604, Grifols Diagnostics Equipment Taiwan Limited 8F., No.367, Fuxing N. RD., 2016 Commercial Distribution and sale of diagnostic products. 100.000 % — 100.000 % — 100.000 % — Grifols Viajes, S.A. Spain Can Guasch, 2 1995 Services Travel agency exclusively serving Group companies. 99.900 % 0.100 % 99.900 % 0.100 % 99.900 % 0.100 % Squadron Reinsurance Designated Activity Company Ireland The Metropolitan Building, 3rd 2003 Services Reinsurance of Group companies’ insurance policies. — 100.000 % — 100.000 % — 100.000 % Grifols Shared Services North America, Inc. United States 2410 Lillivale Avenue 2011 Services Support services for the collection, manufacture, sale and distribution of plasma derivatives and related 100.000 % — 100.000 % — 100.000 % — Gripdan Invest, S.L Avenida Diagonal 477 Barcelona, 2015 Services Rental of industrial buildings 100.000 % — 100.000 % — 100.000 % — Gri-Cel, S.A. (merged with Instituto Grifols, S.A. in 2019) Spain Avenida de la Generalitat 152 2009 Research Research and development in the field of regenerative medicine, awarding of research grants, subscription to collaboration agreements with entities and participation in projects in the area of regenerative medicine. — — — — — — Araclon Biotech, S.L. Spain Paseo de Sagasta, 17 2º izqda. 2012 Research Creation and commercialisation of a blood diagnosis kit for the detection of Alzheimer's and — 75.850 % — 75.100 % — 75.100 % development of effective immunotherapy (vaccine) against this disease. VCN Bioscience, S.L. Avenida de la Generalitat 152 2012 Research Research and development of therapeutic approaches for tumours for which there is currently no — 86.830 % — 86.830 % — 81.340 % Grifols Innovation and New Technologies Limited Grange Castle Business Park, 2016 Research Biotechnology research and development — 100.000 % — 100.000 % — 100.000 % PBS Acquisition Corp. (merged with IBBI in 2019) 2711 Centerville Road Suite 400, 2016 Services Engage in any lawful act or activity for which corporations may be organized under the DGCL — — — — — — Kiro Grifols S.L Spain Polígono Bainuetxe, 5, 2º planta, Aretxabaleta, Guipúzcoa 2014 Research Development of machines and equipment to automate and control key points of hospital processes, and hospital pharmacy processes. 90.000 % — 90.000 % — 90.000 % — Chiquito Acquisition Corp. 2711 Centerville Road Suite 400, Wilmington, Delaware, New Castle County, United States 2017 Corporate Engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware, as amended from time to time (the "DGCL"). — 100.000 % — 100.000 % — 100.000 % Aigües Minerals de Vilajuiga, S.A. Carrer Sant Sebastià, 2, 17493 Vilajuïga, Girona Carrer Sant Sebastià, 2, 17493 Vilajuïga, Girona 2017 Industrial Collection and use of mineral- 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % medicinal waters and obtainment of all necessary administrative concessions for the optimum and widest use of these. Goetech LLC (D/B/A Medkeeper) 7600 Grandview Avenue, Suite 210, Arvada, CO 80002, United States 2018 Industrial Development and distribution of web and mobile-based platforms for hospital pharmacies — 100.000 % — 100.000 % — 54.760 % Interstate Blood Bank, Inc. 5700 Pleasantville Road 2016 Industrial Procuring human plasma. — 100.000 % — 100.000 % — 100.000 % Haema, AG LandsteinerstraBe 1, 04103 Leipzig - Germany 2018 Industrial Procurement of human plasma. — — — — — — BPC Plasma, Inc (formerly Biotest Pharma Corp) 901 Yamato Rd., Suite 101, Boca Raton FL 33431 - USA 2018 Industrial Procurement of human plasma. — — — — — — Alkahest, Inc. 3500 South DuPont Hwy, Dover, County of Kent Estados Unidos 3500 South DuPont Hwy, 2015 Research Development novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS). — 100.000 % — % 42.450 % — — Plasmavita Healthcare GmbH Colmarer Strasse 22, 60528 Frankfurt am Main - Germany Colmarer Strasse 22, 60528 Frankfurt am Main - Germany 2018 Industrial Procurement of human plasma. — 50 % — % 50.000 % — — Plasmavita Healthcare II GmbH Garnisongasse 4/12, 1090 Vienna, Austria Garnisongasse 4/12, 1090 Vienna, Austria 2019 Industrial Procurement of human plasma. — 50 % — 50.000 % — — Grifols Canada Therapeutics Inc. (formerly Green Cross Biotherapeutics; Inc) 2911 Avenue Marie Curie, Arrondissement de Saint-Laurent, Quebec 2020 Industrial Conducting business in Pharmceuticals and Medicines Industry 100.000 % — — 100.000 % — — GCAM, Inc. (merged with Biomat USA) 1561 E Orangethorpe Ave #205, Fullerton, CA 92831 2020 Industrial To engage in any lawful act or activity for which corporations may — — — 100.000 % — — be organized under the General Corporation Law of Delaware and engaging in any and all activities necessary or incidental to the foregoing. Grifols Laboratory Solutions, Inc Corporation Trust Center, 1209, Orange Street, Wilmington, New Castle Country, Delaware, 19801 2020 Services To engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware — 100.000 % — 100.000 % — — Grifols Korea Co., Ltd. 302 Teheran-ro, Gangnam-gu, Seoul (Yeoksam-dong) 2020 Commercial Import, export of diagnostic in vitro products and solutions. 100.000 % — 100.000 % — — — Grifols Middle East & Africa LLC Office No. 534, 5th floor, NamaaBuilding No.155, Ramses Extension Street, Al Hay Al Sades, Nasr City, Cairo 2021 Services Providing consultation (except for those stipulated in Article 27 of the Capital Market Law and its executive regulations) and carry out those commercial activities that are permitted by the law. 99.990 % 0.010 — — — — GigaGen Inc. 407 Cabot Road 2021 Industrial Engage in any lawful act or activity for which corporations may be organized under General Corporation Law. — 100.000 % — 43.960 — 43.960 Grifols Pyrenees Research Center, S.L. C/ Prat de la Creu, 68-76, Planta 3ª, Edifici Administratiu del Comú d'Andorra la Vella 2021 Industrial Constitution, development and management of operations of a research and development center in all areas of immnology, — 80.000 % — — — — dedicated to find possible solutions for therapeutic applications. Grifols Bio North America LLC 251 Little Falls Drive, Wilmington, New Castle County, 19808, Delaware 2021 Industrial To engage in any lawful business permitted by the Act or the laws of any jurisdiction in which the Company may do business. — 100.000 % — — — — Biomat Holdco, LLC. 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 2021 Services Engage in any lawful act or activity for which corporations may be organized under General Corporation Law of Delaware. — 100.000 % — — — — Biomat Newco, Corp. 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 2021 Services Engage in any lawful act or activity for which corporations may be organized under General Corporation Law of Delaware. — 100.000 % — — — — Grifols Escrow Issuer, S.A. Parque Empresarial Can Sant Joan, Avda de la Generalitat, 152-156, Sant Cugat del Vallès, 08174, Barcelona 2021 Services Administration, management and control services for companies and businesses, as well as investment in property, as well as providing advisory services of any investee entities or group companies. 100.000 % — — — — — Prometic Plasma Resources, Inc. 531 Boul. Des Prairies, Building 15 Laval, Quebec H7V 1B7 2021 Industrial Procurement of human plasma. 100.000 % — — — — — Aradigm Corporation 3929 Point Eden Way 2013 Research Development and commercialisation of drugs delivered by inhalation for the — 35.130 % — 35.130 % — 35.130 % prevention and treatment of severe respiratory diseases. TiGenix N.V. Romeinse straat 12 bus 2, 3001 Leuven, Belgium 2013 Research Research and development of therapies based on stem cells taken from adipose tissue. — — — — — — Mecwins, S.L. Avenida Fernandos Casas Novoa, 37 2013 Research Research and production of nanotechnological, biotechnological and chemical solutions. — 24.990 % — 24.990 % — 24.990 % Alkahest, Inc. 3500 South DuPont Hwy, Dover, 2015 Research Development novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS). — — — — — 47.580 % Albajuna Therapeutics, S.L Hospital Germans Trias i Pujol, carretera de Canyet, s/n, Badalona 2016 Research Development and manufacture of therapeutic antibodies against HIV. — 49.000 % — 49.000 % — 49.000 % Interstate Blood Bank, Inc. 5700 Pleasantville Road 2016 Industrial Procurement of human plasma. — — — — — — Bio Blood Components Inc. 5700 Pleasantville Road 2016 Industrial Procurement of human plasma. — — — — — — Plasma Biological Services, LLC 5700 Pleasantville Road 2016 Industrial Procurement of human plasma. — — — — — — Singulex, Inc. 4041 Forest Park Avenue St. Louis, Missouri 2016 Research Development of the Single Molecule Counting (SMC™) technology for — 19.330 % — 19.330 % — 19.330 % clinical diagnostic and scientific discovery. Access Biologicals, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — 49.000 % — 49.000 % — 49.000 % Access Biologicals IC-DISC, Inc. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — 49.000 % — 49.000 % — 49.000 % Access Cell Culture, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro — 49.000 % — 49.000 % — 49.000 % diagnostics, cell culture, and research and development in the diagnostic field. Access Manufacturing, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — — — — — — Access Plasma, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — 49.000 % — 49.000 % — 49.000 % GigaGen Inc. 407 Cabot Road 2017 Industrial Engage in any lawful act or activity for which corporations may be organized under General Corporation Law. — — — 43.960 % — 43.960 % Plasmavita Healthcare GmbH Colmarer Strasse 22, 60528 Frankfurt am Main - Germany 2018 Industrial Procurement of human plasma. — — — — — 50.000 % Medcom Advance, S.A Av. Roma, 35 Entresuelo 1, 08018 Barcelona; Spain 2019 Research Research and development of nanotechnological solutions. — 45.000 % — 45.000 % — 45.000 % Plasmavita Healthcare II GmbH Garnisongasse 4/12, 1090 Vienna, Austria 2019 Industrial Procurement of human plasma. — — — — — 50.000 % Shanghai RAAS Blood Products Co. Ltd. 2009 Wangyuan Road, Fengxian District, Shanghai 2020 Industrial Introducing advanced and applicable technologies, instruments and scientific management systems for manufacturing and diagnosis of blood products, in order to raise the production capacity and enhance quality standards of blood products to the international level. 26.200 % — 26.200 % — — — Grifols Egypt for Plasma Derivatives (S.A.E.) Tolip El Narges Hotel, Teseen Streett, Fifth Settlement, Cairo 2021 Industrial Establish and operate a plasma fractionation plant whether the plasma is collected locally or imported, as well as its filling and packaging. 49.000 % — — — — — |
Appendix II
Appendix II | 12 Months Ended |
Dec. 31, 2021 | |
Appendix II | |
Appendix II | APPENDIX II GRIFOLS, S.A. AND SUBSIDIARIES Operating Segments for the years ended 31 December 2021, 2020 and 2019 (Expressed in thousands of Euros) Bioscience Hospital Diagnostic Bio Supplies Others Intersegments Consolidated 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 Revenues from external customers 3,814,983 4,242,502 3,993,462 141,190 118,675 134,441 779,108 775,889 733,604 225,765 224,090 266,540 39,620 31,989 22,820 (67,548) (53,107) (52,176) 4,933,118 5,340,038 5,098,691 Total operating income 3,814,983 4,242,502 3,993,462 141,190 118,675 134,441 779,108 775,889 733,604 225,765 224,090 266,540 39,620 31,989 22,820 (67,548) (53,107) (52,176) 4,933,118 5,340,038 5,098,691 Profit/(Loss) for the segment 658,691 949,989 1,079,216 (7,735) (12,504) (8,674) 152,948 215,793 215,828 45,990 19,871 16,246 (58,602) 2,241 1,279 (10,896) 4,428 (3,094) 780,396 1,179,818 1,300,801 Unallocated expenses (185,332) (183,686) (169,436) Operating profit/(loss) 595,064 996,132 1,131,365 Finance result (277,799) (177,669) (274,724) Share of profit/(loss) of equity- accounted investee — — — — — — — — (19,794) — — — 33,188 60,166 (19,744) — — — 33,188 60,166 (39,538) Income tax expense (85,126) (169,639) (168,459) Profit for the year after tax 265,327 708,990 648,644 Segment assets 9,467,378 7,975,667 8,416,922 269,487 257,360 274,250 3,513,991 3,371,125 3,676,011 47,446 251,551 226,814 557,884 383,981 77,501 (39,963) (26,773) (32,892) 13,816,223 12,212,911 12,638,606 Equity-accounted investments 31,847 — 10,368 — — — — — — 53,264 46,782 49,922 1,914,665 1,822,238 54,183 — — — 1,999,776 1,869,020 114,473 Unallocated assets — — — — — — — — — — — — — — — — — — 3,417,836 1,192,845 2,789,532 Total assets 19,233,835 15,274,776 15,542,611 Segment liabilities 1,521,634 1,222,664 1,371,352 38,654 32,179 53,441 397,869 372,461 351,799 27,596 120,787 126,289 160,441 121,334 35,581 — — — 2,146,194 1,869,425 1,938,462 Unallocated liabilities — — — — — — — — — — — — — — — — — — 9,770,543 6,685,296 6,758,381 Total liabilities 11,916,737 8,554,721 8,696,843 Other information: Allocated amortisation and depreciation 228,114 201,087 196,335 12,065 12,443 11,686 88,557 63,053 52,224 2,948 21,846 20,415 6,978 2,820 2,147 — — — 338,662 301,249 282,807 Unallocated amortisation and depreciation — — — — — — — — — — — — — — — — — — 21,105 20,284 19,648 Allocated expenses that do not require cash payments 26,051 38,955 43,524 3,349 529 (289) 4,446 (21,335) (22,873) 73 3 393 — (2,977) — — — — 33,919 15,175 20,755 Unallocated expenses that do not require cash — — — — — — — — — — — — — — — — — — 4,991 4,924 2,416 Allocated additions for the year of property, plant & 349,890 289,062 868,103 12,616 11,548 62,298 19,991 34,516 103,911 13,836 10,915 65,448 15,981 1,150 1,768 — — — 412,314 347,191 1,101,528 Unallocated additions for the year of property, plant — — — — — — — — — — — — — — — — — — 55,380 107,178 73,544 This appendix forms an integral part of note 6 to the consolidated financial statements. APPENDIX II GRIFOLS, S.A. AND SUBSIDIARIES Reporting by geographical area for the years ended 31 December 2021, 2020 and 2019 (Expressed in thousands of Euros) Rest of European USA + Canada Rest of World Consolidated Spain Union 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 Net Revenue 362,407 339,169 268,287 544,042 495,323 588,375 3,154,549 3,599,746 3,390,811 872,120 905,800 851,218 4,933,118 5,340,038 5,098,691 Assets by geographical area 1,092,435 1,117,647 2,764,054 5,393,407 2,927,198 3,425,874 10,525,140 9,138,360 9,059,674 2,222,853 2,091,571 293,009 19,233,835 15,274,776 15,542,611 Other information: Additions for the year of property, plant & 71,022 93,787 183,891 91,388 92,873 181,736 295,526 253,442 787,586 9,758 14,267 21,859 467,694 454,369 1,175,072 This appendix forms an integral part of note 6 to the consolidated financial statements. |
Appendix III
Appendix III | 12 Months Ended |
Dec. 31, 2021 | |
Appendix III | |
Appendix III | APPENDIX III GRIFOLS, S.A. AND SUBSIDIARIES Changes in Other Intangible Assets for the year ended 31 December 2021 (Expressed in thousands of Euros) Balance at Business Translation Balance at 31/12/2020 Additions combinations Transfers Disposals differences 31/12/2021 Development costs 701,390 34,671 24,027 — (5,679) 47,197 801,606 Concessions, patents, licenses brands & similar 228,023 57 — — — 16,478 244,558 Computer software 279,651 33,516 — 3,315 (208) 14,217 330,491 Currently marketed products 1,004,665 — — — — 78,636 1,083,301 Other intangible assets 156,644 — — — (12,146) 11,511 156,009 Total cost of intangible assets 2,370,373 68,244 24,027 3,315 (18,033) 168,039 2,615,965 Accum. amort. of development costs (125,875) (44,612) — (60) 5,679 (3,498) (168,366) Accum. amort of concessions, patents, licenses, brands & similar (51,197) (9,909) — — — (3,070) (64,176) Accum. amort. of computer software (167,124) (25,474) — (101) 178 (7,770) (200,291) Accum. amort. of currently marketed products (331,968) (35,989) — — — (26,827) (394,784) Accum. amort. of other intangible assets (71,430) (4,265) — — — (5,603) (81,298) Total accum. amort intangible assets (747,594) (120,249) — (161) 5,857 (46,768) (908,915) Impairment of other intangible assets (65,129) (73) — — — (4,898) (70,100) Carrying amount of intangible assets 1,557,650 (52,078) 24,027 3,154 (12,176) 116,373 1,636,950 (See note 3) This appendix forms an integral part of note 8 to the consolidated financial statements. APPENDIX III GRIFOLS, S.A. AND SUBSIDIARIES Changes in Other Intangible Assets for the year ended 31 December 2020 (Expressed in thousands of Euros) Balance at Business Translation Balance at 31/12/2019 Additions combinations Transfers Disposals differences 31/12/2020 Development costs 435,339 35,301 265,571 — — (34,821) 701,390 Concessions, patents, licenses brands & similar 229,997 16,174 5 (6) — (18,147) 228,023 Computer software 258,597 27,939 2,229 3,963 (11) (13,066) 279,651 Currently marketed products 1,092,834 — — — — (88,169) 1,004,665 Other intangible assets 178,359 3,118 — (399) (10,233) (14,201) 156,644 Total cost of intangible assets 2,195,126 82,532 267,805 3,558 (10,244) (168,404) 2,370,373 Accum. amort. of development costs (103,531) (23,810) — — — 1,466 (125,875) Accum. amort of concessions, patents, licenses, brands & similar (43,656) (8,221) — (1,732) — 2,412 (51,197) Accum. amort. of computer software (143,806) (19,198) — (9,833) 12 5,701 (167,124) Accum. amort. of currently marketed products (322,119) (37,739) — — — 27,890 (331,968) Accum. amort. of other intangible assets (80,836) (6,844) — 9,389 214 6,647 (71,430) Total accum. amort intangible assets (693,948) (95,812) — (2,176) 226 44,116 (747,594) Impairment of other intangible assets (67,644) (2,977) — — — 5,492 (65,129) Carrying amount of intangible assets 1,433,534 (16,257) 267,805 1,382 (10,018) (118,796) 1,557,650 (See note 3) This appendix forms an integral part of note 8 to the consolidated financial statements. |
Appendix IV
Appendix IV | 12 Months Ended |
Dec. 31, 2021 | |
APPENDIX IV | |
APPENDIX IV | APPENDIX IV GRIFOLS, S.A. AND SUBSIDIARIES Movement in Rights of Use for the year ended 31 December 2021 (Expressed in thousands of Euros) Balance at Translation Balance at 31/12/2020 Additions Business combinations Transfers Disposals differences 31/12/2021 Land and buildings 759,120 125,112 4,611 3,337 (3,603) 53,378 941,955 Machinery 5,907 3,412 — (495) (89) 341 9,076 Computer equipment 8,228 641 — (629) (7) 286 8,519 Vehicles 14,152 4,277 — (407) (2,887) 625 15,760 Total cost of rights of use 787,407 133,442 4,611 1,806 (6,586) 54,630 975,310 Accum. depr. of land and buildings (94,118) (57,901) — (3,337) 3,605 (8,080) (159,831) Accum. depr. of machinery (2,236) (2,120) — 587 87 (110) (3,792) Accum.depr. of computer equipment (4,640) (2,269) — 629 7 (202) (6,475) Accum. depr. of vehicles (7,717) (4,430) — 407 2,581 (396) (9,555) Total accum. depr. of rights of use (108,711) (66,720) — (1,714) 6,280 (8,788) (179,653) Carrying amount of rights of use 678,696 66,722 4,611 92 (306) 45,842 795,657 This appendix forms an integral part of note 9 to the consolidated financial statements. APPENDIX IV GRIFOLS, S.A. AND SUBSIDIARIES Movement in Rights of Use for the year ended 31 December 2020 (Expressed in thousands of Euros) Balance at Translation Balance at 31/12/2019 Additions Business combinations Transfers Disposals differences 31/12/2020 Land and buildings 734,846 68,172 19,424 — (10,935) (52,387) 759,120 Machinery 6,167 1,775 — (1,846) (59) (130) 5,907 Computer equipment 6,504 2,449 — (37) (347) (341) 8,228 Vehicles 14,030 2,681 74 (10) (1,914) (709) 14,152 Total cost of rights of use 761,547 75,077 19,498 (1,893) (13,255) (53,567) 787,407 Accum. amort. of land and buildings (49,441) (52,774) — (2) 2,341 5,758 (94,118) Accum. amort of machinery (1,698) (1,588) — 955 55 40 (2,236) Accum. amort. of computer equipment (2,180) (3,012) — 37 347 168 (4,640) Accum. amort. of vehicles (4,370) (5,206) — 7 1,529 323 (7,717) Total accum. amort of rights of use (57,689) (62,580) — 997 4,272 6,289 (108,711) Carrying amount of rights of use 703,858 12,497 19,498 (896) (8,983) (47,278) 678,696 This appendix forms an integral part of note 9 to the consolidated financial statements. |
Appendix V
Appendix V | 12 Months Ended |
Dec. 31, 2021 | |
Appendix V | |
Appendix V | APPENDIX V GRIFOLS, S.A. AND SUBSIDIARIES Movement in Property, Plant and Equipment for the year ended 31 December 2021 (Expressed in thousands of Euros) Balances at Business Translation Balances at 31/12/2020 Additions combination Transfers Disposals differences 31/12/2021 Cost: Land and buildings 780,180 3,361 660 24,830 (123) 51,539 860,447 Plant and machinery 2,200,429 42,747 10,381 171,894 (24,960) 127,253 2,527,744 Fixed Assets under construction 704,582 219,900 (7,300) (199,943) — 46,548 763,787 3,685,191 266,008 3,741 (3,219) (25,083) 225,340 4,151,978 Accumulated depreciation: Buildings (122,948) (19,388) — 2,583 123 (8,452) (148,082) Plant and machinery (1,235,483) (153,408) — (2,609) 18,808 (69,742) (1,442,434) (1,358,431) (172,796) — (26) 18,931 (78,194) (1,590,516) Impairment of other property, plant and equipment (2,653) (11,246) — — — (66) (13,965) Carrying amount 2,324,107 81,966 3,741 (3,245) (6,152) 147,080 2,547,497 (See note 3) This appendix forms an integral part of note 10 to the consolidated financial statements. APPENDIX V GRIFOLS, S.A. AND SUBSIDIARIES Movement in Property, Plant and Equipment for the year ended 31 December 2020 (Expressed in thousands of Euros) Balances at Business Translation Balances at 31/12/2019 Additions combination Transfers Disposals differences 31/12/2020 Cost: Land and buildings 807,195 19,843 14,964 (6,050) (211) (55,561) 780,180 Plant and machinery 2,141,611 50,825 48,408 103,594 (23,830) (120,179) 2,200,429 Fixed Assets under construction 497,164 226,092 121,399 (99,616) — (40,457) 704,582 3,445,970 296,760 184,771 (2,072) (24,041) (216,197) 3,685,191 Accumulated depreciation: Buildings (108,638) (17,974) — (3,826) 171 7,319 (122,948) Plant and machinery (1,175,075) (145,167) — 5,412 22,590 56,757 (1,235,483) (1,283,713) (163,141) — 1,586 22,761 64,076 (1,358,431) Impairment of other property, plant and equipment (2,712) 21 — — — 38 (2,653) Carrying amount 2,159,545 133,640 184,771 (486) (1,280) (152,083) 2,324,107 (See note 3) This appendix forms an integral part of note 10 to the consolidated financial statements. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies | |
Subsidiaries and associates | (a) Subsidiaries and associates Subsidiaries are entities, including special purpose entities (SPE), over which the Group exercises control, either directly or indirectly, through subsidiaries. The Group controls a subsidiary when it has the substantive rights in force that provide the ability to manage relevant activities. The Group is exposed or has the right to variable returns for its involvement in the subsidiaries when the returns obtained vary depending on the economic performance of the subsidiaries. The income, expenses and cash flows of subsidiaries are included in the consolidated financial statements from the date of acquisition, which is when the Group takes control. Subsidiaries are excluded from the consolidated Group from the date on which control is lost. Transactions and balances with Group companies and unrealized gains or losses have been eliminated upon consolidation. The accounting policies of subsidiaries have been adapted to those of the Group for transactions and other events in similar circumstances. The financial statements of consolidated subsidiaries have been prepared as of the same date and for the same reporting period as the financial statements of the Company. Associates are entities over which the Company, either directly or indirectly through subsidiaries, exercises significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those entities. The existence of potential voting rights that are exercisable or convertible at the end of each reporting period, including potential voting rights held by the Group or other entities, are considered when assessing whether an entity has significant influence. Investments in associates are initially recognized at acquisition cost, including any cost directly attributable to the acquisition and any consideration receivable or payable contingent on future events or on compliance with certain conditions. Subsequently, investments in associates are accounted for using the equity method from the date that significant influence commences until the date that significant influence ceases. The excess of the cost of the investment over the Group’s share of the fair values of the identifiable net assets is recognized as goodwill, which is included in the carrying amount of the investment. Any shortfall, once the cost of the investment and the identification and measurement of the associate’s net assets have been evaluated, is recognized as income when determining the investor’s share of the profit and loss of the associate for the year in which it was acquired. The accounting policies of associates have been harmonized in terms of timing and measurement, applying the policies described for subsidiaries. The Group’s share of the profit and loss of an associate from the date of acquisition is recognized as an increase or decrease in the value of the investments, with a credit or debit to share of the profit and loss for the year of “equity-accounted investees” in the consolidated statement of profit and loss (consolidated statement of comprehensive income). The Group’s share of other comprehensive income of associates from the date of acquisition is recognized as an increase or decrease in the investments in associates with a balancing entry recognized by type in other comprehensive income. The distribution of dividends is recognized as a decrease in the value of the investment. The Group’s share of profit and loss, including impairment losses recognized by the associates, is calculated based on income and expenses arising from application of the acquisition method. When the Group’s share of the losses in an investment accounted for using the equity method equals or exceeds its interest in the entity, the Group does not recognize additional losses, unless it has incurred in obligations or made payments on behalf of the other entity. The Group’s share of the profit and loss of an associate and changes in equity is calculated to the extent of the Group’s interest in the associate at year end and does not reflect the possible exercise or conversion of potential voting rights. However, the Group’s share is calculated taking into account the possible exercise of potential voting rights and other derivative financial instruments which, in substance, currently allow access to the economic benefits associated with the interests held, such as entitlement to a share in future dividends and changes in the value of associates. Information on the subsidiaries and associates included in the consolidated Group is presented in Appendix I. |
Business combinations | (b) Business combinations On the date of transition to IFRS-IASB, the Group applied the exception permitted under IFRS 1 “First-time adoption of International Financial Reporting Standards”, whereby only those business combinations performed as from 1 January 2004 have been recognized using the acquisition method. Entities acquired prior to that date were recognized in accordance with accounting prevailing at that time, taking into account the necessary corrections and adjustments at the transition date. The Group applies the revised IFRS 3 “Business combinations” in transactions made subsequent to 1 January 2010. The Group applies the acquisition method for business combinations. The acquisition date is the date on which the Group obtains control of the acquiree. The cost of the business combination is calculated as the sum of the acquisition-date fair values of the assets transferred, the liabilities incurred or assumed, equity instruments issued and any additional consideration contingent on future events or the fulfilment of certain conditions, in exchange for control of the acquiree. The consideration paid excludes all amounts that do not form part of the exchange for the acquired business. Acquisition-related costs are accounted for as expenses when incurred. Share increase costs are recognized as equity when the increase takes place and borrowing costs are deducted from the financial liability when it is recognized. At the acquisition date the Group recognizes at fair value the assets acquired and liabilities assumed. Liabilities assumed include any contingent liabilities that represent present obligations arising from past events for which the fair value can be reliably measured. The Group also recognizes indemnification assets transferred by the seller at the same time and following the same measurement criteria as the item that is subject to indemnification from the acquired business, taking into consideration, where applicable, the insolvency risk and any contractual limit on the indemnity amount. This criterion does not include non-current assets or disposal groups of assets which are classified as held for sale, long-term defined benefit employee benefit liabilities, share-based payment transactions, deferred tax assets and liabilities and intangible assets arising from the acquisition of previously transferred rights. Assumed assets and liabilities are classified and designated for subsequent measurement in accordance with the contractual terms, economic conditions, operating or accounting policies and other factors that exist at the acquisition date, except for leases and insurance contracts. The excess between the consideration transferred and the value of net assets acquired and liabilities assumed, less the value assigned to non-controlling interests, is recognized as goodwill. Where applicable, any shortfall, after evaluating the consideration transferred, the value assigned to non-controlling interests and the identification and measurement of net assets acquired, is recognized in profit and loss. When a business combination has been provisionally determined, net identifiable assets have initially been recognized at their provisional value, and any adjustments made during the measurement period have been recorded as if they had been known at that date. Where applicable, comparative figures for the prior year have been restated. Adjustments to the provisional values only reflect information relating to events and circumstances existing at the acquisition date and which, had they been known, would have affected the amounts recognized at that date. Once this period has elapsed, adjustments are only made to initial values when errors must be corrected. Any potential benefits arising from tax losses and other deferred tax assets of the acquiree that have not been recorded as they did not qualify for recognition at the acquisition date, are accounted for as income tax revenue, provided the adjustments were not made during the measurement period. The contingent consideration is classified in accordance with underlying contractual terms as a financial asset or financial liability, equity instrument or provision. Provided that subsequent changes to the fair value of a financial asset or financial liability do not relate to an adjustment of the measurement period, they are recognized in consolidated profit and loss. The contingent consideration classified, where applicable, as equity is not subject to subsequent change, with settlement being recognized in equity. The contingent consideration classified, where applicable, as a provision is recognized subsequently in accordance with the relevant measurement standard. |
Non-controlling interests | (c) Non-controlling interests Non-controlling interests in subsidiaries acquired after 1 January 2004 are recognized at the acquisition date at the proportional part of the fair value of the identifiable net assets. Non-controlling interests in subsidiaries acquired prior to the transition date were recognized at the proportional part of the equity of the subsidiaries at the date of first consolidation. Non-controlling interests are disclosed in the consolidated balance sheet under equity separately from equity attributable to the Parent. Non-controlling interests’ share in consolidated profit and loss for the year (and in consolidated comprehensive income for the year) is disclosed separately in the consolidated statement of profit and loss (consolidated statement of comprehensive income). The consolidated profit and loss for the year, consolidated comprehensive income and changes in equity of the subsidiaries attributable to the Group and non-controlling interests after consolidation adjustments and eliminations, is determined in accordance with the percentage ownership at year end, without considering the possible exercise or conversion of potential voting rights. However, Group and non-controlling interests are calculated taking into account the possible exercise of potential voting rights and other derivative financial instruments which, in substance, currently allow access to the economic benefits associated with the interests held, such as entitlement to a share in future dividends and changes in the value of subsidiaries. Profit and loss and each component of other comprehensive income are assigned to equity attributable to shareholders of the Parent and to non-controlling interests in proportion to their interest, although this implies a balance receivable from non-controlling interests. Agreements signed between the Group and the non-controlling interests are recognized as a separate transaction. The increase and reduction of non-controlling interests in a subsidiary in which control is retained is recognized as an equity instrument transaction. Consequently, no new acquisition cost arises on increases, nor is a gain recorded on reductions; rather, the difference between the consideration transferred or received and the carrying amount of the non-controlling interests is recognized in the reserves of the investor, without prejudice to reclassifying consolidation reserves and reallocating other comprehensive income between the Group and the non-controlling interests. When a Group’s interest in a subsidiary diminishes, non-controlling interests are recognized at their share of the net consolidated assets, including goodwill. |
Joint arrangements | (d) Joint arrangements Joint arrangements are those in which there is a contractual agreement to share the control over an economic activity, in such a way that the decisions over relevant activities require the unanimous consent of the Group and the remaining venturers. Under IFRS 11 “Joint arrangements” investments in joint arrangements are classified as joint operations or joint ventures. The classification depends on the contractual rights and obligations of each investor, rather than on the legal structure of the joint agreement. Interests in joint ventures are accounted for using the equity method, after initially being recognized at cost in the consolidated balance sheet. The acquisition cost of investments in joint arrangements is determined consistently with that established for investments in associates. |
Foreign currency transactions and balances | (e) Foreign currency transactions and balances (i) Functional and presentation currency The consolidated financial statements are presented in thousands of Euros, which is the functional and presentation currency of the Parent. (ii) Foreign currency transactions, balances and cash flows Foreign currency transactions are translated into the functional currency using the previous month’s exchange rate for all transactions performed during the current month. This method does not differ significantly from applying the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies have been translated into thousands of Euros at the closing rate, while non-monetary assets and liabilities measured at historical cost have been translated at the exchange rate prevailing at the transaction date. Non-monetary assets measured at fair value have been translated into thousands of Euros at the exchange rate at the date that the fair value was determined. In the consolidated statement of cash flows, cash flows from foreign currency transactions have been translated into thousands of Euros at the exchange rates prevailing at the dates the cash flows occur. The effect of exchange rate fluctuations on cash and cash equivalents denominated in foreign currencies is recognized separately in the statement of cash flows as “Effect of exchange rate fluctuations on cash and cash equivalents”. Exchange gains and losses arising on the settlement of foreign currency transactions and the translation into thousands of Euros of monetary assets and liabilities denominated in foreign currencies are recognized in profit and loss. (iii) Translation of foreign operations The translation into thousands of Euros of foreign operations for which the functional currency is not the currency of a hyperinflationary economy is based on the following criteria: ● ● ● |
Borrowing costs | (f) Borrowing costs In accordance with IAS 23 “Borrowing Costs”, the Group recognizes borrowing costs directly attributable to the purchase, construction or production of qualifying assets as an increase in the value of these assets. Qualifying assets are those which require a substantial period of time before they can be used or sold. To the extent that funds are borrowed specifically for the purpose of obtaining a qualifying asset, the amount of borrowing costs eligible for capitalization is determined as the actual borrowing costs incurred, less any investment income on the temporary investment of those funds. Capitalized borrowing costs corresponding to general borrowing are calculated as the weighted average of the qualifying assets without considering specific funds. The amount of borrowing costs capitalized cannot exceed the amount of borrowing costs incurred during that period. The capitalized borrowing costs include adjustments to the carrying amount of financial liabilities arising from the effective portion of hedges entered into by the Group. The Group begins capitalizing borrowing costs as part of the cost of a qualifying asset when it incurs expenditure for the asset, interest is accrued, and it undertakes activities that are necessary to prepare the asset for its intended use or sale, and ceases capitalizing borrowing costs when all or substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete. Nevertheless, capitalization of borrowing costs is suspended when active development is interrupted for extended periods. The remaining interest costs are recognized as an expense in the year in which they are incurred. |
Property, plant and equipment | (g) Property, plant and equipment (i) Initial recognition Property, plant and equipment are recognized at cost, less accumulated depreciation and any accumulated impairment losses. Land is not subject to depreciation. The cost of self-constructed assets is determined using the same principles as for an acquired asset, while also considering the criteria applicable to production costs of inventories. Capitalized production costs are recognized by allocating the costs attributable to the asset to “Self-constructed non-current assets” in the consolidated statement of profit and loss. (ii) Depreciation Property, plant and equipment are depreciated by allocating the depreciable amount of an asset on a systematic basis over its useful life. The depreciable amount is the cost or deemed cost of an asset, less its residual value. The Group determines the depreciation charge separately for each item for a component of property, plant and equipment with a cost that is significant in relation to the total cost of the asset. Property, plant and equipment are depreciated using the following criteria: Depreciation method Rates Buildings Straight line 1% Other property, technical equipment and machinery Straight line 4% - 10% Other property, plant and equipment Straight line 7% The Group reviews residual values, useful lives and depreciation methods at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates. (iii) Subsequent recognition Subsequent to initial recognition of the asset, only those costs incurred which will probably generate future profits and for which the amount may reliably be measured are capitalized. Costs of day-to-day servicing are recognized in profit and loss as incurred. Replacements of property, plant and equipment which qualify for capitalization are recognized as a reduction in the carrying amount of the items replaced. Where the cost of the replaced items has not been depreciated independently and it is not possible to determine the respective carrying amount, the replacement cost is used as indicative of the cost of items at the time of acquisition or construction. (iv) Impairment The Group tests for impairment and reversals of impairment losses on property, plant and equipment based on the criteria set out in note 4(j) below. |
Intangible assets | (h) Intangible assets (i) Goodwill Goodwill is generated on the business combinations and is calculated using the criteria described in the section on business combinations. Goodwill is not amortized but is tested for impairment annually or more frequently whenever there is an indication that goodwill may be impaired. Goodwill acquired in business combinations is allocated to the cash-generating units (CGUs) or groups of CGUs which are expected to benefit from the synergies of the business combination and the criteria described in note 7 are applied. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Gains and losses on the sale of an entity include the carrying amount of the goodwill related to the entity sold. (ii) Internally generated intangible assets Any research and development expenditure incurred during the research phase of projects is recognized as an expense when incurred. Costs related with development activities are capitalized when: ● The Group has technical studies that demonstrate the feasibility of the production process; ● The Group has undertaken a commitment to complete production of the asset, to make it available for sale or internal use; ● The asset will generate sufficient future economic benefits; ● The Group has sufficient technical and financial resources to complete development of the asset and has devised budget control and cost accounting systems that enable monitoring of budgetary costs, modifications and the expenditure actually attributable to the different projects. The cost of internally generated assets by the Group is calculated using the same criteria established for determining production costs of inventories. The production cost is capitalized by allocating the costs attributable to the asset to self-constructed non-current assets in the consolidated statement of profit and loss. Expenditure on activities that contribute to increasing the value of the different businesses in which the Group as a whole operates is expensed when incurred. Replacements or subsequent costs incurred on intangible assets are generally recognized as an expense, except where they increase the future economic benefits expected to be generated by the assets. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. (iii) Other intangible assets Other intangible assets are carried at cost, or at fair value if they arise on business combinations, less accumulated amortization and impairment losses. Intangible assets with indefinite useful lives are not amortized but tested for impairment at least annually. (iv) Intangible assets acquired in business combinations The cost of identifiable intangible assets acquired in business combinations normally includes the fair value of R&D projects, Intellectual Property Patents, current contracts and products currently being marketed, and are included within “Other intangible assets” and “Development expenses” as appropriate. (v) Useful life and amortization rates The Group assesses whether the useful life of each intangible asset acquired is finite or indefinite. An intangible asset is regarded as having an indefinite useful life when there is no foreseeable limit to the period over which the asset will generate net cash inflows. Intangible assets with finite useful lives are amortized by allocating the depreciable amount of an asset on a systematic basis over its useful life, by applying the following criteria: Amortisation method Rates Development expenses Straight line 10% Concessions, patents, licences, trademarks and similar Straight line 4% Computer software Straight line 33% Currently marketed products Straight line 3% The depreciable amount is the cost or deemed cost of an asset, less its residual value. The Group does not consider the residual value of its intangible assets to be material. The Group reviews the residual value, useful life and amortization method for intangible assets at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates. |
Leases | (i) Leases The Group changed its accounting policies in relation to leases when it is a lessee as a result of adopting IFRS 16. The policy is described in note 2(c) and the impact of the change in notes 2 (c) and 9. (i) Definitions Lease contracts A lease contract is a contract that fulfills the following conditions: ● There is an identified asset explicitly specified in the contract or implicitly specified when it is made available for use by the Group. When the asset is a portion of an asset’s capacity it could also be an identified asset if it is physically distinct (a floor of a building, a storage location in a warehouse) or the Group has the right to receive substantially all its of capacity. ● The lessee has the right to direct the use of the identified asset that means the right to determine how and for what purpose the asset will be used. ● The lessee has the right to obtain all the economic benefits from that use throughout the period of use. Non-lease contracts Even if an asset is specified in the contract, if the lessor has a substantive substitution right throughout the period of use, the asset is not identified and the contract does not contain a lease. When the lessee does not have the right to control the use of the asset, the contract does not contain a lease. Non-lease contracts are not under this policy and the accounting treatment will be that of a service contract (usually recognized as an expense). (ii) Accounting policies Lease contracts, where the Group acts as lessee, is recognized at inception of the contract as: ● A lease liability representing its obligation to make future lease payments and, ● A right of use representing its right to use the identified asset. Exception: lease contracts that fulfill any of the following conditions will be recognized as monthly expense over the lease term: ● For lease contracts where the lease term is 12 months or less at the commencement date. ● For lease contracts where the value of the leased asset (individually), when new, is lower than US Dollars 5,000 or its equivalent in another currency. Lease liability Initial measurement The lease liability corresponds to the present value of the lease payments during the lease term using the interest rate implicit in the lease or, if this cannot be readily determined, the incremental borrowing lending rate, as follows: ● Lease payments Only lease components included in the lease contract are part of the liability calculation: - Fixed payments, less any lease incentives receivable; - Variable lease payments that depend on a known index or a rate; - The exercise price of the purchase option if the lessee is reasonably certain to exercise that option; - Any amount already paid at the contract commencement date must not be included. Non-lease components that could be included in a lease contract (e.g. maintenance services, electricity, water, gas and other services such as surveillance, cleaning, etc.) are not part of the lease liability and must be recognized as an expense as soon as the service is rendered to Grifols using the corresponding account according to its nature. ● Lease term The lease term is the non-cancellable period considering the initial term of each contract unless Grifols has a unilateral option to extend or terminate the lease and there is reasonable certainty that this option will be exercised, in which case the corresponding extension term or early termination will be taken into account. The lease liability is calculated at the present value of the future lease payments during the lease term, using an incremental discount rate, except for those contracts in which the implicit interest rate is used because it is specifically mentioned in the contract. ● Discount rate Under IFRS 16, a lessee shall discount the future lease payments using the lease implicit interest rate if this can be reliably determined. Otherwise, the lessee shall use the incremental borrowing rate. The Group uses the incremental borrowing rate. This is the rate that a lessee would have to pay at the commencement date of the lease for a loan of a similar term, and with a similar security, to obtain an asset of similar value to the right-of-use asset in a similar economic environment. The incremental borrowing rate is determined considering the following criteria: - - - - - Subsequent measurement Subsequently, the lease financial liability will be increased by the interest on the lease liability and reduced by the payments made. The liability will be remeasured if there are changes in the amounts payable and the lease terms. Lease liabilities will: ● Increase the carrying amount to interest on the lease liability; ● Reduce the carrying amount to reflect the lease payments made; and ● Remeasure (increase or reduce) the carrying amount to reflect any reassessment or lease modifications. The balancing entry will be a lease expense for retrospective lease payments or right-of-use-assets for future lease payments. The discount rate to be used depends on the event causing the reassessment or modification. Right-of-use asset (ROU asset) Initial measurement ROU assets are initially measured at cost, which comprises: ● The amount of the initial measurement of the lease liability, ● Any lease payments made to the lessor at or before the commencement date, ● Estimated costs to dismantle or to remove the underlying asset, ● Less any discount or incentive received from the lessor. Subsequent measurement The ROU asset is measured at cost, less any accumulated depreciation and any accumulated impairment losses. Net book value of the ROU asset must be adjusted as for any re-measurement of the lease liability. Depreciation method and useful life Depreciation method: straight-line basis. Depreciation starts at the lease commencement date (when the asset is available for use). Useful life: ● If the purchase option is reasonably certain to be exercised: Useful life of the underlying asset. ● Otherwise: The earlier of the end of the useful life of the right-of-use asset or the end of the lease term. |
Impairment of goodwill, other intangible assets and other non-financial assets subject to depreciation or amortization | (j) Impairment of goodwill, other intangible assets and other non-financial assets subject to depreciation or amortization The Group evaluates whether there are indications of possible impairment losses on non-financial assets subject to amortization or depreciation, to verify whether the carrying amount of these assets exceeds the recoverable amount. The Group tests goodwill, intangible assets with indefinite useful lives and intangible assets with finite useful lives that are not available for use for potential impairment at least annually, irrespective of whether there is any indication that the assets may be impaired. The recoverable amount of the assets is the higher of their fair value less costs of disposal and their value in use. An asset’s value in use is calculated, where applicable, based on an estimate of the future cash flows expected to derive from the use of the asset, expectations about possible variations in the amount or timing of those future cash flows, the time value of money, the price for bearing the uncertainty inherent in the asset and other factors that market participants would reflect in pricing the future cash flows deriving from the asset. Negative differences arising from comparison of the carrying amounts of the assets with their recoverable amounts are recognized in the consolidated statement of profit and loss. Recoverable amount is determined for each individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If this is the case, recoverable amount is determined for the cash-generating unit (CGU) to which the asset belongs. Impairment losses recognized for cash-generating units are first allocated to reduce, where applicable, the carrying amount of goodwill allocated to the CGU and then to the other assets of the CGU pro rata on the basis of the carrying amount of each asset. The carrying amount of each asset may not be reduced below the highest of its fair value less costs of disposal, its value in use and zero. At the end of each reporting period the Group assesses whether there is any indication that an impairment loss recognized in prior periods may no longer exist or may have decreased. Impairment losses on goodwill are not reversible. Impairment losses on other assets are only reversed if there has been a change in the estimates used to calculate the recoverable amount of the asset. A reversal of an impairment loss is recognized in consolidated profit and loss. The increased carrying amount of an asset attributable to a reversal of an impairment loss may not exceed the carrying amount that would have been determined, net of depreciation or amortization, had no impairment loss been recognized. A reversal of an impairment loss for a CGU is allocated to the assets of each unit, except goodwill, pro rata with the carrying amounts of those assets. The carrying amount of an asset may not be increased above the lower of its recoverable amount and the carrying amount that would have been disclosed, net of amortization or depreciation, had no impairment loss been recognized. |
Financial instruments | (k) Financial instruments (i) Classification of the financial instruments Financial instruments are classified at the time of their initial recognition as a financial asset, a financial liability or an equity instrument, in accordance with the economic substance of the contractual agreement and with the definitions of financial assets, financial liabilities or equity instruments indicated in IAS 32 “Financial instruments: Presentation”. For purposes of its valuation, the Group classifies financial instruments in the categories of financial assets and financial liabilities at fair value through profit or loss, separating those initially designated from those held for trading or mandatorily measured at fair value through profit or loss, financial assets and financial liabilities valued at amortized cost and financial assets measured at fair value through other comprehensive income, separating the equity instruments designated as such, from other financial assets. The classification depends on the Group’s business model to manage the financial assets and the contractual terms of the cash flows. The Group classifies a financial asset at amortized cost if it is held in the framework of a business model whose objective is to hold financial assets to obtain contractual cash flows and the contractual terms of the financial asset give rise, on specified dates, to cash flows which are only principal and interest payments on the outstanding principal amount (OPIP). The Group classifies a financial asset at fair value through changes in other comprehensive income, if it is maintained in the framework of a business model whose objective is achieved by obtaining contractual cash flows and selling financial assets and the contractual conditions of the financial asset give rise to, at specified dates, to cash flows that are OPIP. The business model is determined by the key personnel of the Group and at a level that reflects the way in which they jointly manage groups of financial assets to achieve a specific business objective. The Group’s business model represents the way in which it manages its financial assets to generate cash flows. Financial assets that are part of a business model whose objective is to hold assets to receive contractual cash flows are managed to generate cash flows in the form of contractual collections during the life of the instrument. The Group manages the assets held in the portfolio to receive these specific contractual cash flows. To determine whether cash flows are obtained through the collection of contractual cash flows from financial assets, the Group considers the frequency, value and timing of sales in prior years, the reasons for those sales and expectations in relation to with the future sales activity. However, the sales themselves do not determine the business model and, therefore, cannot be considered in isolation. Instead, it is the information on past sales and future sales expectations that provides indicative data on how to achieve the stated objective of the Group with respect to the management of financial assets and, more specifically, the way where cash flows are obtained. For assets measured at fair value, losses and gains will be recognized in profit or loss or other comprehensive income. For investments in equity instruments that are not held for trading, it will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for investments in equity at fair value through other comprehensive income (COCI). The Group reclassifies investments in debt when and only when its business model to manage those assets changes. (ii) Measurement At the time of initial recognition, the Group values a financial asset at its fair value plus, in the case of a financial asset that is not at fair value through profit or loss, the costs of the transaction that are directly attributable to the acquisition. The transaction costs of financial assets at fair value through profit or loss are taken to results. In order to determine the fair value of financial assets or liabilities, the Group uses market data as much as possible. Based on the factors used for the measurement, the fair values are hierarchized based on the following levels: ● Level 1: quoted prices (unadjusted) within current markets for assets or liabilities identical to those under consideration. ● Level 2: factors other than the prices considered in Level 1 that come directly from the asset or liability in question, such as those that may derive directly from the price. ● Level 3: factors not based on data directly from the market. In the event that the factors used to determine the fair value of an asset or liability are included in different levels of hierarchy, the fair value will be determined in its entirety based on the significant component located at the lowest level of hierarchy. (iii) Offsetting principles A financial asset and a financial liability are offset only when the Group has the legally enforceable right to set off the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. (iv) Financial assets and liabilities at fair value through profit or loss Financial assets or liabilities at fair value through profit or loss are those that are classified as held for trading or have been designated from the moment of initial recognition. A financial asset or liability is classified as held for trading if: ● It is acquired or incurred mainly for the purpose of selling it or repurchasing it in the near term. ● On initial recognition it is part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent pattern of short-term profit-taking, or ● It is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument. Financial assets and liabilities at fair value through profit or loss are initially recognized at fair value. Transaction costs directly attributable to the purchase or issue are recognized as an expense as incurred. After initial recognition, they are recognized at fair value through profit or loss. The fair value is not reduced by the transaction costs that may be incurred by their eventual sale or disposal by other means. The Group does not reclassify any financial asset or liability to or from this category as long as it is recognized in the consolidated statement of financial position. (v) Financial assets at amortized cost Financial assets at amortized cost are initially recognized at their fair value, including the transaction costs incurred, and are subsequently measured at amortized cost, using the effective interest method. (vi) D bt instruments The subsequent valuation of the debt instruments depends on the Group’s business model to manage the asset and the characteristics of the cash flows of the asset. The Group’s debt instruments consist mainly of trade and other receivables, which the Group classifies as financial assets at amortized cost. Financial assets at amortized cost are assets that the Group holds for the collection of contractual cash flows when these cash flows represent only payments of principal and interest, and are valued at amortized cost. Interest income from these financial assets is included in finance income in accordance with the effective interest rate method. (vii) Equity instruments The Group holds financial assets owned, mainly equity instruments, which are measured at fair value. When Group management has chosen to present the gains and losses on the fair value of the equity investments in other comprehensive income, after the initial recognition, the equity instruments are measured at fair value, recognizing the loss or gain in other comprehensive income. The amounts recognized in other comprehensive income are not subject to reclassification to profit or loss, without prejudice to reclassification to reserves at the time when the instruments are derecognized. Dividends from such investments continue to be recognized in income for the year as other income when the Group’s right to receive payments is established. (viii) Impairment As of 1 January 2018, the Group evaluates, on a prospective basis, the expected credit losses associated with its debt instruments recorded at amortized cost. The Group uses the practical expedients permitted by IFRS 9 to assess the expected credit losses related to commercial accounts using a simplified approach, eliminating the need to evaluate when there has been a significant increase in credit risk. The simplified approach requires that the expected losses be recorded from the initial recognition of receivables, so that the Group determines expected credit losses as a probability-weighted estimate of such losses over the expected life of the financial instrument. The practical expedient applied is the use of a provision matrix based on the segmentation into groups of homogeneous assets, applying the historical information of percentages of non-payment for said groups and applying reasonable information about the future economic conditions. The percentage of non-payment is calculated according to the current experience of non-payment during the last year, as it is a very dynamic market and is adjusted for the differences between current and historical economic conditions and considering projected information, which is reasonably available. (ix) Derecognition of financial assets The Group applies the criteria for the derecognition of financial assets to a part of a financial asset or to a part of a group of similar financial assets or to a financial asset or a group of similar financial assets. Financial assets are derecognized when the rights to receive cash flows related to them have expired or have been transferred and the Group has substantially transferred the risks and rewards derived from their ownership. (x) Financial liabilities at amortized cost Financial liabilities, including trade payables and other accounts payable, that are not classified at fair value through profit or loss, are initially recognized at their fair value, less, if applicable, the transaction costs that are directly attributable to the issue. Subsequent to the initial recognition, liabilities classified under this category are valued at amortized cost using the effective interest rate method. (xi) Derecognition and modification of financial liabilities The Group derecognizes a financial liability or part thereof when it has complied with the obligation contained in the liability, or is legally exempt from the main liability contained in the liability, either by virtue of a judicial process or by the creditor. The Group considers that the conditions are substantially different if the present value of the discounted cash flows under the new conditions, including any commission paid net of any commission received, and using the original effective interest rate to make the discount, differs at least at 10 percent of the discounted present value of the cash flows that still remain of the original financial liability. If the exchange is recorded as a cancellation of the original financial liability, the costs or commissions are recognized in consolidated results forming part of the result of the same. Otherwise, the costs or commissions adjust the carrying amount of the liability and are amortized by the amortized cost method during the remaining life of the modified liability. The Group recognizes the difference between the carrying amount of the financial liability or a part of it that is canceled or assigned to a third party and the consideration paid, including any assigned asset different from the cash or liability assumed in profit or loss. |
Derivative financial instruments and hedging activities | (l) Derivative financial instruments and hedging activities Derivatives are initially recognized at fair value on the date the derivative contract is signed and at the closing date. The gain or loss recognition method depends on whether the derivative financial instrument has been designated as a hedging instrument and, if so, the nature of the item being hedged. For the purpose of their recognition, derivative financial instruments are classified as: (i) Cash flow hedges that qualify for hedge accounting Hedge effectiveness The effectiveness of the hedge is determined at the beginning of the hedging relationship and through periodic evaluations of the effectiveness in order to ensure that there exists an economic relationship between the hedged item and the hedging instrument. In order to evaluate the effectiveness of derivatives such as cross-currency euro/dollar swaps, the Group uses the hypothetical derivative method. This hypothetical derivative is built without including the credit risk and the currency spread. According to the hypothetical derivative method, the cumulative change in the fair value of the real currency swap, excluding the currency spread effect, is compared to the cumulative change in the fair value of the hypothetical swap. Therefore, the hypothetical derivative is built as a cross-currency swap with euro fixed payment and a dollar fixed reception without the inclusion of the credit risk or the currency spread and with a nil fair value at the date of designation. Accounting At the inception of the hedging relationship, the Group documents the economic relationship between the hedging instruments and the hedged items, including whether changes in cash flows of the hedging instruments are expected to offset changes in cash flows of the hedged items. The Group documents its risk management objective and strategy for undertaking its hedging transactions. The effective portion of changes in the fair value of derivative financial instruments that are designated and qualify as cash flow hedges is recognized in the cash flow reserve within equity. For cross-currency swaps it the currency spread of the hedging relationship is excluded in order to be recognized as hedging costs within equity. The gain or loss related to the ineffective portion is recognized immediately in income for the year, under “Changes in fair value of financial instruments”. Cumulative amounts in the cash flow reserve within equity are recognized in the statement of profit and loss when the hedged item affects profit or loss or when ineffectiveness is identified. The fair values of derivative financial instruments designated in hedging relationships are disclosed in note 30. Movements in the hedging reserve included in equity are shown in note 16 (c). (ii) Cash flow hedges that do not qualify for hedge accounting Derivative financial instruments which do not meet the criteria for applying hedge accounting are classified as held for trading. The fair value changes are recognized immediately in the consolidated statement of profit and loss. |
Equity instruments | (m) Equity instruments The Group’s acquisition of equity instruments of the Parent is recognized separately at cost of acquisition in the consolidated balance sheet as a reduction in equity, regardless of the motive of the purchase. Any gains or losses on transactions with treasury equity instruments are not recognized in consolidated profit and loss. The subsequent redemption of Parent shares, where applicable, leads to a reduction in share capital in an amount equivalent to the par value of such shares. Any positive or negative difference between the cost of acquisition and the par value of the shares is debited or credited to reserves. Transaction costs related with treasury equity instruments, including issue costs related to a business combination, are accounted for as a reduction in equity, net of any tax effect. |
Inventories | (n) Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. The costs of conversion of inventories include costs directly related to the units of production and a systematic allocation of fixed and variable production overheads that are incurred in converting materials into finished goods. The allocation of fixed indirect overheads is based on the higher of normal production capacity or actual production. The raw material used to produce hemoderivatives is human plasma, which is obtained from our donation centers using the plasmapheresis method. The cost of inventories includes the amount paid to plasma donors, or the amount billed by the seller when purchased from third parties, as well as the cost of products and devices used in the collection process, rental expenses and storage. This plasma has to be stored before use, which is an essential part of the production process. During the storage period, the plasma undergoes various virological tests and should be kept in quarantine in accordance with FDA and European Medicines Agency regulations, in order to guarantee that all the plasma is suitable for use in the production process. To the extent that plasma storage costs are necessary to the production process, they are included as cost of inventories. Indirect costs such as general management and administration costs are recognized as expenses in the period in which they are incurred. The cost of raw materials and other supplies and the cost of merchandise are allocated to each inventory unit on a weighted average cost basis. The transformation cost is allocated to each inventory unit on a FIFO (first-in, first-out) basis. The Group uses the same cost model for all inventories of the same nature and with a similar use. Volume discounts extended by suppliers are recognized as a reduction in the cost of inventories when it is probable that the conditions for discounts to be received will be met. Discounts for prompt payment are recognized as a reduction in the cost of the inventories acquired. When the cost of inventories exceeds net realizable value, materials are written down to net realizable value, which is understood to be: ● For raw materials and other supplies, replacement cost. Nevertheless, raw materials and other supplies are not written down below cost if the finished goods into which they will be incorporated are expected to be sold at or above cost of production; ● Merchandise and finished goods, estimated selling price less costs to sell; ● Work in progress, the estimated selling price of related finished goods, less the estimated costs of completion and the estimated costs necessary to make the sale. The previously recognized write-down is reversed against profit and loss when the circumstances that previously caused inventories to be written down no longer exist or when there is clear evidence of an increase in net realizable value because of changed economic circumstances. The reversal of the write-down is limited to the lower of the cost and revised net realizable value of the inventories. Write-downs may be reversed with a credit to “Cost of sales”. |
Cash and cash equivalents | (o) Cash and cash equivalents Cash and cash equivalents include cash on hand and demand deposits in financial institutions. They also include other short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. An investment normally qualifies as a cash equivalent when it has a maturity of less than three months from the date of acquisition. The Group classifies cash flows relating to interest received and paid as operating activities, and dividends received and distributed are classified under investing and financing activities, respectively. |
Government grants | (p) Government grants Government grants are recognized when there is reasonable assurance that they will be received and that the Group will comply with the conditions attached. (i) Outright capital grants are initially recognized as deferred income in the consolidated balance sheet. Income from capital grants is recognized in the consolidated statement of profit and loss in line with the depreciation of the corresponding financed assets. (ii) Operating grants received to offset expenses or losses already incurred, or to provide immediate financial support not related to future disbursements, are recognized in the consolidated statement of profit and loss. (iii) Financial liabilities comprising implicit assistance in the form of below-market interest rates are initially recognized at fair value. The difference between this value, adjusted where necessary for the issue costs of the financial liability and the amount received, is recognized as a government grant based on the nature of the grant awarded. |
Employee benefits | (q) Employee benefits (i) The Group recognizes the contributions payable to a defined contribution plan in exchange for a service in the period in which contributions are accrued. Accrued contributions are recognized as an employee benefit expense in the corresponding consolidated statement of profit and loss in the year that the contribution was made. (ii) Termination benefits are recognized at the earlier of the date when the Group can no longer withdraw the offer of those benefits and when the Group recognizes costs for a restructuring that involves the payment of termination benefits. For termination benefits payable as a result of an employee’s decision to accept an offer of benefits, the time when the Group can no longer withdraw the offer of termination benefits is the earlier of when the employee accepts the offer and when a restriction on the Group’s ability to withdraw the offer takes effect. For termination benefits payable as a result of the Group’s decision to make an employee redundant, the Group can no longer withdraw the offer when it has informed the affected employees or union representatives of the plan and the actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made. The plan must identify the number of employees to be made redundant, their job classifications or functions and their locations and the expected completion date. The plan must also establish the termination benefits that employees will receive in sufficient detail that employees can determine the type and amount of benefits they will receive when their employment is terminated. If the Group expects to settle the termination benefits in full more than twelve months after year end, the liability is discounted using the market yield on high quality corporate bonds. (iii) The Group recognizes the expected cost of short-term employee benefits in the form of accumulating compensated absences when the employees render service that increases their entitlement to future compensated absences. In the case of non-accumulating compensated absences, the expense is recognized when the absences occur. The Group recognizes the expected cost of profit-sharing and bonus plans when it has a present legal or constructive obligation to make such payments as a result of past events and a reliable estimate of the obligation can be made. (iv) The Group gives share-based payments to certain employees who render services to the Company. The fair value of the services received is determined based on the estimated fair value of the shares given at the grant date. Because the equity instruments granted do not vest until the employees complete a specified period of service, those services are accounted for during the vesting period in the statement of profit and loss as an expense for the year, with the corresponding increase in equity. The amount recognized corresponds to that settled once the agreed terms have been met and it will not be adjusted or revalued during the accrual period, as the commitment is settled in the form of shares. The total amount recognized is calculated based on the incentive payable in shares, increasing in line with percentages agreed by the Group. If an employee decides to leave his/her job prior to the end of the accrual period, he/she will only receive the agreed incentive in the form of shares and the Company will be able to choose whether to settle in cash or using equity instruments. |
Provisions | (r) Provisions Provisions are recognized when the Group has a present obligation (legal or implicit) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the obligation. No provisions are recognized for future operating losses. The amount recognized as a provision is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account all risks and uncertainties surrounding the amount to be recognized as a provision and, where the time value of money is material, the financial effect of discounting provided that the expenditure to be made each period can be reliably estimated. The discount rate used to determine the present value is a pre-tax rate that reflects the evaluations that the current market is making of the time value of money and the specific risks of the obligation. The increase in the provision due to the passage of time is recognized as an interest expense. If it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation, the provision is reversed against the consolidated statement of profit and loss item where the corresponding expense was recognized. |
Revenue recognition | (s) Revenue recognition Revenue from the sale of goods or services is recognized at an amount that reflects the consideration that the Group expects to be entitled to receive in exchange for transferring goods or services to a customer, at the time when the customer obtains control of the goods or services rendered, this means when the customer has the ability to direct the use of the asset. The consideration that is committed in a contract with a client can include fixed amounts, variable amounts, or both. The amount of the consideration may vary due to discounts, reimbursements, incentives, performance bonuses, penalties or other similar items. Contingent consideration is included in the transaction price when it is highly probable that the amount of revenue recognized is not subject to future significant reversals. Revenue is presented net of the value added tax and any other amount or tax, which in substance corresponds to amounts received on behalf of third parties. (i) Revenue from the sale of goods is recognized when the Group meets the performance obligation by transferring the assets committed to the customer. An asset is transferred when the customer obtains control of that asset. When evaluating the satisfaction of the performance obligation, the Group considers the following indicators of the transfer of control, which include, but are not limited to the following: ● The Group has a present right to payment for the asset ● The customer has the legal right to the asset ● The Group has transferred the physical possession of the asset ● The customer has the significant risks and rewards of ownership of the asset ● The customer has accepted the asset The nature of the assets that the Group is committed to transfer is mainly: sale of goods, sale of equipment, fragmentation agreements, maintenance and technical support, training, licenses, royalties and know-how and engineering projects among others. Transaction price is set under the assumption that goods and/or services are transferred in accordance with the contract terms. The committed consideration to customers can include fixed amounts, variable amounts or both. The transaction price must be estimated taking into account the effect of the variable compensation (when applicable) related to returns, chargeback discounts, volume discounts or other incentives, as long as it is highly probable. The Group participates in the government-managed Medicaid programs in the United States, accounting for Medicaid rebates by recognizing an accrual at the time a sale is recorded for an amount equal to the estimated claims for Medicaid rebates attributable to the sale. Medicaid rebates are estimated based on historical experience, legal interpretations of the applicable laws relating to the Medicaid program and any new information regarding changes in the program regulations and guidelines that would affect rebate amounts. Outstanding Medicaid claims, Medicaid payments and inventory levels are analyzed for each distribution channel and the accrual is adjusted periodically to reflect actual experience. While rebate payments are generally made in the following or subsequent quarter, any adjustments for actual experience have not been material. As is common practice in the sector, the purchase contracts signed by some customers with the Group entitle these customers to price discounts for a minimum purchase volume, volume discounts or prompt payment discounts. The Group recognizes these discounts as a reduction in sales and receivables in the same month that the corresponding sales are invoiced based on the customer’s actual purchase figures or on past experience when the customer’s actual purchases will not be known until a later date. In the USA, the Group enters into agreements with certain customers to establish contract pricing for the products, which these entities purchase from the authorized wholesaler or distributor (collectively, wholesalers) of their choice. Consequently, when the products are purchased from wholesalers by these entities at the contract price which is less than the price charged by the Group to the wholesaler, the Group provides the wholesaler with a credit referred to as a chargeback. The Group records the chargeback accrual at the time of the sale. The allowance for chargebacks is based on Group’s estimate of the wholesaler inventory levels, and the expected sell-through of the products by the wholesalers at the contract price based on historical chargeback experience and other factors. The Group periodically monitors the factors that influence the provision for chargebacks and makes adjustments when it considers that actual chargebacks may differ from established allowances. These adjustments occur in a relatively short period of time. As these chargebacks are typically settled within 30 to 45 days of the sale, adjustments for actual experience have not been material. The amount at closing related to other discounts is settled during the following year within a period of 90 to 180 days depending on the type of provision. (ii) Revenues associated with the rendering of service transactions are recognized by reference to the stage of completion at the consolidated balance sheet date when the outcome of the transaction can be estimated reliably. The outcome of a transaction can be estimated reliably when revenues, the stage of completion, the costs incurred and the costs to complete the transaction can be estimated reliably and it is probable that the economic benefits derived from the transaction will flow to the Group. When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue is recognized only to the extent of costs incurred that are recoverable. |
Income taxes | (t) Income tax The income tax expense or tax income for the year comprises current tax and deferred tax. Current tax is the amount of income taxes payable or recoverable in respect of the consolidated taxable profit or consolidated tax loss for the year. Current tax assets or liabilities are measured at the amount expected to be paid to or recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantially enacted at the reporting date. Deferred tax liabilities are the amounts of income taxes payable in future periods in respect of taxable temporary differences, whereas deferred tax assets are the amounts of income taxes recoverable in future periods in respect of deductible temporary differences, the carryforward of unused tax losses, and the carryforward of unused tax credits. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base. Current and deferred tax are recognized as income or an expense and included in profit and loss for the year, except to the extent that the tax arises from a transaction or event which is recognized, in the same or a different year, directly in equity, or from a business combination. Grifols periodically evaluates the positions taken in the tax declarations regarding the situations in which the applicable tax regulations are subject to interpretation and establishes provisions, if necessary, based on the amounts expected to be paid to the taxation authorities, whose provision is reflected in the tax gain (loss). (i) Taxable temporary differences are recognized in all cases except where: ● ● (ii) Deductible temporary differences are recognized provided that: ● ● Tax planning opportunities are only considered when assessing the recoverability of deferred tax assets and if the Group intends to use these opportunities or it is probable that they will be utilized. (iii) Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the years when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted. The tax consequences that would follow from the manner in which the Group expects to recover or settle the carrying amount of its assets or liabilities are also reflected in the measurement of deferred tax assets and liabilities. At year end the Group reviews the fair value of deferred tax assets to write down the balance if it is not probable that sufficient taxable income will be available to apply the tax asset. Deferred tax assets which do not meet the above conditions are not recognized in the consolidated balance sheet. At year end the Group assesses whether deferred tax assets which were previously not recognized now meet the conditions for recognition. (iv) The Group only offsets current tax assets and current tax liabilities if it has a legally enforceable right to set off the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. The Group only offsets deferred tax assets and liabilities where it has a legally enforceable right, where these relate to income taxes levied by the same taxation authority and where the taxation authority permits the entity to settle on a net basis, or to realize the asset and settle the liability simultaneously for each of the future years in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered. Deferred tax assets and liabilities are recognized in the consolidated balance sheet under non-current assets or liabilities, irrespective of the expected date of recovery or settlement. |
Segment reporting | (u) Segment reporting An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, whose operating results are regularly reviewed by the Group’s chief operating decision maker to make decisions about resources to be allocated to the segment, assess its performance and, based on which, differentiated financial information is available. |
Classification of assets and liabilities as current and non-current | (v) Classification of assets and liabilities as current and non-current The Group classifies assets and liabilities in the consolidated balance sheet as current and non-current. Current assets and liabilities are determined as follows: ● ● ● |
Environmental issues | (w) Environmental issues The Group takes measures to prevent, reduce or repair the damage caused to the environment by its activities. Property, plant and equipment acquired by the Group for long-term use to minimize the environmental impact of its activity and protect and improve the environment, including the reduction and elimination of future pollution from the Group’s operations, are recognized as assets applying the measurement, presentation and disclosure criteria described in note 4(g). |
Basis of Presentation (Tables)
Basis of Presentation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Basis of Presentation | |
Schedule of amendments to IFRS | Effective in 2019 Mandatory application for annual periods beginning on or after: Standards IASB effective date EU effective date IFRS 16 Leases (Issued on 13 January 2016) 1 January 2019 1 January 2019 IFRIC 23 Uncertainty over Income Tax Treatments (issued on 7 June 2017) 1 January 2019 1 January 2019 IFRS 9 Prepayment Features with Negative Compensation (issued on 12 October 2017) 1 January 2019 1 January 2019 IAS 28 Long-term interests in Associates and Joint Ventures (issued on 12 October 2017) 1 January 2019 1 January 2019 Various Annual Improvements to IFRS Standards 2015-2017 Cycle (issued on 12 December 2017) 1 January 2019 1 January 2019 IAS 19 Plan Amendment, Curtailment or Settlement (issued on 7 February 2018) 1 January 2019 1 January 2019 Effective in 2020 Mandatory application for annual periods Standards EU effective date IASB effective date IAS 1 Definition of Material (issued on 31 October 2018) 1 January 2020 1 January 2020 Various Amendments to references to the Conceptual Framework in IFRS Standards (issued on 29 March 2018) 1 January 2020 1 January 2020 IFRS 3 Amendment to IFRS 3 Business Combination (issued on 22 October 2018) 1 January 2020 1 January 2020 IFRS 9 IAS 39 Interest rate Benchmark Reform (issued on 26 September 2019) 1 January 2020 1 January 2020 IFRS 7 IFRS 16 As a consequence of the Covid 19 - Related Rent concessions (issued on 28 May 2020) 1 June 2020 1 June 2020 Effective in 2021 The following standards published by the IASB and the IFRS Interpretations Committee and adopted by the European Union for application in Europe came into force in 2021 and, therefore, have been taken into account in the preparation of these consolidated financial statements: Mandatory application for annual periods Standards EU effective date IASB effective date IFRS 4 Amendments to IFRS 4 Insurance Contracts – deferral of IFRS 9 (issued on 25 June 2020) 1 January 2021 1 January 2021 Various Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2 (issued on 27 August 2020) 1 January 2021 1 January 2021 IFRS 16 Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions beyond 30 June 2021 (issued on 31 March 2021) 1 April 2021 1 April 2021 |
Schedule of lease agreements period | Average lease term Buildings and warehouses 10 to 15 years Donor centers 13 to 15 years PCs and hardware 3 to 5 years Machinery 4 to 5 years Vehicles 3 to 5 years |
Schedule of standards issued but not effective in 2021 | Standards issued but not effective in 2021 At the date these consolidated financial statements were authorized for issue, the following IFRS, amendments and IFRIC interpretations have been published by the European Union but their application is not mandatory until the future periods indicated below: Mandatory application for annual periods Standards EU effective date IASB effective date IFRS 17 Insurance Contracts (issued on 18 May 2017); including 1 January 2023 1 January 2023 IFRS 17 Amendments to IFRS 17 Isurance contracts: Initial Application of IFRS 17 and IFRS 9 - Comparative Information (issued on 9 December 2021) Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current and pending pending IAS 1 Classification of Liabilities as Current or Non-current - Deferral of Effective Date (issued on 23 January 2020 and 15 July 2020 respectively). pending 1 January 2023 IAS 1 Amendments issued 12 February 2021 to:• IAS 1 Presentation of Financial Statements ;• IFRS Practice Statement 2: Disclosure of Accounting policies 1 January 2023 1 January 2023 IAS 8 Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estitmates (issued on 12 February 2021) 1 January 2023 1 January 2023 IAS 12 Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (issued on 7 May 2021) pending 1 January 2023 Various Amendments issued 14 May 2020 to:• IFRS 3 Business Combinations: references to the Conceptual Framework;• IAS 16 Property, Plant and Equipment: Proceeds before Intended Use; • IAS 37 Provisions, Contingent Liabilities and Contingent Assets: Onerous Contracts — Cost of Fulfilling a Contract ; and• Annual Improvements to IFRSs 2018-2020: IFRS 1, IFRS 9, 1 January 2022 1 January 2022 |
Business Combinations (Tables)
Business Combinations (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
GigaGen Inc. | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousandss of Thousandss of Euros US Dollars Consideration paid First repurchase of non-controlling interests 38,201 46,203 Second repurchase of non-controlling interests (discounted amount) 35,227 42,608 Total consideration paid 73,428 88,811 Fair value of the previous investment in the company 50,792 61,434 Fair value of net assets acquired 18,760 22,691 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 105,460 127,554 |
Schedule of fair value assets, liabilities and contingent liabilities recognised on acquisition date | Fair value Thousandss of Thousands of Euros US Dollars Development costs in progress (note 8) 24,027 29,061 Property, plant and equipment (note 8) 1,168 1,413 Non-current financial assets 151 183 Trade and other receivables 56 68 Other current assets 2,368 2,864 Cash and cash equivalents 12,389 14,985 Total assets 40,159 48,574 Non current liabilities (17,792) (21,520) Current liabilities (3,607) (4,363) Total liabilities and contingent liabilities (21,399) (25,883) Total net assets identified 18,760 22,691 |
BPL Plasma, Inc. | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousands of Euros Thousands of US Dollars Consideration paid First payment performed 9,921 12,000 Cash paid at the transaction closing date 308,016 372,548 Total consideration paid 317,937 384,548 Fair value of net assets acquired 15,039 18,190 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 302,898 366,358 |
Schedule of fair value assets, liabilities and contingent liabilities recognised on acquisition date | Fair value Thousands of Euros Thousands of US Dollars Property, plant and equipment (note 10) 14,406 17,424 Non-current financial assets 85 103 Inventories 557 674 Total assets 15,048 18,201 Current liabilities (9) (11) Total liabilities and contingent liabilities (9) (11) Total net assets identified 15,039 18,190 |
Acquisition of plasma centers from Kedplasma, LLC | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousands of Euros Thousands of US Dollars Consideration paid Cash paid 45,638 55,200 Total consideration paid 45,638 55,200 Fair value of net assets acquired 2,692 3,256 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 42,946 51,944 |
Schedule of fair value assets, liabilities and contingent liabilities recognised on acquisition date | Fair value Thousands of Euros Thousands of US Dollars Property, plant and equipment (note 10) 2,448 2,961 Inventories 244 295 Total assets 2,692 3,256 Total net assets identified 2,692 3,256 |
Plasma Donor Centers | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousands of Euros Cost of the business combination Payment in cash 20,500 Total business combination cost 20,500 Fair value of net assets acquired 1,620 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 18,880 |
Interstated Blood Bank, Inc. Group | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousands of Euros Thousands of US Dollars Consideration paid Cash paid 88,984 100,000 Total consideration paid 88,984 100,000 Fair value of the previous investment in the company 94,126 105,779 Fair value of the call option 8,898 10,000 Fair value of net assets acquired 19,345 21,744 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 172,663 194,035 |
Schedule of fair value assets, liabilities and contingent liabilities recognised on acquisition date | Fair value Thousands of Euros Thousands of US Dollars Intangible assets (note 8) 77 87 Property, plant and equipment (note 10) 23,724 26,661 Inventories 10,271 11,543 Trade and other receivables 12,080 13,575 Other current assets 2,015 2,265 Cash and cash equivalents 1,961 2,204 Total assets 50,128 56,335 Non-current liabilities (10,233) (11,500) Current liabilities (20,550) (23,091) Total liabilities and contingent liabilities (30,783) (34,591) Total net assets acquired 19,345 21,744 |
Plasmavita Healthcare | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousands of Euros Consideration paid Cash paid 10,000 Total consideration paid 10,000 Fair value of the previous investment in the company 10,674 Fair value of net assets acquired 21,374 Minority interest (10,687) Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 9,987 |
Schedule of fair value assets, liabilities and contingent liabilities recognised on acquisition date | Fair Value Thousand of Euros Intangible assets (note 8) 177 Rights of use (note 9) 7,856 Property, plant and equipment (note 10) 6,506 Investment in group companies 9,548 Non-current financial assets 5,017 Inventories 1,114 Trade and other receivables 811 Other current assets 333 Cash and cash equivalents 359 Total assets 31,721 Deferred tax liabilities (1,364) Other non current liabilites (7,575) Current liabilities (1,408) Total liabilities and contingent liabilities (10,347) Total net assets acquired 21,374 |
Alkahest, Inc. | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousand of US Thousand of Euros Dollars Cost of the business combination First repurchase of non-controlling interests 18,797 22,235 Second repurchase of non-controlling interests (discounted amount) 104,628 123,765 Total business combination cost 123,425 146,000 Fair value of the previous investment in the company 91,023 107,671 Fair value of net assets acquired 140,076 165,696 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) 74,372 87,975 |
Schedule of fair value assets, liabilities and contingent liabilities recognised on acquisition date | Fair Value Thousand of Thousand of Euros US Dollars Other Intangible Assets (note 8) 265,617 314,198 Property, plant and equipement (note 10) 4,970 5,879 Other non current assets 178 210 Trade and other reeceivables 2,552 3,019 Other current assets 1,610 1,904 Cash and cash equivalents 7,563 8,946 Total assets 282,489 334,156 Non-current financial liabilities (42,269) (50,000) Deferred tax liability (74,372) (87,975) Other non-current liabilities (19,644) (23,237) Trade and other payables (1,863) (2,204) Other current liabilities (4,264) (5,044) Total Liabilities (142,413) (168,460) Fair value of net assets acquired 140,076 165,696 |
Green Cross | |
Business Combinations | |
Disclosure of detailed information about business combination | Thousands of US Thousands of Euros Dollars Consideration paid Cash paid 387,917 457,160 Total consideration paid 387,917 457,160 Fair value of net assets acquired 194,227 228,897 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) 193,690 228,263 |
Schedule of fair value assets, liabilities and contingent liabilities recognised on acquisition date | Fair Value Thousand of Euros Thousand of US Dollars Other Intangible Assets 2,877 3,390 Rights of Use 11,642 13,720 Property, plant and equipement 158,148 186,377 Deferred tax assets 33,081 38,986 Other non current assets 122 144 Inventories 2,999 3,534 Trade and other reeceivables 3,484 4,106 Other current assets 943 1,111 Cash and cash equivalents 6,053 7,133 Total assets 219,349 258,501 Non-current financial liabilities (13,150) (15,497) Current financial liabilities (797) (939) Trade and other payables (11,175) (13,168) Total Liabilities (25,122) (29,604) Fair value of net assets acquired 194,227 228,897 |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies | |
Schedule of property, plant and equipment depreciation rates. | Depreciation method Rates Buildings Straight line 1% Other property, technical equipment and machinery Straight line 4% - 10% Other property, plant and equipment Straight line 7% |
Schedule of intangible assets amortization rates | Amortisation method Rates Development expenses Straight line 10% Concessions, patents, licences, trademarks and similar Straight line 4% Computer software Straight line 33% Currently marketed products Straight line 3% |
Financial Risk Management Pol_2
Financial Risk Management Policy (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Financial Risk Management Policy | |
Return on equity | Thousands of Euros 2021 2020 Profit attributable to the Parent 188,726 618,546 Equity attributable to the Parent 5,523,609 5,108,392 ROE 3 % 12 % |
Segment Reporting (Tables)
Segment Reporting (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Segment Reporting | |
Schedule of details of net sales by groups of products | Details of sales by groups of products for 2021, 2020 and 2019 are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Bioscience Haemoderivatives 3,814,983 4,242,502 3,993,462 Diagnostic Transfusional medicine 712,238 714,164 680,766 Other diagnostic 23,625 27,630 19,937 Hospital Fluid therapy and nutrition 46,670 41,359 47,677 Hospital supplies 70,217 58,303 67,489 Bio supplies 225,765 224,090 266,540 Others 39,620 31,990 22,820 Total 4,933,118 5,340,038 5,098,691 |
Goodwill (Tables)
Goodwill (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill | |
Schedule of details of and movement in goodwill | Details of and movement in this caption of the consolidated balance sheet at 31 December 2021 were as follows: Thousands of Euros Balance at Business Translation Balance at Segment 31/12/2020 Combination Transfers differences 31/12/2021 Net value Grifols UK.Ltd. (UK) Bioscience 7,674 — — 511 8,185 Grifols Italia.S.p.A. (Italy) Bioscience 6,118 — — — 6,118 Biomat USA, Inc.(USA) Bioscience 234,791 345,844 51,364 44,322 676,321 Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) Diagnostic 9,538 — — 214 9,752 Grifols Therapeutics, Inc. (USA) Bioscience 1,816,404 — — 145,620 1,962,024 Araclon Biotech, S.L. (Spain) Diagnostic 6,000 (6,000) — — — Progenika Biopharma, S.A. (Spain) Diagnostic 40,516 — — — 40,516 Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) Diagnostic 2,376,978 — — 188,515 2,565,493 Kiro Grifols S.L. (Spain) Hospital 24,376 — — — 24,376 Goetech LLC (USA) Hospital 55,167 — — 4,423 59,590 Haema AG (Germany) Bioscience 190,014 — — — 190,014 BPC Plasma, Inc. (formerly Biotest Pharma Corp; USA) Bioscience 140,334 — — 11,250 151,584 Interstate Blood Bank, Inc. (USA) Bioscience 158,479 — — 12,705 171,184 Plasmavita Healthcare GmbH (Alemania) Bioscience 9,987 — — — 9,987 Alkahest, Inc (EEUU) Others 71,910 — — 5,765 77,675 Grifols Canada Therapeutics, Inc (formerly Green Cross Biotherapeutics, Inc.) (Canada) Bioscience 134,569 16,667 — 12,225 163,461 GCAM, Inc (formerly Green Cross America Inc.) (USA) Bioscience 49,416 — (51,364) 1,948 — GigaGen, Inc (ver nota 3) Others 105,460 — 7,161 112,621 5,332,271 461,971 0 434,659 6,228,901 Details of and movement in this caption of the consolidated balance sheet at 31 December 2020 are as follows: Thousands of Euros Balance at Business Translation Balance at Segment 31/12/2019 Combination Disposals differences 31/12/2020 Net value Grifols UK.Ltd. (UK) Bioscience 8,107 — — (433) 7,674 Grifols Italia.S.p.A. (Italy) Bioscience 6,118 — — — 6,118 Biomat USA, Inc.(USA) Bioscience 255,896 — — (21,105) 234,791 Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) Diagnostic 9,472 — — 66 9,538 Grifols Therapeutics, Inc. (USA) Bioscience 1,979,678 — — (163,274) 1,816,404 Araclon Biotech, S.L. (Spain) Diagnostic 6,000 — — — 6,000 Progenika Biopharma, S.A. (Spain) Diagnostic 40,516 — — — 40,516 Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) Diagnostic 2,600,950 — (12,902) (211,070) 2,376,978 Kiro Grifols S.L. (Spain) Hospital 24,376 — — — 24,376 Goetech LLC (USA) Hospital 60,126 — — (4,959) 55,167 Haema AG (Germany) Bioscience 190,014 — — — 190,014 BPC Plasma, Inc. (formerly Biotest Pharma Corp; USA) Bioscience 152,948 — — (12,614) 140,334 Interstate Blood Bank, Inc. (USA) Bioscience 172,862 — — (14,383) 158,479 Plasmavita Healthcare GmbH (Germany) Bioscience — 9,987 — — 9,987 Alkahest, Inc (USA) Others — 74,372 — (2,462) 71,910 Green Cross Biotherapeutics, Inc. (Canada) Bioscience — 133,443 — 1,126 134,569 Green Cross America Inc.(USA) Bioscience — 51,299 — (1,883) 49,416 5,507,063 269,101 (12,902) (430,991) 5,332,271 (See note 3) |
Schedule of key assumptions used in calculating impairment of CGUs | The key assumptions used in calculating impairment testing of the CGUs for 2020 were as follows: Perpetual Growth rate Pre-tax discount rate Bioscience 1.9 % 8.9 % Diagnostic 1.9 % 9.5 % Hospital 1.4 % 10.8 % The key assumptions used in calculating impairment testing of the CGUs for 2021 have been as follows: Perpetual Growth rate Pre-tax discount rate Bioscience 2.0 % 9.0 % Diagnostic 2.0 % 9.3 % Hospital 1.5 % 10.9 % |
Schedule of reasonably possible changes in key assumptions considered in the calculation of the CGUs' recoverable amount | The reasonably possible changes considered for the Bioscience, Diagnostic and Hospital CGUs are a variation in the discount rate, as well as in the estimated perpetual growth rate, as follows: Perpetual Growth rate Pre-tax discount rate Bioscience +/- 50 bps +/- 50 bps Diagnostic +/- 50 bps +/- 50 bps Hospital +/-100 bps +/-100 bps |
Other Intangible Assets (Tables
Other Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Other Intangible Assets | |
Schedule of cost and accumulated amortization of currently marketed products | The cost and accumulated amortization of currently marketed products acquired from Talecris and Progenika at 31 December 2020 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2019 Additions differences 31/12/2020 Cost of currently marketed products - Gamunex 1,069,042 — (88,169) 980,873 Cost of currently marketed products - Progenika 23,792 — — 23,792 Accumulated amortisation of currently marketed products - Gamunex (305,865) (35,360) 27,890 (313,335) Accumulated amortisation of currently marketed products - Progenika (16,254) (2,379) 0 (18,633) Carrying amount of currently marketed products 770,715 (37,739) (60,279) 672,697 The cost and accumulated amortization of currently marketed products acquired from Talecris, Progenika and Gigagen at 31 December 2021 is as follows: Thousands of Euros Balance at Translation Balance at 31/12/2020 Additions differences 31/12/2021 Cost of currently marketed products - Gamunex 980,873 — 78,636 1,059,509 Cost of currently marketed products - Progenika 23,792 — — 23,792 Accumulated amortisation of currently marketed products - Gamunex (313,335) (33,610) (26,827) (373,772) Accumulated amortisation of currently marketed products - Progenika (18,633) (2,379) — (21,012) Carrying amount of currently marketed products 672,697 (35,989) 51,809 688,517 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Leases | |
Schedule of details of leases in the consolidated balance sheet | Right-of-use assets Thousands of Euros 31/12/2021 31/12/2020 Land and Buildings 782,125 665,002 Machinery 5,283 3,671 Computer equipment 2,044 3,588 Vehicles 6,205 6,435 795,657 678,696 Lease liabilities Thousands of Euros 31/12/2021 31/12/2020 Non-current 825,157 690,857 Current 48,567 42,642 873,724 733,499 |
Schedule of amounts recognized in the consolidated statement of profit and loss related to lease agreements | Right-of-use depreciation Thousands of Euros 31/12/2021 31/12/2020 Buildings 57,901 52,774 Machinery 2,120 1,588 Computer equipment 2,269 3,012 Vehicles 4,430 5,206 66,720 62,580 Thousands of Euros 31/12/2021 31/12/2020 Finance lease expenses (note 27) 35,786 35,205 35,786 35,205 Thousands of Euros 31/12/2021 31/12/2020 Expenses related to short-term contracts 3,106 3,569 Expenses related to low-value contracts 13,404 11,254 Other operating lease expenses 16,435 13,353 32,945 28,176 |
Equity-Accounted Investees (Tab
Equity-Accounted Investees (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity-Accounted Investees | |
Schedule of details of equity accounted investees | Thousands of Euros Thousands of Euros % ownership 31/12/2021 % ownership 31/12/2020 Access Biologicals LLC 49.00 % 53,264 49.00 % 46,782 Shanghai RAAS Blood Products Co., Ltd. 26.20 % 1,909,596 26.20 % 1,800,578 Grifols Egypt Plasma Derivatives 49.00 % 31,847 0.00 % — Total equity accounted investees with similar activity to that of the Group 1,994,707 1,847,360 Albajuna Therapeutics, S.L 49.00 % 1,910 49.00 % 3,378 GigaGen, Inc. 100.00 % — 43.96 % 15,677 Mecwins, S.A. 24.99 % 3,159 24.99 % 2,605 Total of the rest of equity accounted investees 5,069 21,660 Total equity-accounted investees 1,999,776 1,869,020 |
Schedule of movement in investments in equity-accounted investees | Movement in the investments in equity-accounted investees for the year ended 31 December 2019 is as follows: Thousands of Euros 2019 Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees Shanghai Access RAAS Blood Albajuna Biologicals Plasmavita Products Co., Therapeutics, Mecwins, Medcom LLC IBBI Group Healthcare Ltd. Total Alkahest, Inc. S.L Singulex, Inc. GigaGen, Inc. S.A. Advance, S.A Total Total Balance at 1 January 47,742 89,627 9,920 — 147,289 28,336 1,106 19,256 28,363 2,555 — 79,616 226,905 Acquisitions — — — — — — 3,750 — — — 8,619 12,369 12,369 Transfers — (94,127) — — (94,127) — — — — — — — (94,127) Share of profit / (losses) 3,938 4,586 448 — 8,972 (14,218) 383 — (5,002) (217) (690) (19,744) (10,772) Share of other comprehensive income / translation differences 966 1,658 — — 2,624 590 (11) 538 636 — (17) 1,736 4,360 Impairment losses — — — — — — — (19,794) — — — (19,794) (19,794) Collected dividends (2,725) (1,744) — — (4,469) — — — — — — — (4,469) Balance at 31 December 49,921 — 10,368 — 60,289 14,708 5,228 — 23,997 2,338 7,912 54,183 114,472 Movement in the investments in equity-accounted investees for the year ended 31 December 2020 is as follows: Thousands of Euros 2020 Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees Shanghai Access RAAS Blood Albajuna Biologicals Plasmavita Products Co., Therapeutics, Medcom LLC Healthcare Ltd. Total Alkahest, Inc. S.L GigaGen, Inc. Mecwins, S.A. Advance, S.A Total Total Balance at 1 January 49,921 10,368 — 60,289 14,708 5,228 23,997 2,338 7,912 54,183 114,472 Acquisitions — — 1,807,351 1,807,351 — — — — — — 1,807,351 Transfers — (10,674) — (10,674) (91,023) — — — — (91,023) (101,697) Share of profit / (losses) 8,962 306 11,531 20,799 76,414 (1,878) (6,725) 267 — 68,078 88,877 Share of other comprehensive income / translation differences (4,160) — (16,090) (20,250) (99) 28 (1,595) — — (1,666) (21,916) Impairment losses — — — — — — — — (7,912) (7,912) (7,912) Collected dividends (7,941) — (2,214) (10,155) — — — — — — (10,155) Balance at 31 December 46,782 — 1,800,578 1,847,360 — 3,378 15,677 2,605 — 21,660 1,869,020 Movement in the investments in equity-accounted investees for the year ended 31 December 2021 is as follows: Thousands of Euros 2021 Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees Shanghai RAAS Grifols Egypt Albajuna Access Blood Products Plasma Therapeutics, Biologicals LLC Co., Ltd. Derivatives Total S.L GigaGen, Inc. Mecwins, S.A. Total Total Balance at 1 January 46,782 1,800,578 — 1,847,360 3,378 15,677 2,605 21,660 1,869,020 Acquisitions — — 30,454 30,454 — — 860 860 31,314 Transfers — — — — — (50,794) — (50,794) (50,794) Share of profit / (losses) 8,298 24,835 (578) 32,555 (1,463) 34,957 (306) 33,188 65,743 Share of other comprehensive income / translation differences 3,929 89,886 1,971 95,786 (5) 160 — 155 95,941 Collected dividends (5,745) (5,703) — (11,448) — — — — (11,448) Balance at 31 December 53,264 1,909,596 31,847 1,994,707 1,910 — 3,159 5,069 1,999,776 |
Schedule of last financial statements available for the main equity-accounted investments of Grifols | 31/12/2021 31/12/2020 Thousands of Euros Thousands of Euros Access Access SRAAS Biologicals SRAAS Biologicals Non-current assets 2,877,382 2,707 2,617,024 2,795 Current assets 549,977 23,287 402,876 19,619 Cash and cash equivalents 401,117 3,790 250,073 4,178 Non-current liabilities (3,313) (36) (5,074) (1,497) Non-current financial liabilities (453) — — — Current liabilities (191,133) (3,615) (29,088) (3,670) Current financial liabilities — (2,649) (969) (1,486) Net assets 3,633,577 23,484 3,234,842 19,939 31/12/2021 31/12/2020 Thousands of Euros Thousands of Euros Access Access SRAAS Biologicals SRAAS Biologicals Net revenue 395,812 45,689 259,429 50,093 Profit for the year 181,395 17,380 139,459 17,221 |
Financial Assets (Tables)
Financial Assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Financial Assets [Abstract] | |
Schedule of non-current financial assets | Thousands of Euros 31/12/2021 31/12/2020 Financial investments in listed shares 2,038 3,008 Non-current derivatives (see note 30) 2,068 — Total Non-current financial assets measured at fair value 4,106 3,008 Non-current guarantee deposits 7,763 6,268 Other non-current financial assets (a) 261,294 108,030 Non-current loans to related parties (see note 31) 89,104 80,851 Total Non-current financial assets measured at amortized cost 358,161 195,149 |
Schedule of other current financial assets | Thousands of Euros 31/12/2021 31/12/2020 Current derivatives (see note 30) 3,238 — Total Non-current financial assets measured at fair value 3,238 — Thousands of Euros 31/12/2021 31/12/2020 Deposits and guarantees 561 162 Other current financial assets (a) 2,025,869 10,861 Current loans to third parties 39 95 Total other current financial assets measured at amortized cost 2,026,469 11,118 |
Schedule of other non-current and current financial assets | Thousands of Euros 31/12/2021 31/12/2020 Other financial assets with related parties (see note 31) 220,947 114,825 Other financial assets with third parties 2,066,216 4,066 Total other non-current and current financial assets 2,287,163 118,891 |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Inventories. | |
Schedule of inventories | Thousands of Euros 31/12/2021 31/12/2020 Goods for resale 137,887 158,049 Raw materials and supplies 657,060 595,392 Work in progress and semi-finished goods 721,088 654,724 Finished goods 743,319 594,116 2,259,354 2,002,281 |
Schedule of movement in inventory provision | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Balance at 1 January 122,613 104,251 48,840 Net charge for the year 28,092 42,255 42,096 Cancellations for the year (269) (189) (118) Translation differences 8,288 (23,704) 13,433 Balance at 31 December 158,724 122,613 104,251 |
Trade and Other Receivables (Ta
Trade and Other Receivables (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Trade and Other Receivables | |
Schedule of trade and other receivables | Thousands of Euros 31/12/2021 31/12/2020 Trade receivables 324,442 404,771 Receivables from 131,764 1,447 Impairment losses (note (24,009) (22,985) Trade receivables 432,197 383,233 Other receivables (note 11,014 8,324 Personnel 654 822 Advance payments (note 6,210 16,053 Taxation authorities, VAT 35,389 38,747 Other public entities 1,796 8,414 Other receivables 55,063 72,360 Current income tax assets 12,448 64,565 Total trade and other receivables 499,708 520,158 |
Cash and Cash Equivalents (Tabl
Cash and Cash Equivalents (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Cash and Cash Equivalents | |
Schedule of cash and cash equivalents | Thousands of Euros 31/12/2021 31/12/2020 Current deposits — 134,875 Cash in hand and at banks 655,493 444,772 Total cash and cash equivalents recognized in the balance sheet 655,493 579,647 Restricted cash 2,020,118 — Total cash and cash equivalents recognized in the statement of cash flows 2,675,611 579,647 |
Equity (Tables)
Equity (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity | |
Distribution of profit | The proposed distribution of profit of the Parent Grifols, S.A. for the years ended 31 December 2021, and the distribution of profit approved for 2020, presented at the general meeting held on 21 May 2021, is as follows: Thousands of Euros 31/12/2021 31/12/2020 Voluntary reserve (140,728) 62,134 Dividends — 2,614 Profit of the Parent (140,728) 64,748 The following dividends were paid in 2020: 31/12/2020 % of par value Euros per share Thousands of Euros Ordinary shares 65 % 0.16 68,859 Non-voting shares 323 % 0.16 41,757 Non-voting shares (preferred dividend) 20 % 0.01 2,614 Total dividends paid 113,230 The following dividends were paid in 2021: 31/12/2021 % of par value Euros per share Thousands of Euros Ordinary shares 146 % 0.36 154,005 Non-voting shares 729 % 0.36 93,515 Non-voting shares (preferred dividend) 20 % 0.01 2,614 Total dividends paid 250,134 |
Share capital | |
Equity | |
Movement in outstanding shares | Movement in outstanding shares during 2020 is as follows: Class A shares Class B shares Balance at 1 January 2020 426,129,798 258,010,058 (Acquisition) / disposal of treasury stock (note 16 (d)) — 402,888 Balance at 31 December 2020 426,129,798 258,412,946 Movement in outstanding shares during 2021 is as follows: Class A shares Class B shares Balance at 1 January 2021 426,129,798 258,412,946 (Acquisition) / disposal of treasury stock (note 16 (d)) (3,944,430) (2,058,366) Balance at 31 December 2021 422,185,368 256,354,580 |
Treasury stock | |
Equity | |
Movement in outstanding shares | Movement in Class A treasury stock during the year ended 31 December 2021 is as follows: No. of Class A shares Thousands of Euros Balance at 1 January 2021 — — Disposal Class A shares — — Acquisition Class A shares 3,944,430 89,959 Balance at 31 December 2021 3,944,430 89,959 Movement in Class B treasury stock during 2020 was as follows: No. of Class B shares Thousands of Euros Balance at 1 January 2020 3,415,052 49,584 Disposal Class B shares (402,888) (5,850) Balance at 31 December 2020 3,012,164 43,734 Movement in Class B treasury stock during 2021 is as follows: No. of Class B shares Thousands of Euros Balance at 1 January 2021 3,012,164 43,734 Disposal Class B shares (361,530) (5,248) Acquisition Class B shares 2,419,896 35,744 Balance at 31 December 2021 5,070,530 74,230 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share | |
Schedule of Earnings Per Share | Details of the calculation of basic earnings per share are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Profit for the year attributable to shareholders of the Parent (Thousands of Euros) 188,726 618,546 625,146 Weighted average number of ordinary shares outstanding 681,556,937 685,515,740 685,115,836 Basic earnings per share (Euros per share) 0.28 0.90 0.91 The weighted average of the ordinary shares outstanding (basic) is as follows: Number of shares 31/12/2021 31/12/2020 31/12/2019 Issued shares outstanding at 1 January 685,601,126 685,198,238 684,794,839 Effect of shares issued — — — Effect of treasury stock (4,044,189) 317,502 320,997 Average weighted number of ordinary shares outstanding (basic) at 31 December 681,556,937 685,515,740 685,115,836 Diluted earnings per share are calculated by dividing profit for the year attributable to shareholders of the Parent by the weighted average number of ordinary shares in circulation considering the diluting effects of potential ordinary shares. The RSU Plan granted by the Group and payable in shares, assumes the existence of dilutive potential shares. Diluted earnings per share have been calculated as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Profit for the year attributable to shareholders of the Parent (Thousands of Euros) 188,726 618,546 625,146 Weighted average number of ordinary shares outstanding (diluted) 681,404,922 685,142,749 684,719,195 Diluted earnings per share (Euros per share) 0.28 0.90 0.91 The weighted average number of ordinary shares outstanding diluted has been calculated as follows: Number of shares 31/12/2021 31/12/2020 31/12/2019 Issued shares outstanding at 1 January 685,601,126 685,198,238 684,794,839 Effect of RSU shares (152,015) (372,991) (396,641) Effect of shares issued — — — Effect of treasury stock (4,044,189) 317,502 320,997 Average weighted number of ordinary shares outstanding (diluted) at 31 December 681,404,922 685,142,749 684,719,195 |
Non-Controlling Interests (Tabl
Non-Controlling Interests (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of subsidiaries [line items] | |
Details of non-controlling interests and movement | Details of non-controlling interests and movement at 31 December 2021 are as follows: Thousands of Euros Business combinations / Balance at Perimeter Dividends Translation Balance at 31/12/2020 Additions additions paid differences 31/12/2021 Grifols (Thailand) Pte Ltd 4,338 218 — — (139) 4,417 Grifols Malaysia Sdn Bhd 2,923 810 (843) — 169 3,059 Araclon Biotech, S.A. (1,088) (1,119) 2,447 — — 240 VCN Bioscience, S.L 316 (219) — — — 97 Kiro Grifols , S.L. 598 (314) — — — 284 Haema AG 231,284 2,258 — — — 233,542 BPC Plasma, Inc (formerly Biotest US Corporation) 274,995 8,014 — — 22,267 305,276 Grifols Diagnostic Solutions, Inc. 1,087,632 65,894 — (6,503) 87,827 1,234,850 Plasmavita Healthcare (see note 3) 10,665 1,059 — — — 11,724 1,611,663 76,601 1,604 (6,503) 110,124 1,793,489 Details of non-controlling interests and movement at 31 December 2020 are as follows: Thousands of Euros Business combinations / Balance at Perimeter Translation Balance at 31/12/2019 Additions additions differences 31/12/2020 Grifols (Thailand) Pte Ltd 4,549 221 — (432) 4,338 Grifols Malaysia Sdn Bhd 2,171 932 — (180) 2,923 Araclon Biotech, S.A. 429 (1,517) 0 — (1,088) VCN Bioscience, S.L (152) (235) 703 — 316 Kiro Grifols , S.L. 24 (426) 1,000 — 598 Haema AG 226,071 5,213 — — 231,284 BPC Plasma, Inc (formerly Biotest US Corporation) 280,010 19,032 — (24,047) 274,995 Grifols Diagnostic Solutions, Inc. 1,510,547 69,520 (408,675) (83,760) 1,087,632 Plasmavita Healthcare (see note 3) — (22) 10,687 — 10,665 Alkahest, Inc. — (2,274) 2,274 — 0 2,023,649 90,444 (394,011) (108,419) 1,611,663 |
Haema AG and BPC Plasma, Inc. | |
Disclosure of subsidiaries [line items] | |
Summary of financial information on the non-controlling interests | At 31 December 2021 and 2020, the summary financial information on the non-controlling interests of Haema AG and BPC Plasma, Inc., is as follows: Thousands of Euros Thousands of Euros 31/12/2021 31/12/2020 BPC Plasma, Inc BPC Plasma, Inc (formerly Biotest (formerly Biotest Haema AG US Corporation) Haema AG US Corporation) Non-current assets 292,454 409,674 249,806 336,321 Current assets 52,211 33,404 31,237 43,750 Total Assets 344,665 443,078 281,043 380,071 Non-current liabilities 27,137 54,991 27,123 52,977 Current liabilities 83,986 82,811 22,636 52,099 Total Liabilities 111,123 137,802 49,759 105,076 Total equity 233,542 305,276 231,284 274,995 31/12/2021 31/12/2020 Thousands of Euros Thousands of Euros BPC Plasma, Inc BPC Plasma, Inc Haema AG (formerly Biotest Haema AG (formerly Biotest US Corporation) US Corporation) Profit for the year 2,258 8,014 5,213 19,032 |
GDS Group | |
Disclosure of subsidiaries [line items] | |
Summary of financial information on the non-controlling interests | At 31 December 2021 and 2020, the summary financial information on the non-controlling interests of GDS Group is as follows: Thousands of Euros 31/12/2021 31/12/2020 Non-current assets 3,796,855 3,393,188 Current assets 291,371 277,834 Total Assets 4,088,226 3,671,022 Non-current liabilities 278,620 256,244 Current liabilities 91,299 131,754 Total Liabilities 369,919 387,998 Total equity 3,718,307 3,283,024 Thousands of Euros 31/12/2021 31/12/2020 Profit for the year 198,416 198,182 |
Grants (Tables)
Grants (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Grants | |
Summary of details of grants | Thousands of Euros 31/12/2021 31/12/2020 Capital grants 14,646 16,509 Interest rate grants (preference loans) (See note 21 (d)) 390 499 15,036 17,008 |
Provision (Tables)
Provision (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Provisions | |
Schedule of details of provisions | Thousands of Euros Non-current provisions (a) 31/12/2021 31/12/2020 Provisions for pensions and similar obligations 6,717 6,767 Other provisions 17,405 20,504 Non-current provisions 24,122 27,271 Thousands of Euros Current provisions (b) 31/12/2021 31/12/2020 Trade provisions 31,407 11,175 Current provisions 31,407 11,175 |
Schedule of movement in provisions | (a) Non-current provisions At 31 December 2021, 2020 and 2019 provisions for pensions and similar obligations mainly comprise a provision made by certain foreign subsidiaries in respect of labor commitments with certain employees. Movement in provisions during 2019 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2018 Net charge Cancellations Reclassifications differences 31/12/2019 Non-current provisions 6,114 1,467 (30) 464 15 8,030 6,114 1,467 (30) 464 15 8,030 Movement in provisions during 2020 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2019 Net charge Cancellations Reclassifications differences 31/12/2020 Non-current provisions 8,030 414 (175) 20,527 (1,525) 27,271 8,030 414 (175) 20,527 (1,525) 27,271 Movement in provisions during 2021 is as follows: Thousands of Euros Balance at Translation Balance at 31/12/2020 Net charge Cancellations Reclassifications differences 31/12/2021 Non-current provisions 27,271 838 (77) (5,196) 1,286 24,122 27,271 838 (77) (5,196) 1,286 24,122 (b) Current provisions Movement in trade provisions during 2019 was as follows: Thousands of Euros Balance at Translation Balance at 31/12/2018 Net charge Cancellations differences 31/12/2019 Trade provisions 80,055 (25,249) (3,142) 1,445 53,109 80,055 (25,249) (3,142) 1,445 53,109 Movement in trade provisions during 2020 was as follows: Thousands of Euros Balance at Business Translation Balance at 31/12/2019 combination Net charge Cancellations Reclassifications differences 31/12/2020 Trade provisions 53,109 954 (21,998) (247) (20,059) (584) 11,175 53,109 954 (21,998) (247) (20,059) (584) 11,175 Movement in trade provisions during 2021 is as follows: Thousands of Euros Balance at Business Translation Balance at 31/12/2020 combination Net charge Cancellations Reclassifications differences 31/12/2021 Trade provisions 11,175 32 14,826 (717) 4,523 1,568 31,407 11,175 32 14,826 (717) 4,523 1,568 31,407 |
Financial Liabilities (Tables)
Financial Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Financial Liabilities | |
Schedule of financial liabilities | Thousands of Euros Financial liabilities 31/12/2021 31/12/2020 Non-current bonds (a) 2,577,465 2,675,000 Senior secured debt (b) 3,296,025 3,335,415 Other loans (b) 480,836 183,771 Other non-current financial liabilities (d) 838,826 10,272 Non-current lease liabilities (note 9) 825,157 690,857 Loan transaction costs (249,359) (293,215) Total non-current financial liabilities 7,768,950 6,602,100 Current bonds (a) 2,270,474 125,843 Senior secured debt (b) — 34,035 Other loans (b) 165,139 170,730 Other current financial liabilities (d) 43,234 105,041 Current financial derivatives (note 30) 875 — Current lease liabilities (note 9) 48,567 42,642 Loan transaction costs (89,998) (53,679) Total current financial liabilities 2,438,291 424,612 |
Schedule of details of movement in the Senior Unsecured Notes | Thousands of Euros Opening Opening outstanding balance Exchange outstanding balance 01/01/21 Issue differences 31/12/21 Senior unsecured notes (nominal value) 2017 1,000,000 — — 1,000,000 Senior secured notes (nominal value) 2019 1,675,000 — — 1,675,000 Senior unsecured notes (nominal value) Euros 2021 — 1,400,000 — 1,400,000 Senior unsecured notes (nominal value) US Dollars 2021 — 598,970 23,492 622,462 Total 2,675,000 1,998,970 23,492 4,697,462 |
Schedule of current obligation captions including issue of bearer promissory notes to Group employees | 31/12/2020 Promissory Buy backs or Interest Nominal amount notes subscribed redemptions pending accrual Maturity of promissory Interest (Thousands of (Thousands of (Thousands of Issue date date notes (Euros) rate Euros) Euros) Euros) Issue of bearer promissory notes 04/05/20 04/05/21 3,000 3.00 % 116,352 (3,612) (1,118) 31/12/2021 Promissory Buy backs or Interest Nominal amount notes subscribed redemptions pending accrual Maturity of promissory Interest (Thousands of (Thousands of (Thousands of Issue date date notes (Euros) rate Euros) Euros) Euros) Issue of bearer promissory notes 04/05/21 04/05/22 3,000 2.50 % 119,325 (1,740) (975) |
Schedule of details of loans and borrowings | Thousands of Euros 31/12/2021 31/12/2020 Amount Carrying Amount Carrying Credit Currency Interest rate Date awarded Maturity date extended amount extended amount Senior debt - Tranche B Euros Euribor + 2.25% 15/11/2019 15/11/2027 1,360,000 1,258,554 1,360,000 1,332,800 Senior debt - Tranche B US Dollars Libor + 2.00% 15/11/2019 15/11/2027 2,227,171 2,037,471 2,227,171 2,002,615 Total senior debt 3,587,171 3,296,025 3,587,171 3,335,415 EIB Loan Euros 2.40% 20/11/2015 20/11/2025 100,000 31,875 100,000 42,500 EIB Loan Euros 2.02% 22/12/2017 22/12/2027 85,000 53,125 85,000 63,750 EIB Loan Euros 2.15% 25/09/2018 25/09/2028 85,000 63,750 85,000 74,375 Total EIB Loan 270,000 148,750 270,000 180,625 Revolving Credit USD Libor + 1.5% 07/05/2020 15/11/2025 882,924 330,000 817,394 — Total Revolving Credit 882,924 330,000 817,394 — Other non-current loans Euros 1.93% 25/03/2010 30/09/2024 10,000 2,086 10,000 3,146 Loan transaction costs — (197,703) — (223,944) Non-current loans and borrowings 4,750,095 3,579,158 4,684,565 3,295,242 Thousands of Euros 31/12/2021 31/12/2020 Credit Currency Interest rate Date awarded Maturity date Amount extended Carrying amount Amount extended Carrying amount Senior debt - Tranche B Euros Euribor + 2.25% 15/11/2019 15/11/2027 (*) — (*) 13,600 Senior debt - Tranche B US Dollars Libor + 2.00% 15/11/2019 15/11/2027 (*) — (*) 20,435 Total senior debt — — — 34,035 EIB Loan Euros 2.40% 20/11/2015 20/11/2025 (*) 10,625 (*) 10,625 EIB Loan Euros 2.02% 22/12/2017 22/12/2027 (*) 21,250 (*) 21,250 Total EIB Loan — 31,875 — 31,875 Other current loans 0.10% - 2.50% 211,901 133,264 241,895 138,855 Loan transaction costs — (37,244) — (35,209) Current loans and borrowings 211,901 127,895 241,895 169,556 (*) See amount granted under non-current debt |
Schedule of details of maturity of other financial liabilities | Thousands of Euros 31/12/2021 31/12/2020 Maturity at: Up to one year 43,234 105,041 Two years 88,144 3,945 Three years 88,947 1,976 Four years 89,027 1,580 Five years 88,871 1,141 Over five years 483,837 1,630 882,060 115,313 |
Schedule of changes in liabilities derived from financing activities | Thousands of Euros Senior Secured debt & Other Finance lease Other financial Bonds loans liabilities liabilities Total Carrying amount at 1 January 2019 1,102,978 5,165,765 12,885 95,217 6,376,845 New financing 1,778,218 (1,522,466) — 12,249 268,001 Refunds (100,215) (145,261) (73,785) (8,152) (327,413) Interest accrued 37,095 171,535 34,558 1,166 244,354 Other movements (note 2) (108,874) 24,121 761,682 — 676,929 Interest paid/received (32,000) (204,179) — — (236,179) Business combinations (note 3) — 10,233 — — 10,233 Foreign exchange differences — 187,991 5,350 1,269 194,610 Balance at 31 December 2019 2,677,202 3,687,739 740,690 101,749 7,207,380 New financing 116,352 — — — 116,352 Refunds (105,564) (66,047) (79,037) (22,681) (273,329) Interest accrued 81,880 124,840 35,084 2,073 243,877 Other movements — (10,468) 88,867 4,837 83,236 Interest paid/received (60,355) (95,433) — — (155,788) Business combinations (note 3) — — — 34,778 34,778 Foreign exchange differences — (172,246) (52,105) (5,443) (229,794) Balance at December 31, 2020 2,709,515 3,468,385 733,499 115,313 7,026,712 New financing 2,126,979 329,555 — 829,937 3,286,471 Refunds (114,480) (266,659) (82,692) (3,507) (467,338) Interest accrued 100,948 130,327 35,786 2,165 269,226 Other movements (33,920) 5,445 135,697 729 107,951 Interest paid/received (64,031) (91,089) — — (155,120) Business combinations (note 3) — — — (64,749) (64,749) Foreign exchange differences 18,523 131,084 51,434 3,047 204,088 Balance at 31 December 2021 4,743,534 3,707,048 873,724 882,935 10,207,241 |
Senior Debt Tranche B Maturity in 2027 | |
Financial Liabilities | |
Schedule of senior secured debt by maturity | Details of Tranche B by maturity at 31 December 2021 are as follows: US Tranche B Tranche B in Euros Principal in Thousands Amortization in Principal in Thousands of Currency of US Dollars Thousands of Euros Currency Euros Maturity 2023 US Dollars 6,015 5,310 Euros 3,269 2024 US Dollars 24,058 21,242 Euros 13,076 2025 US Dollars 24,058 21,242 Euros 13,076 2026 US Dollars 24,058 21,242 Euros 13,076 2027 US Dollars 2,235,700 1,973,954 Euros 1,216,058 Total US Dollars 2,313,889 2,042,990 Euros 1,258,555 |
Trade and Other Payables (Table
Trade and Other Payables (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Trade and other payables | |
Schedule of trade and other payables | Thousands of Euros 31/12/2021 31/12/2020 Suppliers 628,992 601,618 VAT payable 13,011 11,694 Taxation authorities, withholdings payable 7,267 6,829 Social security payable 39,191 32,640 Other public entities 92,365 89,926 Other payables 151,834 141,089 Current income tax liabilities 4,516 3,482 785,342 746,189 |
Other Current Liabilities (Tabl
Other Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Other Current Liabilities | |
Schedule of other current liabilities | Thousands of Euros 31/12/2021 31/12/2020 Salaries payable 175,710 121,972 Other payables 23 1,046 Deferred income 32,970 22,934 Advances received 10,569 7,210 Other current 219,272 153,162 |
Net Revenues (Tables)
Net Revenues (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Net Revenues | |
Schedule of distribution of net consolidated revenues by segment | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Bioscience 3,814,983 4,242,502 3,993,462 Diagnostic 779,108 775,889 733,604 Hospital 141,190 118,675 134,441 Bio supplies 225,765 224,090 266,540 Others 39,620 31,989 22,820 Intersegments (67,548) (53,107) (52,176) 4,933,118 5,340,038 5,098,691 |
Schedule of geographical distribution of net consolidated revenues | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 USA and Canada 3,154,549 3,599,746 3,390,811 Spain 362,407 339,169 268,287 European Union 544,042 495,323 588,375 Rest of the world 872,120 905,800 851,218 Consolidated 4,933,118 5,340,038 5,098,691 |
Schedule of discounts and other reductions in gross income | Details of discounts and other reductions in gross income are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Gross sales 6,234,277 6,806,005 6,429,762 Chargebacks (1,101,896) (1,247,153) (1,119,540) Cash discounts (60,019) (68,912) (70,340) Volume rebates (49,043) (57,858) (56,426) Medicare and Medicaid (53,440) (61,089) (50,442) Other discounts (36,761) (30,955) (34,323) Net sales 4,933,118 5,340,038 5,098,691 |
Schedule of movement in discounts and other reductions in gross income | Movement in discounts and other reductions in gross income during 2019 was as follows: Thousands of Euros Cash Volume Medicare / Other Chargebacks discounts rebates Medicaid discounts Total Balance at 31 December 2018 75,175 6,441 24,797 22,941 8,837 138,191 Current estimate related to sales made in current and prior year 1,119,540 70,340 56,426 50,442 34,323 1,331,071 (1) (Actual returns or credits in current period related to sales made in current period) (1,104,493) (64,523) (28,014) (34,486) (22,490) (1,254,006) (2) (Actual returns or credits in current period related to sales made in prior periods) 275 (6,385) (25,050) (20,375) (5,652) (57,187) (3) Translation differences (9) 24 546 389 53 1,003 Balance at 31 December 2019 90,488 5,897 28,705 18,911 15,071 159,072 Movement in discounts and other reductions to gross income during 2020 was as follows: Thousands of Euros Cash Volume Medicare / Other Chargebacks discounts rebates Medicaid discounts Total Balance at 31 December 2019 90,488 5,897 28,705 18,911 15,071 159,072 Current estimate related to sales made in current and prior year 1,247,153 68,912 57,858 61,089 30,955 1,465,966 (1) (Actual returns or credits in current period related to sales made in current period) (1,033,053) (61,387) (27,798) (34,564) (30,509) (1,187,311) (2) (Actual returns or credits in current period related to sales made in prior periods) (97,504) (6,030) (26,481) (14,526) (3,615) (148,156) (3) Translation differences (16,215) (597) (2,614) (2,459) (139) (22,023) Balance at 31 December 2020 190,869 6,795 29,670 28,451 11,763 267,548 Movement in discounts and other reductions to gross income during 2021 was as follows: Thousands of Euros Cash Volume Medicare / Other Chargebacks discounts rebates Medicaid discounts Total Balance at 31 December 2020 190,869 6,795 29,670 28,451 11,763 267,548 Current estimate related to sales made in current and prior year 1,101,896 60,019 49,043 53,440 36,761 1,301,159 (1) (Actual returns or credits in current period related to sales made in current period) (1,080,304) (54,554) (29,617) (42,890) (27,036) (1,234,401) (2) (Actual returns or credits in current period related to sales made in prior periods) (65,681) (6,964) (29,304) (15,422) (11,057) (128,428) (3) Translation differences 13,066 405 1,454 2,035 154 17,114 Balance at 31 December 2021 159,846 5,701 21,246 25,614 10,585 222,992 (1) Net impact in income statement: estimate for the current year plus prior years’ adjustments. Adjustments made during the year corresponding to prior years’ estimates have not been significant. (2) Amounts credited and posted against provisions for current period (3) Amounts credited and posted against provisions for prior period |
Personnel Expenses (Tables)
Personnel Expenses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Personnel Expenses | |
Schedule of personnel expenses by function | Details of personnel expenses by function are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Cost of sales 999,347 1,058,132 988,689 Research and development 138,629 110,682 106,472 Selling, general & administration expenses 401,390 383,851 382,472 1,539,366 1,552,665 1,477,633 |
Schedule of personnel expenses by nature | Details by nature are as follows: Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Wages and salaries 1,231,812 1,234,761 1,178,527 Contributions to pension plans (see note 29) 31,757 33,226 29,941 Other social charges 27,387 27,462 28,785 Social Security 248,410 257,216 240,380 1,539,366 1,552,665 1,477,633 |
Expenses by Nature (Tables)
Expenses by Nature (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Expenses by Nature | |
Schedule of amortization and depreciation expense classified by functions | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Cost of sales 211,676 198,310 193,081 Research and development 55,311 32,814 22,471 Selling, general & administration expenses 92,780 90,409 86,903 359,767 321,533 302,455 |
Schedule of other operating income and expenses by function | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Cost of sales 535,058 500,415 467,705 Research and development 165,884 156,994 166,177 Selling, general & administration expenses 532,056 499,218 457,921 1,232,998 1,156,627 1,091,803 |
Schedule of other operating income and expenses by nature | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Changes in trade provisions 4,844 (14,059) (19,811) Professional services 258,371 265,539 244,355 Commissions 28,671 27,147 32,178 Supplies and auxiliary materials 197,893 187,370 170,021 Operating leases (note 9) 32,945 28,176 33,235 Freight 148,797 137,466 130,663 Repair and maintenance expenses 150,308 147,039 136,377 Advertising 71,280 55,073 59,063 Insurance 38,724 30,776 25,647 Royalties 48,446 40,634 10,674 Travel expenses 30,334 23,005 61,346 External services 74,858 71,240 64,099 R&D Expenses 106,873 101,410 103,053 Other 40,654 55,811 40,903 Other operating income&expenses 1,232,998 1,156,627 1,091,803 |
Finance Result (Tables)
Finance Result (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Finance Result | |
Schedule of finance result | Thousands of Euros 31/12/2020 31/12/2020 31/12/2019 Finance income 11,551 8,021 114,197 Finance costs from Senior Unsecured Notes (104,944) (85,182) (41,920) Finance costs from senior debt (note 21 (b)) (111,719) (119,140) (262,797) Finance costs from sale of receivables (note 14) (10,292) (10,964) (9,171) Capitalized interest (note 10) 18,636 16,606 14,894 Finance lease expenses (note 9) (35,786) (35,205) (34,558) Other finance costs (33,889) (15,754) (9,413) Finance costs (277,994) (249,639) (342,965) Impairment and gains / (losses) on disposal of financial instruments — — (37,666) Change in fair value of financial instruments (note 11) 246 55,703 1,326 Exchange differences (11,602) 8,246 (9,616) Finance result (277,799) (177,669) (274,724) |
Taxation (Tables)
Taxation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Taxation | |
Schedule of income tax expense and income tax related to profit | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Profit before income tax from continuing operations 350,453 878,629 817,103 Tax at 25% 87,613 219,657 204,276 Permanent differences 2,503 (7,181) 6,104 Effect of different tax rates (8,720) (30,686) (22,564) Tax credits (deductions) (14,998) (14,980) (12,702) Prior year income tax expense 18,908 517 (3,722) Other income tax expenses/(income) (180) 2,312 (2,933) Total income tax expense 85,126 169,639 168,459 Deferred tax 17,754 43,138 58,275 Current tax 67,372 126,501 110,184 Total income tax expense 85,126 169,639 168,459 |
Schedule of deferred tax assets and liabilities | Thousands of Euros Tax effect 31/12/2021 31/12/2020 31/12/2019 Assets Provisions 8,387 3,942 6,228 Inventories 47,908 59,129 51,838 Tax credits (deductions) 26,425 57,896 61,476 Tax loss carryforwards 51,750 53,063 36,066 Other 19,993 11,004 6,531 Subtotal, assets 154,463 185,034 162,139 Goodwill (2,106) (30,040) (27,721) Fixed assets, amortisation and depreciation 3,151 (3,011) (2,821) Intangible assets (3,001) (2,062) (8,573) Subtotal, net liabilities (1,956) (35,113) (39,115) Deferred assets, net 152,507 149,921 123,024 Liabilities Goodwill (272,596) (215,907) (194,964) Intangible assets (288,819) (270,145) (214,993) Fixed assets (86,899) (78,325) (88,498) Debt cancellation costs (61,543) (66,720) (65,967) Subtotal, liabilities (709,857) (631,097) (564,422) Tax loss carryforwards 2,160 12,024 24,734 Inventories 5,532 1,673 2,408 Provisions 37,671 36,663 39,366 Other 30,510 23,924 34,087 Subtotal, net assets 75,873 74,284 100,595 Net deferred Liabilities (633,984) (556,813) (463,827) |
Schedule of movement in deferred tax assets and liabilities | Thousands of Euros Deferred tax assets and liabilities 31/12/2021 31/12/2020 31/12/2019 Balance at 1 January (406,892) (340,803) (291,859) Movements during the year (17,754) (43,138) (58,275) Business combination (note 3) (16,400) (47,988) — Translation differences (40,431) 25,037 9,331 Balance at 31 December (481,477) (406,892) (340,803) |
Schedule of details about deferred tax assets and liabilities by jurisdiction | Detail of assets and liabilities by jurisdiction at 31 December 2021 are as follows: USA Spain Other Total 31/12/2021 31/12/2021 31/12/2021 31/12/2021 Net deferred tax (578,061) (17,963) 36,372 (559,652) Tax credit rigths — 26,425 — 26,425 Tax loss carryforwards 15,236 4,808 31,706 51,750 (562,825) 13,270 68,078 (481,477) Detail of assets and liabilities by jurisdiction at 31 December 2020 are as follows: USA Spain Other Total 31/12/2020 31/12/2020 31/12/2020 31/12/2020 Net deferred tax (466,961) (36,298) (26,616) (529,875) Tax credit rigths — 57,861 35 57,896 Tax loss carryforwards 21,277 4,928 38,882 65,087 (445,684) 26,491 12,301 (406,892) Detail of assets and liabilities by jurisdiction at 31 December 2019 are as follows: USA Spain Other Total 31/12/2019 31/12/2019 31/12/2019 31/12/2019 Net deferred tax (392,040) (35,117) (35,921) (463,078) Tax credit rigths 54,340 5,162 1,297 60,799 Tax loss carryforwards — 61,476 — 61,476 (337,700) 31,521 (34,624) (340,803) |
Other Commitments with Third _2
Other Commitments with Third Parties and Other Contingent Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Other Commitments with Third Parties and Other Contingent Liabilities | |
Schedule of Group's raw material purchase commitments | Details of the Group’s raw material purchase commitments at 31 December 2021 are as follows: Thousands of Euros 2022 90,413 2023 78,909 2024 72,103 2025 1,116 2026 651 More than 5 years — |
Financial Instruments (Tables)
Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Financial Instruments | |
Schedule of financial instruments by nature, category and fair value | Disclosure of financial instruments by nature, category and fair value is as follows: Thousands of Euros 31/12/2021 Carrying amount Fair Value Financial assets Financial Financial Other at amortised Financial assets assets at FV liabilities at financial costs at FVTPL to OCI Hedges amortised costs liabilities Total Level 1 Level 2 Level 3 Total Non-current financial assets — 7 2,031 — — — 2,038 7 — 2,031 2,038 Derivatives instruments — — — 5,306 — — 5,306 — 5,306 — 5,306 Trade receivables — — 216,433 — — — 216,433 — 216,433 — 216,433 Financial assets measured at fair value — 7 218,464 5,306 — — 223,777 Non-current financial assets 358,161 — — — — — 358,161 Other current financial assets 2,026,469 — — — — — 2,026,469 Trade and other receivables 270,827 — — — — — 270,827 Cash and cash equivalents 655,493 — — — — — 655,493 Financial assets not measured at fair value 3,310,950 — — — — — 3,310,950 Derivatives instruments — (875) — — — (875) — (875) — (875) Financial liabilities measured at fair value — (875) — — — — (875) Senior Unsecured & Secured Notes — — — — (4,626,919) — (4,626,919) (4,697,328) — — (4,697,328) Promissory Notes — — — — (116,610) — (116,610) Senior secured debt — — — — (3,061,078) — (3,061,078) — (3,262,901) — (3,262,901) Other bank loans — — — — (645,975) — (645,975) Lease liabilities — — — — (873,724) — (873,724) Other financial liabilities — — — — (882,060) — (882,060) Other non-current debts — — — — — (333) (333) Trade and other payables — — — — (780,826) — (780,826) Other current liabilities — — — — — (219,272) (219,272) Financial liabilities not measured at fair value — — — — (10,987,192) (219,605) (11,206,797) 3,310,950 (868) 218,464 5,306 (10,987,192) (219,605) (7,672,945) The Group does not provide details of the fair value of certain financial instruments as their carrying amount is very similar to their fair value because of its short term. Thousands of Euros 31/12/2020 Carrying amount Fair Value Financial assets Financial Financial Financial Other at amortised assests at assets at FV liabilities at financial costs FV to profit or loss to OCI amortised costs liabilities Total Level 1 Level 2 Level 3 Total Non-current financial assets — 1,128 1,880 — — 3,008 1,128 — 1,880 3,008 Trade receivables — — 308,485 — — 308,485 — 308,485 — 308,485 Financial assets measured at fair value — 1,128 310,365 — — 311,493 Non-current financial assets 195,149 — — — — 195,149 Other current financial assets 11,118 — — — — 11,118 Trade and other receivables 147,108 — — — — 147,108 Cash and cash equivalents 579,647 — — — — 579,647 Financial assets not measured at fair value 933,022 — — — — 933,022 Senior Unsecured & Secured Notes — — — (2,601,479) — (2,601,479) (2,705,437) — — (2,705,437) Promissory Notes — — — (111,622) — (111,622) Senior secured debt — — — (3,110,298) — (3,110,298) — (3,358,729) — (3,358,729) Other bank loans — — — (354,501) — (354,501) Lease liabilities — — — (733,499) — (733,499) Other financial liabilities — — — (115,313) — (115,313) Other non-current debts — — — — (16,391) (16,391) Trade and other payables — — — (742,707) — (742,707) Other current liabilities — — — — (153,162) (153,162) Financial liabilities not measured at fair value — — — (7,769,419) (169,553) (7,938,972) 933,022 1,128 310,365 (7,769,419) (169,553) (6,694,457) |
Schedule of financial derivatives | Thousands of Euros Notional Notional amount at amount at Value at Value at Financial derivatives Currency 31/12/2021 31/12/2020 31/12/21 31/12/20 Maturity Cross currency interest rate swap US Dollar 500,000,000 — 5,306 — 15/10/2024 Foreign exchange rate forward Canadian dollar 51,000,000 — (875) — 25/01/2022 Total 4,431 — Total Assets (notes 2 and 11) 5,306 — Total Liabilities (notes 21 and 30) (875) — |
Schedule of exposure to credit risk | The carrying amount of financial assets represents the maximum exposure to credit risk. At 31 December 2021 and 2020 the maximum level of exposure to credit risk is as follows: Thousands of Euros Carrying amount Note 31/12/2021 31/12/2020 Non-current financial assets 12 362,267 198,157 Other current financial assets 12 2,029,707 11,118 Trade receivables 14 432,197 383,233 Other receivables 14 17,224 24,377 Cash and cash equivalents 15 655,493 579,647 3,496,888 1,196,532 The maximum level of exposure to risk associated with receivables at 31 December 2021 and 2020, by geographical area, is as follows. Thousands of Euros Carrying amount 31/12/2021 31/12/2020 Spain 62,108 62,358 EU countries 40,897 84,962 United States of America 108,685 157,395 Other European countries 25,163 10,525 Other regions 212,568 92,370 449,421 407,610 |
Schedule of trade receivables net of the bad debt provision by seniority | A breakdown of the trade and other receivables net of the impairment losses by ageing as of 31 December 2020 is as follows: Thousands of Euros Total net trade Total gross carrying receivable third ECL Rate amount Provision party Not matured 0.19 % 283,612 (515) 283,097 Past due 0-30 days 0.19 % 34,282 (54) 34,228 Past due 31-60 days 0.62 % 9,157 (57) 9,100 Past due 61-90 days 2.03 % 6,155 (125) 6,030 Past due 91-180 days 3.01 % 16,546 (211) 16,335 Past due 181-365 days 8.52 % 34,768 (325) 34,443 More than one year 100.00 % 4,861 (4,861) — Customers with objective evidence of impairment 16,837 (16,837) — 406,218 (22,985) 383,233 A breakdown of the trade and other receivables net of the impairment losses by seniority at 31 December 2021 is as follows: Thousands of Euros Total net trade Total gross carrying receivable third ECL Rate amount Provision party Not matured 0.19 % 362,599 (445) 362,154 Past due 0-30 days 0.19 % 32,623 (51) 32,572 Past due 31-60 days 0.62 % 14,144 (79) 14,065 Past due 61-90 days 2.03 % 6,556 (133) 6,423 Past due 91-180 days 3.01 % 11,000 (311) 10,689 Past due 181-365 days 8.52 % 6,543 (249) 6,294 More than one year 100.00 % 3,911 (3,911) — — Customers with objective evidence of impairment 18,830 (18,830) — 456,206 (24,009) 432,197 |
Schedule of movement in the bad debt provision | Thousands of Euros 31/12/2021 31/12/2020 31/12/2019 Opening balance 22,985 22,291 20,531 Net charges for the year 6,471 2,436 4,971 Net cancellations for the year (6,269) (124) (3,142) Transfers — (29) (19) Translation differences 822 (1,589) (50) Closing balance 24,009 22,985 22,291 |
Schedule of contractual maturity dates of financial liabilities | Thousands of Euros Carrying amount at Contractual 6 months 6 - 12 1-2 2 - 5 More than Carrying amount Note 31/12/21 flows or less months years years 5 years Financial liabilities Bank loans 21 3,707,053 4,309,621 476,397 78,524 102,070 3,641,777 10,853 Other financial liabilities 21 882,060 1,294,873 41,934 1,300 164,718 448,161 638,760 Bonds and other marketable securities 21 4,743,529 5,663,320 2,215,138 170,572 48,538 3,145,255 83,817 Lease liabilities 21 873,724 873,723 24,640 23,927 47,595 184,032 593,529 Payable to suppliers 22 628,992 628,992 622,091 6,901 — — — Other current liabilities 23 43,562 43,562 42,387 1,175 — — — Financial derivatives 875 875 875 — — — — Total 10,879,795 12,814,966 3,423,462 282,399 362,921 7,419,225 1,326,959 Thousands of Euros Carrying amount at Contractual 6 months 6 - 12 1-2 2 - 5 More than Carrying amount Note 31/12/20 flows or less months years years 5 years Financial liabilities Bank loans 21 3,464,799 4,176,075 190,659 89,704 134,789 502,605 3,258,318 Other financial liabilities 21 115,313 115,314 103,397 1,645 3,372 5,515 1,385 Bonds and other marketable securities 21 2,713,101 3,119,194 144,756 32,016 64,031 2,091,066 787,325 Lease liabilities 21 733,499 733,499 21,896 20,746 40,961 158,032 491,864 Payable to suppliers 22 601,618 601,618 601,585 33 — — — Other current liabilities 23 31,190 31,190 30,369 821 — — — Total 7,659,520 8,776,890 1,092,662 144,965 243,153 2,757,218 4,538,892 |
Schedule of Group's exposure to currency risk | The Group’s exposure to currency risk is as follows: Thousands of Euros 31/12/2021 Euros (*) Dollars (**) Trade receivables 2,023 14,800 Receivables from Group companies 141,285 7,101 Loans to Group companies 464,789 21 Cash and cash equivalents 25,766 82 Trade payables (27,098) (23,349) Payables to Group companies (62,930) (6,480) Loans from Group companies (11,495) (3) Bank loans (372,500) — Balance sheet exposure 159,840 (7,828) (*) Balances in Euros in subsidiaries with US Dollars functional currency (**) Balances in US Dollars in subsidiaries with Euros functional currency Thousands of Euros 31/12/2020 Euros (*) Dollars (**) Trade receivables 1,468 19,938 Receivables from Group companies 112,442 6,140 Loans to Group companies 221,135 55 Cash and cash equivalents 35,034 416 Trade payables (46,318) (10,822) Payables to Group companies (61,421) (72,693) Loans from Group companies (18,391) (1,726) Bank loans (53,125) — Balance sheet exposure 190,824 (58,692) (*) (**) The most significant exchange rates applied at 2021 and 2020 year ends are as follows: Closing exchange rate Euros 31/12/2021 31/12/2020 US Dollars 1.1326 1.2234 |
Schedule of profile of interest on interest-bearing financial instruments | Thousands of Euros 31/12/2021 31/12/2020 Fixed-interest financial instruments Financial liabilities (4,878,087) (2,887,500) (4,878,087) (2,887,500) Variable-interest financial instruments Financial liabilities (3,296,025) (3,369,451) (3,296,025) (3,369,451) (8,174,112) (6,256,951) |
Balances and Transactions wit_2
Balances and Transactions with Related Parties (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Balances and Transactions with Related Parties | |
Schedule of details of balances with related parties | Thousands of Euros 31/12/2021 31/12/2020 Receivables from associates (note 14) 131,764 1,447 Trade payables associates (3) (133) Loans to other related parties (note 12) 89,104 80,851 Other financial assets with other related parties 220,947 114,825 Debts with key management personnel (6,644) (5,934) Payables to other related parties (3,824) (6,613) 431,344 184,443 |
Schedule of group transactions with related parties | Group transactions with related parties during 2019 were as follows: Thousands of Euros Key management Other related Board of directors Associates personnel parties of the Company Net sales 10,196 — — — Purchases (48,300) — — — Other service expenses (25,638) — (5,586) (220) Remuneration — (16,795) — (5,517) Payments for rights of use — — (7,104) — Finance income 2,265 — — — Finance cost (158) — — — (61,635) (16,795) (12,690) (5,737) Group transactions with related parties during 2020 were as follows: Thousands of Euros Key management Other related Board of directors Associates personnel parties of the Company Net sales 10,522 — — — Purchases (459) — — — Other service expenses (15,010) — (10,344) — Remuneration — (17,164) — (4,966) Payments for rights of use — — (5,137) — Purchase of property, plant and equipment — — (13,500) — Finance income 10,939 — — — 5,992 (17,164) (28,981) (4,966) Group transactions with related parties during 2021 are as follows: Thousands of Euros Key management Other related Board of directors Associates personnel parties of the Company Net sales 220,808 — — — Purchases (613) — — — Other service expenses (2,709) — (3,963) — Remuneration — (15,136) — (4,417) Payments for rights of use — — (5,332) — Purchase of property, plant and equipment — — 7,326 — Finance income 2,638 — — — 220,124 (15,136) (1,969) (4,417) |
Subsequent events (Tables)
Subsequent events (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
BPL Plasma, Inc. | |
Events after the Reporting Period | |
Disclosure of detailed information about business combination | Thousands of Euros Thousands of US Dollars Consideration paid First payment performed 9,921 12,000 Cash paid at the transaction closing date 308,016 372,548 Total consideration paid 317,937 384,548 Fair value of net assets acquired 15,039 18,190 Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) 302,898 366,358 |
Appendix I (Tables)
Appendix I (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Appendix I | |
Schedule of information on group companies associates and others | Acquisition / 12/31/2021 12/31/2020 12/31/2019 Registered Registered Incorporation % shares % shares % shares Name Offices Office date Activity Statutory Activity Direct Indirect Direct Indirect Direct Indirect Fully Consolidated Companies Diagnostic Grifols, S.A. Spain Polígono Levante 1987 Industrial Development and manufacture of diagnostic equipment, instruments and reagents. — 100.000 % — 100.000 % — 100.000 % Instituto Grifols, S.A. Spain Polígono Levante 1987 Industrial Plasma fractioning and the manufacture of haemoderivative pharmaceutical products. 99.998 % 0.002 % 99.998 % 0.002 % 99.998 % 0.002 % Grifols Worldwide Operations Spain, S.A (formerly Logister, S.A.) Spain Polígono Levante 1987 Services Manufacture, sale and purchase, commercialisation and distribution of all types of computer products and materials. — — — — — — Laboratorios Grifols, S.A. Spain Polígono Levante 1989 Industrial Production of glass- and plastic-packaged parenteral solutions, parenteral and enteral nutrition products 98.600 % 1.400 % 98.600 % 1.400 % 98.600 % 1.400 % Biomat, S.A. Spain Polígono Levante 1991 Industrial Analysis and certification of the quality of plasma used by Instituto Grifols, S.A. It also provides 99.900 % 0.100 % 99.900 % 0.100 % 99.900 % 0.100 % centres with plasma virus inactivation services (I.P.T.H). Grifols Engineering, S.A. Spain Polígono Levante 2000 Industrial Design and development of the Group’s manufacturing installations and part of the equipment and 99.950 % 0.050 % 99.950 % 0.050 % 99.950 % 0.050 % Biomat USA, Inc. United States 2410 Lillyvale Avenue 2002 Industrial Procuring human plasma. — 100.000 % — 100.000 % — 100.000 % Grifols Biologicals LLC. United States 5555 Valley Boulevard 2003 Industrial Plasma fractioning and the production of haemoderivatives. — 100.000 % — 100.000 % — 100.000 % Grifols Australia Pty Ltd. Australia Unit 5/80 Fairbank 2009 Industrial Distribution of pharmaceutical products and the development and manufacture of reagents for 100.000 % — 100.000 % — 100.000 % — Medion Grifols Diagnostic AG Switzerland Bonnstrasse,9 2009 Industrial Development and manufacturing activities in the area of biotechnology and diagnostics. — 100.000 % — 100.000 % — 100.000 % Grifols Therapeutics LLC. United States 4101 Research Commons 2011 Industrial Plasma fractioning and the production of haemoderivatives. — 100.000 % — 100.000 % — 100.000 % Talecris Plasma Resources, Inc. United States 4101 Research Commons 2011 Industrial Procurement of human plasma. — 100.000 % — 100.000 % — 100.000 % Grifols Worldwide Operations Limited Grange Castle Business Park, 2012 Industrial Packaging, labelling, storage, distribution, manufacture and development of pharmaceutical products 100.000 % — 100.000 % — 100.000 % — Progenika Biopharma, S.A. Parque Tecnológico de Vizcaya, 2013 Industrial Development, production and commercialisation of biotechnological solutions. 91.880 % 8.120 % 91.880 % 8.120 % 91.880 % 8.120 % Asociación I+D Progenika Parque Tecnológico de Vizcaya, 2013 Industrial Coordination, representation, management and promotion of the common interests of associated — — — — — — Grifols Diagnostics Solutions Inc (formerly G-C Diagnostics Corp.) 4560 Horton Street 2013 Industrial Manufacture and sale of blood testing products — 55.000 % — 55.000 % — 55.000 % Grifols Worldwide Operations USA Inc. 13111 Temple Avenue, City of 2014 Industrial The manufacture, warehousing, and logistical support for biological products. — 100.000 % — 100.000 % — 100.000 % Grifols Asia Pacific Pte, Ltd Singapore 501 Orchard Road nº20-01 2003 Commercial Distribution and sale of medical and pharmaceutical products. 100.000 % — 100.000 % — 100.000 % — Grifols Movaco, S.A. Polígono Levante 1987 Commercial Distribution and sale of reagents, chemical products and other pharmaceutical specialities, and of medical and surgical materials, equipment and instruments for use by laboratories and health centres. 99.999 % 0.001 % 99.999 % 0.001 % 99.999 % 0.001 % Grifols Portugal Productos Farmacéuticos e Hospitalares, Lda. Portugal Rua de Sao Sebastiao,2 1988 Commercial Import, export and commercialisation of pharmaceutical and hospital equipment and products, particularly Grifols products. 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % Grifols Chile, S.A. Chile Avda. Americo Vespucio, 2242 1990 Commercial Development of pharmaceutical businesses, which can involve the import, production, commercialisation and export of related products. 99.000 % — 99.000 % — 99.000 % — Grifols USA, LLC. United States 2410 Lillyvale Avenue 1990 Commercial Distribution and marketing of company products. — 100.000 % — 100.000 % — 100.000 % Grifols Argentina, S.A. Argentina Bartolomé Mitre 3690/3790, 1991 Commercial Clinical and biological research. Preparation of reagents and therapeutic and diet products. 95.010 % 4.990 % 95.010 % 4.990 % 95.010 % 4.990 % Manufacture and commercialisation of other pharmaceutical specialities. Grifols s.r.o. Czech Republic Calle Zitna,2 1992 Commercial Purchase, sale and distribution of chemical-pharmaceutical products, including human plasma. 100.000 % — 100.000 % — 100.000 % — Grifols (Thailand) Ltd Thailand 191 Silom Complex Building, 2003 Commercial Import, export and distribution of pharmaceutical products. — 48.000 % — 48.000 % — 48.000 % Grifols Malaysia Sdn Bhd Malaysia Level 18, The Gardens North 2003 Commercial Distribution and sale of pharmaceutical products. — 49.000 % — 30.000 % — 30.000 % Grifols International, S.A. Spain Polígono Levante 1997 Commercial Coordination of the marketing, sales and logistics for all the Group’s subsidiaries operating in other 99.998 % 0.002 % 99.998 % 0.002 % 99.998 % 0.002 % Grifols Italia S.p.A Italy Via Carducci, 62d 1997 Commercial Purchase, sale and distribution of chemical-pharmaceutical products. 100.000 % — 100.000 % — 100.000 % — Grifols UK Ltd. United Kingdom Gregory Rowcliffe & Milners, 1 1997 Commercial Distribution and sale of therapeutic and other pharmaceutical products, especially haemoderivatives. 100.000 % — 100.000 % — 100.000 % — Grifols Brasil, Lda. Brazil Rua Umuarama, 263 1998 Commercial Import and export, preparation, distribution and 100.000 % 0.000 % 100.000 % 0.000 % 100.000 % 0.000 % CEP 83.325-000 Pinhais sale of pharmaceutical and chemical products for Grifols France, S.A.R.L. France Arteparc, Rue de la Belle du Canet, 1999 Commercial Commercialisation of chemical and healthcare products. 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % Grifols Polska Sp.z.o.o. Poland Grzybowska 87 street00-844 2003 Commercial Distribution and sale of pharmaceutical, cosmetic and other products. 100.000 % — 100.000 % — 100.000 % — Logística Grifols, S.A. de C.V. Mexico Calle Eugenio Cuzin, nº 909-913 2008 Commercial Manufacture and commercialisation of pharmaceutical products for human and veterinary use. 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % Grifols México, S.A. de C.V. Mexico Calle Eugenio Cuzin, nº 909-913 1993 Commercial Production, manufacture, adaptation, conditioning, sale and purchase, commissioning, representation 99.980 % 0.020 % 99.980 % 0.020 % 99.980 % 0.020 % Medion Diagnostics GmbH Germany Lochamer Schlag, 12D 2009 Commercial Distribution and sale of biotechnological and diagnostic products. — — — — — — Grifols Nordic, AB Sweden Sveavägen 166 2010 Commercial Research and development, production and marketing of pharmaceutical products, medical devices and 100.000 % — 100.000 % — 100.000 % — Grifols Colombia, Ltda Colombia Carrera 7 No. 71 52 Torre B piso 2010 Commercial Sale, commercialisation and distribution of medicines, pharmaceutical (including but not limited to 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % Grifols Deutschland GmbH Germany Lyoner Strasse 15, D- 2011 Commercial Procurement of the official permits and necessary approval for the production, commercialisation and 100.000 % — 100.000 % — 100.000 % — health centres Grifols Canada, Ltd. Canada 5060 Spectrum Way, Suite 405 2011 Commercial Distribution and sale of biotechnological products. — 100.000 % — 100.000 % — 100.000 % Grifols Pharmaceutical Technology (Shanghai) Co., Ltd. Unit 901-902, Tower 2, No. 2013 Commercial Pharmaceutical consultancy services (except for diagnosis), technical and logistical consultancy 100.000 % — 100.000 % — 100.000 % — Grifols Switzerland AG Steinengraben, 5 2013 Commercial Research, development, import and export and commercialisation of pharmaceutical products, devices — — 100.000 % — 100.000 % — Grifols (H.K.), Limited Units 1505-7 BerKshire House, 2014 Commercial Distribution and sale of diagnostic products. — 100.000 % — 100.000 % — 100.000 % Grifols Japan K.K. Hilton Plaza West Office Tower, 19th floor. 2-2, Umeda 2-chome, Kita-ku Osaka-shi Japón Hilton Plaza West Office Tower, 2014 Commercial Research, development, import and export and commercialisation of pharmaceutical products, devices 100.000 % — 100.000 % — 100.000 % — Grifols India Healthcare Private Ltd Regus Business Centre 2014 Commercial Distribution and sale of pharmaceutical products. 99.984 % 0.016 % 99.984 % 0.016 % 99.984 % 0.016 % Mumbai - 400604, Grifols Diagnostics Equipment Taiwan Limited 8F., No.367, Fuxing N. RD., 2016 Commercial Distribution and sale of diagnostic products. 100.000 % — 100.000 % — 100.000 % — Grifols Viajes, S.A. Spain Can Guasch, 2 1995 Services Travel agency exclusively serving Group companies. 99.900 % 0.100 % 99.900 % 0.100 % 99.900 % 0.100 % Squadron Reinsurance Designated Activity Company Ireland The Metropolitan Building, 3rd 2003 Services Reinsurance of Group companies’ insurance policies. — 100.000 % — 100.000 % — 100.000 % Grifols Shared Services North America, Inc. United States 2410 Lillivale Avenue 2011 Services Support services for the collection, manufacture, sale and distribution of plasma derivatives and related 100.000 % — 100.000 % — 100.000 % — Gripdan Invest, S.L Avenida Diagonal 477 Barcelona, 2015 Services Rental of industrial buildings 100.000 % — 100.000 % — 100.000 % — Gri-Cel, S.A. (merged with Instituto Grifols, S.A. in 2019) Spain Avenida de la Generalitat 152 2009 Research Research and development in the field of regenerative medicine, awarding of research grants, subscription to collaboration agreements with entities and participation in projects in the area of regenerative medicine. — — — — — — Araclon Biotech, S.L. Spain Paseo de Sagasta, 17 2º izqda. 2012 Research Creation and commercialisation of a blood diagnosis kit for the detection of Alzheimer's and — 75.850 % — 75.100 % — 75.100 % development of effective immunotherapy (vaccine) against this disease. VCN Bioscience, S.L. Avenida de la Generalitat 152 2012 Research Research and development of therapeutic approaches for tumours for which there is currently no — 86.830 % — 86.830 % — 81.340 % Grifols Innovation and New Technologies Limited Grange Castle Business Park, 2016 Research Biotechnology research and development — 100.000 % — 100.000 % — 100.000 % PBS Acquisition Corp. (merged with IBBI in 2019) 2711 Centerville Road Suite 400, 2016 Services Engage in any lawful act or activity for which corporations may be organized under the DGCL — — — — — — Kiro Grifols S.L Spain Polígono Bainuetxe, 5, 2º planta, Aretxabaleta, Guipúzcoa 2014 Research Development of machines and equipment to automate and control key points of hospital processes, and hospital pharmacy processes. 90.000 % — 90.000 % — 90.000 % — Chiquito Acquisition Corp. 2711 Centerville Road Suite 400, Wilmington, Delaware, New Castle County, United States 2017 Corporate Engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware, as amended from time to time (the "DGCL"). — 100.000 % — 100.000 % — 100.000 % Aigües Minerals de Vilajuiga, S.A. Carrer Sant Sebastià, 2, 17493 Vilajuïga, Girona Carrer Sant Sebastià, 2, 17493 Vilajuïga, Girona 2017 Industrial Collection and use of mineral- 99.990 % 0.010 % 99.990 % 0.010 % 99.990 % 0.010 % medicinal waters and obtainment of all necessary administrative concessions for the optimum and widest use of these. Goetech LLC (D/B/A Medkeeper) 7600 Grandview Avenue, Suite 210, Arvada, CO 80002, United States 2018 Industrial Development and distribution of web and mobile-based platforms for hospital pharmacies — 100.000 % — 100.000 % — 54.760 % Interstate Blood Bank, Inc. 5700 Pleasantville Road 2016 Industrial Procuring human plasma. — 100.000 % — 100.000 % — 100.000 % Haema, AG LandsteinerstraBe 1, 04103 Leipzig - Germany 2018 Industrial Procurement of human plasma. — — — — — — BPC Plasma, Inc (formerly Biotest Pharma Corp) 901 Yamato Rd., Suite 101, Boca Raton FL 33431 - USA 2018 Industrial Procurement of human plasma. — — — — — — Alkahest, Inc. 3500 South DuPont Hwy, Dover, County of Kent Estados Unidos 3500 South DuPont Hwy, 2015 Research Development novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS). — 100.000 % — % 42.450 % — — Plasmavita Healthcare GmbH Colmarer Strasse 22, 60528 Frankfurt am Main - Germany Colmarer Strasse 22, 60528 Frankfurt am Main - Germany 2018 Industrial Procurement of human plasma. — 50 % — % 50.000 % — — Plasmavita Healthcare II GmbH Garnisongasse 4/12, 1090 Vienna, Austria Garnisongasse 4/12, 1090 Vienna, Austria 2019 Industrial Procurement of human plasma. — 50 % — 50.000 % — — Grifols Canada Therapeutics Inc. (formerly Green Cross Biotherapeutics; Inc) 2911 Avenue Marie Curie, Arrondissement de Saint-Laurent, Quebec 2020 Industrial Conducting business in Pharmceuticals and Medicines Industry 100.000 % — — 100.000 % — — GCAM, Inc. (merged with Biomat USA) 1561 E Orangethorpe Ave #205, Fullerton, CA 92831 2020 Industrial To engage in any lawful act or activity for which corporations may — — — 100.000 % — — be organized under the General Corporation Law of Delaware and engaging in any and all activities necessary or incidental to the foregoing. Grifols Laboratory Solutions, Inc Corporation Trust Center, 1209, Orange Street, Wilmington, New Castle Country, Delaware, 19801 2020 Services To engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware — 100.000 % — 100.000 % — — Grifols Korea Co., Ltd. 302 Teheran-ro, Gangnam-gu, Seoul (Yeoksam-dong) 2020 Commercial Import, export of diagnostic in vitro products and solutions. 100.000 % — 100.000 % — — — Grifols Middle East & Africa LLC Office No. 534, 5th floor, NamaaBuilding No.155, Ramses Extension Street, Al Hay Al Sades, Nasr City, Cairo 2021 Services Providing consultation (except for those stipulated in Article 27 of the Capital Market Law and its executive regulations) and carry out those commercial activities that are permitted by the law. 99.990 % 0.010 — — — — GigaGen Inc. 407 Cabot Road 2021 Industrial Engage in any lawful act or activity for which corporations may be organized under General Corporation Law. — 100.000 % — 43.960 — 43.960 Grifols Pyrenees Research Center, S.L. C/ Prat de la Creu, 68-76, Planta 3ª, Edifici Administratiu del Comú d'Andorra la Vella 2021 Industrial Constitution, development and management of operations of a research and development center in all areas of immnology, — 80.000 % — — — — dedicated to find possible solutions for therapeutic applications. Grifols Bio North America LLC 251 Little Falls Drive, Wilmington, New Castle County, 19808, Delaware 2021 Industrial To engage in any lawful business permitted by the Act or the laws of any jurisdiction in which the Company may do business. — 100.000 % — — — — Biomat Holdco, LLC. 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 2021 Services Engage in any lawful act or activity for which corporations may be organized under General Corporation Law of Delaware. — 100.000 % — — — — Biomat Newco, Corp. 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 2021 Services Engage in any lawful act or activity for which corporations may be organized under General Corporation Law of Delaware. — 100.000 % — — — — Grifols Escrow Issuer, S.A. Parque Empresarial Can Sant Joan, Avda de la Generalitat, 152-156, Sant Cugat del Vallès, 08174, Barcelona 2021 Services Administration, management and control services for companies and businesses, as well as investment in property, as well as providing advisory services of any investee entities or group companies. 100.000 % — — — — — Prometic Plasma Resources, Inc. 531 Boul. Des Prairies, Building 15 Laval, Quebec H7V 1B7 2021 Industrial Procurement of human plasma. 100.000 % — — — — — Aradigm Corporation 3929 Point Eden Way 2013 Research Development and commercialisation of drugs delivered by inhalation for the — 35.130 % — 35.130 % — 35.130 % prevention and treatment of severe respiratory diseases. TiGenix N.V. Romeinse straat 12 bus 2, 3001 Leuven, Belgium 2013 Research Research and development of therapies based on stem cells taken from adipose tissue. — — — — — — Mecwins, S.L. Avenida Fernandos Casas Novoa, 37 2013 Research Research and production of nanotechnological, biotechnological and chemical solutions. — 24.990 % — 24.990 % — 24.990 % Alkahest, Inc. 3500 South DuPont Hwy, Dover, 2015 Research Development novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS). — — — — — 47.580 % Albajuna Therapeutics, S.L Hospital Germans Trias i Pujol, carretera de Canyet, s/n, Badalona 2016 Research Development and manufacture of therapeutic antibodies against HIV. — 49.000 % — 49.000 % — 49.000 % Interstate Blood Bank, Inc. 5700 Pleasantville Road 2016 Industrial Procurement of human plasma. — — — — — — Bio Blood Components Inc. 5700 Pleasantville Road 2016 Industrial Procurement of human plasma. — — — — — — Plasma Biological Services, LLC 5700 Pleasantville Road 2016 Industrial Procurement of human plasma. — — — — — — Singulex, Inc. 4041 Forest Park Avenue St. Louis, Missouri 2016 Research Development of the Single Molecule Counting (SMC™) technology for — 19.330 % — 19.330 % — 19.330 % clinical diagnostic and scientific discovery. Access Biologicals, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — 49.000 % — 49.000 % — 49.000 % Access Biologicals IC-DISC, Inc. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — 49.000 % — 49.000 % — 49.000 % Access Cell Culture, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro — 49.000 % — 49.000 % — 49.000 % diagnostics, cell culture, and research and development in the diagnostic field. Access Manufacturing, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — — — — — — Access Plasma, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. — 49.000 % — 49.000 % — 49.000 % GigaGen Inc. 407 Cabot Road 2017 Industrial Engage in any lawful act or activity for which corporations may be organized under General Corporation Law. — — — 43.960 % — 43.960 % Plasmavita Healthcare GmbH Colmarer Strasse 22, 60528 Frankfurt am Main - Germany 2018 Industrial Procurement of human plasma. — — — — — 50.000 % Medcom Advance, S.A Av. Roma, 35 Entresuelo 1, 08018 Barcelona; Spain 2019 Research Research and development of nanotechnological solutions. — 45.000 % — 45.000 % — 45.000 % Plasmavita Healthcare II GmbH Garnisongasse 4/12, 1090 Vienna, Austria 2019 Industrial Procurement of human plasma. — — — — — 50.000 % Shanghai RAAS Blood Products Co. Ltd. 2009 Wangyuan Road, Fengxian District, Shanghai 2020 Industrial Introducing advanced and applicable technologies, instruments and scientific management systems for manufacturing and diagnosis of blood products, in order to raise the production capacity and enhance quality standards of blood products to the international level. 26.200 % — 26.200 % — — — Grifols Egypt for Plasma Derivatives (S.A.E.) Tolip El Narges Hotel, Teseen Streett, Fifth Settlement, Cairo 2021 Industrial Establish and operate a plasma fractionation plant whether the plasma is collected locally or imported, as well as its filling and packaging. 49.000 % — — — — — |
Appendix II (Tables)
Appendix II (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Appendix II | |
Schedule of operating segments | (Expressed in thousands of Euros) Bioscience Hospital Diagnostic Bio Supplies Others Intersegments Consolidated 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 Revenues from external customers 3,814,983 4,242,502 3,993,462 141,190 118,675 134,441 779,108 775,889 733,604 225,765 224,090 266,540 39,620 31,989 22,820 (67,548) (53,107) (52,176) 4,933,118 5,340,038 5,098,691 Total operating income 3,814,983 4,242,502 3,993,462 141,190 118,675 134,441 779,108 775,889 733,604 225,765 224,090 266,540 39,620 31,989 22,820 (67,548) (53,107) (52,176) 4,933,118 5,340,038 5,098,691 Profit/(Loss) for the segment 658,691 949,989 1,079,216 (7,735) (12,504) (8,674) 152,948 215,793 215,828 45,990 19,871 16,246 (58,602) 2,241 1,279 (10,896) 4,428 (3,094) 780,396 1,179,818 1,300,801 Unallocated expenses (185,332) (183,686) (169,436) Operating profit/(loss) 595,064 996,132 1,131,365 Finance result (277,799) (177,669) (274,724) Share of profit/(loss) of equity- accounted investee — — — — — — — — (19,794) — — — 33,188 60,166 (19,744) — — — 33,188 60,166 (39,538) Income tax expense (85,126) (169,639) (168,459) Profit for the year after tax 265,327 708,990 648,644 Segment assets 9,467,378 7,975,667 8,416,922 269,487 257,360 274,250 3,513,991 3,371,125 3,676,011 47,446 251,551 226,814 557,884 383,981 77,501 (39,963) (26,773) (32,892) 13,816,223 12,212,911 12,638,606 Equity-accounted investments 31,847 — 10,368 — — — — — — 53,264 46,782 49,922 1,914,665 1,822,238 54,183 — — — 1,999,776 1,869,020 114,473 Unallocated assets — — — — — — — — — — — — — — — — — — 3,417,836 1,192,845 2,789,532 Total assets 19,233,835 15,274,776 15,542,611 Segment liabilities 1,521,634 1,222,664 1,371,352 38,654 32,179 53,441 397,869 372,461 351,799 27,596 120,787 126,289 160,441 121,334 35,581 — — — 2,146,194 1,869,425 1,938,462 Unallocated liabilities — — — — — — — — — — — — — — — — — — 9,770,543 6,685,296 6,758,381 Total liabilities 11,916,737 8,554,721 8,696,843 Other information: Allocated amortisation and depreciation 228,114 201,087 196,335 12,065 12,443 11,686 88,557 63,053 52,224 2,948 21,846 20,415 6,978 2,820 2,147 — — — 338,662 301,249 282,807 Unallocated amortisation and depreciation — — — — — — — — — — — — — — — — — — 21,105 20,284 19,648 Allocated expenses that do not require cash payments 26,051 38,955 43,524 3,349 529 (289) 4,446 (21,335) (22,873) 73 3 393 — (2,977) — — — — 33,919 15,175 20,755 Unallocated expenses that do not require cash — — — — — — — — — — — — — — — — — — 4,991 4,924 2,416 Allocated additions for the year of property, plant & 349,890 289,062 868,103 12,616 11,548 62,298 19,991 34,516 103,911 13,836 10,915 65,448 15,981 1,150 1,768 — — — 412,314 347,191 1,101,528 Unallocated additions for the year of property, plant — — — — — — — — — — — — — — — — — — 55,380 107,178 73,544 |
Schedule of reporting by geographical area | (Expressed in thousands of Euros) Rest of European USA + Canada Rest of World Consolidated Spain Union 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 2021 2020 2019 Net Revenue 362,407 339,169 268,287 544,042 495,323 588,375 3,154,549 3,599,746 3,390,811 872,120 905,800 851,218 4,933,118 5,340,038 5,098,691 Assets by geographical area 1,092,435 1,117,647 2,764,054 5,393,407 2,927,198 3,425,874 10,525,140 9,138,360 9,059,674 2,222,853 2,091,571 293,009 19,233,835 15,274,776 15,542,611 Other information: Additions for the year of property, plant & 71,022 93,787 183,891 91,388 92,873 181,736 295,526 253,442 787,586 9,758 14,267 21,859 467,694 454,369 1,175,072 |
Appendix III (Tables)
Appendix III (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Appendix III | |
Schedule of changes in other intangible assets | (Expressed in thousands of Euros) Balance at Business Translation Balance at 31/12/2020 Additions combinations Transfers Disposals differences 31/12/2021 Development costs 701,390 34,671 24,027 — (5,679) 47,197 801,606 Concessions, patents, licenses brands & similar 228,023 57 — — — 16,478 244,558 Computer software 279,651 33,516 — 3,315 (208) 14,217 330,491 Currently marketed products 1,004,665 — — — — 78,636 1,083,301 Other intangible assets 156,644 — — — (12,146) 11,511 156,009 Total cost of intangible assets 2,370,373 68,244 24,027 3,315 (18,033) 168,039 2,615,965 Accum. amort. of development costs (125,875) (44,612) — (60) 5,679 (3,498) (168,366) Accum. amort of concessions, patents, licenses, brands & similar (51,197) (9,909) — — — (3,070) (64,176) Accum. amort. of computer software (167,124) (25,474) — (101) 178 (7,770) (200,291) Accum. amort. of currently marketed products (331,968) (35,989) — — — (26,827) (394,784) Accum. amort. of other intangible assets (71,430) (4,265) — — — (5,603) (81,298) Total accum. amort intangible assets (747,594) (120,249) — (161) 5,857 (46,768) (908,915) Impairment of other intangible assets (65,129) (73) — — — (4,898) (70,100) Carrying amount of intangible assets 1,557,650 (52,078) 24,027 3,154 (12,176) 116,373 1,636,950 (See note 3) This appendix forms an integral part of note 8 to the consolidated financial statements. APPENDIX III GRIFOLS, S.A. AND SUBSIDIARIES Changes in Other Intangible Assets for the year ended 31 December 2020 (Expressed in thousands of Euros) Balance at Business Translation Balance at 31/12/2019 Additions combinations Transfers Disposals differences 31/12/2020 Development costs 435,339 35,301 265,571 — — (34,821) 701,390 Concessions, patents, licenses brands & similar 229,997 16,174 5 (6) — (18,147) 228,023 Computer software 258,597 27,939 2,229 3,963 (11) (13,066) 279,651 Currently marketed products 1,092,834 — — — — (88,169) 1,004,665 Other intangible assets 178,359 3,118 — (399) (10,233) (14,201) 156,644 Total cost of intangible assets 2,195,126 82,532 267,805 3,558 (10,244) (168,404) 2,370,373 Accum. amort. of development costs (103,531) (23,810) — — — 1,466 (125,875) Accum. amort of concessions, patents, licenses, brands & similar (43,656) (8,221) — (1,732) — 2,412 (51,197) Accum. amort. of computer software (143,806) (19,198) — (9,833) 12 5,701 (167,124) Accum. amort. of currently marketed products (322,119) (37,739) — — — 27,890 (331,968) Accum. amort. of other intangible assets (80,836) (6,844) — 9,389 214 6,647 (71,430) Total accum. amort intangible assets (693,948) (95,812) — (2,176) 226 44,116 (747,594) Impairment of other intangible assets (67,644) (2,977) — — — 5,492 (65,129) Carrying amount of intangible assets 1,433,534 (16,257) 267,805 1,382 (10,018) (118,796) 1,557,650 |
Appendix IV (Tables)
Appendix IV (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
APPENDIX IV | |
Schedule of movement of rights of use | Balance at Translation Balance at 31/12/2020 Additions Business combinations Transfers Disposals differences 31/12/2021 Land and buildings 759,120 125,112 4,611 3,337 (3,603) 53,378 941,955 Machinery 5,907 3,412 — (495) (89) 341 9,076 Computer equipment 8,228 641 — (629) (7) 286 8,519 Vehicles 14,152 4,277 — (407) (2,887) 625 15,760 Total cost of rights of use 787,407 133,442 4,611 1,806 (6,586) 54,630 975,310 Accum. depr. of land and buildings (94,118) (57,901) — (3,337) 3,605 (8,080) (159,831) Accum. depr. of machinery (2,236) (2,120) — 587 87 (110) (3,792) Accum.depr. of computer equipment (4,640) (2,269) — 629 7 (202) (6,475) Accum. depr. of vehicles (7,717) (4,430) — 407 2,581 (396) (9,555) Total accum. depr. of rights of use (108,711) (66,720) — (1,714) 6,280 (8,788) (179,653) Carrying amount of rights of use 678,696 66,722 4,611 92 (306) 45,842 795,657 This appendix forms an integral part of note 9 to the consolidated financial statements. APPENDIX IV GRIFOLS, S.A. AND SUBSIDIARIES Movement in Rights of Use for the year ended 31 December 2020 (Expressed in thousands of Euros) Balance at Translation Balance at 31/12/2019 Additions Business combinations Transfers Disposals differences 31/12/2020 Land and buildings 734,846 68,172 19,424 — (10,935) (52,387) 759,120 Machinery 6,167 1,775 — (1,846) (59) (130) 5,907 Computer equipment 6,504 2,449 — (37) (347) (341) 8,228 Vehicles 14,030 2,681 74 (10) (1,914) (709) 14,152 Total cost of rights of use 761,547 75,077 19,498 (1,893) (13,255) (53,567) 787,407 Accum. amort. of land and buildings (49,441) (52,774) — (2) 2,341 5,758 (94,118) Accum. amort of machinery (1,698) (1,588) — 955 55 40 (2,236) Accum. amort. of computer equipment (2,180) (3,012) — 37 347 168 (4,640) Accum. amort. of vehicles (4,370) (5,206) — 7 1,529 323 (7,717) Total accum. amort of rights of use (57,689) (62,580) — 997 4,272 6,289 (108,711) Carrying amount of rights of use 703,858 12,497 19,498 (896) (8,983) (47,278) 678,696 |
Appendix V (Tables)
Appendix V (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Appendix V | |
Schedule of movement in property, plant and equipment | (Expressed in thousands of Euros) Balances at Business Translation Balances at 31/12/2020 Additions combination Transfers Disposals differences 31/12/2021 Cost: Land and buildings 780,180 3,361 660 24,830 (123) 51,539 860,447 Plant and machinery 2,200,429 42,747 10,381 171,894 (24,960) 127,253 2,527,744 Fixed Assets under construction 704,582 219,900 (7,300) (199,943) — 46,548 763,787 3,685,191 266,008 3,741 (3,219) (25,083) 225,340 4,151,978 Accumulated depreciation: Buildings (122,948) (19,388) — 2,583 123 (8,452) (148,082) Plant and machinery (1,235,483) (153,408) — (2,609) 18,808 (69,742) (1,442,434) (1,358,431) (172,796) — (26) 18,931 (78,194) (1,590,516) Impairment of other property, plant and equipment (2,653) (11,246) — — — (66) (13,965) Carrying amount 2,324,107 81,966 3,741 (3,245) (6,152) 147,080 2,547,497 (See note 3) This appendix forms an integral part of note 10 to the consolidated financial statements. APPENDIX V GRIFOLS, S.A. AND SUBSIDIARIES Movement in Property, Plant and Equipment for the year ended 31 December 2020 (Expressed in thousands of Euros) Balances at Business Translation Balances at 31/12/2019 Additions combination Transfers Disposals differences 31/12/2020 Cost: Land and buildings 807,195 19,843 14,964 (6,050) (211) (55,561) 780,180 Plant and machinery 2,141,611 50,825 48,408 103,594 (23,830) (120,179) 2,200,429 Fixed Assets under construction 497,164 226,092 121,399 (99,616) — (40,457) 704,582 3,445,970 296,760 184,771 (2,072) (24,041) (216,197) 3,685,191 Accumulated depreciation: Buildings (108,638) (17,974) — (3,826) 171 7,319 (122,948) Plant and machinery (1,175,075) (145,167) — 5,412 22,590 56,757 (1,235,483) (1,283,713) (163,141) — 1,586 22,761 64,076 (1,358,431) Impairment of other property, plant and equipment (2,712) 21 — — — 38 (2,653) Carrying amount 2,159,545 133,640 184,771 (486) (1,280) (152,083) 2,324,107 (See note 3) |
Nature, Principal Activities _2
Nature, Principal Activities and Subsidiaries (Details) - IPO € / shares in Units, € in Millions | May 17, 2006EUR (€)€ / sharesshares |
Nature, principal activities and subsidiaries | |
Number of ordinary shares issued through public offering | shares | 71,000,000 |
Par value (in Euros per share) | € 0.50 |
Share premium | € 3.90 |
Total capital increase (including the share premium) | € | € 312.4 |
Issue price | € 4.40 |
Basis of Presentation (Details)
Basis of Presentation (Details) € in Thousands, $ in Thousands | Mar. 08, 2021EUR (€) | Mar. 08, 2021USD ($) | Dec. 02, 2020EUR (€) | Dec. 01, 2020 | Sep. 02, 2020USD ($) | Apr. 14, 2020EUR (€) | Mar. 30, 2020shares | Dec. 03, 2019EUR (€)item | Jul. 24, 2019EUR (€)shares | Jul. 23, 2019 | Apr. 16, 2019EUR (€)item | Jul. 05, 2017 | Oct. 31, 2021EUR (€) | Jun. 30, 2021EUR (€) | Jun. 30, 2021USD ($) | May 31, 2021 | Dec. 31, 2019EUR (€) | Jul. 31, 2019EUR (€) | Jun. 30, 2019 | Apr. 30, 2019EUR (€) | Dec. 31, 2021EUR (€)shares | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2017 | Dec. 31, 2021USD ($) | Aug. 26, 2021USD ($) | Mar. 08, 2021USD ($) | Oct. 01, 2020EUR (€)facilityCenter | Oct. 01, 2020USD ($)facilityCenter | Jul. 20, 2020EUR (€)Centerfacility | Jul. 20, 2020USD ($)Centerfacility | Dec. 31, 2018EUR (€) | Dec. 28, 2018USD ($) | May 11, 2016EUR (€)Centeritem | May 11, 2016USD ($)Centeritem |
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Share of Profit (Loss) of Associates and Joint Ventures Accounted for Using Equity Method, Excluding Impairment Loss | € 65,743 | € 88,877 | € (10,772) | ||||||||||||||||||||||||||||||||
Consideration received in shares | shares | 1,766,000,000 | ||||||||||||||||||||||||||||||||||
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity | (89) | 1,716,147 | |||||||||||||||||||||||||||||||||
Other current assets | 64,079 | 51,750 | |||||||||||||||||||||||||||||||||
Deferred tax liability (asset) | € 340,803 | 481,477 | 406,892 | 340,803 | € 291,859 | ||||||||||||||||||||||||||||||
Deferred tax assets | € 152,507 | 149,921 | |||||||||||||||||||||||||||||||||
Recovery period of tax credits | 5 years | ||||||||||||||||||||||||||||||||||
Tax loss carryforwards | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Deferred tax liability (asset) | (61,476) | € (51,750) | (65,087) | (61,476) | |||||||||||||||||||||||||||||||
Deferred tax assets | € 60,700 | 53,910 | 60,700 | ||||||||||||||||||||||||||||||||
Tax loss carryforwards that will be recovered in less than 5 years | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Deferred tax assets | 48,453 | 48,000 | |||||||||||||||||||||||||||||||||
Plasmavita Healthcare GmbH (Germany) | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Contribution Made | € 10,000 | ||||||||||||||||||||||||||||||||||
Ownership interest in joint venture (as a percent) | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||
Non-controlling interests [Member] | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity | € 1,522 | (405,698) | 1,517,180 | ||||||||||||||||||||||||||||||||
Translation differences | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity | (22,009) | ||||||||||||||||||||||||||||||||||
Shanghai RAAS Blood Products Co., Ltd. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Proportion of ownership interest in associate | 26.20% | ||||||||||||||||||||||||||||||||||
Shanghai RAAS Blood Products Co., Ltd. | Grifols Diagnostics Solutions, Inc. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Number of shares to be delivered | shares | 90 | ||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 40.00% | ||||||||||||||||||||||||||||||||||
Government of Andorra | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Proportion of ownership interest in associate | 20.00% | ||||||||||||||||||||||||||||||||||
GigaGen Inc. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Share of Profit (Loss) of Associates and Joint Ventures Accounted for Using Equity Method, Excluding Impairment Loss | € 34,957 | € (6,725) | € (5,002) | ||||||||||||||||||||||||||||||||
Proportion of ownership interest in associate | 43.96% | 100.00% | 43.96% | ||||||||||||||||||||||||||||||||
ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod | € 34,525 | $ 41,758 | |||||||||||||||||||||||||||||||||
Green Cross | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Consideration transferred | € 387,917 | $ 457,160 | |||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 387,917 | $ 457,160 | |||||||||||||||||||||||||||||||||
Number of purification facilities | facility | 2 | 2 | 2 | 2 | |||||||||||||||||||||||||||||||
Number of plasma collection centers | Center | 11 | 11 | 11 | 11 | |||||||||||||||||||||||||||||||
GigaGen Inc. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Proportion of ownership interest in associate | 100.00% | 100.00% | |||||||||||||||||||||||||||||||||
Total consideration | $ | $ 90,500 | ||||||||||||||||||||||||||||||||||
Consideration transferred | € 73,428 | $ 88,811 | |||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 100.00% | 100.00% | |||||||||||||||||||||||||||||||||
Prometic Plasma Resources, Inc. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Consideration transferred | $ | $ 8,805 | ||||||||||||||||||||||||||||||||||
Grifols Escrow Issuer, S.A [Member] | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Consideration transferred | $ | $ 60 | ||||||||||||||||||||||||||||||||||
Biotest Us Corporation and Haema AG | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Consideration for sale of subsidiary | $ | $ 538,014 | ||||||||||||||||||||||||||||||||||
Alkahest, Inc. (USA) | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 57.55% | ||||||||||||||||||||||||||||||||||
Consideration transferred | $ | $ 146,000 | ||||||||||||||||||||||||||||||||||
Grifols Malaysia Sdn Bhd | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 49.00% | 49.00% | 30.00% | 49.00% | |||||||||||||||||||||||||||||||
Share capital increase | € 6 | $ 7 | |||||||||||||||||||||||||||||||||
Grifols (Thailand) Ltd. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Number of classes of shares | shares | 2 | ||||||||||||||||||||||||||||||||||
Interstate Blood Bank, Inc., Bio-Blood Components, Inc. and Plasma Biological Services, LLC | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 88,215 | $ 100,000 | |||||||||||||||||||||||||||||||||
Call option price | $ | 100,000 | ||||||||||||||||||||||||||||||||||
Agreed payment amount for call option | € 9,007 | $ 10,000 | |||||||||||||||||||||||||||||||||
Interstate Blood Bank, Inc | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 49.19% | 49.19% | |||||||||||||||||||||||||||||||||
Bio Blood Components Inc. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 48.97% | 48.97% | |||||||||||||||||||||||||||||||||
Plasma Biological Services, LLC. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 48.90% | 48.90% | |||||||||||||||||||||||||||||||||
Number of plasma collection centers | Center | 26 | 26 | |||||||||||||||||||||||||||||||||
Number of blood donation centers | Center | 9 | 9 | |||||||||||||||||||||||||||||||||
Number of laboratories | item | 1 | 1 | |||||||||||||||||||||||||||||||||
VCN Bioscience S.L | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 86.83% | 81.34% | |||||||||||||||||||||||||||||||||
Share capital increase | € 5,000 | ||||||||||||||||||||||||||||||||||
Progenika Biopharma, S.A. (Spain) | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 100.00% | 99.99% | 100.00% | 99.99% | |||||||||||||||||||||||||||||||
Share capital increase | € 4 | ||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 4 | ||||||||||||||||||||||||||||||||||
Number of shares acquired | shares | 33 | ||||||||||||||||||||||||||||||||||
Grifols Diagnostics Solutions, Inc. | Shanghai RAAS Blood Products Co., Ltd. | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Economic rights (as a percent) | 45.00% | ||||||||||||||||||||||||||||||||||
Grifols Pyrenees Research Center, SL | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 80.00% | ||||||||||||||||||||||||||||||||||
Contribution made | € 2 | ||||||||||||||||||||||||||||||||||
Araclon Biotech S.L | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 75.10% | 75.10% | 75.85% | 75.10% | 75.10% | ||||||||||||||||||||||||||||||
Share capital increase | € 5,900 | € 16,800 | € 10,000 | € 5,900 | € 16,800 | ||||||||||||||||||||||||||||||
Number of share capital increases | item | 2 | 2 | |||||||||||||||||||||||||||||||||
Minimum | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 20.00% | ||||||||||||||||||||||||||||||||||
Maximum | |||||||||||||||||||||||||||||||||||
Basis of presentation. | |||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 50.00% |
Basis of Presentation - IFRS 16
Basis of Presentation - IFRS 16 Leases (Details) | Jan. 01, 2019 | Dec. 31, 2021 | Dec. 31, 2020 |
Minimum | |||
Leases | |||
Incremental interest rate applied to lease liabilities recognised at date of initial application of IFRS 16 | 2.12% | 1.55% | |
Maximum | |||
Leases | |||
Incremental interest rate applied to lease liabilities recognised at date of initial application of IFRS 16 | 8.37% | 7.21% | |
Buildings and warehouses | Minimum | |||
Leases | |||
Lease term | 10 years | ||
Buildings and warehouses | Maximum | |||
Leases | |||
Lease term | 15 years | ||
Donor centers | Minimum | |||
Leases | |||
Lease term | 13 years | ||
Donor centers | Maximum | |||
Leases | |||
Lease term | 15 years | ||
Computer equipment | Minimum | |||
Leases | |||
Lease term | 3 years | ||
Computer equipment | Maximum | |||
Leases | |||
Lease term | 5 years | ||
Machinery | Minimum | |||
Leases | |||
Lease term | 4 years | ||
Machinery | Maximum | |||
Leases | |||
Lease term | 5 years | ||
Vehicles | Minimum | |||
Leases | |||
Lease term | 3 years | ||
Vehicles | Maximum | |||
Leases | |||
Lease term | 5 years |
Business Combinations - Cost, F
Business Combinations - Cost, FV of Assets, Goodwill and Other (Details) € in Thousands | Mar. 31, 2021EUR (€)l | Mar. 08, 2021EUR (€) | Mar. 08, 2021USD ($) | Feb. 28, 2021EUR (€)l | Oct. 15, 2020EUR (€) | Oct. 01, 2020EUR (€)facilityCenterl | Sep. 02, 2020EUR (€) | Sep. 02, 2020USD ($) | Jul. 20, 2020EUR (€)Centerfacility | Apr. 14, 2020EUR (€) | Jan. 01, 2020EUR (€) | May 31, 2019EUR (€)USD ($) | Apr. 30, 2019EUR (€) | Jan. 01, 2019EUR (€) | Nov. 30, 2017Centerperson | Dec. 31, 2020EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2021EUR (€) | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€)l | Dec. 31, 2021USD ($) | Mar. 31, 2021USD ($)l | Mar. 08, 2021USD ($) | Mar. 07, 2021 | Feb. 28, 2021USD ($)l | Oct. 15, 2020USD ($) | Oct. 01, 2020USD ($)facilityCenter | Sep. 02, 2020USD ($) | Jul. 20, 2020USD ($)Centerfacility | Apr. 30, 2019USD ($) | Dec. 31, 2018EUR (€) | Dec. 28, 2018USD ($) | May 11, 2016EUR (€)Centeritem | May 11, 2016USD ($)Centeritem |
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Investments accounted for using equity method | € 1,869,020 | € 1,869,020 | € 114,472 | € 1,999,776 | € 1,999,776 | € 1,869,020 | € 114,472 | € 226,905 | ||||||||||||||||||||||||||||
Biotest Us Corporation and Haema AG | ||||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Consideration for sale of subsidiary | $ | $ 538,014,000 | |||||||||||||||||||||||||||||||||||
Plasmavita Healthcare | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 10,000 | |||||||||||||||||||||||||||||||||||
Total consideration paid | 10,000 | |||||||||||||||||||||||||||||||||||
Fair value of the previous investment in the company | 10,674 | |||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 21,374 | |||||||||||||||||||||||||||||||||||
Minority interest | (10,687) | |||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 9,987 | |||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | 10,000 | |||||||||||||||||||||||||||||||||||
Cash transferred | 10,000 | |||||||||||||||||||||||||||||||||||
Development costs in progress | 177 | |||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Contribution | 10,000 | |||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | € 6,506 | |||||||||||||||||||||||||||||||||||
Ownership interest in entity, prior to acquisition of remaining shares (as a percent) | 50.00% | |||||||||||||||||||||||||||||||||||
Ownership interest in joint venture (as a percent) | 50.00% | |||||||||||||||||||||||||||||||||||
Number of plasma centers | Center | 10 | |||||||||||||||||||||||||||||||||||
Variation between the fair value of the previous investment and the book value | 5,357 | |||||||||||||||||||||||||||||||||||
Minority interest's share of the contribution made | € 5,000 | 5,000 | ||||||||||||||||||||||||||||||||||
Plasmavita Healthcare | Other partners | ||||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Ownership interest in joint venture (as a percent) | 50.00% | |||||||||||||||||||||||||||||||||||
Number of partners in joint venture | person | 2 | |||||||||||||||||||||||||||||||||||
Alkahest, Inc. | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Other non-current assets | € 178 | $ 210,000 | ||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | 18,797 | 22,235,000 | ||||||||||||||||||||||||||||||||||
Second repurchase of non-controlling interests (discounted amount) | 104,628 | 123,765,000 | ||||||||||||||||||||||||||||||||||
Total consideration paid | 123,425 | 146,000,000 | ||||||||||||||||||||||||||||||||||
Fair value of the previous investment in the company | 91,023 | 107,671,000 | ||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 140,076 | 165,696,000 | ||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 74,372 | 87,975,000 | ||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | 123,425 | 146,000,000 | ||||||||||||||||||||||||||||||||||
Percentage of voting equity interests acquired | 57.55% | 57.55% | ||||||||||||||||||||||||||||||||||
Development costs in progress | 265,617 | 314,198,000 | ||||||||||||||||||||||||||||||||||
Consolidated results | (12,317) | |||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | € 4,970 | $ 5,879,000 | ||||||||||||||||||||||||||||||||||
Ownership interest in entity, prior to acquisition of remaining shares (as a percent) | 42.45% | 42.45% | ||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 57.55% | 57.55% | ||||||||||||||||||||||||||||||||||
Ownership in subsidiary (as a percent) | 100.00% | |||||||||||||||||||||||||||||||||||
Increase (decrease) in combined profit had the acquisition taken place on January 1 | € 30,045 | |||||||||||||||||||||||||||||||||||
Consolidated results | (12,317) | |||||||||||||||||||||||||||||||||||
Variation between the fair value of the previous investment and the book value | € 86,743 | $ 102,552,000 | ||||||||||||||||||||||||||||||||||
Liabilities recognised at amortized cost | € 121,149 | $ 143,706,000 | ||||||||||||||||||||||||||||||||||
Decrease in non-controlling interests | 121,486 | 143,307,000 | ||||||||||||||||||||||||||||||||||
Other reserves | € 337 | $ 399,000 | ||||||||||||||||||||||||||||||||||
Amounts payable | 100,492 | € 100,492 | € 100,492 | |||||||||||||||||||||||||||||||||
Green Cross | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 387,917 | $ 457,160,000 | ||||||||||||||||||||||||||||||||||
Total consideration paid | € 387,917 | $ 457,160,000 | ||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 194,227 | 228,897,000 | ||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 193,690 | 228,263,000 | ||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | 387,917 | 457,160,000 | ||||||||||||||||||||||||||||||||||
Cash transferred | 387,917 | 457,160,000 | ||||||||||||||||||||||||||||||||||
Consideration payable | € 387,917 | $ 457,160,000 | ||||||||||||||||||||||||||||||||||
Development costs in progress | 2,877 | 3,390,000 | ||||||||||||||||||||||||||||||||||
Consolidated results | (5,023) | |||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | € 158,148 | $ 186,377,000 | ||||||||||||||||||||||||||||||||||
Number of purification facilities | facility | 2 | 2 | 2 | 2 | ||||||||||||||||||||||||||||||||
Number of plasma collection centers | Center | 11 | 11 | 11 | 11 | ||||||||||||||||||||||||||||||||
Increase (decrease) in combined revenue had the acquisition taken place on January 1 | 31,197 | |||||||||||||||||||||||||||||||||||
Increase (decrease) in combined profit had the acquisition taken place on January 1 | € 32,423 | |||||||||||||||||||||||||||||||||||
Revenue of acquiree since acquisition date | 4,625 | |||||||||||||||||||||||||||||||||||
Consolidated results | € (5,023) | |||||||||||||||||||||||||||||||||||
Fractionation capacity (in liters) | l | 1,500,000 | |||||||||||||||||||||||||||||||||||
Collection volume of plasma achieved by collection centers (in liters) | l | 350,000 | |||||||||||||||||||||||||||||||||||
Period for supply of certain output of plasma | 24 months | |||||||||||||||||||||||||||||||||||
Consideration payable | € 387,917 | $ 457,160,000 | ||||||||||||||||||||||||||||||||||
Plasma Donor Centers | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 20,500 | |||||||||||||||||||||||||||||||||||
Total consideration paid | 20,500 | |||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 1,620 | |||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 18,880 | |||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | 20,500 | |||||||||||||||||||||||||||||||||||
Cash transferred | 20,500 | |||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | € 1,396 | |||||||||||||||||||||||||||||||||||
Interstated Blood Bank, Inc. Group | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 88,984 | $ 100,000,000 | € 88,215 | $ 100,000,000 | ||||||||||||||||||||||||||||||||
Total consideration paid | 88,984 | 100,000,000 | ||||||||||||||||||||||||||||||||||
Fair value of the previous investment in the company | 94,126 | 105,779,000 | ||||||||||||||||||||||||||||||||||
Fair value of the call option | 8,898 | 10,000,000 | ||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 19,345 | 21,744,000 | ||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 172,663 | 194,035,000 | ||||||||||||||||||||||||||||||||||
Purchase price for the remaining stakes | $ | 100,000,000 | |||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | 88,984 | 100,000,000 | ||||||||||||||||||||||||||||||||||
Cash transferred | 88,984 | 100,000,000 | 88,215 | 100,000,000 | ||||||||||||||||||||||||||||||||
Development costs in progress | 77 | 87,000 | ||||||||||||||||||||||||||||||||||
Non current liabilities | 10,233 | 11,500,000 | ||||||||||||||||||||||||||||||||||
Consolidated results | 280 | |||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | 23,724 | $ 26,661,000 | ||||||||||||||||||||||||||||||||||
Agreed payment amount for call option | € 9,007 | $ 10,000,000 | ||||||||||||||||||||||||||||||||||
Number of blood donation centers | Center | 9 | 9 | ||||||||||||||||||||||||||||||||||
Number of plasma collection centers | Center | 26 | 26 | ||||||||||||||||||||||||||||||||||
Number of laboratories | item | 1 | 1 | ||||||||||||||||||||||||||||||||||
Increase (decrease) in combined revenue had the acquisition taken place on January 1 | € 10,146 | |||||||||||||||||||||||||||||||||||
Increase (decrease) in combined profit had the acquisition taken place on January 1 | € (1,436) | |||||||||||||||||||||||||||||||||||
Revenue of acquiree since acquisition date | 13,364 | |||||||||||||||||||||||||||||||||||
Consolidated results | € 280 | |||||||||||||||||||||||||||||||||||
Variation between the fair value of the previous investment and the book value | € 4,521 | |||||||||||||||||||||||||||||||||||
Interstate Blood Bank, Inc | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Percentage of voting equity interests acquired | 49.19% | 49.19% | ||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 49.19% | 49.19% | ||||||||||||||||||||||||||||||||||
Bio Blood Components Inc. | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Percentage of voting equity interests acquired | 48.97% | 48.97% | ||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 48.97% | 48.97% | ||||||||||||||||||||||||||||||||||
Plasma Biological Services, LLC. | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Percentage of voting equity interests acquired | 48.90% | 48.90% | ||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 48.90% | 48.90% | ||||||||||||||||||||||||||||||||||
Kedplasma Centers | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Number of Plasma Donation Centers Acquired | $ | 4 | |||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Number of plasma donation centers acquired | $ | 4 | |||||||||||||||||||||||||||||||||||
Goetech, LLC (USA) | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Percentage of voting equity interests acquired | 51.00% | 51.00% | 51.00% | |||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 51.00% | 51.00% | 51.00% | |||||||||||||||||||||||||||||||||
Kiro Grifols S.L. (Spain) | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Percentage of voting equity interests acquired | 40.00% | 40.00% | 40.00% | |||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 40.00% | 40.00% | 40.00% | |||||||||||||||||||||||||||||||||
GigaGen Inc. | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Second repurchase of non-controlling interests (discounted amount) | € 35,227 | $ 42,608,000 | ||||||||||||||||||||||||||||||||||
Total consideration | $ | 90,500,000 | |||||||||||||||||||||||||||||||||||
Total consideration paid | 73,428 | 88,811,000 | ||||||||||||||||||||||||||||||||||
Consideration paid | 38,201 | $ 46,203,000 | € 38,201 | |||||||||||||||||||||||||||||||||
Fair value of the previous investment in the company | 50,792 | 61,434,000 | ||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 18,760 | 22,691,000 | ||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 105,460 | 127,554,000 | ||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | € 73,428 | $ 88,811,000 | ||||||||||||||||||||||||||||||||||
Percentage of voting equity interests acquired | 100.00% | 100.00% | ||||||||||||||||||||||||||||||||||
Percentage of shareholding | 100.00% | 100.00% | ||||||||||||||||||||||||||||||||||
Development costs in progress | € 24,027 | $ 29,061,000 | ||||||||||||||||||||||||||||||||||
Consolidated results | € 4,350 | |||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Proportion of ownership interest in associate | 100.00% | 100.00% | ||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | € 1,168 | $ 1,413,000 | ||||||||||||||||||||||||||||||||||
Transaction costs | € 404 | |||||||||||||||||||||||||||||||||||
Ownership interest in entity, prior to acquisition of remaining shares (as a percent) | 43.96% | |||||||||||||||||||||||||||||||||||
Ownership interest acquired (as a percent) | 100.00% | 100.00% | ||||||||||||||||||||||||||||||||||
Consolidated results | 4,350 | |||||||||||||||||||||||||||||||||||
Variation between the fair value of the previous investment and the book value | € 34,525 | $ 41,758,000 | ||||||||||||||||||||||||||||||||||
Amounts payable | € 36,591 | € 36,591 | ||||||||||||||||||||||||||||||||||
BPL Plasma, Inc. | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
First payment performed | 9,921 | $ 12,000,000 | ||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | 308,016 | 372,548,000 | ||||||||||||||||||||||||||||||||||
Total consideration paid | 317,937 | 384,548,000 | ||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 15,039 | 18,190,000 | ||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 302,898 | 366,358,000 | ||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | 317,937 | 384,548,000 | ||||||||||||||||||||||||||||||||||
Cash transferred | € 308,016 | $ 372,548,000 | ||||||||||||||||||||||||||||||||||
Number of Plasma Donation Centers Acquired | 25 | |||||||||||||||||||||||||||||||||||
Quantity of Plasma Obtained | l | 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||
Acquisition, First Cash Transferred | € 9,921 | $ 12,000,000 | ||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | 14,406 | $ 17,424,000 | ||||||||||||||||||||||||||||||||||
Transaction costs | € 2,764 | |||||||||||||||||||||||||||||||||||
Number of plasma donation centers acquired | 25 | |||||||||||||||||||||||||||||||||||
Quantity of plasma obtained (in liters) | l | 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||
Kedplasma, LLC | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
First repurchase of non-controlling interests | € 45,638 | $ 55,200,000 | ||||||||||||||||||||||||||||||||||
Total consideration paid | 45,638 | 55,200,000 | ||||||||||||||||||||||||||||||||||
Fair value of net assets acquired | 2,692 | 3,256,000 | ||||||||||||||||||||||||||||||||||
Goodwill (excess of the cost of the business combination over the fair value of net assets acquired) (note 7) | 42,946 | 51,944,000 | ||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | 45,638 | 55,200,000 | ||||||||||||||||||||||||||||||||||
Cash transferred | € 45,638 | $ 55,200,000 | ||||||||||||||||||||||||||||||||||
Number of Plasma Donation Centers Acquired | 7 | |||||||||||||||||||||||||||||||||||
Quantity of Plasma Obtained | l | 240,000 | 240,000 | ||||||||||||||||||||||||||||||||||
Other disclosures: | ||||||||||||||||||||||||||||||||||||
Property, plant and equipment recognised as of acquisition date | € 2,448 | $ 2,961,000 | ||||||||||||||||||||||||||||||||||
Transaction costs | € 625 | |||||||||||||||||||||||||||||||||||
Number of plasma donation centers acquired | 7 | |||||||||||||||||||||||||||||||||||
Quantity of plasma obtained (in liters) | l | 240,000 | 240,000 | ||||||||||||||||||||||||||||||||||
Prometic Plasma Resources, Inc. | ||||||||||||||||||||||||||||||||||||
Business Combinations | ||||||||||||||||||||||||||||||||||||
Total consideration paid | $ | $ 8,805,000 | |||||||||||||||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | $ | $ 8,805,000 |
Business Combinations - Amounts
Business Combinations - Amounts Determined at Acquisition (Details) € in Thousands, $ in Thousands | Dec. 31, 2021USD ($) | Mar. 31, 2021USD ($) | Mar. 31, 2021EUR (€) | Mar. 08, 2021USD ($) | Mar. 08, 2021EUR (€) | Feb. 28, 2021USD ($) | Feb. 28, 2021EUR (€) | Oct. 01, 2020USD ($) | Oct. 01, 2020EUR (€) | Sep. 02, 2020USD ($) | Sep. 02, 2020EUR (€) | Jul. 20, 2020USD ($) | Jul. 20, 2020EUR (€) | Apr. 14, 2020EUR (€) | Apr. 30, 2019USD ($) | Apr. 30, 2019EUR (€) |
Interstated Blood Bank, Inc. Group | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Cash and cash equivalents | $ 2,204 | € 1,961 | ||||||||||||||
Trade and other receivables | 13,575 | 12,080 | ||||||||||||||
Inventories | 11,543 | 10,271 | ||||||||||||||
Intangible assets | 87 | 77 | ||||||||||||||
Property, plant and equipment | 26,661 | 23,724 | ||||||||||||||
Other current assets | 2,265 | 2,015 | ||||||||||||||
Goodwill | 194,035 | 172,663 | ||||||||||||||
Total assets | 56,335 | 50,128 | ||||||||||||||
Long-term liabilities | (11,500) | (10,233) | ||||||||||||||
Current liabilities | (23,091) | (20,550) | ||||||||||||||
Total liabilities and contingent liabilities | (34,591) | (30,783) | ||||||||||||||
Total net assets acquired | 21,744 | 19,345 | ||||||||||||||
Total consideration paid | $ 100,000 | € 88,984 | ||||||||||||||
Plasmavita Healthcare | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Cash and cash equivalents | € 359 | |||||||||||||||
Trade and other receivables | 811 | |||||||||||||||
Inventories | 1,114 | |||||||||||||||
Rights of use | 7,856 | |||||||||||||||
Intangible assets | 177 | |||||||||||||||
Investment in group companies | 9,548 | |||||||||||||||
Non-current financial assets | 5,017 | |||||||||||||||
Property, plant and equipment | 6,506 | |||||||||||||||
Other current assets | 333 | |||||||||||||||
Goodwill | 9,987 | |||||||||||||||
Total assets | 31,721 | |||||||||||||||
Deferred tax liabilites | (1,364) | |||||||||||||||
Other non current liabilities | (7,575) | |||||||||||||||
Current liabilities | (1,408) | |||||||||||||||
Total liabilities and contingent liabilities | (10,347) | |||||||||||||||
Total net assets acquired | 21,374 | |||||||||||||||
Total consideration paid | € 10,000 | |||||||||||||||
Alkahest, Inc. | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Cash and cash equivalents | $ 8,946 | € 7,563 | ||||||||||||||
Trade and other receivables | 3,019 | 2,552 | ||||||||||||||
Intangible assets | 314,198 | 265,617 | ||||||||||||||
Property, plant and equipment | 5,879 | 4,970 | ||||||||||||||
Other non-current assets | 210 | 178 | ||||||||||||||
Other current assets | 1,904 | 1,610 | ||||||||||||||
Goodwill | 87,975 | 74,372 | ||||||||||||||
Total assets | 334,156 | 282,489 | ||||||||||||||
Non-current financial liabilities | (50,000) | (42,269) | ||||||||||||||
Trade and other payables | (2,204) | (1,863) | ||||||||||||||
Deferred tax liabilites | (87,975) | (74,372) | ||||||||||||||
Other non current liabilities | (23,237) | (19,644) | ||||||||||||||
Other current liabilities | (5,044) | (4,264) | ||||||||||||||
Total liabilities and contingent liabilities | (168,460) | (142,413) | ||||||||||||||
Total net assets acquired | 165,696 | 140,076 | ||||||||||||||
Total consideration paid | $ 146,000 | € 123,425 | ||||||||||||||
Green Cross | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Cash and cash equivalents | $ 7,133 | € 6,053 | ||||||||||||||
Trade and other receivables | 4,106 | 3,484 | ||||||||||||||
Inventories | 3,534 | 2,999 | ||||||||||||||
Rights of use | 13,720 | 11,642 | ||||||||||||||
Intangible assets | 3,390 | 2,877 | ||||||||||||||
Property, plant and equipment | 186,377 | 158,148 | ||||||||||||||
Other current assets | 1,111 | 943 | ||||||||||||||
Deferred tax assets | 38,986 | 33,081 | ||||||||||||||
Non-current assets | 144 | 122 | ||||||||||||||
Goodwill | 228,263 | 193,690 | ||||||||||||||
Total assets | 258,501 | 219,349 | ||||||||||||||
Non-current financial liabilities | (15,497) | (13,150) | ||||||||||||||
Trade and other payables | (13,168) | (11,175) | ||||||||||||||
Current financial liabilities | (939) | (797) | ||||||||||||||
Total liabilities and contingent liabilities | (29,604) | (25,122) | ||||||||||||||
Total net assets acquired | $ 228,897 | € 194,227 | ||||||||||||||
Total consideration paid | $ 457,160 | € 387,917 | ||||||||||||||
BPL Plasma, Inc. | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Inventories | $ 674 | € 557 | ||||||||||||||
Non-current financial assets | 103 | 85 | ||||||||||||||
Property, plant and equipment | 17,424 | 14,406 | ||||||||||||||
Goodwill | 366,358 | 302,898 | ||||||||||||||
Total assets | 18,201 | 15,048 | ||||||||||||||
Current liabilities | (11) | (9) | ||||||||||||||
Total liabilities and contingent liabilities | (11) | (9) | ||||||||||||||
Total net assets acquired | 18,190 | 15,039 | ||||||||||||||
Total consideration paid | $ 384,548 | € 317,937 | ||||||||||||||
GigaGen Inc. | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Cash and cash equivalents | $ 14,985 | € 12,389 | ||||||||||||||
Trade and other receivables | 68 | 56 | ||||||||||||||
Intangible assets | 29,061 | 24,027 | ||||||||||||||
Non-current financial assets | 183 | 151 | ||||||||||||||
Property, plant and equipment | 1,413 | 1,168 | ||||||||||||||
Other current assets | 2,864 | 2,368 | ||||||||||||||
Goodwill | 127,554 | 105,460 | ||||||||||||||
Total assets | 48,574 | 40,159 | ||||||||||||||
Non-current financial liabilities | (21,520) | (17,792) | ||||||||||||||
Current liabilities | (4,363) | (3,607) | ||||||||||||||
Total liabilities and contingent liabilities | (25,883) | (21,399) | ||||||||||||||
Total net assets acquired | 22,691 | 18,760 | ||||||||||||||
Total consideration paid | $ 88,811 | € 73,428 | ||||||||||||||
Kedplasma, LLC | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Inventories | $ 295 | € 244 | ||||||||||||||
Property, plant and equipment | 2,961 | 2,448 | ||||||||||||||
Goodwill | 51,944 | 42,946 | ||||||||||||||
Total assets | 3,256 | 2,692 | ||||||||||||||
Total net assets acquired | 3,256 | 2,692 | ||||||||||||||
Total consideration paid | $ 55,200 | € 45,638 | ||||||||||||||
Prometic Plasma Resources, Inc. | ||||||||||||||||
Amounts determined at the date of acquisition of assets, liabilities and contingent liabilities: | ||||||||||||||||
Total consideration paid | $ | $ 8,805 |
Significant Accounting Polici_4
Significant Accounting Policies - Property, plant and equipment (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Buildings | Minimum | |
Property, Plant and Equipment | |
Depreciation rates | 1.00% |
Buildings | Maximum | |
Property, Plant and Equipment | |
Depreciation rates | 3.00% |
Other property, technical equipment and machinery | Minimum | |
Property, Plant and Equipment | |
Depreciation rates | 4.00% |
Other property, technical equipment and machinery | Maximum | |
Property, Plant and Equipment | |
Depreciation rates | 10.00% |
Other property, plant and equipment | Minimum | |
Property, Plant and Equipment | |
Depreciation rates | 7.00% |
Other property, plant and equipment | Maximum | |
Property, Plant and Equipment | |
Depreciation rates | 33.00% |
Significant Accounting Polici_5
Significant Accounting Policies - Intangible assets (Details) € in Thousands | 12 Months Ended |
Dec. 31, 2021EUR (€) | |
Other Intangible Assets | |
Impairment loss | € 0 |
Development costs | |
Other Intangible Assets | |
Amortization rates | 10.00% |
Computer software | |
Other Intangible Assets | |
Amortization rates | 33.00% |
Minimum | Concessions, patents, licenses brands & similar | |
Other Intangible Assets | |
Amortization rates | 4.00% |
Minimum | Currently marketed products | |
Other Intangible Assets | |
Amortization rates | 3.00% |
Maximum | Concessions, patents, licenses brands & similar | |
Other Intangible Assets | |
Amortization rates | 20.00% |
Maximum | Currently marketed products | |
Other Intangible Assets | |
Amortization rates | 10.00% |
Significant Accounting Polici_6
Significant Accounting Policies - Financial instruments (Details) € in Thousands | Dec. 31, 2021EUR (€) |
Significant Accounting Policies | |
Interest rate used as a threshold to determine if there has been a substantial modification to the initially recognized financial liability | 10.00% |
Provision for future operating losses | € 0 |
Financial Risk Management Pol_3
Financial Risk Management Policy - Concentration of credit risk, Liquidity Risk and Interest Rate Risk (Details) € in Thousands, $ in Millions | 1 Months Ended | 12 Months Ended | |||||||||||
Sep. 30, 2018EUR (€) | Dec. 31, 2021EUR (€)item | Dec. 31, 2021USD ($)item | Oct. 31, 2021EUR (€)item | Oct. 31, 2021USD ($)item | Oct. 05, 2021EUR (€) | Oct. 05, 2021USD ($) | Dec. 31, 2020EUR (€) | May 07, 2020USD ($) | May 06, 2020USD ($) | Nov. 15, 2019EUR (€)item | Nov. 15, 2019USD ($)item | Apr. 18, 2017EUR (€) | |
Financial Risk Management Policy | |||||||||||||
Number of bonds issued | item | 2 | 2 | |||||||||||
Cash position | € 655,493 | € 579,647 | |||||||||||
Trade receivables, Collection period | 30 days | ||||||||||||
Senior Debt | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Amount of borrowings refinanced | € 5,800,000 | ||||||||||||
Senior Secured Notes | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 1,675,000 | ||||||||||||
Number of bonds issued | item | 2 | 2 | |||||||||||
Senior Unsecured Notes | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 1,000,000 | ||||||||||||
Senior Unsecured Notes, Tranche one | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 1,400,000 | € 1,400,000 | |||||||||||
Senior Unsecured Notes, Tranche one | Euros | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 1,400,000 | ||||||||||||
Senior Unsecured Notes, Tranche two | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | $ | $ 705 | $ 705 | |||||||||||
Revolving Credit Facility, Maturing in 2025 | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Maximum borrowing capacity | $ | $ 500 | ||||||||||||
Carrying amount | $ | 330 | ||||||||||||
Revolving Credit Facility, Maturing in 2025 | Maximum | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Maximum borrowing capacity | $ | $ 1,000 | ||||||||||||
Senior notes | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | 4,697,462 | 2,675,000 | |||||||||||
EIB Loan | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Carrying amount | 180,625 | 212,500 | |||||||||||
EIB Loan, Maturing in 2028 | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 85,000 | ||||||||||||
Debt term | 10 years | ||||||||||||
Grace period | 2 years | ||||||||||||
Liquidity risk | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Number of bonds issued | item | 2 | 2 | |||||||||||
Cash position | 655,493 | 579,647 | |||||||||||
Unused credit facility | 621,989 | 922,553 | |||||||||||
Liquidity risk | Term Loan B | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 1,360,000 | $ 2,500 | |||||||||||
Liquidity risk | Senior Secured Notes | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 1,675,000 | ||||||||||||
Liquidity risk | Senior Unsecured Notes, Tranche one | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 1,400,000 | $ 705 | |||||||||||
Liquidity risk | Senior Unsecured Notes, Tranche two | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | $ | $ 705 | ||||||||||||
Liquidity risk | Revolving Credit Facility, Maturing in 2025 | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Unused credit facility | 534,429 | 817,394 | |||||||||||
Liquidity risk | Revolving Credit Facility, Maturing in 2025 | Maximum | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Maximum borrowing capacity | $ | $ 500 | ||||||||||||
Liquidity risk | EIB Loan | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Carrying amount | € 180,625 | € 212,500 | |||||||||||
Liquidity risk | EIB Loan, Maturing in 2028 | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 85,000 | ||||||||||||
Debt term | 10 years | ||||||||||||
Grace period | 2 years | ||||||||||||
Interest rate risk | Senior Debt | Euros | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Percentage of total senior debt in euros of the Group's total senior debt | 38.00% | 38.00% | 40.00% | ||||||||||
Interest rate risk | Senior notes | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Principal amount | € 4,878,000 | ||||||||||||
Interest rate risk | Senior notes | Euros | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Percentage of fixed rate interest debt of the total debt | 60.00% | 60.00% | 46.00% | ||||||||||
Currency risk | Currency swaps | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Exposure to risk | $ | $ 500 | ||||||||||||
Currency risk | Euros | |||||||||||||
Financial Risk Management Policy | |||||||||||||
Exposure to risk | € 159,840 | € 190,824 |
Financial Risk Management Pol_4
Financial Risk Management Policy - Capital Management (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Financial Risk Management Policy | |||
Profit attributable to the Parent | € 188,726 | € 618,546 | € 625,146 |
Equity attributable to the Parent | € 5,523,609 | € 5,108,392 | |
Return on equity | 3.00% | 12.00% | |
Treasury stock as a percentage of capital, held by parent | 1.31% | 0.40% |
Segment Reporting - Additional
Segment Reporting - Additional Information (Details) | 12 Months Ended |
Dec. 31, 2021segmentarealocation | |
Segment Reporting | |
Number of areas Group companies are divided into | area | 4 |
Geographical information | |
Number of geographical areas | location | 4 |
Number of geographical segments | segment | 4 |
Segment Reporting - Net Sales b
Segment Reporting - Net Sales by Groups of Products (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | € 4,933,118 | € 5,340,038 | € 5,098,691 |
Haemoderivatives | |||
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | 3,814,983 | 4,242,502 | 3,993,462 |
Transfusional medicine | |||
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | 712,238 | 714,164 | 680,766 |
Other diagnostic | |||
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | 23,625 | 27,630 | 19,937 |
Fluid therapy and nutrition | |||
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | 46,670 | 41,359 | 47,677 |
Hospital supplies | |||
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | 70,217 | 58,303 | 67,489 |
Bio supplies | |||
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | 225,765 | 224,090 | 266,540 |
Other Product | |||
Net sales by groups of products | |||
Net revenue (notes 6 and 24) | € 39,620 | € 31,990 | € 22,820 |
Segment Reporting - Main Custom
Segment Reporting - Main Customer (Details) - customer | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of major customers | |||
Number of customers | 0 | 0 | |
Percentage of entity's revenue (as a percent) | 10.00% | 10.00% | |
Goods or services recognized at point in time | |||
Disclosure of major customers | |||
Percentage of entity's revenue (as a percent) | 97.40% | 97.50% | 97.20% |
Bioscience | Customer | |||
Disclosure of major customers | |||
Number of customers | 1 | ||
Percentage of entity's revenue (as a percent) | 10.38% |
Goodwill - Details of and movem
Goodwill - Details of and movement in goodwill (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Goodwill | ||
Goodwill at beginning of the year | € 5,332,271 | € 5,507,063 |
Business Combination | 461,971 | 269,101 |
Disposals | (12,902) | |
Transfer | 0 | |
Translation differences | 434,659 | (430,991) |
Goodwill at end of the year | 6,228,901 | 5,332,271 |
Grifols UK Ltd. (UK) | ||
Goodwill | ||
Goodwill at beginning of the year | 7,674 | 8,107 |
Translation differences | 511 | (433) |
Goodwill at end of the year | 8,185 | 7,674 |
Grifols Italia S.p.A. (Italy) | ||
Goodwill | ||
Goodwill at beginning of the year | 6,118 | 6,118 |
Goodwill at end of the year | 6,118 | 6,118 |
Biomat USA, Inc. (USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 234,791 | 255,896 |
Business Combination | 345,844 | |
Transfer | 51,364 | |
Translation differences | 44,322 | (21,105) |
Goodwill at end of the year | 676,321 | 234,791 |
Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) | ||
Goodwill | ||
Goodwill at beginning of the year | 9,538 | 9,472 |
Translation differences | 214 | 66 |
Goodwill at end of the year | 9,752 | 9,538 |
Grifols Therapeutics, Inc. (USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 1,816,404 | 1,979,678 |
Translation differences | 145,620 | (163,274) |
Goodwill at end of the year | 1,962,024 | 1,816,404 |
Araclon Biotech, S.L. (Spain) | ||
Goodwill | ||
Goodwill at beginning of the year | 6,000 | 6,000 |
Business Combination | (6,000) | |
Goodwill at end of the year | 6,000 | |
Progenika Biopharma, S.A. (Spain) | ||
Goodwill | ||
Goodwill at beginning of the year | 40,516 | 40,516 |
Goodwill at end of the year | 40,516 | 40,516 |
Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) | ||
Goodwill | ||
Goodwill at beginning of the year | 2,376,978 | 2,600,950 |
Disposals | (12,902) | |
Translation differences | 188,515 | (211,070) |
Goodwill at end of the year | 2,565,493 | 2,376,978 |
Kiro Grifols S.L. (Spain) | ||
Goodwill | ||
Goodwill at beginning of the year | 24,376 | 24,376 |
Goodwill at end of the year | 24,376 | 24,376 |
Goetech, LLC (USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 55,167 | 60,126 |
Translation differences | 4,423 | (4,959) |
Goodwill at end of the year | 59,590 | 55,167 |
Haema AG. | ||
Goodwill | ||
Goodwill at beginning of the year | 190,014 | 190,014 |
Goodwill at end of the year | 190,014 | 190,014 |
BPC Plasma, Inc. (formerly Biotest Pharma Corp; USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 140,334 | 152,948 |
Translation differences | 11,250 | (12,614) |
Goodwill at end of the year | 151,584 | 140,334 |
Interstate Blood Bank, Inc. (USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 158,479 | 172,862 |
Translation differences | 12,705 | (14,383) |
Goodwill at end of the year | 171,184 | 158,479 |
Plasmavita Healthcare GmbH (Germany) | ||
Goodwill | ||
Goodwill at beginning of the year | 9,987 | |
Business Combination | 9,987 | |
Goodwill at end of the year | 9,987 | |
Alkahest, Inc. (USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 71,910 | |
Business Combination | 74,372 | |
Translation differences | (2,462) | |
Goodwill at end of the year | 71,910 | |
Green Cross Biotherapeutics, Inc. (Canada) | ||
Goodwill | ||
Goodwill at beginning of the year | 134,569 | |
Business Combination | 133,443 | |
Translation differences | 1,126 | |
Goodwill at end of the year | 134,569 | |
Green Cross America Inc. (USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 49,416 | |
Business Combination | 51,299 | |
Translation differences | (1,883) | |
Goodwill at end of the year | 49,416 | |
Plasmavita Healthcare GmbH (Alemania) | ||
Goodwill | ||
Goodwill at beginning of the year | 9,987 | |
Goodwill at end of the year | 9,987 | 9,987 |
Alkahest, Inc (EEUU) | ||
Goodwill | ||
Goodwill at beginning of the year | 71,910 | |
Translation differences | 5,765 | |
Goodwill at end of the year | 77,675 | 71,910 |
Grifols Canada Therapeutics, Inc (formerly Green Cross Biotherapeutics, Inc.) (Canada) | ||
Goodwill | ||
Goodwill at beginning of the year | 134,569 | |
Business Combination | 16,667 | |
Translation differences | 12,225 | |
Goodwill at end of the year | 163,461 | 134,569 |
GCAM, Inc (formerly Green Cross America Inc.) (USA) | ||
Goodwill | ||
Goodwill at beginning of the year | 49,416 | |
Transfer | (51,364) | |
Translation differences | 1,948 | |
Goodwill at end of the year | € 49,416 | |
GigaGen, Inc (ver nota 3) | ||
Goodwill | ||
Business Combination | 105,460 | |
Translation differences | 7,161 | |
Goodwill at end of the year | € 112,621 |
Goodwill - Impairment testing (
Goodwill - Impairment testing (Details) - EUR (€) € in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Impairment Testing | ||
Term of the government bonds | 10 years | |
Stock market capitalization | € 9,834 | € 14,207 |
Kiro Grifols S.L. (Spain) | ||
Impairment Testing | ||
Percentage of voting equity interests acquired | 40.00% | |
Goetech, LLC (USA) | ||
Impairment Testing | ||
Percentage of voting equity interests acquired | 51.00% | |
Bioscience | ||
Impairment Testing | ||
Perpetual growth rate | 2.00% | 1.90% |
Pre-tax discount rate | 9.00% | 8.90% |
Diagnostic | ||
Impairment Testing | ||
Perpetual growth rate | 2.00% | 1.90% |
Pre-tax discount rate | 9.30% | 9.50% |
Hospital | ||
Impairment Testing | ||
Perpetual growth rate | 1.50% | 1.40% |
Pre-tax discount rate | 10.90% | 10.80% |
Goodwill - Schedule of reasonab
Goodwill - Schedule of reasonable possible changes (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Bioscience | |
Disclosure of information for cash-generating units [line items] | |
Reasonably possible change in perpetual growth rate (as a percent) | 50.00% |
Reasonably possible change in pre-tax discount rate (as a percent) | 50.00% |
Diagnostic | |
Disclosure of information for cash-generating units [line items] | |
Reasonably possible change in perpetual growth rate (as a percent) | 50.00% |
Reasonably possible change in pre-tax discount rate (as a percent) | 50.00% |
Hospital | |
Disclosure of information for cash-generating units [line items] | |
Reasonably possible change in perpetual growth rate (as a percent) | 100.00% |
Reasonably possible change in pre-tax discount rate (as a percent) | 100.00% |
Other Intangible Assets - Curre
Other Intangible Assets - Currently marketed products acquired from Talecris and Progenika (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Other Intangible Assets | ||
Intangible assets at beginning of the year | € 1,557,650 | € 1,433,534 |
Translation differences | 116,373 | (118,796) |
Intangible assets at end of the year | 1,636,950 | 1,557,650 |
Gross carrying amount | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | 2,370,373 | 2,195,126 |
Translation differences | 168,039 | (168,404) |
Intangible assets at end of the year | 2,615,965 | 2,370,373 |
Accumulated depreciation and amortisation | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | (747,594) | (693,948) |
Translation differences | (46,768) | 44,116 |
Intangible assets at end of the year | (908,915) | (747,594) |
Currently marketed products. | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | 672,697 | 770,715 |
Additions | (35,989) | (37,739) |
Translation differences | 51,809 | (60,279) |
Intangible assets at end of the year | 688,517 | 672,697 |
Currently marketed products. | Gross carrying amount | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | 1,004,665 | 1,092,834 |
Translation differences | 78,636 | (88,169) |
Intangible assets at end of the year | 1,083,301 | 1,004,665 |
Currently marketed products. | Accumulated depreciation and amortisation | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | (331,968) | (322,119) |
Translation differences | (26,827) | 27,890 |
Intangible assets at end of the year | € (394,784) | € (331,968) |
Talecris | Currently marketed products. | ||
Other Intangible Assets | ||
Estimated useful life | 30 years | 30 years |
Residual useful life | 19 years 5 months | 20 years 5 months |
Talecris | Currently marketed products. | Gross carrying amount | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | € 980,873 | € 1,069,042 |
Translation differences | 78,636 | (88,169) |
Intangible assets at end of the year | 1,059,509 | 980,873 |
Talecris | Currently marketed products. | Accumulated depreciation and amortisation | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | (313,335) | (305,865) |
Additions | (33,610) | (35,360) |
Translation differences | (26,827) | 27,890 |
Intangible assets at end of the year | € (373,772) | € (313,335) |
Progenika Biopharma, S.A. (Spain) | Currently marketed products. | ||
Other Intangible Assets | ||
Estimated useful life | 10 years | 10 years |
Residual useful life | 1 year 2 months | 2 years 2 months |
Progenika Biopharma, S.A. (Spain) | Currently marketed products. | Gross carrying amount | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | € 23,792 | € 23,792 |
Intangible assets at end of the year | 23,792 | 23,792 |
Progenika Biopharma, S.A. (Spain) | Currently marketed products. | Accumulated depreciation and amortisation | ||
Other Intangible Assets | ||
Intangible assets at beginning of the year | (18,633) | (16,254) |
Additions | (2,379) | (2,379) |
Translation differences | 0 | |
Intangible assets at end of the year | € (21,012) | € (18,633) |
Other Intangible Assets - Other
Other Intangible Assets - Others (Details) € in Thousands, $ in Millions | 12 Months Ended | |||
Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2019EUR (€) | |
Other Intangible Assets | ||||
Other intangible assets | € 1,636,950 | € 1,557,650 | € 1,433,534 | |
Intangible asset purchase commitments | 431 | 9 | ||
Profit (loss) incurred on disposals of intangible assets | 30 | 0 | ||
Plasma center licenses | ||||
Other Intangible Assets | ||||
Other intangible assets | 29,394 | 27,351 | ||
Regulatory milestones - initial payment | ||||
Other Intangible Assets | ||||
Other intangible assets | $ | $ 30 | |||
Regulatory milestones - additional payment | ||||
Other Intangible Assets | ||||
Other intangible assets | $ | $ 17.5 | |||
Development costs in progress | ||||
Other Intangible Assets | ||||
Other intangible assets | 432,534 | 350,626 | ||
Self-constructed | ||||
Other Intangible Assets | ||||
Other intangible assets | € 34,034 | € 32,548 |
Leases - Details of leases in t
Leases - Details of leases in the consolidated balance sheet (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Total right-of-use assets | € 795,657 | € 678,696 | € 703,858 |
Lease liabilities | |||
Non-current | 825,157 | 690,857 | |
Current | 48,567 | 42,642 | |
Lease liability recognised | 873,724 | 733,499 | |
Land and Buildings | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Total right-of-use assets | 782,125 | 665,002 | |
Machinery | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Total right-of-use assets | 5,283 | 3,671 | |
Computer equipment | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Total right-of-use assets | 2,044 | 3,588 | |
Vehicles | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Total right-of-use assets | € 6,205 | € 6,435 |
Leases - Leases After IFRS 16 a
Leases - Leases After IFRS 16 application - Maturity detail (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Leases | ||
Additions to right-of-use assets | € 133,442 | € 75,077 |
Leases - Amounts recognized in
Leases - Amounts recognized in the consolidated statement of profit and loss (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Right-of-use depreciation | € 66,720 | € 62,580 | |
Finance lease expenses | 35,786 | 35,205 | € 34,558 |
Expenses related to short-term contracts | 3,106 | 3,569 | |
Expenses related to low-value contracts | 13,404 | 11,254 | |
Other operating lease expenses | 16,435 | 13,353 | |
Total operating lease expenses | 32,945 | 28,176 | € 33,235 |
Lease payments | 82,692 | 79,037 | |
Accumulated depreciation and amortisation | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Right-of-use depreciation | 66,720 | 62,580 | |
Buildings | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Right-of-use depreciation | 57,901 | 52,774 | |
Machinery | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Right-of-use depreciation | 2,120 | 1,588 | |
Computer equipment | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Right-of-use depreciation | 2,269 | 3,012 | |
Vehicles | |||
DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems | |||
Right-of-use depreciation | € 4,430 | € 5,206 |
Property, Plant and Equipment -
Property, Plant and Equipment - Activity (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Property, Plant and Equipment | |||
Capitalized interests | € 18,636 | € 16,606 | € 14,894 |
Losses on disposals of property, plant and equipment | € 2,720 | € 150 |
Property, Plant and Equipment_2
Property, Plant and Equipment - Self Constructed PP&E and Commitments (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Property, Plant and Equipment | |||
Property, plant and equipment (note 10) | € 2,547,497 | € 2,324,107 | € 2,159,545 |
Self-constructed property, plant and equipment | |||
Property, Plant and Equipment | |||
Property, plant and equipment (note 10) | € 87,885 | € 85,691 |
Property, Plant and Equipment_3
Property, Plant and Equipment - Purchase Commitments (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment | ||
Purchase commitments | € 40,596 | € 44,007 |
Property, Plant and Equipment_4
Property, Plant and Equipment - Impairment Testing (Details) € in Millions | 12 Months Ended |
Dec. 31, 2021EUR (€) | |
Property, Plant and Equipment | |
Impairment | € 11.5 |
Equity-Accounted Investees - Ow
Equity-Accounted Investees - Ownership and Carrying Amount (Details) - EUR (€) € in Thousands | Jul. 29, 2021 | Mar. 30, 2020 | Oct. 22, 2018 | Jul. 05, 2017 | Jan. 12, 2017 | Mar. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Equity-Accounted investees | ||||||||||
Carrying value | € 1,999,776 | € 1,869,020 | € 114,472 | € 226,905 | ||||||
Total equity accounted investees with similar activity to that of the Group. | ||||||||||
Equity-Accounted investees | ||||||||||
Carrying value | € 1,994,707 | € 1,847,360 | 60,289 | 147,289 | ||||||
Access Biologicals | ||||||||||
Equity-Accounted investees | ||||||||||
Ownership interest (as a percent) | 49.00% | 49.00% | 49.00% | |||||||
Carrying value | € 53,264 | € 46,782 | ||||||||
Shanghai RAAS Blood Products Co., Ltd. | ||||||||||
Equity-Accounted investees | ||||||||||
Ownership interest (as a percent) | 26.20% | 26.20% | 26.20% | 26.20% | ||||||
Carrying value | € 1,909,596 | € 1,800,578 | ||||||||
Grifols Egypt Plasma Derivatives [Member] | ||||||||||
Equity-Accounted investees | ||||||||||
Ownership interest (as a percent) | 49.00% | 49.00% | 0.00% | |||||||
Carrying value | € 31,847 | |||||||||
Total of the rest of equity accounted investees [Member] | ||||||||||
Equity-Accounted investees | ||||||||||
Carrying value | € 5,069 | € 21,660 | 54,183 | 79,616 | ||||||
Albajuna Therapeutics, S.L. | ||||||||||
Equity-Accounted investees | ||||||||||
Ownership interest (as a percent) | 49.00% | 49.00% | ||||||||
Carrying value | € 1,910 | € 3,378 | ||||||||
GigaGen Inc. | ||||||||||
Equity-Accounted investees | ||||||||||
Ownership interest (as a percent) | 43.96% | 100.00% | 43.96% | |||||||
Carrying value | € 15,677 | 23,997 | 28,363 | |||||||
Mecwins, S.A | ||||||||||
Equity-Accounted investees | ||||||||||
Ownership interest (as a percent) | 24.99% | 24.99% | 24.99% | |||||||
Carrying value | € 3,159 | € 2,605 | € 2,338 | € 2,555 |
Equity-Accounted Investees - Eq
Equity-Accounted Investees - Equity accounted investees - Movements In Investments Carrying Amount (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | € 1,869,020 | € 114,472 | € 226,905 |
Acquisitions | 31,314 | 1,807,351 | 12,369 |
Transfers | (50,794) | (101,697) | (94,127) |
Share of profit / (losses) | 65,743 | 88,877 | (10,772) |
Share of other comprehensive income / translation differences | 95,941 | (21,916) | 4,360 |
Impairment losses | (7,912) | (19,794) | |
Collected dividends | (11,448) | (10,155) | (4,469) |
Balance at 31 December | 1,999,776 | 1,869,020 | 114,472 |
Total equity accounted investees with similar activity to that of the Group. | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 1,847,360 | 60,289 | 147,289 |
Acquisitions | 30,454 | 1,807,351 | |
Transfers | (10,674) | (94,127) | |
Share of profit / (losses) | 32,555 | 20,799 | 8,972 |
Share of other comprehensive income / translation differences | 95,786 | (20,250) | 2,624 |
Collected dividends | (11,448) | (10,155) | (4,469) |
Balance at 31 December | 1,994,707 | 1,847,360 | 60,289 |
Access Biologicals, LLC. | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 46,782 | 49,921 | 47,742 |
Share of profit / (losses) | 8,298 | 8,962 | 3,938 |
Share of other comprehensive income / translation differences | 3,929 | (4,160) | 966 |
Collected dividends | (5,745) | (7,941) | (2,725) |
Balance at 31 December | 53,264 | 46,782 | 49,921 |
IBBI Group | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 89,627 | ||
Transfers | (94,127) | ||
Share of profit / (losses) | 4,586 | ||
Share of other comprehensive income / translation differences | 1,658 | ||
Collected dividends | (1,744) | ||
Plasmavita Healthcare | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 10,368 | 9,920 | |
Transfers | (10,674) | ||
Share of profit / (losses) | 306 | 448 | |
Balance at 31 December | 10,368 | ||
Shanghai RAAS Blood Products Co., Ltd. | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 1,800,578 | ||
Acquisitions | 1,807,351 | ||
Share of profit / (losses) | 24,835 | 11,531 | |
Share of other comprehensive income / translation differences | 89,886 | (16,090) | |
Collected dividends | (5,703) | (2,214) | |
Balance at 31 December | 1,909,596 | 1,800,578 | |
Grifols Egypt Plasma Derivatives [Member] | |||
Movement in the investments in equity-accounted investees | |||
Acquisitions | 30,454 | ||
Share of profit / (losses) | (578) | ||
Share of other comprehensive income / translation differences | 1,971 | ||
Balance at 31 December | 31,847 | ||
Total of the rest of equity accounted investees [Member] | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 21,660 | 54,183 | 79,616 |
Acquisitions | 860 | 12,369 | |
Transfers | (50,794) | (91,023) | |
Share of profit / (losses) | 33,188 | 68,078 | (19,744) |
Share of other comprehensive income / translation differences | 155 | (1,666) | 1,736 |
Impairment losses | (7,912) | (19,794) | |
Balance at 31 December | 5,069 | 21,660 | 54,183 |
Alkahest, Inc. | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 14,708 | 28,336 | |
Transfers | (91,023) | ||
Share of profit / (losses) | 76,414 | (14,218) | |
Share of other comprehensive income / translation differences | (99) | 590 | |
Balance at 31 December | 14,708 | ||
Albajuna Therapeutics, S.L | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 3,378 | 5,228 | 1,106 |
Acquisitions | 3,750 | ||
Share of profit / (losses) | (1,463) | (1,878) | 383 |
Share of other comprehensive income / translation differences | (5) | 28 | (11) |
Balance at 31 December | 1,910 | 3,378 | 5,228 |
Singulex, Inc. | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 19,256 | ||
Share of other comprehensive income / translation differences | 538 | ||
Impairment losses | (19,794) | ||
GigaGen Inc. | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 15,677 | 23,997 | 28,363 |
Transfers | (50,794) | ||
Share of profit / (losses) | 34,957 | (6,725) | (5,002) |
Share of other comprehensive income / translation differences | 160 | (1,595) | 636 |
Balance at 31 December | 15,677 | 23,997 | |
Mecwins, S.A | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 2,605 | 2,338 | 2,555 |
Acquisitions | 860 | ||
Share of profit / (losses) | (306) | 267 | (217) |
Balance at 31 December | € 3,159 | 2,605 | 2,338 |
Medcom Advance, S.A | |||
Movement in the investments in equity-accounted investees | |||
Balance at 1 January | 7,912 | ||
Acquisitions | 8,619 | ||
Share of profit / (losses) | (690) | ||
Share of other comprehensive income / translation differences | (17) | ||
Impairment losses | € (7,912) | ||
Balance at 31 December | € 7,912 |
Equity-Accounted Investees - Gr
Equity-Accounted Investees - Grifols Egypt Plasma Derivatives (GEPD) and Shanghai RAAS Blood Products Co. Ltd (Details) $ in Thousands | Jul. 29, 2021EUR (€) | Jul. 29, 2021USD ($) | Mar. 30, 2020EUR (€) | Mar. 31, 2020EUR (€) | Mar. 31, 2019shares | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€)shares | Dec. 31, 2021¥ / shares | Dec. 31, 2020¥ / shares |
Disclosure of associates [line items] | ||||||||||
Change in fair value of financial instruments | € 246,000 | € 55,703,000 | € 1,326,000 | |||||||
Share capital | € 119,603,705 | 119,603,705 | ||||||||
Shanghai RAAS Blood Products Co., Ltd. | ||||||||||
Disclosure of associates [line items] | ||||||||||
Number of shares received in exchange for investment | shares | 1,766,000,000 | |||||||||
Minority shareholder interest | 45.00% | |||||||||
Change in fair value of financial instruments | € 56,526,000 | € 56,526,000 | ||||||||
Increase in other current financial asset | € 1,717,000,000 | |||||||||
Increase (decrease) through changes in ownership interest on non-controlling interests | 1,511,000,000 | |||||||||
Increase in reserves | 227,000,000 | |||||||||
Decrease in translation differences | 22,000,000 | |||||||||
Profit recognized as a result of change in contractual right value | € 1,000,000 | |||||||||
Transaction costs | € 34,088,000 | |||||||||
Quoted value of shares | ¥ / shares | ¥ 6.8 | ¥ 7.4 | ||||||||
Percentage of shareholding | 26.20% | 26.20% | 26.20% | 26.20% | ||||||
Grifols Egypt Plasma Derivatives [Member] | ||||||||||
Disclosure of associates [line items] | ||||||||||
Contribution made | € 30,454,000 | $ 36,750 | ||||||||
Percentage of shareholding | 49.00% | 49.00% | 49.00% | 0.00% | ||||||
Share capital | $ | $ 300,000 | |||||||||
Grifols Diagnostics Solutions, Inc. | Shanghai RAAS Blood Products Co., Ltd. | ||||||||||
Disclosure of associates [line items] | ||||||||||
Number of subsidiary's shares delivered in exchange for investment | shares | 90 | 90 | ||||||||
Economic rights (as a percent) | 45.00% | |||||||||
Voting rights (in percent) | 40.00% | |||||||||
Number of shares received in exchange for investment | shares | 1,766,000,000 |
Equity-Accounted Investees - Pl
Equity-Accounted Investees - Plasmavita Healthcare GmbH (Details) - Plasmavita Healthcare GmbH (Germany) € in Millions | Apr. 14, 2020EUR (€) | Dec. 31, 2017person |
Disclosure of joint ventures [line items] | ||
Contribution | € | € 10 | |
Ownership interest in joint venture (as a percent) | 50.00% | 50.00% |
European partners | ||
Disclosure of joint ventures [line items] | ||
Ownership interest in joint venture (as a percent) | 50.00% | |
Number of partners in joint venture | person | 2 |
Equity-Accounted Investees - Ac
Equity-Accounted Investees - Access Biologicals LLC (Details) - Access Biologicals - USD ($) $ in Millions | Jan. 12, 2017 | Dec. 31, 2021 | Dec. 31, 2020 |
Equity Accounted Investees | |||
Ownership interest (as a percent) | 49.00% | 49.00% | 49.00% |
Consideration | $ 51 | ||
Option to purchase remaining voting rights (as a percent) | 51.00% | ||
Option to purchase remaining voting rights, term (in years) | 5 years |
Equity-Accounted Investees - Al
Equity-Accounted Investees - Alkahest, Inc (Details) - Alkahest, Inc. € in Thousands, $ in Thousands | Sep. 02, 2020USD ($) | Sep. 02, 2020EUR (€) | Sep. 01, 2020 |
Disclosure of joint ventures [line items] | |||
Consideration | $ 146,000 | € 123,425 | |
Ownership interest (as a percent) | 42.45% | ||
Difference between fair value and book value of investments accounted for using equity method, recognized in profit (loss) of equity accounted investees | $ 102,552 | € 86,743 |
Equity-Accounted Investees - Me
Equity-Accounted Investees - Medcom Advance,S.A. (Details) - Medcom Advance, S.A. € in Thousands | 1 Months Ended |
Feb. 28, 2019EUR (€) | |
Disclosure of associates [line items] | |
Ownership interest (as a percent) | 45.00% |
Consideration | € 8,602 |
Equity-Accounted Investees - _2
Equity-Accounted Investees - Mecwins, S.A. (Details) - Mecwins, S.A - EUR (€) € in Millions | Oct. 22, 2018 | Dec. 31, 2021 | Dec. 31, 2020 |
Equity Accounted Investees | |||
Share capital increase | € 2 | ||
Ownership interest (as a percent) | 24.99% | 24.99% | 24.99% |
CRB Inverbio | |||
Equity Accounted Investees | |||
Share capital increase | € 2 |
Equity-Accounted Investees - Gi
Equity-Accounted Investees - GigaGen Inc (Details) - Grifols Innovation and New Technologies Limited - USD ($) $ in Millions | Mar. 08, 2021 | Jul. 05, 2017 |
Equity Accounted Investees | ||
Ownership in subsidiary (as a percent) | 100.00% | |
GigaGen | ||
Equity Accounted Investees | ||
Ownership in subsidiary (as a percent) | 100.00% | |
Ownership interest (as a percent) | 43.96% | |
Consideration | $ 35 | |
Collaboration fee | $ 15 | |
Consideration | $ 90.5 |
Equity-Accounted Investees - Si
Equity-Accounted Investees - Singulex (Details) - Singulex, Inc. € in Thousands, $ in Millions | May 17, 2016USD ($) | May 17, 2016EUR (€) |
Equity Accounted Investees | ||
Contribution made | $ 50 | € 44,107 |
Ownership interest (as a percent) | 19.33% | 19.33% |
Pre-money valuation | $ 200 |
Equity-Accounted Investees - In
Equity-Accounted Investees - Interstate Blood Bank, Inc. (IBBI) (Details) € in Thousands, $ in Millions | May 11, 2016USD ($)item | May 11, 2016EUR (€) | May 11, 2016EUR (€)item |
Interstated Blood Bank, Inc. Group | |||
Disclosure of associates [line items] | |||
Contribution made | $ 100 | € 88,215 | |
Purchase price for the remaining stakes | $ | 100 | ||
Price of option to purchase remaining stakes | $ 10 | € 9,007 | |
Number of plasma collection centers | 26 | 26 | |
Number of blood donation centers | 9 | 9 | |
Number of laboratories | 1 | 1 | |
Interstate Blood Bank, Inc | |||
Disclosure of associates [line items] | |||
Ownership interest (as a percent) | 49.19% | 49.19% | |
Bio Blood Components Inc. | |||
Disclosure of associates [line items] | |||
Ownership interest (as a percent) | 48.97% | 48.97% | |
Plasma Biological Services, LLC. | |||
Disclosure of associates [line items] | |||
Ownership interest (as a percent) | 48.90% | 48.90% |
Equity-Accounted Investees - La
Equity-Accounted Investees - Last financial statements available for main equity-accounted investments of Grifols (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of associates [line items] | |||
Non-current assets | € 13,723,555 | € 12,109,822 | |
Cash and cash equivalents | 655,493 | 579,647 | |
Non-current financial liabilities | (7,768,950) | (6,602,100) | |
Current financial liabilities | (2,438,291) | (424,612) | |
Net revenue (notes 6 and 24) | 4,933,118 | 5,340,038 | € 5,098,691 |
Profit for the year | 265,327 | 708,990 | € 648,644 |
Shanghai RAAS Blood Products Co., Ltd. | |||
Disclosure of associates [line items] | |||
Non-current assets | 2,877,382 | 2,617,024 | |
Current assets | 549,977 | 402,876 | |
Cash and cash equivalents | 401,117 | 250,073 | |
Non-current liabilities | (3,313) | (5,074) | |
Non-current financial liabilities | (453) | ||
Current liabilities | (191,133) | (29,088) | |
Current financial liabilities | (969) | ||
Net assets | 3,633,577 | 3,234,842 | |
Net revenue (notes 6 and 24) | 395,812 | 259,429 | |
Profit for the year | 181,395 | 139,459 | |
Access Biologicals | |||
Disclosure of associates [line items] | |||
Non-current assets | 2,707 | 2,795 | |
Current assets | 23,287 | 19,619 | |
Cash and cash equivalents | 3,790 | 4,178 | |
Non-current liabilities | (36) | (1,497) | |
Current liabilities | (3,615) | (3,670) | |
Current financial liabilities | (2,649) | (1,486) | |
Net assets | 23,484 | 19,939 | |
Net revenue (notes 6 and 24) | 45,689 | 50,093 | |
Profit for the year | € 17,380 | € 17,221 |
Financial Assets - Non current
Financial Assets - Non current financial assets (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Financial Assets [Abstract] | ||
Financial investments in listed shares | € 2,038 | € 3,008 |
Non-current derivatives (see note 30) | 2,068 | 0 |
Total Non-current financial assets measured at fair value | 4,106 | 3,008 |
Non-current guarantee deposits | 7,763 | 6,268 |
Other non-current financial assets (a) | 261,294 | 108,030 |
Non-current loans to related parties (see note 31) | 89,104 | 80,851 |
Total Non-current financial assets measured at amortized cost | € 358,161 | € 195,149 |
Financial Assets - Other curren
Financial Assets - Other current financial assets (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Financial Assets [Abstract] | ||
Current derivatives (see note 30) | € 3,238 | € 0 |
Total current financial assets measured at fair value | 3,238 | 0 |
Deposits and guarantees | 561 | 162 |
Other current financial assets (a) | 2,025,869 | 10,861 |
Current loans to third parties | 39 | 95 |
Total other current financial assets measured at amortized cost | € 2,026,469 | € 11,118 |
Financial Assets - Other non-cu
Financial Assets - Other non-current and current financial assets (Details) € in Thousands, $ in Millions | Oct. 05, 2021 | Dec. 31, 2021EUR (€)item | Dec. 31, 2021USD ($)item | Dec. 31, 2020EUR (€) |
Financial Assets | ||||
Other financial assets with related parties (see note 31) | € 220,947 | € 114,825 | ||
Other financial assets with third parties | 2,066,216 | 4,066 | ||
Total other non-current and current financial assets | € 2,287,163 | € 118,891 | ||
ImmunoTek Bio Centers, LLC | ||||
Financial Assets | ||||
Number of plasma centers to be opened | item | 21 | 21 | ||
Cash advances and loans made to other parties, classified as investing activities | € 42,300 | $ 47.5 | ||
Tiancheng (Germany) Pharmaceutical Holdings | ||||
Financial Assets | ||||
Percentage of Interest in Ordinary Shares | 89.88% | 90.00% | 90.00% | |
Percentage of Interest in Preferred Shares | 1.08% | 1.00% | 1.00% |
Inventories (Details)
Inventories (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Details of inventories | |||
Goods for resale | € 137,887 | € 158,049 | |
Raw materials and supplies | 657,060 | 595,392 | |
Work in progress and semi-finished goods | 721,088 | 654,724 | |
Finished goods | 743,319 | 594,116 | |
Total inventories | 2,259,354 | 2,002,281 | |
Movement in the inventory provision | |||
Impairment on inventories | 5,000 | ||
Inventory provision | |||
Movement in the inventory provision | |||
Balance at 1 January | 122,613 | 104,251 | € 48,840 |
Net charge for the year | 28,092 | 42,255 | 42,096 |
Cancellations for the year | (269) | (189) | (118) |
Translation differences | 8,288 | (23,704) | 13,433 |
Balance at 31 December | € 158,724 | € 122,613 | € 104,251 |
Trade and Other Receivables - S
Trade and Other Receivables - Summary (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Trade and Other Receivables | ||||
Trade receivables | € 324,442 | € 404,771 | ||
Receivables from associates (note 31) | 131,764 | 1,447 | ||
Impairment losses (note 30) | (24,009) | (22,985) | € (22,291) | € (20,531) |
Trade receivables | 432,197 | 383,233 | ||
Other receivables (note 30) | 11,014 | 8,324 | ||
Personnel | 654 | 822 | ||
Advance payments (note 30) | 6,210 | 16,053 | ||
Taxation authorities, VAT recoverable | 35,389 | 38,747 | ||
Other public entities | 1,796 | 8,414 | ||
Other receivables | 55,063 | 72,360 | ||
Current income tax assets | 12,448 | 64,565 | ||
Trade and other receivables (note 14) | € 499,708 | € 520,158 |
Trade and Other Receivables - O
Trade and Other Receivables - Other Receivables (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
IFRS Statement [Line Items] | |||
Short-term debt recognized for consideration received from the factor for the receivables assignment contracts | € 23,450 | € 18,264 | |
Total receivables sold without recourse to financial institutions | 2,975,343 | 2,735,973 | € 1,593,260 |
Finance costs from sale of receivables | € 10,292 | € 10,964 | € 9,171 |
Minimum | |||
IFRS Statement [Line Items] | |||
Advanced collection of rate on assigned credits | 70.00% | 70.00% | 70.00% |
Initial payment usually received under some contracts, expressed as a percentage of the nominal amount of receivables | 90.00% | 90.00% | 90.00% |
Maximum | |||
IFRS Statement [Line Items] | |||
Advanced collection of rate on assigned credits | 100.00% | 100.00% | 100.00% |
Initial payment usually received under some contracts, expressed as a percentage of the nominal amount of receivables | 100.00% | 100.00% | 100.00% |
Cash and Cash Equivalents (Deta
Cash and Cash Equivalents (Details) € in Thousands, $ in Millions | Dec. 31, 2021EUR (€)item | Dec. 31, 2021USD ($)item | Oct. 05, 2021EUR (€) | Oct. 05, 2021USD ($) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) | Apr. 18, 2017EUR (€) |
Disclosure of detailed information about borrowings [line items] | ||||||||
Current deposits | € 134,875 | |||||||
Cash in hand and at banks | € 655,493 | 444,772 | ||||||
Total cash and cash equivalents recognized in the balance sheet | 655,493 | 579,647 | ||||||
Restricted cash | 2,020,118 | |||||||
Total cash and cash equivalents recognized in the statement of cash flows | € 2,675,611 | € 579,647 | € 741,982 | € 1,033,792 | ||||
Number Of Bonds Issued | item | 2 | 2 | ||||||
Senior Unsecured Notes | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional amount | € 1,000,000 | |||||||
Senior Unsecured Notes, Tranche one | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional amount | € 1,400,000 | € 1,400,000 | ||||||
Senior Unsecured Notes, Tranche two | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional amount | $ | $ 705 | $ 705 |
Equity - Share Capital - Genera
Equity - Share Capital - General Information (Details) - EUR (€) | Dec. 31, 2021 | Dec. 31, 2020 |
Equity | ||
Share capital | € 119,603,705 | € 119,603,705 |
Class A, Ordinary shares | ||
Equity | ||
Number of shares issued (in shares) | 426,129,798 | 426,129,798 |
Par value (in Euros per share) | € 0.25 | € 0.25 |
Class B, Preference shares | ||
Equity | ||
Number of shares issued (in shares) | 261,425,110 | 261,425,110 |
Par value (in Euros per share) | € 0.05 | € 0.05 |
Equity - Share Capital - Class
Equity - Share Capital - Class B Shares (Details) | Dec. 31, 2021item€ / shares | Dec. 31, 2020item€ / shares | Jul. 23, 2012 | Jul. 22, 2012 |
Disclosure of classes of share capital [line items] | ||||
Preference shares, annual preferred dividend, minimum (in Euros per share) | € / shares | € 0.01 | € 0.01 | ||
Exchange ratio | 1 | 2 | ||
Interests representing more than 10% of total capital | item | 0 | 0 | ||
Class B, Preference shares | ||||
Disclosure of classes of share capital [line items] | ||||
Exchange ratio | 1 |
Equity - Share Capital - Moveme
Equity - Share Capital - Movement in Outstanding Shares (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Class A, Ordinary shares | ||
Reconciliation of number of shares outstanding | ||
Number of shares outstanding at beginning of the year | 426,129,798 | 426,129,798 |
(Acquisition) / disposal of treasury stock (note 16 (d)) | (3,944,430) | |
Number of shares outstanding at end of the year | 422,185,368 | 426,129,798 |
Class B, Preference shares | ||
Reconciliation of number of shares outstanding | ||
Number of shares outstanding at beginning of the year | 258,412,946 | 258,010,058 |
(Acquisition) / disposal of treasury stock (note 16 (d)) | (2,058,366) | 402,888 |
Number of shares outstanding at end of the year | 256,354,580 | 258,412,946 |
Equity - Reserves - Drawdown of
Equity - Reserves - Drawdown of Accumulated Gains (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Equity | ||
Restricted reserves | € 29,486 | € 40,362 |
Equity - Reserves - Subsidiarie
Equity - Reserves - Subsidiaries (Details) € in Thousands, $ in Thousands, EquityInstruments in Millions | Apr. 14, 2020EUR (€) | Mar. 30, 2020EUR (€) | Dec. 03, 2019EUR (€) | Jul. 24, 2019 | Jul. 23, 2019 | Apr. 16, 2019EUR (€) | Oct. 31, 2021EUR (€) | Jun. 30, 2021EUR (€)shares | Jun. 30, 2021USD ($)shares | May 31, 2021 | Apr. 30, 2021EUR (€) | Apr. 30, 2021USD ($) | Dec. 31, 2019EUR (€)EquityInstruments | Jul. 31, 2019EUR (€)shares | Jun. 30, 2019EUR (€) | Apr. 30, 2019EUR (€) | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€)EquityInstrumentsshares | Dec. 31, 2017 | Sep. 02, 2020EUR (€) | Sep. 02, 2020USD ($) |
Equity | ||||||||||||||||||||||
Increase (decrease) in reserves | € (89) | € 1,716,147 | ||||||||||||||||||||
Dividend paid | € 8,811 | $ 10,485 | ||||||||||||||||||||
Alkahest, Inc. | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Consideration transferred, acquisition-date fair value | € 123,425 | $ 146,000 | ||||||||||||||||||||
Araclon Biotech S.L | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Increased capital | € 5,900 | € 16,800 | € 10,000 | € 5,900 | € 16,800 | |||||||||||||||||
Proportion of ownership interest (as a percent) | 75.10% | 75.10% | 75.85% | 75.10% | 75.10% | |||||||||||||||||
VCN Bioscience, S.L. | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Increased capital | € 5,000 | |||||||||||||||||||||
Indirect (as a percent) | 86.827% | |||||||||||||||||||||
Progenika Biopharma, S.A. (Spain) | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Increased capital | € 4 | |||||||||||||||||||||
Acquired Capital (in shares) | shares | 33 | |||||||||||||||||||||
Proportion of ownership interest (as a percent) | 100.00% | 99.99% | 100.00% | 99.99% | ||||||||||||||||||
Grifols Malaysia Sdn Bhd | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Increased capital | € 6 | $ 7 | ||||||||||||||||||||
Acquired Capital (in shares) | shares | 28,500 | 28,500 | ||||||||||||||||||||
Proportion of ownership interest (as a percent) | 49.00% | 49.00% | 30.00% | 49.00% | ||||||||||||||||||
Kiro Grifols | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Increased capital | € 7,500 | € 10,000 | ||||||||||||||||||||
Proportion of ownership interests held by non-controlling interests | 10.00% | 10.00% | ||||||||||||||||||||
Proportion of direct ownership interest | 90.00% | 90.00% | ||||||||||||||||||||
GDS Group | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Acquired Capital (in shares) | shares | 90 | |||||||||||||||||||||
Increase (decrease) in reserves | € 408,000 | € 227,000 | ||||||||||||||||||||
Consideration transferred, in shares | EquityInstruments | 1,766 | 1,766 | ||||||||||||||||||||
Shanghai RAAS Blood Products Co., Ltd. | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Acquired Capital (in shares) | shares | 0 | |||||||||||||||||||||
Proportion of direct ownership interest | 26.20% | |||||||||||||||||||||
Plasmavita Healthcare GmbH (Germany) | ||||||||||||||||||||||
Equity | ||||||||||||||||||||||
Contribution Made | € 10,000 | |||||||||||||||||||||
Proportion of ownership interest in joint venture | 50.00% | 50.00% |
Equity - Reserves - Legal Reser
Equity - Reserves - Legal Reserve (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Equity | ||
Percentage of annual profits to transfer to legal reserve (as a percent) | 10.00% | |
Limit to transfers to legal reserve as a percentage of share capital (as a percent) | 20.00% | 20.00% |
Nominal value of the total share capital after the increase (as a percent) | 10.00% | |
Legal reserve | € 23,921 | € 23,921 |
Spanish companies other than parent | ||
Equity | ||
Legal reserve | 2,066 | 2,066 |
Foreign companies other than Spanish companies and parent | ||
Equity | ||
Legal reserve | € 3,805 | € 3,677 |
Equity - Treasury Stock - Class
Equity - Treasury Stock - Class A Treasury Stock (Details) - Class A, Ordinary shares - shares | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Equity | |||
Number of shares outstanding | 422,185,368 | 426,129,798 | 426,129,798 |
Treasury stock | |||
Equity | |||
Number of shares outstanding | (3,944,430) |
Equity - Treasury Stock - Tabul
Equity - Treasury Stock - Tabular Disclosure - Shares (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Class B, Preference shares | ||
Reconciliation of number of shares outstanding | ||
Number of shares outstanding at beginning of the year | (258,412,946) | (258,010,058) |
Number of shares outstanding at end of the year | (256,354,580) | (258,412,946) |
Class A, Ordinary shares | ||
Reconciliation of number of shares outstanding | ||
Number of shares outstanding at beginning of the year | (426,129,798) | (426,129,798) |
Number of shares outstanding at end of the year | (422,185,368) | (426,129,798) |
Treasury stock | Class B, Preference shares | ||
Reconciliation of number of shares outstanding | ||
Number of shares outstanding at beginning of the year | 3,012,164 | 3,415,052 |
Disposal of shares | (361,530) | (402,888) |
Acquisition of shares | 2,419,896 | |
Number of shares outstanding at end of the year | 5,070,530 | 3,012,164 |
Treasury stock | Class A, Ordinary shares | ||
Reconciliation of number of shares outstanding | ||
Acquisition of shares | 3,944,430 | |
Number of shares outstanding at end of the year | 3,944,430 |
Equity - Treasury Stock - Tab_2
Equity - Treasury Stock - Tabular Disclosure - Value (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity | ||
Balance at beginning of the year | € (6,720,055) | € (6,845,768) |
Balance at end of the year | (7,317,098) | (6,720,055) |
Treasury stock | ||
Equity | ||
Balance at beginning of the year | 43,734 | 49,584 |
Balance at end of the year | 164,189 | 43,734 |
Treasury stock | Class A, Ordinary shares | ||
Equity | ||
Acquisition of shares | 89,959 | |
Balance at end of the year | 89,959 | |
Treasury stock | Class B, Preference shares | ||
Equity | ||
Balance at beginning of the year | 43,734 | 49,584 |
Disposal of shares | (5,248) | (5,850) |
Acquisition of shares | 35,744 | |
Balance at end of the year | € 74,230 | € 43,734 |
Equity - Treasury Stock - Addit
Equity - Treasury Stock - Additional Information (Details) - shares | 1 Months Ended | |||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Equity | ||||
Treasury stock as a percentage of capital, held by parent | 1.31% | 0.40% | ||
Treasury stock | Class B, Preference shares | Restricted share unit retention plan | ||||
Equity | ||||
Number of shares delivered to eligible employees as a compensation for the Restricted Share Unit Retention Plan | 361,530 | 402,888 | ||
Treasury stock | Class A and Class B shares | ||||
Equity | ||||
Treasury stock as a percentage of capital, held by parent | 1.30% | |||
Treasury stock | Class B Shares | ||||
Equity | ||||
Treasury stock as a percentage of capital, held by parent | 0.40% |
Equity - Distribution of Profit
Equity - Distribution of Profit - Proposed Distribution of Profit (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity | ||
Voluntary reserve | € (140,728) | € 62,134 |
Dividends | 2,614 | |
Profit of the Parent | € (140,728) | € 64,748 |
Equity - Distribution of Prof_2
Equity - Distribution of Profit - Dividends Paid (Details) - EUR (€) € / shares in Units, € in Thousands | May 21, 2021 | Oct. 08, 2020 | Dec. 31, 2021 | Dec. 31, 2020 |
Equity | ||||
Dividends paid | € 113,230 | |||
Interim dividends paid | € 0 | € 0 | ||
Dividends paid | € 250,134 | |||
Class A, Ordinary shares | ||||
Equity | ||||
Dividends paid, % of par value (as a percent) | 146.00% | 65.00% | ||
Dividends paid, per share (in Euros per share) | € 0.36 | € 0.16 | ||
Dividends paid | € 154,005 | € 68,859 | ||
Class B, Preference shares | ||||
Equity | ||||
Dividend approved (in Euros per share) | € 0.01 | € 0.01 | ||
Preference shares, no preferred dividend | ||||
Equity | ||||
Dividends paid, % of par value (as a percent) | 729.00% | 323.00% | ||
Dividends paid, per share (in Euros per share) | € 0.36 | € 0.16 | ||
Dividends paid | € 93,515 | € 41,757 | ||
Preference shares, preferred dividend | ||||
Equity | ||||
Dividends paid, % of par value (as a percent) | 20.00% | 20.00% | ||
Dividends paid, per share (in Euros per share) | € 0.01 | € 0.01 | ||
Dividends paid | € 2,614 | € 2,614 | ||
Class A and Class B shares | ||||
Equity | ||||
Dividends paid | € 247,520 | |||
Dividend approved (in Euros per share) | € 0.36 |
Equity - Distribution of Prof_3
Equity - Distribution of Profit - Additional Information (Details) - € / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Preference shares, preferred dividend | ||
Equity | ||
Dividends paid, per share (in Euros per share) | € 0.01 | € 0.01 |
Equity - Restricted Share Unit
Equity - Restricted Share Unit Retention Plan (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Equity | ||
Cumulative accrual amount | € 9,838 | € 13,880 |
Earnings Per Share - Calculatio
Earnings Per Share - Calculation of Basic Earnings per Share (Details) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Earnings Per Share | |||
Profit for the year attributable to shareholders of the Parent | € 188,726 | € 618,546 | € 625,146 |
Weighted average number of ordinary shares outstanding (in shares) | 681,556,937 | 685,515,740 | 685,115,836 |
Basic earnings per share (in Euros per share) | € 0.28 | € 0.90 | € 0.91 |
Earnings Per Share - Weighted A
Earnings Per Share - Weighted Average Ordinary Shares Outstanding Basic (Details) - shares | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Weighted average ordinary shares and adjusted weighted average ordinary shares | |||
Issued shares outstanding at 1 January (in shares) | 685,601,126 | 685,198,238 | 684,794,839 |
Effect of treasury stock (in shares) | (4,044,189) | 317,502 | 320,997 |
Average weighted number of ordinary shares outstanding (basic) at 31 December (in shares) | 681,556,937 | 685,515,740 | 685,115,836 |
Earnings Per Share - Calculat_2
Earnings Per Share - Calculation of Diluted Earnings per Share (Details) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Profit (loss), attributable to ordinary equity holders of parent entity [abstract] | |||
Profit for the year attributable to shareholders of the Parent | € 188,726 | € 618,546 | € 625,146 |
Weighted average number of ordinary shares outstanding (diluted) (in shares) | 681,404,922 | 685,142,749 | 684,719,195 |
Diluted earnings per share (in Euros per share) | € 0.28 | € 0.90 | € 0.91 |
Earnings Per Share - Weighted_2
Earnings Per Share - Weighted Average Ordinary Shares Outstanding Diluted (Details) - shares | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Weighted average ordinary shares and adjusted weighted average ordinary shares | |||
Issued shares outstanding at 1 January (in shares) | 685,601,126 | 685,198,238 | 684,794,839 |
Effect of RSU shares (in shares) | (152,015) | (372,991) | (396,641) |
Effect of treasury stock (in shares) | (4,044,189) | 317,502 | 320,997 |
Average weighted number of ordinary shares outstanding (diluted) at 31 December (in shares) | 681,404,922 | 685,142,749 | 684,719,195 |
Non-Controlling Interests - Mov
Non-Controlling Interests - Movement (Details) € in Thousands, $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Apr. 30, 2021EUR (€) | Apr. 30, 2021USD ($) | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | |
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | € 6,720,055 | € 6,845,768 | ||
Dividends paid | € 8,811 | $ 10,485 | ||
Balance at end of the year | 7,317,098 | 6,720,055 | ||
Non-controlling interests | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 1,611,663 | 2,023,649 | ||
Additions | 76,601 | 90,444 | ||
Business combination / Perimeter additions | 1,604 | (394,011) | ||
Dividends paid | (6,503) | |||
Translation differences | 110,124 | (108,419) | ||
Balance at end of the year | 1,793,489 | 1,611,663 | ||
Non-controlling interests | Grifols (Thailand) Ltd. | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 4,338 | 4,549 | ||
Additions | 218 | 221 | ||
Translation differences | (139) | (432) | ||
Balance at end of the year | 4,417 | 4,338 | ||
Non-controlling interests | Grifols Malaysia Sdn Bhd | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 2,923 | 2,171 | ||
Additions | 810 | 932 | ||
Business combination / Perimeter additions | (843) | |||
Translation differences | 169 | (180) | ||
Balance at end of the year | 3,059 | 2,923 | ||
Non-controlling interests | Araclon Biotech, S.A. | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | (1,088) | 429 | ||
Additions | (1,119) | (1,517) | ||
Business combination / Perimeter additions | 2,447 | 0 | ||
Balance at end of the year | 240 | (1,088) | ||
Non-controlling interests | VCN Bioscience, S.L. | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 316 | (152) | ||
Additions | (219) | (235) | ||
Business combination / Perimeter additions | 703 | |||
Balance at end of the year | 97 | 316 | ||
Non-controlling interests | Kiro Grifols , S.L. | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 598 | 24 | ||
Additions | (314) | (426) | ||
Business combination / Perimeter additions | 1,000 | |||
Balance at end of the year | 284 | 598 | ||
Non-controlling interests | Haema AG. | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 231,284 | 226,071 | ||
Additions | 2,258 | 5,213 | ||
Balance at end of the year | 233,542 | 231,284 | ||
Non-controlling interests | BPC Plasma, Inc (formerly Biotest US Corporation) | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 274,995 | 280,010 | ||
Additions | 8,014 | 19,032 | ||
Translation differences | 22,267 | (24,047) | ||
Balance at end of the year | 305,276 | 274,995 | ||
Non-controlling interests | Grifols Diagnostic Solutions, Inc. | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 1,087,632 | 1,510,547 | ||
Additions | 65,894 | 69,520 | ||
Business combination / Perimeter additions | (408,675) | |||
Dividends paid | (6,503) | |||
Translation differences | 87,827 | (83,760) | ||
Balance at end of the year | 1,234,850 | 1,087,632 | ||
Non-controlling interests | Plasmavita Healthcare | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | 10,665 | |||
Additions | 1,059 | (22) | ||
Business combination / Perimeter additions | 10,687 | |||
Balance at end of the year | 11,724 | 10,665 | ||
Non-controlling interests | Alkahest, Inc. (USA) | ||||
Disclosure of subsidiaries [line items] | ||||
Balance at beginning of the year | € 0 | |||
Additions | (2,274) | |||
Business combination / Perimeter additions | 2,274 | |||
Balance at end of the year | € 0 |
Non-Controlling Interests - Sum
Non-Controlling Interests - Summary of Financial Information (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Disclosure of subsidiaries [line items] | ||||
Non-current assets | € 13,723,555 | € 12,109,822 | ||
Current assets | 5,510,280 | 3,164,954 | ||
Total assets | 19,233,835 | 15,274,776 | € 15,542,611 | |
Non-current liabilities | 8,442,425 | 7,219,583 | ||
Current liabilities | 3,474,312 | 1,335,138 | ||
Total liabilities | 11,916,737 | 8,554,721 | 8,696,843 | |
Total equity | 7,317,098 | 6,720,055 | 6,845,768 | € 4,696,604 |
Profit (loss) for the year | 76,601 | 90,444 | 23,498 | |
Non-controlling interests [Member] | ||||
Disclosure of subsidiaries [line items] | ||||
Total equity | 1,793,489 | 1,611,663 | 2,023,649 | € 471,050 |
Non-controlling interests [Member] | Haema AG | Haema AG | ||||
Disclosure of subsidiaries [line items] | ||||
Non-current assets | 292,454 | 249,806 | ||
Current assets | 52,211 | 31,237 | ||
Total assets | 344,665 | 281,043 | ||
Non-current liabilities | 27,137 | 27,123 | ||
Current liabilities | 83,986 | 22,636 | ||
Total liabilities | 111,123 | 49,759 | ||
Total equity | 233,542 | 231,284 | ||
Profit (loss) for the year | 2,258 | 5,213 | ||
Non-controlling interests [Member] | BPC Plasma, Inc (formerly Biotest US Corporation) | ||||
Disclosure of subsidiaries [line items] | ||||
Total equity | 305,276 | 274,995 | € 280,010 | |
Non-controlling interests [Member] | BPC Plasma, Inc (formerly Biotest US Corporation) | BPC Plasma, Inc (formerly Biotest US Corporation) | ||||
Disclosure of subsidiaries [line items] | ||||
Non-current assets | 409,674 | 336,321 | ||
Current assets | 33,404 | 43,750 | ||
Total assets | 443,078 | 380,071 | ||
Non-current liabilities | 54,991 | 52,977 | ||
Current liabilities | 82,811 | 52,099 | ||
Total liabilities | 137,802 | 105,076 | ||
Total equity | 305,276 | 274,995 | ||
Profit (loss) for the year | 8,014 | 19,032 | ||
Non-controlling interests [Member] | GDS Group | GDS Group | ||||
Disclosure of subsidiaries [line items] | ||||
Non-current assets | 3,796,855 | 3,393,188 | ||
Current assets | 291,371 | 277,834 | ||
Total assets | 4,088,226 | 3,671,022 | ||
Non-current liabilities | 278,620 | 256,244 | ||
Current liabilities | 91,299 | 131,754 | ||
Total liabilities | 369,919 | 387,998 | ||
Total equity | 3,718,307 | 3,283,024 | ||
Profit (loss) for the year | € 198,416 | € 198,182 |
Grants (Details)
Grants (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Grants | ||
Capital grants | € 14,646 | € 16,509 |
Interest rate grants (preference loans) (See note 21 (d)) | 390 | 499 |
Total Grants | 15,036 | 17,008 |
Grants transferred to consolidated statement of profit and loss | € 5,608 | € 1,683 |
Provisions - Summary (Details)
Provisions - Summary (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Non-current provisions (a) | ||||
Provisions for pensions and similar obligations | € 6,717 | € 6,767 | ||
Other provisions | 17,405 | 20,504 | ||
Non-current provisions | 24,122 | 27,271 | € 8,030 | € 6,114 |
Current provisions (b) | ||||
Trade provisions | 31,407 | 11,175 | ||
Current Provisions | € 31,407 | € 11,175 | € 53,109 | € 80,055 |
Provisions - Non-current provis
Provisions - Non-current provisions (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Non-current provisions (a) | |||
Beginning balance, Non-current Provisions | € 27,271 | € 8,030 | € 6,114 |
Net charge | 838 | 414 | 1,467 |
Cancellations | (77) | (175) | (30) |
Reclassifications | (5,196) | 20,527 | 464 |
Translation differences | 1,286 | (1,525) | 15 |
Ending balance, Non-current Provisions | € 24,122 | € 27,271 | € 8,030 |
Provisions - Current provisions
Provisions - Current provisions (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Current provisions (b) | |||
Beginning balance, Trade provisions | € 11,175 | € 53,109 | € 80,055 |
Business combinations | 32 | (954) | |
Net charge | 14,826 | (21,998) | (25,249) |
Cancellations | (717) | (247) | (3,142) |
Reclassifications | 4,523 | (20,059) | |
Translation differences | 1,568 | (584) | 1,445 |
Ending balance, Trade provisions | € 31,407 | € 11,175 | € 53,109 |
Financial Liabilities - Summary
Financial Liabilities - Summary (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Financial Liabilities | ||
Non-current bonds | € 2,577,465 | € 2,675,000 |
Senior secured debt | 3,296,025 | 3,335,415 |
Other loans | 480,836 | 183,771 |
Other non-current financial liabilities | 838,826 | 10,272 |
Non-current lease liabilities | 825,157 | 690,857 |
Loan transaction costs | (249,359) | (293,215) |
Total non-current financial liabilities | 7,768,950 | 6,602,100 |
Current bonds | 2,270,474 | 125,843 |
Senior secured debt | 34,035 | |
Other loans | 165,139 | 170,730 |
Other current financial liabilities | 43,234 | 105,041 |
Current financial derivatives | 875 | |
Current lease liabilities | 48,567 | 42,642 |
Loan transaction costs | (89,998) | (53,679) |
Total current financial liabilities | € 2,438,291 | € 424,612 |
Financial Liabilities - Other (
Financial Liabilities - Other (Details) € in Thousands, $ in Millions | 1 Months Ended | 12 Months Ended | ||||||||||||
Sep. 30, 2018EUR (€) | Dec. 31, 2021EUR (€)item | Dec. 31, 2019EUR (€) | Dec. 31, 2021USD ($)item | Oct. 05, 2021EUR (€) | Oct. 05, 2021USD ($) | Dec. 31, 2020EUR (€) | May 07, 2020USD ($) | May 06, 2020USD ($) | Nov. 15, 2019EUR (€)item | Nov. 15, 2019USD ($)item | Dec. 05, 2017EUR (€) | Apr. 18, 2017EUR (€) | Oct. 28, 2015EUR (€) | |
Borrowings | ||||||||||||||
Number of bonds issued | item | 2 | 2 | ||||||||||||
Gain on modification of financial liabilities after adoption of IFRS 9 | € 97,850 | |||||||||||||
Senior Debt | ||||||||||||||
Borrowings | ||||||||||||||
Amount of borrowings refinanced | € 5,800,000 | |||||||||||||
Gain on modification of financial liabilities after adoption of IFRS 9 | € 97,850 | |||||||||||||
Senior Debt Tranche B, Maturity in 2027 | ||||||||||||||
Borrowings | ||||||||||||||
Debt term | 8 years | |||||||||||||
Senior Debt Tranche B, Maturity in 2027 | US Dollar | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | $ | $ 2,500 | |||||||||||||
Senior Debt Tranche B, Maturity in 2027 | Euros | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | 1,360,000 | |||||||||||||
Revolving Credit Facility, Maturing in 2025 | ||||||||||||||
Borrowings | ||||||||||||||
Maximum borrowing capacity | $ | $ 1,000 | $ 1,000 | $ 500 | $ 500 | ||||||||||
Carrying amount | $ | 330 | |||||||||||||
EIB Loan | ||||||||||||||
Borrowings | ||||||||||||||
Loan arrangements | € 85,000 | € 100,000 | ||||||||||||
Carrying amount | € 180,625 | € 212,500 | ||||||||||||
EIB Loan, Maturing in 2028 | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | € 85,000 | |||||||||||||
Debt term | 10 years | |||||||||||||
Grace period | 2 years | |||||||||||||
Senior Secured Notes | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | € 1,675,000 | |||||||||||||
Number of bonds issued | item | 2 | 2 | ||||||||||||
Senior Unsecured Notes | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | € 1,000,000 | |||||||||||||
Senior Unsecured Notes, Tranche one | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | € 1,400,000 | € 1,400,000 | ||||||||||||
Senior Unsecured Notes, Tranche one | Euros | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | € 1,400,000 | |||||||||||||
Senior Unsecured Notes, Tranche two | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | $ | $ 705 | $ 705 | ||||||||||||
Senior Unsecured Notes, Tranche two | US Dollar | ||||||||||||||
Borrowings | ||||||||||||||
Notional amount | $ | $ 705 |
Financial Liabilities - Senior
Financial Liabilities - Senior Notes (Details) € in Thousands, $ in Millions | Oct. 05, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021EUR (€) | Oct. 05, 2021EUR (€) | Nov. 15, 2019EUR (€)item | Apr. 18, 2017EUR (€) |
Tiancheng (Germany) Pharmaceutical Holdings | ||||||
Borrowings | ||||||
Consideration transferred | € 1,100 | |||||
Ownership interest in ordinary shares (in percent) | 89.88% | 90.00% | ||||
Ownership interest in preferred shares (in percent) | 1.08% | 1.00% | ||||
Senior Secured Notes | ||||||
Borrowings | ||||||
Notional amount | € 1,675,000 | |||||
Number of notes issued | item | 2 | |||||
Secured Secured Notes, Maturing in 2027 | ||||||
Borrowings | ||||||
Notional amount | € 770,000 | |||||
Borrowings, interest rate | 2.25% | |||||
Secured Secured Notes, Maturing in 2025 | ||||||
Borrowings | ||||||
Notional amount | € 905,000 | |||||
Borrowings, interest rate | 1.625% | |||||
Senior Unsecured Notes | ||||||
Borrowings | ||||||
Notional amount | € 1,000,000 | |||||
Borrowings, interest rate | 3.20% | |||||
Senior Unsecured Notes, Tranche one | ||||||
Borrowings | ||||||
Notional amount | € 1,400,000 | € 1,400,000 | ||||
Borrowings, interest rate | 3.875% | 3.875% | ||||
Senior Unsecured Notes, Tranche two | ||||||
Borrowings | ||||||
Notional amount | $ | $ 705 | $ 705 | ||||
Borrowings, interest rate | 4.75% | 4.75% |
Financial Liabilities - Movemen
Financial Liabilities - Movement in Senior Notes (Details) € in Thousands, $ in Thousands | Dec. 02, 2021USD ($) | Dec. 31, 2021EUR (€) |
Senior notes | ||
Borrowings | ||
Nominal amount, beginning balance | € 2,675,000 | |
Issue | 1,998,970 | |
Exchange differences | 23,492 | |
Nominal amount, ending balance | 4,697,462 | |
Amount of repurchase offer for senior notes, same price plus unpaid accrued interests | $ | $ 110,317 | |
Senior unsecured notes (nominal value) 2017 | ||
Borrowings | ||
Nominal amount, beginning balance | 1,000,000 | |
Nominal amount, ending balance | 1,000,000 | |
Senior unsecured notes (nominal value) Euros 2021 | ||
Borrowings | ||
Issue | 1,400,000 | |
Nominal amount, ending balance | 1,400,000 | |
Senior unsecured notes (nominal value) US Dollars 2021 | ||
Borrowings | ||
Issue | 598,970 | |
Exchange differences | 23,492 | |
Nominal amount, ending balance | 622,462 | |
Senior secured notes (nominal value) 2019 | ||
Borrowings | ||
Nominal amount, beginning balance | 1,675,000 | |
Nominal amount, ending balance | € 1,675,000 |
Financial Liabilities - Promiss
Financial Liabilities - Promissory Notes (Details) - EUR (€) | Dec. 31, 2021 | Dec. 31, 2020 |
Promissory Notes Maturing May 2019 | ||
Borrowings | ||
Nominal amount of promissory notes | € 3,000 | |
Nominal interest rate for loans received | 3.00% | |
Promissory notes subscribed | € 116,352,000 | |
Buy back | (3,612,000) | |
Interest pending accrual | € (1,118,000) | |
Promissory Notes Maturing May 2020 | ||
Borrowings | ||
Nominal amount of promissory notes | € 3,000 | |
Nominal interest rate for loans received | 2.50% | |
Promissory notes subscribed | € 119,325,000 | |
Buy back | (1,740,000) | |
Interest pending accrual | € (975,000) |
Financial Liabilities - Loans a
Financial Liabilities - Loans and Borrowings (Details) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Nov. 15, 2019 | Dec. 31, 2018 | |
Borrowings | |||||
Amount extended | € 4,750,095 | € 4,684,565 | |||
Amount extended | 211,901 | 241,895 | |||
Non-current, Loan transaction costs | (249,359) | (293,215) | |||
Non-current loans and borrowings | 3,579,158 | 3,295,242 | |||
Current loans, Loan transaction costs | (89,998) | (53,679) | |||
Current loans and borrowings | 127,895 | 169,556 | |||
Current loans and borrowings, accrued interest | € 7,682 | 7,262 | |||
Loans and Borrowings | |||||
Borrowings | |||||
Percentage of original effective interest rate | 10.00% | ||||
Non-current, Loan transaction costs | € (197,703) | (223,944) | |||
Current loans, Loan transaction costs | (37,244) | (35,209) | |||
Senior Debt | |||||
Borrowings | |||||
Amount extended | 3,587,171 | 3,587,171 | |||
Non-current loans and borrowings, Carrying amount | 3,296,025 | 3,335,415 | |||
Current loans and borrowings, Carrying Amount | 34,035 | ||||
EIB Loan | |||||
Borrowings | |||||
Amount extended | 270,000 | 270,000 | |||
Non-current loans and borrowings, Carrying amount | 148,750 | 180,625 | |||
Current loans and borrowings, Carrying Amount | 31,875 | 31,875 | |||
Revolving credit facility | |||||
Borrowings | |||||
Amount extended | 882,924 | € 817,394 | |||
Non-current loans and borrowings, Carrying amount | € 330,000 | ||||
Revolving Credit Facility, Maturing in 2025 | |||||
Borrowings | |||||
Interest rate basis | US Libor | ||||
Adjustment to interest rate basis (as a percent) | 1.50% | ||||
Other Non-current Loans | |||||
Borrowings | |||||
Interest rate basis | 1.93% | 1.93% | |||
Amount extended | € 10,000 | € 10,000 | |||
Non-current loans and borrowings, Carrying amount | 2,086 | 3,146 | |||
Other Current Loans | |||||
Borrowings | |||||
Amount extended | 211,901 | 241,895 | |||
Current loans and borrowings, Carrying Amount | € 133,264 | € 138,855 | |||
Other Current Loans | Minimum | |||||
Borrowings | |||||
Nominal interest rate for loans received | 0.10% | 0.10% | |||
Other Current Loans | Maximum | |||||
Borrowings | |||||
Nominal interest rate for loans received | 2.50% | 2.50% | |||
US Dollar | Senior Debt Tranche B, Maturity in 2027 | |||||
Borrowings | |||||
Interest rate basis | Libor | ||||
Adjustment to interest rate basis (as a percent) | 2.00% | 2.00% | 2.00% | ||
Amount extended | € 2,227,171 | € 2,227,171 | |||
Non-current loans and borrowings, Carrying amount | € 2,037,471 | 2,002,615 | |||
Current loans and borrowings, Carrying Amount | € 20,435 | ||||
US Dollar | Revolving Credit Facility, Maturing in 2025 | |||||
Borrowings | |||||
Adjustment to interest rate basis (as a percent) | 1.50% | 1.50% | |||
Amount extended | € 882,924 | € 817,394 | |||
Non-current loans and borrowings, Carrying amount | € 330,000 | ||||
Euros | Senior Debt Tranche B Maturity in 2027 | |||||
Borrowings | |||||
Current loans and borrowings, Carrying Amount | € 13,600 | ||||
Euros | Senior Debt Tranche B, Maturity in 2027 | |||||
Borrowings | |||||
Interest rate basis | Euribor | ||||
Adjustment to interest rate basis (as a percent) | 2.25% | 2.25% | 2.25% | 2.25% | |
Amount extended | € 1,360,000 | € 1,360,000 | |||
Non-current loans and borrowings, Carrying amount | € 1,258,554 | € 1,332,800 | |||
Euros | EIB Loan, Maturing in 2025 | |||||
Borrowings | |||||
Nominal interest rate for loans received | 2.40% | 2.40% | 2.40% | 2.40% | |
Amount extended | € 100,000 | € 100,000 | |||
Non-current loans and borrowings, Carrying amount | 31,875 | 42,500 | |||
Current loans and borrowings, Carrying Amount | € 10,625 | € 10,625 | |||
Euros | EIB Loan, Maturing in 2027 | |||||
Borrowings | |||||
Nominal interest rate for loans received | 2.02% | 2.02% | |||
Amount extended | € 85,000 | € 85,000 | |||
Non-current loans and borrowings, Carrying amount | 53,125 | 63,750 | |||
Current loans and borrowings, Carrying Amount | € 21,250 | € 21,250 | |||
Euros | EIB Loan, Maturing in 2028 | |||||
Borrowings | |||||
Nominal interest rate for loans received | 2.15% | 2.15% | |||
Amount extended | € 85,000 | € 85,000 | |||
Non-current loans and borrowings, Carrying amount | € 63,750 | € 74,375 |
Financial Liabilities - Senio_2
Financial Liabilities - Senior Debt (Details) € in Thousands, $ in Thousands | 12 Months Ended | |||||
Dec. 31, 2021EUR (€)tranche | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2021USD ($)tranche | Nov. 19, 2019EUR (€) | Nov. 19, 2019USD ($) | |
Disclosure of detailed information about borrowings [line items] | ||||||
Refinance costs | € 277,994 | € 249,639 | € 342,965 | |||
Income from refinancing effect | 97,850 | |||||
Repayments of borrowings, classified as financing activities | 495,327 | € 272,877 | 53,809 | |||
Senior Debt | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Refinance costs | € 84,400 | |||||
Income from refinancing effect | € 97,850 | |||||
Senior Debt Tranche B Maturing 2027 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Number of tranches | tranche | 2 | 2 | ||||
US Dollar | Senior Debt Tranche B Maturing 2027 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | € 2,042,990 | $ 2,313,889 | $ 2,500,000 | |||
Adjustment to interest rate basis (as a percent) | 2.00% | 2.00% | ||||
Interest rate basis | US Libor | |||||
Details by maturity: | ||||||
Principal amount | € 2,042,990 | $ 2,313,889 | $ 2,500,000 | |||
US Dollar | Senior Debt Tranche B Maturing 2027 | 2023 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 5,310 | 6,015 | ||||
Details by maturity: | ||||||
Principal amount | 5,310 | 6,015 | ||||
US Dollar | Senior Debt Tranche B Maturing 2027 | 2024 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 21,242 | 24,058 | ||||
Details by maturity: | ||||||
Principal amount | 21,242 | 24,058 | ||||
US Dollar | Senior Debt Tranche B Maturing 2027 | 2025 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 21,242 | 24,058 | ||||
Details by maturity: | ||||||
Principal amount | 21,242 | 24,058 | ||||
US Dollar | Senior Debt Tranche B Maturing 2027 | 2026 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 21,242 | 24,058 | ||||
Details by maturity: | ||||||
Principal amount | 21,242 | 24,058 | ||||
US Dollar | Senior Debt Tranche B Maturing 2027 | 2027 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 1,973,954 | 2,235,700 | ||||
Details by maturity: | ||||||
Principal amount | 1,973,954 | $ 2,235,700 | ||||
US Dollar | Tranche B | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Repayments of borrowings, classified as financing activities | 124,798 | |||||
Euros | Senior Debt Tranche B Maturing 2027 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | € 1,258,555 | € 1,360,000 | ||||
Adjustment to interest rate basis (as a percent) | 2.25% | 2.25% | ||||
Interest rate basis | Euribor | |||||
Details by maturity: | ||||||
Principal amount | € 1,258,555 | € 1,360,000 | ||||
Euros | Senior Debt Tranche B Maturing 2027 | 2023 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 3,269 | |||||
Details by maturity: | ||||||
Principal amount | 3,269 | |||||
Euros | Senior Debt Tranche B Maturing 2027 | 2024 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 13,076 | |||||
Details by maturity: | ||||||
Principal amount | 13,076 | |||||
Euros | Senior Debt Tranche B Maturing 2027 | 2025 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 13,076 | |||||
Details by maturity: | ||||||
Principal amount | 13,076 | |||||
Euros | Senior Debt Tranche B Maturing 2027 | 2026 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 13,076 | |||||
Details by maturity: | ||||||
Principal amount | 13,076 | |||||
Euros | Senior Debt Tranche B Maturing 2027 | 2027 | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Principal amount | 1,216,058 | |||||
Details by maturity: | ||||||
Principal amount | 1,216,058 | |||||
Euros | Tranche B | ||||||
Disclosure of detailed information about borrowings [line items] | ||||||
Repayments of borrowings, classified as financing activities | € 74,246 |
Financial Liabilities - Revolvi
Financial Liabilities - Revolving Facility and Other (Details) € in Millions, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2021USD ($) | Dec. 31, 2020EUR (€) | May 07, 2020USD ($) | May 06, 2020USD ($) | Nov. 15, 2019USD ($) | |
Disclosure of detailed information about borrowings [line items] | |||||
Amount drawn from credit facility | $ 600 | ||||
Revolving Credit Facility, Maturing in 2025 | |||||
Disclosure of detailed information about borrowings [line items] | |||||
Maximum borrowing capacity | $ 1,000 | $ 1,000 | $ 500 | $ 500 | |
Interest rate basis | US Libor | ||||
Adjustment to interest rate basis (as a percent) | 1.50% | ||||
Borrowings | $ 330 | ||||
Percentage of consolidated assets and consolidated EBITDA applied as guaranty of borrowings | 70.00% | ||||
Refinancing of credit facility | € | € 9.3 |
Financial Liabilities - Other F
Financial Liabilities - Other Financial Liabilities (Details) $ / shares in Units, € in Thousands, $ in Millions | Dec. 31, 2021EUR (€) | Dec. 31, 2021$ / shares | Jun. 30, 2021USD ($)shares | Dec. 31, 2020EUR (€) |
Financial Liabilities | ||||
Amount of interest free loans extended by governmental institutions | € 9,637 | € 12,060 | ||
Portion of interest-free loans extended by governmental institutions that is considered a grant | 390 | 499 | ||
Other financial liabilities | 882,060 | 115,313 | ||
Other non-current financial liabilities | 838,826 | 10,272 | ||
Dividend paid per share | $ / shares | $ 4,168,000 | |||
Redemption Price Per Share | $ / shares | $ 52,105,263.16 | |||
Less than 12 months | ||||
Financial Liabilities | ||||
Other financial liabilities | 43,234 | 105,041 | ||
2023 | ||||
Financial Liabilities | ||||
Other financial liabilities | 88,144 | 3,945 | ||
2024 | ||||
Financial Liabilities | ||||
Other financial liabilities | 88,947 | 1,976 | ||
2025 | ||||
Financial Liabilities | ||||
Other financial liabilities | 89,027 | 1,580 | ||
2026 | ||||
Financial Liabilities | ||||
Other financial liabilities | 88,871 | 1,141 | ||
More than 5 years | ||||
Financial Liabilities | ||||
Other financial liabilities | 483,837 | 1,630 | ||
Biomat USA Group | ||||
Financial Liabilities | ||||
Value of ordinary shares exchanged for liability | $ | $ 990 | |||
Number of class B ordinary shares exchanged | shares | 10 | |||
Biomat Newco, Corp. | ||||
Financial Liabilities | ||||
Number of class B ordinary shares exchanged | shares | 9 | |||
GigaGen Inc. | ||||
Financial Liabilities | ||||
Amount payable relating to acquisition included in Other current financial liabilities | 39,075 | |||
Alkahest, Inc. | ||||
Financial Liabilities | ||||
Amount payable relating to acquisition included in Other current financial liabilities | € 100,492 | |||
GIC | ||||
Financial Liabilities | ||||
Other non-current financial liabilities | € 829,937 |
Financial Liabilities - Changes
Financial Liabilities - Changes in Liabilities Derived from Financing Activities (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Changes in liabilities derived from financing activities | |||
Balance at beginning of year | € 7,026,712 | € 7,207,380 | € 6,376,845 |
New financing | 3,286,471 | 116,352 | 268,001 |
Refunds | (467,338) | (273,329) | (327,413) |
Bear of interests | 269,226 | 243,877 | 244,354 |
Other movements | 107,951 | 83,236 | 676,929 |
Collection / Payment of interests | (155,120) | (155,788) | (236,179) |
Business combination (note 3) | (64,749) | 34,778 | 10,233 |
Foreign exchange differences | 204,088 | (229,794) | 194,610 |
Balance at end of year | 10,207,241 | 7,026,712 | 7,207,380 |
Bonds | |||
Changes in liabilities derived from financing activities | |||
Balance at beginning of year | 2,709,515 | 2,677,202 | 1,102,978 |
New financing | 2,126,979 | 116,352 | 1,778,218 |
Refunds | (114,480) | (105,564) | (100,215) |
Bear of interests | 100,948 | 81,880 | 37,095 |
Other movements | (33,920) | (108,874) | |
Collection / Payment of interests | (64,031) | (60,355) | (32,000) |
Foreign exchange differences | 18,523 | ||
Balance at end of year | 4,743,534 | 2,709,515 | 2,677,202 |
Senior Secured debt & Other loans | |||
Changes in liabilities derived from financing activities | |||
Balance at beginning of year | 3,468,385 | 3,687,739 | 5,165,765 |
New financing | 329,555 | (1,522,466) | |
Refunds | (266,659) | (66,047) | (145,261) |
Bear of interests | 130,327 | 124,840 | 171,535 |
Other movements | 5,445 | (10,468) | 24,121 |
Collection / Payment of interests | (91,089) | (95,433) | (204,179) |
Business combination (note 3) | 10,233 | ||
Foreign exchange differences | 131,084 | (172,246) | 187,991 |
Balance at end of year | 3,707,048 | 3,468,385 | 3,687,739 |
Finance lease liabilities | |||
Changes in liabilities derived from financing activities | |||
Balance at beginning of year | 733,499 | 740,690 | 12,885 |
Refunds | (82,692) | (79,037) | (73,785) |
Bear of interests | 35,786 | 35,084 | 34,558 |
Other movements | 135,697 | 88,867 | 761,682 |
Foreign exchange differences | 51,434 | (52,105) | 5,350 |
Balance at end of year | 873,724 | 733,499 | 740,690 |
Other Financial Liabilities [Member] | |||
Changes in liabilities derived from financing activities | |||
Balance at beginning of year | 115,313 | 101,749 | 95,217 |
New financing | 829,937 | 12,249 | |
Refunds | (3,507) | (22,681) | (8,152) |
Bear of interests | 2,165 | 2,073 | 1,166 |
Other movements | 729 | 4,837 | |
Business combination (note 3) | (64,749) | 34,778 | |
Foreign exchange differences | 3,047 | (5,443) | 1,269 |
Balance at end of year | € 882,935 | € 115,313 | € 101,749 |
Trade and Other Payables (Detai
Trade and Other Payables (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Trade and other payables | ||
Suppliers | € 628,992 | € 601,618 |
VAT payable | 13,011 | 11,694 |
Taxation authorities, withholdings payable | 7,267 | 6,829 |
Social security payable | 39,191 | 32,640 |
Other public entities | 92,365 | 89,926 |
Other payables | 151,834 | 141,089 |
Current income tax liabilities | 4,516 | 3,482 |
Total trade and other payables (note 22) | € 785,342 | € 746,189 |
Other Current Liabilities (Deta
Other Current Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Other Current Liabilities | ||
Salaries payable | € 175,710 | € 121,972 |
Other payables | 23 | 1,046 |
Deferred income | 32,970 | 22,934 |
Advances received | 10,569 | 7,210 |
Other current liabilities | € 219,272 | € 153,162 |
Net Revenues - Distribution by
Net Revenues - Distribution by Segment (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | € 4,933,118 | € 5,340,038 | € 5,098,691 |
Operating Segments | |||
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | 4,933,118 | 5,340,038 | 5,098,691 |
Intersegments | |||
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | (67,548) | (53,107) | (52,176) |
Bioscience | Operating Segments | |||
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | 3,814,983 | 4,242,502 | 3,993,462 |
Diagnostic | Operating Segments | |||
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | 779,108 | 775,889 | 733,604 |
Hospital | Operating Segments | |||
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | 141,190 | 118,675 | 134,441 |
Bio supplies. | Operating Segments | |||
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | 225,765 | 224,090 | 266,540 |
Others | Operating Segments | |||
Distribution of net consolidated revenues by segment | |||
Net revenue (notes 6 and 24) | € 39,620 | € 31,989 | € 22,820 |
Net Revenues - Geographical Dis
Net Revenues - Geographical Distribution (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Geographical distribution of net consolidated revenues | |||
Net revenue (notes 6 and 24) | € 4,933,118 | € 5,340,038 | € 5,098,691 |
USA and Canada | |||
Geographical distribution of net consolidated revenues | |||
Net revenue (notes 6 and 24) | 3,154,549 | 3,599,746 | 3,390,811 |
Spain | |||
Geographical distribution of net consolidated revenues | |||
Net revenue (notes 6 and 24) | 362,407 | 339,169 | 268,287 |
European Union | |||
Geographical distribution of net consolidated revenues | |||
Net revenue (notes 6 and 24) | 544,042 | 495,323 | 588,375 |
Rest of the world | |||
Geographical distribution of net consolidated revenues | |||
Net revenue (notes 6 and 24) | € 872,120 | € 905,800 | € 851,218 |
Net Revenues - Discounts and Ot
Net Revenues - Discounts and Other Reductions (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Discounts and other reductions in gross income | |||
Gross sales | € 6,234,277 | € 6,806,005 | € 6,429,762 |
Chargebacks | (1,101,896) | (1,247,153) | (1,119,540) |
Cash discounts | (60,019) | (68,912) | (70,340) |
Volume rebates | (49,043) | (57,858) | (56,426) |
Medicare and Medicaid | (53,440) | (61,089) | (50,442) |
Other discounts | (36,761) | (30,955) | (34,323) |
Total net sales | € 4,933,118 | € 5,340,038 | € 5,098,691 |
Net Revenues - Movement in Disc
Net Revenues - Movement in Discounts and Other Reductions (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Movement in Chargebacks | |||
Balance at beginning of year | € 190,869 | € 90,488 | € 75,175 |
Current estimate related to sales made in current and prior year | 1,101,896 | 1,247,153 | 1,119,540 |
(Actual returns or credits in current period related to sales made in current period) | (1,080,304) | (1,033,053) | (1,104,493) |
(Actual returns or credits in current period related to sales made in prior periods) | (65,681) | (97,504) | 275 |
Translation differences | 13,066 | (16,215) | (9) |
Balance at end of year | 159,846 | 190,869 | 90,488 |
Movement in Cash discounts | |||
Balance at beginning of year | 6,795 | 5,897 | 6,441 |
Current estimate related to sales made in current and prior year | 60,019 | 68,912 | 70,340 |
(Actual returns or credits in current period related to sales made in current period) | (54,554) | (61,387) | (64,523) |
(Actual returns or credits in current period related to sales made in prior periods) | (6,964) | (6,030) | (6,385) |
Translation differences | 405 | (597) | 24 |
Balance at end of year | 5,701 | 6,795 | 5,897 |
Movement in Volume rebates | |||
Balance at beginning of year | 29,670 | 28,705 | 24,797 |
Current estimate related to sales made in current and prior year | 49,043 | 57,858 | 56,426 |
(Actual returns or credits in current period related to sales made in current period) | (29,617) | (27,798) | (28,014) |
(Actual returns or credits in current period related to sales made in prior periods) | (29,304) | (26,481) | (25,050) |
Translation differences | 1,454 | (2,614) | 546 |
Balance at end of year | 21,246 | 29,670 | 28,705 |
Movement in Medicare / Medicaid | |||
Balance at beginning of year | 28,451 | 18,911 | 22,941 |
Current estimate related to sales made in current and prior year | 53,440 | 61,089 | 50,442 |
(Actual returns or credits in current period related to sales made in current period) | (42,890) | (34,564) | (34,486) |
(Actual returns or credits in current period related to sales made in prior periods) | (15,422) | (14,526) | (20,375) |
Translation differences | 2,035 | (2,459) | 389 |
Balance at end of year | 25,614 | 28,451 | 18,911 |
Movement in Other discounts | |||
Balance at beginning of year | 11,763 | 15,071 | 8,837 |
Current estimate related to sales made in current and prior year | 36,761 | 30,955 | 34,323 |
(Actual returns or credits in current period related to sales made in current period) | (27,036) | (30,509) | (22,490) |
(Actual returns or credits in current period related to sales made in prior periods) | (11,057) | (3,615) | (5,652) |
Translation differences | 154 | (139) | 53 |
Balance at end of year | 10,585 | 11,763 | 15,071 |
Total movement in discounts and other reductions | |||
Balance at beginning of year | 267,548 | 159,072 | 138,191 |
Current estimate related to sales made in current and prior year | 1,301,159 | 1,465,966 | 1,331,071 |
(Actual returns or credits in current period related to sales made in current period) | (1,234,401) | (1,187,311) | (1,254,006) |
(Actual returns or credits in current period related to sales made in prior periods) | (128,428) | (148,156) | (57,187) |
Translation differences | 17,114 | (22,023) | 1,003 |
Balance at end of year | € 222,992 | € 267,548 | € 159,072 |
Personnel Expenses (Details)
Personnel Expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Details of personnel expenses by function: | |||
Personnel expenses | € 1,539,366 | € 1,552,665 | € 1,477,633 |
Details by nature: | |||
Wages and salaries | 1,231,812 | 1,234,761 | 1,178,527 |
Contributions to pension plans (see note 29) | 31,757 | 33,226 | 29,941 |
Other social charges | 27,387 | 27,462 | 28,785 |
Social Security | 248,410 | 257,216 | 240,380 |
Total personnel expenses | 1,539,366 | 1,552,665 | 1,477,633 |
Personnel expenses resulted from discontinuation of the Blood Collection Systems activity | 6,900 | ||
Cost of sales | |||
Details of personnel expenses by function: | |||
Personnel expenses | 999,347 | 1,058,132 | 988,689 |
Details by nature: | |||
Total personnel expenses | 999,347 | 1,058,132 | 988,689 |
Research and development | |||
Details of personnel expenses by function: | |||
Personnel expenses | 138,629 | 110,682 | 106,472 |
Details by nature: | |||
Total personnel expenses | 138,629 | 110,682 | 106,472 |
Selling, general & administration expenses | |||
Details of personnel expenses by function: | |||
Personnel expenses | 401,390 | 383,851 | 382,472 |
Details by nature: | |||
Total personnel expenses | € 401,390 | € 383,851 | € 382,472 |
Expenses by Nature - Amortizati
Expenses by Nature - Amortization and Depreciation (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of attribution of expenses by nature to their function [line items] | |||
Amortization and depreciation | € 359,767 | € 321,533 | € 302,455 |
Cost of sales | |||
Disclosure of attribution of expenses by nature to their function [line items] | |||
Amortization and depreciation | 211,676 | 198,310 | 193,081 |
Research and development | |||
Disclosure of attribution of expenses by nature to their function [line items] | |||
Amortization and depreciation | 55,311 | 32,814 | 22,471 |
Selling, general & administration expenses | |||
Disclosure of attribution of expenses by nature to their function [line items] | |||
Amortization and depreciation | € 92,780 | € 90,409 | € 86,903 |
Expenses by Nature - Other Oper
Expenses by Nature - Other Operating Income and Expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of attribution of expenses by nature to their function [line items] | |||
Other operating income and expenses | € 1,232,998 | € 1,156,627 | € 1,091,803 |
Cost of sales | |||
Disclosure of attribution of expenses by nature to their function [line items] | |||
Other operating income and expenses | 535,058 | 500,415 | 467,705 |
Research and development | |||
Disclosure of attribution of expenses by nature to their function [line items] | |||
Other operating income and expenses | 165,884 | 156,994 | 166,177 |
Selling, general & administration expenses | |||
Disclosure of attribution of expenses by nature to their function [line items] | |||
Other operating income and expenses | € 532,056 | € 499,218 | € 457,921 |
Expenses by Nature - Other Op_2
Expenses by Nature - Other Operating Income and Expenses, Components (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Details by nature: | |||
Changes in trade provisions | € 4,844 | € (14,059) | € (19,811) |
Professional services | 258,371 | 265,539 | 244,355 |
Commissions | 28,671 | 27,147 | 32,178 |
Supplies and auxiliary materials | 197,893 | 187,370 | 170,021 |
Operating leases (note 9) | 32,945 | 28,176 | 33,235 |
Freight | 148,797 | 137,466 | 130,663 |
Repair and maintenance expenses | 150,308 | 147,039 | 136,377 |
Advertising | 71,280 | 55,073 | 59,063 |
Insurance | 38,724 | 30,776 | 25,647 |
Royalties | 48,446 | 40,634 | 10,674 |
Travel expenses | 30,334 | 23,005 | 61,346 |
External services | 74,858 | 71,240 | 64,099 |
R&D Expenses | 106,873 | 101,410 | 103,053 |
Other | 40,654 | 55,811 | 40,903 |
Total other operating income and expenses | € 1,232,998 | € 1,156,627 | € 1,091,803 |
Finance Result (Details)
Finance Result (Details) - EUR (€) € in Thousands | Mar. 30, 2020 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Finance Result | ||||||
Finance income | € 11,551 | € 8,021 | € 114,197 | |||
Finance cost from Senior Unsecured Notes | (104,944) | (85,182) | (41,920) | |||
Finance cost from senior debt | (111,719) | (119,140) | (262,797) | |||
Finance cost from sale of receivables | (10,292) | (10,964) | (9,171) | |||
Capitalized interest | 18,636 | 16,606 | 14,894 | |||
Finance lease expense | (35,786) | (35,205) | (34,558) | |||
Other finance costs | (33,889) | (15,754) | (9,413) | |||
Finance costs | (277,994) | (249,639) | (342,965) | |||
Impairment and gains / (losses) on disposal of financial instruments | (37,666) | |||||
Change in fair value of financial instruments | 246 | 55,703 | 1,326 | |||
Exchange differences | (11,602) | 8,246 | (9,616) | |||
Finance result | € (277,799) | € (177,669) | (274,724) | |||
Income from refinancing effect | 97,850 | |||||
Minimum | ||||||
Finance Result | ||||||
Capitalized interest rate (as a percent) | 3.71% | 3.72% | ||||
Maximum | ||||||
Finance Result | ||||||
Capitalized interest rate (as a percent) | 4.15% | 4.70% | ||||
Shanghai RAAS Blood Products Co., Ltd. | ||||||
Finance Result | ||||||
Change in fair value of financial instruments | € 56,526 | € 56,526 | ||||
Profit recognized as a result of change in contractual right value | € 1,000 | |||||
Shanghai RAAS Blood Products Co., Ltd. | Grifols Diagnostics Solutions, Inc. | ||||||
Finance Result | ||||||
Number of subsidiary's shares delivered in exchange for investment | 90 | 90 |
Taxation - Reconciliation of Ac
Taxation - Reconciliation of Accounting and Taxable Income (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation of accounting and taxable income | |||
Profit before income tax from continuing operations | € 350,453 | € 878,629 | € 817,103 |
Tax at 25% | 87,613 | 219,657 | 204,276 |
Permanent differences | 2,503 | (7,181) | 6,104 |
Effect of different tax rates | (8,720) | (30,686) | (22,564) |
Tax credits (deductions) | (14,998) | (14,980) | (12,702) |
Prior year income tax expense | 18,908 | 517 | (3,722) |
Other income tax expenses/(income) | (180) | 2,312 | (2,933) |
Total income tax expense | € 85,126 | € 169,639 | € 168,459 |
United States | |||
Taxation | |||
Tax rate of the companies domiciled in the U.S.A (as a percent) | 22.00% | ||
Spain. | |||
Reconciliation of accounting and taxable income | |||
Tax rate (as a percent) | 25.00% |
Taxation - Income Tax Expense -
Taxation - Income Tax Expense - Deferred Tax Assets and Liabilities (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation of accounting and taxable income | |||
Deferred tax | € 17,754 | € 43,138 | € 58,275 |
Current tax | 67,372 | 126,501 | 110,184 |
Total income tax expense | € 85,126 | € 169,639 | € 168,459 |
Taxation - Deferred Tax Assets
Taxation - Deferred Tax Assets and Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Deferred tax assets and liabilities | |||
Deferred assets, net | € 152,507 | € 149,921 | € 123,024 |
Net deferred Liabilities | (633,984) | (556,813) | (463,827) |
Assets. | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | 154,463 | 185,034 | 162,139 |
Net deferred Liabilities | 75,873 | 74,284 | 100,595 |
Assets. | Provisions. | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | 8,387 | 3,942 | 6,228 |
Net deferred Liabilities | 37,671 | 36,663 | 39,366 |
Assets. | Inventories | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | 47,908 | 59,129 | 51,838 |
Net deferred Liabilities | 5,532 | 1,673 | 2,408 |
Assets. | Tax credit rights | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | 26,425 | 57,896 | 61,476 |
Assets. | Tax loss carryforwards | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | 51,750 | 53,063 | 36,066 |
Net deferred Liabilities | 2,160 | 12,024 | 24,734 |
Assets. | Other | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | 19,993 | 11,004 | 6,531 |
Net deferred Liabilities | 30,510 | 23,924 | 34,087 |
Liabilities | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | (1,956) | (35,113) | (39,115) |
Net deferred Liabilities | (709,857) | (631,097) | (564,422) |
Liabilities | Goodwill [member] | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | (2,106) | (30,040) | (27,721) |
Net deferred Liabilities | (272,596) | (215,907) | (194,964) |
Liabilities | Fixed assets, amortisation and depreciation | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | 3,151 | (3,011) | (2,821) |
Net deferred Liabilities | (86,899) | (78,325) | (88,498) |
Liabilities | Intangible assets | |||
Deferred tax assets and liabilities | |||
Deferred assets, net | (3,001) | (2,062) | (8,573) |
Net deferred Liabilities | (288,819) | (270,145) | (214,993) |
Liabilities | Debt cancellation costs | |||
Deferred tax assets and liabilities | |||
Net deferred Liabilities | € (61,543) | € (66,720) | € (65,967) |
Taxation - Movement in Deferred
Taxation - Movement in Deferred Tax Assets and Liabilities (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Deferred tax assets and liabilities | |||
Balance at 1 January | € 406,892 | € 340,803 | € 291,859 |
Movements during the year | (17,754) | (43,138) | (58,275) |
Business combination (note 3) | (16,400) | (47,988) | |
Translation differences | (40,431) | 25,037 | 9,331 |
Balance at 31 December | € 481,477 | € 406,892 | € 340,803 |
Taxation - Deferred Tax Asset_2
Taxation - Deferred Tax Assets and Liabilities by Jurisdiction (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | € 481,477 | € 406,892 | € 340,803 | € 291,859 |
United States | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | 562,825 | 445,684 | 337,700 | |
Spain | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (13,270) | (26,491) | (31,521) | |
Others. | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (68,078) | (12,301) | 34,624 | |
Net deferred tax | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | 559,652 | 529,875 | 463,078 | |
Net deferred tax | United States | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | 578,061 | 466,961 | 392,040 | |
Net deferred tax | Spain | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | 17,963 | 36,298 | 35,117 | |
Net deferred tax | Others. | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (36,372) | 26,616 | 35,921 | |
Tax credit rights | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (26,425) | (57,896) | (60,799) | |
Tax credit rights | United States | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (54,340) | |||
Tax credit rights | Spain | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (26,425) | (57,861) | (5,162) | |
Tax credit rights | Others. | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (35) | (1,297) | ||
Tax loss carryforwards | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (51,750) | (65,087) | (61,476) | |
Tax loss carryforwards | United States | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (15,236) | (21,277) | ||
Tax loss carryforwards | Spain | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | (4,808) | (4,928) | € (61,476) | |
Tax loss carryforwards | Others. | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Net deferred tax | € (31,706) | € (38,882) |
Taxation - Deferred Tax Asset_3
Taxation - Deferred Tax Assets and Liabilities, Others (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Deferred tax assets and liabilities | ||||
Net deferred tax assets | € 152,507 | € 149,921 | € 123,024 | |
Deferred tax assets | 152,507 | 149,921 | ||
Net deferred tax liability (asset) | 481,477 | 406,892 | 340,803 | € 291,859 |
Unrecognized deferred tax on investments in subsidiaries | € 52,119 | 51,537 | ||
Spain. | ||||
Deferred tax assets and liabilities | ||||
Tax deduction maturity term | 18 years | |||
Estimated period for application of entire amount of tax deduction | 5 years | |||
Tax credit carryforward, exclusively for Spanish companies registered in the Basque Country (in years) | 15 years | |||
United States | ||||
Deferred tax assets and liabilities | ||||
Tax credit carryforward (in years) | 20 years | |||
Net deferred tax liability (asset) | € 562,825 | 445,684 | 337,700 | |
Less than 12 months | ||||
Deferred tax assets and liabilities | ||||
Net deferred tax assets | 57,183 | 89,750 | ||
Tax loss carryforwards that will be recovered in less than 5 years | ||||
Deferred tax assets and liabilities | ||||
Deferred tax assets | € 48,453 | 48,000 | ||
Period available to offset the pending tax loss carryforwards | 5 years | |||
Tax loss carryforwards | ||||
Deferred tax assets and liabilities | ||||
Deferred tax assets | € 53,910 | 60,700 | ||
Net deferred tax liability (asset) | (51,750) | (65,087) | € (61,476) | |
Unrecognized deferred tax assets | 123,407 | 93,585 | ||
Tax loss carryforwards | United States | ||||
Deferred tax assets and liabilities | ||||
Net deferred tax liability (asset) | € (15,236) | € (21,277) |
Other Commitments with Third _3
Other Commitments with Third Parties and Other Contingent Liabilities (Details) € in Thousands, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2021EUR (€)directoritem | Dec. 31, 2021USD ($)item | Dec. 31, 2020EUR (€) | Dec. 31, 2020USD ($) | Dec. 31, 2021USD ($)directoritem | |
Other Commitments with Third Parties and Other Contingent Liabilities | |||||
Annual contribution to defined contribution pension plans | € 948 | € 896 | |||
Agreements with employees/directors | director | 50 | 50 | |||
Number of executives with whom contract entered | item | 5 | 5 | |||
Percentage of annual bonus in Grifols Class B Shares or Grifols ADS | 50.00% | 50.00% | |||
Percentage of employee contributions vested one | 4.00% | 4.00% | |||
Percentage employee contributions vested two | 2.00% | 2.00% | |||
Vesting Period | 2 years 1 day | 2 years 1 day | |||
Exchange ratio | 1 | 1 | |||
Amount settled under RSU plan | € 7,782 | 7,552 | |||
Equity-settled commitment | € 9,838 | € 13,880 | |||
Percentage of Group contribution matching to first 4% of employee contributions | 100.00% | 100.00% | |||
Percentage of Group contribution matching to the next 2% following the first 4% of employee contributions | 50.00% | 50.00% | |||
Hearing suspension period | 60 days | 60 days | |||
Total cost of matching contributions | $ | $ 31.8 | $ 32.2 | |||
Number of Biomat donors for Illinois Biomat Centers | item | 54,000 | 54,000 | |||
Period of Biomat Donors | 4 years | 4 years | |||
BIPA penalty for negligent violation | € 1,000 | ||||
Legal proceedings contingent liability | SIEMENS HEALTHCARE DIAGNOSTICS, INC. adv. ORTHO-CLINICAL DIAGNOSTICS, INC., GRIFOLS DIAGNOSTIC SOLUTIONS INC. | |||||
Other Commitments with Third Parties and Other Contingent Liabilities | |||||
Amount awarded to the company/Ortho | $ | $ 12 | ||||
Legal proceedings contingent liability | ABBOTT LABORATORIES v. GRIFOLS DIAGNOSTIC SOLUTIONS INC., GRIFOLS WORLDWIDE OPERATIONS LIMITED AND NOVARTIS VACCINES AND DIAGNOSTICS, INC | |||||
Other Commitments with Third Parties and Other Contingent Liabilities | |||||
Amount awarded to the company/Ortho | $ | $ 4 | ||||
Minimum | |||||
Other Commitments with Third Parties and Other Contingent Liabilities | |||||
Number of years of salary for employees/directors | 2 years | 2 years | |||
Number of years of salary for executives | 1 year | 1 year | |||
Maximum | |||||
Other Commitments with Third Parties and Other Contingent Liabilities | |||||
Number of years of salary for employees/directors | 5 years | 5 years | |||
Number of years of salary for executives | 4 years | 4 years | |||
Matching percentage to the employees contribution | 50.00% | 50.00% |
Other Commitments with Third _4
Other Commitments with Third Parties and Other Contingent Liabilities - Purchase commitments (Details) € in Thousands | Dec. 31, 2021EUR (€) |
Less than 12 months | |
Other Commitments with Third Parties and Other Contingent Liabilities | |
Purchase commitments | € 90,413 |
2023 | |
Other Commitments with Third Parties and Other Contingent Liabilities | |
Purchase commitments | 78,909 |
2024 | |
Other Commitments with Third Parties and Other Contingent Liabilities | |
Purchase commitments | 72,103 |
2025 | |
Other Commitments with Third Parties and Other Contingent Liabilities | |
Purchase commitments | 1,116 |
2026 | |
Other Commitments with Third Parties and Other Contingent Liabilities | |
Purchase commitments | € 651 |
Financial Instruments - Classif
Financial Instruments - Classification by Nature, Category and Fair Value (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Financial instruments | ||
Financial Assets (Liabilities) | € (7,672,945) | |
Measured at fair value | ||
Financial instruments | ||
Financial assets | 223,777 | € 311,493 |
Financial liabilities, at fair value | (875) | |
Measured at fair value | Non-current financial asset | ||
Financial instruments | ||
Financial assets | 2,038 | 3,008 |
Financial assets, at fair value | 2,038 | 3,008 |
Measured at fair value | Trade receivables | ||
Financial instruments | ||
Financial assets | 216,433 | 308,485 |
Financial assets, at fair value | 216,433 | 308,485 |
Measured at fair value | Derivatives Instrument | ||
Financial instruments | ||
Financial assets | 5,306 | |
Financial assets, at fair value | 5,306 | |
Financial liabilities | (875) | |
Financial liabilities, at fair value | (875) | |
Measured at fair value | Level 1 | Non-current financial asset | ||
Financial instruments | ||
Financial assets, at fair value | 7 | 1,128 |
Measured at fair value | Level 2 | Trade receivables | ||
Financial instruments | ||
Financial assets, at fair value | 216,433 | 308,485 |
Measured at fair value | Level 2 | Derivatives Instrument | ||
Financial instruments | ||
Financial assets, at fair value | 5,306 | |
Financial liabilities | (875) | |
Measured at fair value | Level 3 | Non-current financial asset | ||
Financial instruments | ||
Financial assets, at fair value | 2,031 | 1,880 |
Not measured at fair value | ||
Financial instruments | ||
Financial assets | 3,310,950 | 933,022 |
Financial liabilities | (11,206,797) | (7,938,972) |
Financial Assets (Liabilities) | (6,694,457) | |
Not measured at fair value | Senior Unsecured and Secured Notes | ||
Financial instruments | ||
Financial liabilities | (2,601,479) | |
Financial liabilities, at fair value | (2,705,437) | |
Not measured at fair value | Senior Unsecured Notes | ||
Financial instruments | ||
Financial liabilities | (4,626,919) | |
Financial liabilities, at fair value | (4,697,328) | |
Not measured at fair value | Promissory Notes | ||
Financial instruments | ||
Financial liabilities | (116,610) | (111,622) |
Not measured at fair value | Senior Secured debt | ||
Financial instruments | ||
Financial liabilities | (3,061,078) | (3,110,298) |
Financial liabilities, at fair value | (3,262,901) | (3,358,729) |
Not measured at fair value | Other bank loans | ||
Financial instruments | ||
Financial liabilities | (645,975) | (354,501) |
Not measured at fair value | Lease liabilities. | ||
Financial instruments | ||
Financial liabilities | (873,724) | (733,499) |
Not measured at fair value | Other Financial Liabilities [Member] | ||
Financial instruments | ||
Financial liabilities | (882,060) | (115,313) |
Not measured at fair value | Other non-current debt | ||
Financial instruments | ||
Financial liabilities | (333) | (16,391) |
Not measured at fair value | Trade payables. | ||
Financial instruments | ||
Financial liabilities | (780,826) | (742,707) |
Not measured at fair value | Other current liabilities | ||
Financial instruments | ||
Financial liabilities | (219,272) | (153,162) |
Not measured at fair value | Non-current financial assets. | ||
Financial instruments | ||
Financial assets | 358,161 | 195,149 |
Not measured at fair value | Other current financial assets | ||
Financial instruments | ||
Financial assets | 2,026,469 | 11,118 |
Not measured at fair value | Trade and other receivables | ||
Financial instruments | ||
Financial assets | 270,827 | 147,108 |
Not measured at fair value | Cash and cash equivalents | ||
Financial instruments | ||
Financial assets | 655,493 | 579,647 |
Not measured at fair value | Level 1 | Senior Unsecured and Secured Notes | ||
Financial instruments | ||
Financial liabilities, at fair value | (2,705,437) | |
Not measured at fair value | Level 1 | Senior Unsecured Notes | ||
Financial instruments | ||
Financial liabilities, at fair value | (4,697,328) | |
Not measured at fair value | Level 2 | Senior Secured debt | ||
Financial instruments | ||
Financial liabilities, at fair value | (3,262,901) | (3,358,729) |
Amortised cost. | Not measured at fair value | ||
Financial instruments | ||
Financial liabilities | (10,987,192) | (7,769,419) |
Financial Assets (Liabilities) | (10,987,192) | (7,769,419) |
Amortised cost. | Not measured at fair value | Senior Unsecured and Secured Notes | ||
Financial instruments | ||
Financial liabilities | (2,601,479) | |
Amortised cost. | Not measured at fair value | Senior Unsecured Notes | ||
Financial instruments | ||
Financial liabilities | (4,626,919) | |
Amortised cost. | Not measured at fair value | Promissory Notes | ||
Financial instruments | ||
Financial liabilities | (116,610) | (111,622) |
Amortised cost. | Not measured at fair value | Senior Secured debt | ||
Financial instruments | ||
Financial liabilities | (3,061,078) | (3,110,298) |
Amortised cost. | Not measured at fair value | Other bank loans | ||
Financial instruments | ||
Financial liabilities | (645,975) | (354,501) |
Amortised cost. | Not measured at fair value | Lease liabilities. | ||
Financial instruments | ||
Financial liabilities | (873,724) | (733,499) |
Amortised cost. | Not measured at fair value | Other Financial Liabilities [Member] | ||
Financial instruments | ||
Financial liabilities | (882,060) | (115,313) |
Amortised cost. | Not measured at fair value | Trade payables. | ||
Financial instruments | ||
Financial liabilities | (780,826) | (742,707) |
Other financial liabilities. | Not measured at fair value | ||
Financial instruments | ||
Financial liabilities | (219,605) | (169,553) |
Financial Assets (Liabilities) | (219,605) | (169,553) |
Other financial liabilities. | Not measured at fair value | Other non-current debt | ||
Financial instruments | ||
Financial liabilities | (333) | (16,391) |
Other financial liabilities. | Not measured at fair value | Other current liabilities | ||
Financial instruments | ||
Financial liabilities | (219,272) | (153,162) |
Amortised cost | Not measured at fair value | ||
Financial instruments | ||
Financial assets | 3,310,950 | 933,022 |
Financial Assets (Liabilities) | 3,310,950 | 933,022 |
Amortised cost | Not measured at fair value | Non-current financial assets. | ||
Financial instruments | ||
Financial assets | 358,161 | 195,149 |
Amortised cost | Not measured at fair value | Other current financial assets | ||
Financial instruments | ||
Financial assets | 2,026,469 | 11,118 |
Amortised cost | Not measured at fair value | Trade and other receivables | ||
Financial instruments | ||
Financial assets | 270,827 | 147,108 |
Amortised cost | Not measured at fair value | Cash and cash equivalents | ||
Financial instruments | ||
Financial assets | 655,493 | 579,647 |
Financial assets at fair value through profit or loss | Measured at fair value | ||
Financial instruments | ||
Financial assets | 7 | 1,128 |
Financial liabilities, at fair value | (875) | |
Financial Assets (Liabilities) | (868) | 1,128 |
Financial assets at fair value through profit or loss | Measured at fair value | Non-current financial asset | ||
Financial instruments | ||
Financial assets | 7 | 1,128 |
Financial assets at fair value through profit or loss | Measured at fair value | Derivatives Instrument | ||
Financial instruments | ||
Financial liabilities | (875) | |
Financial assets at fair value through OCI | Measured at fair value | ||
Financial instruments | ||
Financial assets | 218,464 | 310,365 |
Financial Assets (Liabilities) | 218,464 | 310,365 |
Financial assets at fair value through OCI | Measured at fair value | Non-current financial asset | ||
Financial instruments | ||
Financial assets | 2,031 | 1,880 |
Financial assets at fair value through OCI | Measured at fair value | Trade receivables | ||
Financial instruments | ||
Financial assets | 216,433 | € 308,485 |
Hedges | ||
Financial instruments | ||
Financial Assets (Liabilities) | 5,306 | |
Hedges | Measured at fair value | ||
Financial instruments | ||
Financial assets | 5,306 | |
Hedges | Measured at fair value | Derivatives Instrument | ||
Financial instruments | ||
Financial assets | € 5,306 |
Financial Instruments - Financi
Financial Instruments - Financial derivatives (Details) € in Thousands, $ in Thousands | Dec. 31, 2021EUR (€) | Dec. 31, 2021USD ($) | Oct. 05, 2021USD ($) |
Derivatives Instrument | |||
Disclosure of detailed information about financial instruments [line items] | |||
Total | € 4,431 | ||
Total Assets (notes 2 and 11) | 5,306 | ||
Total Liabilities (notes 21 and 30) | (875) | ||
Currency swap contract | |||
Disclosure of detailed information about financial instruments [line items] | |||
Notional amount | $ | $ 500,000,000 | ||
Total Assets (notes 2 and 11) | $ | $ 5,306 | ||
Currency swap contract | US Dollar | |||
Disclosure of detailed information about financial instruments [line items] | |||
Notional amount | $ | $ 500,000 | ||
Foreign exchange rate forward | |||
Disclosure of detailed information about financial instruments [line items] | |||
Notional amount | 51,000,000 | ||
Total Liabilities (notes 21 and 30) | € (875) |
Financial Instruments - Finan_2
Financial Instruments - Financial derivatives - Hedging derivative financial instruments (Details) € in Thousands, $ in Thousands | Oct. 05, 2021EUR (€)item | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2021USD ($) | Oct. 05, 2021USD ($) |
Disclosure of detailed information about financial instruments [line items] | ||||||
Number of cross currency interest-rate swap | item | 3 | |||||
Loans received | € 3,707,053 | € 3,464,799 | ||||
Net finance cost | (277,799) | € (177,669) | € (274,724) | |||
Euros | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Loans received | € 431,600 | |||||
US Dollar | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Loans given | $ | $ 500,000 | |||||
Derivatives Instrument | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Net finance cost | € 280 | |||||
Currency swap contract | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Notional amount | $ | $ 500,000,000 | |||||
Currency swap contract | Euros | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Nominal interest rate for loans received | 3.78% | 3.78% | ||||
Currency swap contract | US Dollar | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Notional amount | $ | $ 500,000 | |||||
Nominal interest rate for loans given | 4.75% |
Financial Instruments - Maximum
Financial Instruments - Maximum Level of Exposure to Credit Risk (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Credit risk | ||
Maximum exposure to credit risk | € 3,496,888 | € 1,196,532 |
Non-current financial assets. | ||
Credit risk | ||
Maximum exposure to credit risk | 362,267 | 198,157 |
Other current financial assets | ||
Credit risk | ||
Maximum exposure to credit risk | 2,029,707 | 11,118 |
Trade receivables | ||
Credit risk | ||
Maximum exposure to credit risk | 432,197 | 383,233 |
Other receivables | ||
Credit risk | ||
Maximum exposure to credit risk | 17,224 | 24,377 |
Cash and cash equivalents | ||
Credit risk | ||
Maximum exposure to credit risk | 655,493 | 579,647 |
Trade and other receivables | ||
Credit risk | ||
Maximum exposure to credit risk | 449,421 | 407,610 |
Trade and other receivables | Spain. | ||
Credit risk | ||
Maximum exposure to credit risk | 62,108 | 62,358 |
Trade and other receivables | Rest of European Union | ||
Credit risk | ||
Maximum exposure to credit risk | 40,897 | 84,962 |
Trade and other receivables | United States | ||
Credit risk | ||
Maximum exposure to credit risk | 108,685 | 157,395 |
Trade and other receivables | Other European countries | ||
Credit risk | ||
Maximum exposure to credit risk | 25,163 | 10,525 |
Trade and other receivables | Other regions | ||
Credit risk | ||
Maximum exposure to credit risk | € 212,568 | € 92,370 |
Financial Instruments - Credit
Financial Instruments - Credit Risk - Trade receivables net of the bad debt provision by ageing (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Credit risk | ||
Trade receivables | € 432,197 | € 383,233 |
Gross carrying amount | ||
Credit risk | ||
Trade receivables | 456,206 | 406,218 |
Provision | ||
Credit risk | ||
Trade receivables | € (24,009) | € (22,985) |
not matured | ||
Credit risk | ||
ECL Rate | 0.19% | 0.19% |
Trade receivables | € 362,154 | € 283,097 |
not matured | Gross carrying amount | ||
Credit risk | ||
Trade receivables | 362,599 | 283,612 |
not matured | Provision | ||
Credit risk | ||
Trade receivables | € (445) | € (515) |
Less than 1 month | ||
Credit risk | ||
ECL Rate | 0.19% | 0.19% |
Trade receivables | € 32,572 | € 34,228 |
Less than 1 month | Gross carrying amount | ||
Credit risk | ||
Trade receivables | 32,623 | 34,282 |
Less than 1 month | Provision | ||
Credit risk | ||
Trade receivables | € (51) | € (54) |
Past due 31-60 days | ||
Credit risk | ||
ECL Rate | 0.62% | 0.62% |
Trade receivables | € 14,065 | € 9,100 |
Past due 31-60 days | Gross carrying amount | ||
Credit risk | ||
Trade receivables | 14,144 | 9,157 |
Past due 31-60 days | Provision | ||
Credit risk | ||
Trade receivables | € (79) | € (57) |
Past due 61-90 days | ||
Credit risk | ||
ECL Rate | 2.03% | 2.03% |
Trade receivables | € 6,423 | € 6,030 |
Past due 61-90 days | Gross carrying amount | ||
Credit risk | ||
Trade receivables | 6,556 | 6,155 |
Past due 61-90 days | Provision | ||
Credit risk | ||
Trade receivables | € (133) | € (125) |
Past due 91-180 days | ||
Credit risk | ||
ECL Rate | 3.01% | 3.01% |
Trade receivables | € 10,689 | € 16,335 |
Past due 91-180 days | Gross carrying amount | ||
Credit risk | ||
Trade receivables | 11,000 | 16,546 |
Past due 91-180 days | Provision | ||
Credit risk | ||
Trade receivables | € (311) | € (211) |
6 - 12 months | ||
Credit risk | ||
ECL Rate | 8.52% | 8.52% |
Trade receivables | € 6,294 | € 34,443 |
6 - 12 months | Gross carrying amount | ||
Credit risk | ||
Trade receivables | 6,543 | 34,768 |
6 - 12 months | Provision | ||
Credit risk | ||
Trade receivables | € (249) | € (325) |
More than one year | ||
Credit risk | ||
ECL Rate | 100.00% | 100.00% |
More than one year | Gross carrying amount | ||
Credit risk | ||
Trade receivables | € 3,911 | € 4,861 |
More than one year | Provision | ||
Credit risk | ||
Trade receivables | (3,911) | (4,861) |
Customers with Objective Evidence of Impairment [Member] | Gross carrying amount | ||
Credit risk | ||
Trade receivables | 18,830 | 16,837 |
Customers with Objective Evidence of Impairment [Member] | Provision | ||
Credit risk | ||
Trade receivables | € (18,830) | € (16,837) |
Financial Instruments - Trade R
Financial Instruments - Trade Receivables - Movement in the bad debt provision (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Movement in the bad debt provision | |||
Opening balance | € 22,985 | € 22,291 | € 20,531 |
Net charges for the year | 6,471 | 2,436 | 4,971 |
Net cancellations for the year | (6,269) | (124) | (3,142) |
Transfers | (29) | (19) | |
Translation differences | 822 | (1,589) | (50) |
Closing balance | € 24,009 | € 22,985 | € 22,291 |
Financial Instruments - Contrac
Financial Instruments - Contractual Maturity Dates of Financial Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Carrying amount at | ||
Bank loans | € 3,707,053 | € 3,464,799 |
Other financial liabilities | 882,060 | 115,313 |
Bonds and other marketable securities | 4,743,529 | 2,713,101 |
Lease liabilities | 873,724 | 733,499 |
Payable to suppliers | 628,992 | 601,618 |
Other current liabilities | 43,562 | 31,190 |
Financial derivatives | 875 | |
Financial derivatives | 875 | |
Total carrying amount | 10,879,795 | 7,659,520 |
Contractual flows | ||
Bank loans | 4,309,621 | 4,176,075 |
Other financial liabilities | 1,294,873 | 115,314 |
Bonds and other marketable securities | 5,663,320 | 3,119,194 |
Lease liabilities | 873,723 | 733,499 |
Payable to suppliers | 628,992 | 601,618 |
Other current liabilities | 43,562 | 31,190 |
Financial derivatives | 875 | |
Financial liabilities for hedging derivatives | 875 | |
Total contractual flows | 12,814,966 | 8,776,890 |
6 months or less | ||
Carrying amount at | ||
Financial derivatives | 875 | |
Contractual flows | ||
Bank loans | 476,397 | 190,659 |
Other financial liabilities | 41,934 | 103,397 |
Bonds and other marketable securities | 2,215,138 | 144,756 |
Lease liabilities | 24,640 | 21,896 |
Payable to suppliers | 622,091 | 601,585 |
Other current liabilities | 42,387 | 30,369 |
Financial derivatives | 875 | |
Financial liabilities for hedging derivatives | 875 | |
Total contractual flows | 3,423,462 | 1,092,662 |
6 - 12 months | ||
Contractual flows | ||
Bank loans | 78,524 | 89,704 |
Other financial liabilities | 1,300 | 1,645 |
Bonds and other marketable securities | 170,572 | 32,016 |
Lease liabilities | 23,927 | 20,746 |
Payable to suppliers | 6,901 | 33 |
Other current liabilities | 1,175 | 821 |
Total contractual flows | 282,399 | 144,965 |
2023 | ||
Contractual flows | ||
Bank loans | 102,070 | 134,789 |
Other financial liabilities | 164,718 | 3,372 |
Bonds and other marketable securities | 48,538 | 64,031 |
Lease liabilities | 47,595 | 40,961 |
Total contractual flows | 362,921 | 243,153 |
2-5 years | ||
Contractual flows | ||
Bank loans | 3,641,777 | 502,605 |
Other financial liabilities | 448,161 | 5,515 |
Bonds and other marketable securities | 3,145,255 | 2,091,066 |
Lease liabilities | 184,032 | 158,032 |
Total contractual flows | 7,419,225 | 2,757,218 |
More than 5 years | ||
Contractual flows | ||
Bank loans | 10,853 | 3,258,318 |
Other financial liabilities | 638,760 | 1,385 |
Bonds and other marketable securities | 83,817 | 787,325 |
Lease liabilities | 593,529 | 491,864 |
Total contractual flows | € 1,326,959 | € 4,538,892 |
Financial Instruments - Currenc
Financial Instruments - Currency Risk (Details) € in Thousands | Dec. 31, 2021EUR (€)$ / € | Dec. 31, 2020EUR (€)$ / € |
US Dollar | ||
Sensitivity analysis | ||
Closing foreign exchange rate | $ / € | 1.1326 | 1.2234 |
Currency risk | ||
Sensitivity analysis | ||
Rate increase (as a percent) | 10.00% | |
Increase in equity if exchange rate strengthened | € 812,285 | € 750,646 |
Increase (decrease) in profit due to foreign exchange differences if exchange rate strengthened | € 15,201 | (13,213) |
Rate decrease (as a percent) | 10.00% | |
Currency risk | Euros | ||
Financial instrument risk | ||
Balance sheet exposure | € 159,840 | 190,824 |
Currency risk | Euros | Trade receivables | ||
Financial instrument risk | ||
Balance sheet exposure | 2,023 | 1,468 |
Currency risk | Euros | Receivables from Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | 141,285 | 112,442 |
Currency risk | Euros | Loans to Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | 464,789 | 221,135 |
Currency risk | Euros | Cash and cash equivalents | ||
Financial instrument risk | ||
Balance sheet exposure | 25,766 | 35,034 |
Currency risk | Euros | Trade payables. | ||
Financial instrument risk | ||
Balance sheet exposure | (27,098) | (46,318) |
Currency risk | Euros | Payables to Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | (62,930) | (61,421) |
Currency risk | Euros | Loans from Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | (11,495) | (18,391) |
Currency risk | Euros | Bank loans | ||
Financial instrument risk | ||
Balance sheet exposure | (372,500) | (53,125) |
Currency risk | US Dollar | ||
Financial instrument risk | ||
Balance sheet exposure | (7,828) | (58,692) |
Currency risk | US Dollar | Trade receivables | ||
Financial instrument risk | ||
Balance sheet exposure | 14,800 | 19,938 |
Currency risk | US Dollar | Receivables from Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | 7,101 | 6,140 |
Currency risk | US Dollar | Loans to Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | 21 | 55 |
Currency risk | US Dollar | Cash and cash equivalents | ||
Financial instrument risk | ||
Balance sheet exposure | 82 | 416 |
Currency risk | US Dollar | Trade payables. | ||
Financial instrument risk | ||
Balance sheet exposure | (23,349) | (10,822) |
Currency risk | US Dollar | Payables to Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | (6,480) | (72,693) |
Currency risk | US Dollar | Loans from Group companies | ||
Financial instrument risk | ||
Balance sheet exposure | € (3) | € (1,726) |
Financial Instruments - Interes
Financial Instruments - Interest Rate Risk (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Fixed-interest | ||
Financial instrument risk | ||
Financial liabilities | € (4,878,087) | € (2,887,500) |
Variable-interest | ||
Financial instrument risk | ||
Financial liabilities | (3,296,025) | (3,369,451) |
Interest rate risk | ||
Financial instrument risk | ||
Financial liabilities | € (8,174,112) | € (6,256,951) |
Sensitivity analysis | ||
Higher rate increment (as a percent) | 100.00% | 100.00% |
Increase in interest expense if rate had been higher | € 35,449 | € 36,153 |
Balances and Transactions wit_3
Balances and Transactions with Related Parties (Details) € in Thousands, $ in Thousands | Dec. 28, 2018EUR (€) | Dec. 31, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2019USD ($) | Dec. 31, 2011USD ($)director | Dec. 28, 2018USD ($) |
Details of balances with related parties | ||||||||
Other financial assets with other related parties | € 220,947 | € 114,825 | ||||||
Net receivable (payable) | € 431,344 | € 184,443 | ||||||
Group transactions with related parties | ||||||||
Percentage of profit before tax contribution to non profit organization | 0.70% | 0.70% | 0.70% | 0.70% | 0.70% | |||
Contributions to non-profit organization | € 3,963 | € 10,344 | € 5,586 | |||||
Number of directors involved in consulting services contract | director | 1 | |||||||
Term of consulting services contract (in years) | 3 years | |||||||
Consulting services fee | $ | $ 1,000 | $ 250 | $ 1,000 | |||||
Additional bonus | $ | $ 2,000 | |||||||
Remuneration of directors representing shareholders interest | 965 | 965 | ||||||
Biotest Us Corporation and Haema AG | ||||||||
Group transactions with related parties | ||||||||
Consideration for sale of subsidiary | $ | $ 538,014 | |||||||
Scranton Enterprises BV | ||||||||
Details of balances with related parties | ||||||||
Loans | € 82,969 | $ 95,000 | ||||||
Scranton Enterprises BV | Fixed-interest | ||||||||
Group transactions with related parties | ||||||||
Compensation percentage | 2.00% | 2.00% | ||||||
Scranton Enterprises BV | Variable-interest | ||||||||
Group transactions with related parties | ||||||||
Compensation on loan | EURIBOR | |||||||
Associates | ||||||||
Details of balances with related parties | ||||||||
Receivables | 131,764 | 1,447 | ||||||
Trade payables | (3) | (133) | ||||||
Group transactions with related parties | ||||||||
Net sales | 220,808 | 10,522 | 10,196 | |||||
Purchases | (613) | (459) | (48,300) | |||||
Other service expenses | (2,709) | (15,010) | (25,638) | |||||
Finance income | 2,638 | 10,939 | 2,265 | |||||
Finance cost | (158) | |||||||
Total income (expense) | 220,124 | 5,992 | (61,635) | |||||
Key management personnel | ||||||||
Details of balances with related parties | ||||||||
Debts | (6,644) | (5,934) | ||||||
Group transactions with related parties | ||||||||
Remuneration | (15,136) | (17,164) | (16,795) | |||||
Total income (expense) | (15,136) | (17,164) | (16,795) | |||||
Other related parties | ||||||||
Details of balances with related parties | ||||||||
Trade payables | (3,824) | (6,613) | ||||||
Loans | 89,104 | 80,851 | ||||||
Other financial assets with other related parties | 220,947 | 114,825 | ||||||
Group transactions with related parties | ||||||||
Other service expenses | (3,963) | (10,344) | (5,586) | |||||
Payments for rights of use | (5,332) | (5,137) | (7,104) | |||||
Sale of fixed assets to related party | 7,326 | |||||||
Purchase of property, plant and equipment | (13,500) | |||||||
Sale of investments | 7,326 | |||||||
Total income (expense) | (1,969) | (28,981) | (12,690) | |||||
Directors | ||||||||
Group transactions with related parties | ||||||||
Other service expenses | (220) | |||||||
Remuneration | (4,417) | (4,966) | (5,517) | |||||
Total income (expense) | € (4,417) | € (4,966) | € (5,737) |
Subsequent events - Acquisition
Subsequent events - Acquisitions (Details) € / shares in Units, € in Thousands, $ in Millions | Apr. 29, 2022EUR (€)€ / sharesshares | Feb. 28, 2022USD ($) | Apr. 29, 2022EUR (€)€ / sharesshares | Dec. 31, 2021€ / sharesshares | Apr. 30, 2022€ / shares | Oct. 05, 2021EUR (€) | Sep. 30, 2021Center | Dec. 31, 2020€ / sharesshares |
Ordinary shares | ||||||||
Events after the Reporting Period | ||||||||
Par value (in Euros per share) | € 0.25 | € 0.25 | ||||||
Number of shares issued (in shares) | shares | 426,129,798 | 426,129,798 | ||||||
Preference shares | ||||||||
Events after the Reporting Period | ||||||||
Par value (in Euros per share) | € 0.05 | € 0.05 | ||||||
Number of shares issued (in shares) | shares | 261,425,110 | 261,425,110 | ||||||
Tiancheng (Germany) Pharmaceutical Holdings | ||||||||
Events after the Reporting Period | ||||||||
Consideration transferred | € | € 1,100 | |||||||
Maximum | ||||||||
Events after the Reporting Period | ||||||||
Proportion of ownership interest (as a percent) | 50.00% | |||||||
Acquisition of ownership interest | Tiancheng (Germany) Pharmaceutical Holdings | Biotest AG [Member] | ||||||||
Events after the Reporting Period | ||||||||
Loan receivable | € | € 318,000 | € 318,000 | ||||||
Acquisition of ownership interest | Biotest AG [Member] | ||||||||
Events after the Reporting Period | ||||||||
Proportion of voting rights held in subsidiary | 96.20% | |||||||
Proportion of ownership interest (as a percent) | 69.72% | |||||||
Acquisition of ownership interest | Tiancheng (Germany) Pharmaceutical Holdings | ||||||||
Events after the Reporting Period | ||||||||
Agreed consideration to acquire entire share capital | € | € 1,091,000 | 1,091,000 | ||||||
Consideration paid for additional shares in subsidiary | € | € 362,000 | |||||||
Acquisition of ownership interest | Tiancheng (Germany) Pharmaceutical Holdings | Ordinary shares | ||||||||
Events after the Reporting Period | ||||||||
Consideration paid, per share | € 43 | € 43 | ||||||
Number of additional shares in subsidiary acquired | shares | 1,250,298 | |||||||
Acquisition of ownership interest | Tiancheng (Germany) Pharmaceutical Holdings | Preference shares | ||||||||
Events after the Reporting Period | ||||||||
Consideration paid, per share | € 37 | € 37 | ||||||
Number of additional shares in subsidiary acquired | shares | 8,340,577 | |||||||
Acquisition of ownership interest | Tiancheng (Germany) Pharmaceutical Holdings | Tiancheng (Germany) Pharmaceutical Holdings | Ordinary shares | Biotest AG [Member] | ||||||||
Events after the Reporting Period | ||||||||
Share value, per share | € 43 | |||||||
Acquisition of ownership interest | Tiancheng (Germany) Pharmaceutical Holdings | Tiancheng (Germany) Pharmaceutical Holdings | Preference shares | Biotest AG [Member] | ||||||||
Events after the Reporting Period | ||||||||
Number of shares issued (in shares) | shares | 214.581 | 214.581 | ||||||
Share value, per share | € 37 | € 37 | ||||||
Strategic investment in Biotest | Biotest AG [Member] | ||||||||
Events after the Reporting Period | ||||||||
Number of plasma donor centers acquired | Center | 2 | |||||||
Number of plasma donation centers | Center | 28 | |||||||
Collaboration with Endpoint Health, Inc | Endpoint Health, Inc | ||||||||
Events after the Reporting Period | ||||||||
Upfront investment | $ | $ 10 | |||||||
Percentage of Preferred Shares Received | 5.00% | |||||||
Collaboration with Endpoint Health, Inc | Endpoint Health, Inc | Maximum | ||||||||
Events after the Reporting Period | ||||||||
Future investments | $ | $ 125 |
Appendix I - Information on Gro
Appendix I - Information on Group Companies, Associates and others (Details) | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Diagnostic Grifols, S.A. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Instituto Grifols, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.998% | 99.998% | 99.998% |
Proportion of indirect ownership interest | 0.002% | 0.002% | 0.002% |
Laboratorios Grifols, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 98.60% | 98.60% | 98.60% |
Proportion of indirect ownership interest | 1.40% | 1.40% | 1.40% |
Biomat, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.90% | 99.90% | 99.90% |
Proportion of indirect ownership interest | 0.10% | 0.10% | 0.10% |
Grifols Engineering, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.95% | 99.95% | 99.95% |
Proportion of indirect ownership interest | 0.05% | 0.05% | 0.05% |
Biomat USA, Inc. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Biologicals LLC | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Australia Pty Ltd. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Medion Grifols Diagnostic AG | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Therapeutics LLC | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Talecris Plasma Resources, Inc. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Worldwide Operations Limited | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Progenika Biopharma, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 91.88% | 91.88% | 91.88% |
Proportion of indirect ownership interest | 8.12% | 8.12% | 8.12% |
Grifols Diagnostics Solutions Inc (formerly G-C Diagnostics Corp.) | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 55.00% | 55.00% | 55.00% |
Grifols Worldwide Operations USA Inc. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Asia Pacific Pte, Ltd | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Movaco, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.999% | 99.999% | 99.999% |
Proportion of indirect ownership interest | 0.001% | 0.001% | 0.001% |
Grifols Portugal Productos Farmacuticos e Hospitalares, Lda. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 0.01% | 0.01% | 0.01% |
Proportion of indirect ownership interest | 99.99% | 99.99% | 99.99% |
Grifols Chile, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.00% | 99.00% | 99.00% |
Grifols USA, LLC. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Argentina, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 95.01% | 95.01% | 95.01% |
Proportion of indirect ownership interest | 4.99% | 4.99% | 4.99% |
Grifols s.r.o. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols (Thailand) Ltd | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 48.00% | 48.00% | 48.00% |
Grifols Malaysia Sdn Bhd | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 49.00% | 30.00% | 30.00% |
Grifols International, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.998% | 99.998% | 99.998% |
Proportion of indirect ownership interest | 0.002% | 0.002% | 0.002% |
Grifols Italia S.p.A | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols UK Ltd. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Brasil, Lda. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Proportion of indirect ownership interest | 0.00% | 0.00% | 0.00% |
Grifols France, S.A.R.L. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.99% | 99.99% | 99.99% |
Proportion of indirect ownership interest | 0.01% | 0.01% | 0.01% |
Grifols Polska Sp.z.o.o. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Logstica Grifols, S.A. de C.V. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.99% | 99.99% | 99.99% |
Proportion of indirect ownership interest | 0.01% | 0.01% | 0.01% |
Grifols Mexico, S.A. de C.V. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.98% | 99.98% | 99.98% |
Proportion of indirect ownership interest | 0.02% | 0.02% | 0.02% |
Grifols Nordic, AB | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Colombia, Ltda | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.99% | 99.99% | 99.99% |
Proportion of indirect ownership interest | 0.01% | 0.01% | 0.01% |
Grifols Deutschland GmbH | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Canada, Ltd. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Pharmaceutical Technology (Shanghai) Co., Ltd. (formerly Grifols Pharmaceutical Consulting (Shanghai) Co., Ltd.) | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Switzerland AG | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | |
Grifols (H.K.), Limited | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Japan K.K. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols India Healthcare Private Ltd | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.984% | 99.984% | 99.984% |
Proportion of indirect ownership interest | 0.016% | 0.016% | 0.016% |
Grifols Diagnostics Equipment Taiwan Limited | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Viajes, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.90% | 99.90% | 99.90% |
Proportion of indirect ownership interest | 0.10% | 0.10% | 0.10% |
Squadron Reinsurance Designated Activity Company (formerly Squadron Reinsurance Ltd.) | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Grifols Shared Services North America, Inc. (formerly Grifols Inc.) | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Gripdan Invest, S.L | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | 100.00% |
Araclon Biotech, S.L. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 75.85% | 75.10% | 75.10% |
VCN Bioscience, S.L | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 86.83% | 86.83% | 81.34% |
Grifols Innovation and New Technologies Limited | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Kiro Grifols S. L (formerly Kiro Robotics S.L) | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 90.00% | 90.00% | 90.00% |
Chiquito Acquisition Corp. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Aiges Minerals de Vilajuiga, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.99% | 99.99% | 99.99% |
Proportion of indirect ownership interest | 0.01% | 0.01% | 0.01% |
Goetech LLC (D/B/A Medkeeper) | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 54.76% |
Interstate Blood Bank, Inc | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | 100.00% |
Alkahest Inc [Member] | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 42.45% | |
Plasmavita Healthcare GmbH (Germany) | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 50.00% | 50.00% | |
Grifols Canada Therapeutics, Inc (formerly Green Cross Biotherapeutics, Inc.) (Canada) | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | ||
Proportion of indirect ownership interest | 100.00% | ||
Plasmavita Healthcare II GmbH. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 50.00% | 50.00% | |
GCAM, Inc. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | ||
Aradigm Corporation | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 35.13% | 35.13% | 35.13% |
Mecwins, S.L. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 24.99% | 24.99% | 24.99% |
Alkahest, Inc | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 47.58% | ||
Albajuna Therapeutics, S.L [Member] | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 49.00% | 49.00% | 49.00% |
Singulex, Inc | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 19.33% | 19.33% | 19.33% |
Access Biologicals, LLC. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 49.00% | 49.00% | 49.00% |
Access Biologicals IC-DISC, Inc | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 49.00% | 49.00% | 49.00% |
Access Cell Culture, LLC | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 49.00% | 49.00% | 49.00% |
Access Plasma, LLC | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 49.00% | 49.00% | 49.00% |
Grifols Pyreness Research Center ,S.L. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 80.00% | ||
Grifols Laboratory Solutions, Inc | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 100.00% | |
Grifols Korea Co., Ltd. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | 100.00% | |
Grifols Middle East & Africa LLC | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 99.99% | ||
Proportion of indirect ownership interest | 0.01% | ||
GigaGen Inc. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | 43.96% | 43.96% |
Grifols Bio North America LLC | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | ||
Biomat Holdco, LLC. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | ||
Biomat Newco, Corp. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 100.00% | ||
Grifols Escrow Issuer, S.A. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | ||
Prometic Plasma Resources, Inc. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 100.00% | ||
GigaGen Inc.. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 43.96% | 43.96% | |
Plasmavita Healthcare GmbH | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 50.00% | ||
Medcom Advance, S.A. | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 45.00% | 45.00% | 45.00% |
Plasmavita Healthcare II GmbH | |||
Information on group companies associates and others | |||
Proportion of indirect ownership interest | 50.00% | ||
Shanghai RAAS Blood Products Co., Ltd. | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 26.20% | 26.20% | |
Grifols Egypt for Plasma Derivatives (S.A.E.) | |||
Information on group companies associates and others | |||
Proportion of direct ownership interest | 49.00% |
Appendix II - Operating Segment
Appendix II - Operating Segments (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Segment Reporting | ||||
Revenues from external customers | € 4,933,118 | € 5,340,038 | € 5,098,691 | |
Profit/(Loss) for the segment | 595,064 | 996,132 | 1,131,365 | |
Finance result | (277,799) | (177,669) | (274,724) | |
Share of profit/(loss) of equity- accounted investee | 33,188 | 60,166 | (39,538) | |
Income tax expense (note 28) | (85,126) | (169,639) | (168,459) | |
Consolidated profit for the year | 265,327 | 708,990 | 648,644 | |
Investment in equity-accounted investees (note 11) | 1,999,776 | 1,869,020 | 114,472 | € 226,905 |
Assets | 19,233,835 | 15,274,776 | 15,542,611 | |
Liabilities | 11,916,737 | 8,554,721 | 8,696,843 | |
Other information: | ||||
Amortisation and depreciation | 359,767 | 321,533 | 302,455 | |
Additions for the year of property, plant & equipment, intangible assets and rights of use | 467,694 | 454,369 | 1,175,072 | |
Operating Segments | ||||
Segment Reporting | ||||
Revenues from external customers | 4,933,118 | 5,340,038 | 5,098,691 | |
Total operating income | 4,933,118 | 5,340,038 | 5,098,691 | |
Profit/(Loss) for the segment | 780,396 | 1,179,818 | 1,300,801 | |
Segment assets | 13,816,223 | 12,212,911 | 12,638,606 | |
Investment in equity-accounted investees (note 11) | 1,999,776 | 1,869,020 | 114,473 | |
Liabilities | 2,146,194 | 1,869,425 | 1,938,462 | |
Other information: | ||||
Amortisation and depreciation | 338,662 | 301,249 | 282,807 | |
Expenses that do not require cash payments | 33,919 | 15,175 | 20,755 | |
Additions for the year of property, plant & equipment, intangible assets and rights of use | 412,314 | 347,191 | 1,101,528 | |
Unallocated | ||||
Segment Reporting | ||||
Profit/(Loss) for the segment | (185,332) | (183,686) | (169,436) | |
Assets | 3,417,836 | 1,192,845 | 2,789,532 | |
Liabilities | 9,770,543 | 6,685,296 | 6,758,381 | |
Other information: | ||||
Amortisation and depreciation | 21,105 | 20,284 | 19,648 | |
Expenses that do not require cash payments | 4,991 | 4,924 | 2,416 | |
Additions for the year of property, plant & equipment, intangible assets and rights of use | 55,380 | 107,178 | 73,544 | |
Intersegments | ||||
Segment Reporting | ||||
Revenues from external customers | (67,548) | (53,107) | (52,176) | |
Total operating income | (67,548) | (53,107) | (52,176) | |
Profit/(Loss) for the segment | (10,896) | 4,428 | (3,094) | |
Segment assets | (39,963) | (26,773) | (32,892) | |
Bioscience | Operating Segments | ||||
Segment Reporting | ||||
Revenues from external customers | 3,814,983 | 4,242,502 | 3,993,462 | |
Total operating income | 3,814,983 | 4,242,502 | 3,993,462 | |
Profit/(Loss) for the segment | 658,691 | 949,989 | 1,079,216 | |
Segment assets | 9,467,378 | 7,975,667 | 8,416,922 | |
Investment in equity-accounted investees (note 11) | 31,847 | 10,368 | ||
Liabilities | 1,521,634 | 1,222,664 | 1,371,352 | |
Other information: | ||||
Amortisation and depreciation | 228,114 | 201,087 | 196,335 | |
Expenses that do not require cash payments | 26,051 | 38,955 | 43,524 | |
Additions for the year of property, plant & equipment, intangible assets and rights of use | 349,890 | 289,062 | 868,103 | |
Hospital | Operating Segments | ||||
Segment Reporting | ||||
Revenues from external customers | 141,190 | 118,675 | 134,441 | |
Total operating income | 141,190 | 118,675 | 134,441 | |
Profit/(Loss) for the segment | (7,735) | (12,504) | (8,674) | |
Segment assets | 269,487 | 257,360 | 274,250 | |
Liabilities | 38,654 | 32,179 | 53,441 | |
Other information: | ||||
Amortisation and depreciation | 12,065 | 12,443 | 11,686 | |
Expenses that do not require cash payments | 3,349 | 529 | (289) | |
Additions for the year of property, plant & equipment, intangible assets and rights of use | 12,616 | 11,548 | 62,298 | |
Diagnostic | ||||
Segment Reporting | ||||
Share of profit/(loss) of equity- accounted investee | (19,794) | |||
Diagnostic | Operating Segments | ||||
Segment Reporting | ||||
Revenues from external customers | 779,108 | 775,889 | 733,604 | |
Total operating income | 779,108 | 775,889 | 733,604 | |
Profit/(Loss) for the segment | 152,948 | 215,793 | 215,828 | |
Segment assets | 3,513,991 | 3,371,125 | 3,676,011 | |
Liabilities | 397,869 | 372,461 | 351,799 | |
Other information: | ||||
Amortisation and depreciation | 88,557 | 63,053 | 52,224 | |
Expenses that do not require cash payments | 4,446 | (21,335) | (22,873) | |
Additions for the year of property, plant & equipment, intangible assets and rights of use | 19,991 | 34,516 | 103,911 | |
Bio supplies. | Operating Segments | ||||
Segment Reporting | ||||
Revenues from external customers | 225,765 | 224,090 | 266,540 | |
Total operating income | 225,765 | 224,090 | 266,540 | |
Profit/(Loss) for the segment | 45,990 | 19,871 | 16,246 | |
Segment assets | 47,446 | 251,551 | 226,814 | |
Investment in equity-accounted investees (note 11) | 53,264 | 46,782 | 49,922 | |
Liabilities | 27,596 | 120,787 | 126,289 | |
Other information: | ||||
Amortisation and depreciation | 2,948 | 21,846 | 20,415 | |
Expenses that do not require cash payments | 73 | 3 | 393 | |
Additions for the year of property, plant & equipment, intangible assets and rights of use | 13,836 | 10,915 | 65,448 | |
Others | ||||
Segment Reporting | ||||
Share of profit/(loss) of equity- accounted investee | 33,188 | 60,166 | (19,744) | |
Others | Operating Segments | ||||
Segment Reporting | ||||
Revenues from external customers | 39,620 | 31,989 | 22,820 | |
Total operating income | 39,620 | 31,989 | 22,820 | |
Profit/(Loss) for the segment | (58,602) | 2,241 | 1,279 | |
Segment assets | 557,884 | 383,981 | 77,501 | |
Investment in equity-accounted investees (note 11) | 1,914,665 | 1,822,238 | 54,183 | |
Liabilities | 160,441 | 121,334 | 35,581 | |
Other information: | ||||
Amortisation and depreciation | 6,978 | 2,820 | 2,147 | |
Expenses that do not require cash payments | (2,977) | |||
Additions for the year of property, plant & equipment, intangible assets and rights of use | € 15,981 | € 1,150 | € 1,768 |
Appendix II - Reporting by Geog
Appendix II - Reporting by Geographical Area (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of products and services | |||
Net revenue (notes 6 and 24) | € 4,933,118 | € 5,340,038 | € 5,098,691 |
Assets by geographical area | 19,233,835 | 15,274,776 | 15,542,611 |
Other information: | |||
Additions for the year of property, plant & equipment, intangible assets and rights of use | 467,694 | 454,369 | 1,175,072 |
Spain. | |||
Disclosure of products and services | |||
Net revenue (notes 6 and 24) | 362,407 | 339,169 | 268,287 |
Assets by geographical area | 1,092,435 | 1,117,647 | 2,764,054 |
Other information: | |||
Additions for the year of property, plant & equipment, intangible assets and rights of use | 71,022 | 93,787 | 183,891 |
Rest of European Union | |||
Disclosure of products and services | |||
Net revenue (notes 6 and 24) | 544,042 | 495,323 | 588,375 |
Assets by geographical area | 5,393,407 | 2,927,198 | 3,425,874 |
Other information: | |||
Additions for the year of property, plant & equipment, intangible assets and rights of use | 91,388 | 92,873 | 181,736 |
USA and Canada. | |||
Disclosure of products and services | |||
Net revenue (notes 6 and 24) | 3,154,549 | 3,599,746 | 3,390,811 |
Assets by geographical area | 10,525,140 | 9,138,360 | 9,059,674 |
Other information: | |||
Additions for the year of property, plant & equipment, intangible assets and rights of use | 295,526 | 253,442 | 787,586 |
Rest of the world | |||
Disclosure of products and services | |||
Net revenue (notes 6 and 24) | 872,120 | 905,800 | 851,218 |
Assets by geographical area | 2,222,853 | 2,091,571 | 293,009 |
Other information: | |||
Additions for the year of property, plant & equipment, intangible assets and rights of use | € 9,758 | € 14,267 | € 21,859 |
Appendix III - Changes in Other
Appendix III - Changes in Other Intangible Assets (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | € 1,557,650 | € 1,433,534 |
Additions | 52,078 | 16,257 |
Business combinations | 24,027 | 267,805 |
Transfers | 3,154 | 1,382 |
Disposals | (12,176) | (10,018) |
Translation differences | 116,373 | (118,796) |
Intangible assets at end of the year | 1,636,950 | 1,557,650 |
Currently marketed products. | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | 672,697 | 770,715 |
Translation differences | 51,809 | (60,279) |
Intangible assets at end of the year | 688,517 | 672,697 |
Gross carrying amount | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | 2,370,373 | 2,195,126 |
Additions | 68,244 | 82,532 |
Business combinations | 24,027 | 267,805 |
Transfers | 3,315 | 3,558 |
Disposals | (18,033) | (10,244) |
Translation differences | 168,039 | (168,404) |
Intangible assets at end of the year | 2,615,965 | 2,370,373 |
Gross carrying amount | Development costs | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | 701,390 | 435,339 |
Additions | 34,671 | 35,301 |
Business combinations | 24,027 | 265,571 |
Disposals | (5,679) | |
Translation differences | 47,197 | (34,821) |
Intangible assets at end of the year | 801,606 | 701,390 |
Gross carrying amount | Concessions, patents, licenses brands & similar | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | 228,023 | 229,997 |
Additions | 57 | 16,174 |
Business combinations | 5 | |
Transfers | (6) | |
Translation differences | 16,478 | (18,147) |
Intangible assets at end of the year | 244,558 | 228,023 |
Gross carrying amount | Computer software | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | 279,651 | 258,597 |
Additions | 33,516 | 27,939 |
Business combinations | 2,229 | |
Transfers | 3,315 | 3,963 |
Disposals | (208) | (11) |
Translation differences | 14,217 | (13,066) |
Intangible assets at end of the year | 330,491 | 279,651 |
Gross carrying amount | Currently marketed products. | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | 1,004,665 | 1,092,834 |
Translation differences | 78,636 | (88,169) |
Intangible assets at end of the year | 1,083,301 | 1,004,665 |
Gross carrying amount | Other Intangible assets [Member] | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | 156,644 | 178,359 |
Additions | 3,118 | |
Transfers | (399) | |
Disposals | (12,146) | (10,233) |
Translation differences | 11,511 | (14,201) |
Intangible assets at end of the year | 156,009 | 156,644 |
Accumulated depreciation and amortisation | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | (747,594) | (693,948) |
Additions | (120,249) | (95,812) |
Transfers | (161) | (2,176) |
Disposals | 5,857 | 226 |
Translation differences | (46,768) | 44,116 |
Intangible assets at end of the year | (908,915) | (747,594) |
Accumulated depreciation and amortisation | Development costs | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | (125,875) | (103,531) |
Additions | (44,612) | (23,810) |
Transfers | (60) | |
Disposals | 5,679 | |
Translation differences | (3,498) | 1,466 |
Intangible assets at end of the year | (168,366) | (125,875) |
Accumulated depreciation and amortisation | Concessions, patents, licenses brands & similar | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | (51,197) | (43,656) |
Additions | (9,909) | (8,221) |
Transfers | (1,732) | |
Translation differences | (3,070) | 2,412 |
Intangible assets at end of the year | (64,176) | (51,197) |
Accumulated depreciation and amortisation | Computer software | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | (167,124) | (143,806) |
Additions | (25,474) | (19,198) |
Transfers | (101) | (9,833) |
Disposals | 178 | 12 |
Translation differences | (7,770) | 5,701 |
Intangible assets at end of the year | (200,291) | (167,124) |
Accumulated depreciation and amortisation | Currently marketed products. | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | (331,968) | (322,119) |
Additions | (35,989) | (37,739) |
Translation differences | (26,827) | 27,890 |
Intangible assets at end of the year | (394,784) | (331,968) |
Accumulated depreciation and amortisation | Other Intangible assets [Member] | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | (71,430) | (80,836) |
Additions | (4,265) | (6,844) |
Transfers | 9,389 | |
Disposals | 214 | |
Translation differences | (5,603) | 6,647 |
Intangible assets at end of the year | (81,298) | (71,430) |
Accumulated impairment | Other Intangible assets [Member] | ||
Changes in Other Intangible Assets | ||
Intangible assets at beginning of the year | (65,129) | (67,644) |
Additions | (73) | (2,977) |
Translation differences | (4,898) | 5,492 |
Intangible assets at end of the year | € (70,100) | € (65,129) |
Appendix IV - Movement in Right
Appendix IV - Movement in Rights of Use (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | € 678,696 | € 703,858 |
Additions | 133,442 | 75,077 |
Additions | (66,720) | (62,580) |
Additions | 66,722 | 12,497 |
Business combinations | 4,611 | 19,498 |
Transfers | 92 | (896) |
Disposals | (306) | (8,983) |
Translation differences | 45,842 | (47,278) |
Right-of-use assets, at end of period | 795,657 | 678,696 |
Land and Buildings | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 665,002 | |
Right-of-use assets, at end of period | 782,125 | 665,002 |
Buildings | ||
Movement in Right of Use | ||
Additions | (57,901) | (52,774) |
Machinery | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 3,671 | |
Additions | (2,120) | (1,588) |
Right-of-use assets, at end of period | 5,283 | 3,671 |
Computer equipment | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 3,588 | |
Additions | (2,269) | (3,012) |
Right-of-use assets, at end of period | 2,044 | 3,588 |
Vehicles | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 6,435 | |
Additions | (4,430) | (5,206) |
Right-of-use assets, at end of period | 6,205 | 6,435 |
Gross carrying amount | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 787,407 | 761,547 |
Additions | 133,442 | 75,077 |
Business combinations | 4,611 | 19,498 |
Transfers | 1,806 | (1,893) |
Disposals | (6,586) | (13,255) |
Translation differences | 54,630 | (53,567) |
Right-of-use assets, at end of period | 975,310 | 787,407 |
Gross carrying amount | Land and Buildings | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 759,120 | 734,846 |
Additions | 125,112 | 68,172 |
Business combinations | 4,611 | 19,424 |
Transfers | 3,337 | |
Disposals | (3,603) | (10,935) |
Translation differences | 53,378 | (52,387) |
Right-of-use assets, at end of period | 941,955 | 759,120 |
Gross carrying amount | Machinery | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 5,907 | 6,167 |
Additions | 3,412 | 1,775 |
Transfers | (495) | (1,846) |
Disposals | (89) | (59) |
Translation differences | 341 | (130) |
Right-of-use assets, at end of period | 9,076 | 5,907 |
Gross carrying amount | Computer equipment | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 8,228 | 6,504 |
Additions | 641 | 2,449 |
Transfers | (629) | (37) |
Disposals | (7) | (347) |
Translation differences | 286 | (341) |
Right-of-use assets, at end of period | 8,519 | 8,228 |
Gross carrying amount | Vehicles | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | 14,152 | 14,030 |
Additions | 4,277 | 2,681 |
Business combinations | 74 | |
Transfers | (407) | (10) |
Disposals | (2,887) | (1,914) |
Translation differences | 625 | (709) |
Right-of-use assets, at end of period | 15,760 | 14,152 |
Accumulated depreciation and amortisation | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | (108,711) | (57,689) |
Additions | (66,720) | (62,580) |
Transfers | (1,714) | 997 |
Disposals | 6,280 | 4,272 |
Translation differences | (8,788) | 6,289 |
Right-of-use assets, at end of period | (179,653) | (108,711) |
Accumulated depreciation and amortisation | Land and Buildings | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | (94,118) | (49,441) |
Additions | (57,901) | (52,774) |
Transfers | (3,337) | (2) |
Disposals | 3,605 | 2,341 |
Translation differences | (8,080) | 5,758 |
Right-of-use assets, at end of period | (159,831) | (94,118) |
Accumulated depreciation and amortisation | Machinery | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | (2,236) | (1,698) |
Additions | (2,120) | (1,588) |
Transfers | 587 | 955 |
Disposals | 87 | 55 |
Translation differences | (110) | 40 |
Right-of-use assets, at end of period | (3,792) | (2,236) |
Accumulated depreciation and amortisation | Computer equipment | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | (4,640) | (2,180) |
Additions | (2,269) | (3,012) |
Transfers | 629 | 37 |
Disposals | 7 | 347 |
Translation differences | (202) | 168 |
Right-of-use assets, at end of period | (6,475) | (4,640) |
Accumulated depreciation and amortisation | Vehicles | ||
Movement in Right of Use | ||
Right-of-use assets, at beginning of period | (7,717) | (4,370) |
Additions | (4,430) | (5,206) |
Transfers | 407 | 7 |
Disposals | 2,581 | 1,529 |
Translation differences | (396) | 323 |
Right-of-use assets, at end of period | € (9,555) | € (7,717) |
Appendix V - Movement in Proper
Appendix V - Movement in Property, Plant and Equipment (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | € 2,324,107 | € 2,159,545 |
Additions | 81,966 | 133,640 |
Business combination | 3,741 | 184,771 |
Transfers | (3,245) | (486) |
Disposals | (6,152) | (1,280) |
Translation differences | 147,080 | (152,083) |
Property, plant and equipment at end of period | 2,547,497 | 2,324,107 |
Gross carrying amount | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | 3,685,191 | 3,445,970 |
Additions | 266,008 | 296,760 |
Business combination | 3,741 | 184,771 |
Transfers | (3,219) | (2,072) |
Disposals | (25,083) | (24,041) |
Translation differences | 225,340 | (216,197) |
Property, plant and equipment at end of period | 4,151,978 | 3,685,191 |
Gross carrying amount | Land and Buildings | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | 780,180 | 807,195 |
Additions | 3,361 | 19,843 |
Business combination | 660 | 14,964 |
Transfers | 24,830 | (6,050) |
Disposals | (123) | (211) |
Translation differences | 51,539 | (55,561) |
Property, plant and equipment at end of period | 860,447 | 780,180 |
Gross carrying amount | Plant and machinery | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | 2,200,429 | 2,141,611 |
Additions | 42,747 | 50,825 |
Business combination | 10,381 | 48,408 |
Transfers | 171,894 | 103,594 |
Disposals | (24,960) | (23,830) |
Translation differences | 127,253 | (120,179) |
Property, plant and equipment at end of period | 2,527,744 | 2,200,429 |
Gross carrying amount | Fixed assets under construction | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | 704,582 | 497,164 |
Additions | 219,900 | 226,092 |
Business combination | 7,300 | 121,399 |
Transfers | (199,943) | (99,616) |
Translation differences | 46,548 | (40,457) |
Property, plant and equipment at end of period | 763,787 | 704,582 |
Accumulated depreciation and amortisation | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | (1,358,431) | (1,283,713) |
Additions | (172,796) | (163,141) |
Transfers | (26) | 1,586 |
Disposals | 18,931 | 22,761 |
Translation differences | (78,194) | 64,076 |
Property, plant and equipment at end of period | (1,590,516) | (1,358,431) |
Accumulated depreciation and amortisation | Buildings | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | (122,948) | (108,638) |
Additions | (19,388) | (17,974) |
Transfers | 2,583 | (3,826) |
Disposals | 123 | 171 |
Translation differences | (8,452) | 7,319 |
Property, plant and equipment at end of period | (148,082) | (122,948) |
Accumulated depreciation and amortisation | Plant and machinery | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | (1,235,483) | (1,175,075) |
Additions | (153,408) | (145,167) |
Transfers | (2,609) | 5,412 |
Disposals | 18,808 | 22,590 |
Translation differences | (69,742) | 56,757 |
Property, plant and equipment at end of period | (1,442,434) | (1,235,483) |
Accumulated impairment | ||
Movement in Property, Plant and Equipment | ||
Property, plant and equipment at beginning of period | (2,653) | (2,712) |
Additions | (11,246) | 21 |
Translation differences | (66) | 38 |
Property, plant and equipment at end of period | € (13,965) | € (2,653) |